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we mimicked the intermediates arising during CSR by the action of activation induced cytidine deaminase
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SUMMARY	
Tightly-controlled	cell	division	is	of	critical	importance	for	multicellular	organisms	to	be	able	to	grow	
and	 survive	 over	 long	 periods	 of	 time.	 The	 most	 demanding	 step	 in	 this	 process	 is	 the	 faithful	
replication	of	the	genome.	If	a	cell	fails	to	copy	its	DNA	molecule	in	an	error-free	manner,	the	genetic	
changes	in	the	DNA	can	lead	to	cell	death	or,	in	the	worst	case,	to	uncontrolled	cell	division,	resulting	
in	genome	instability	and	cancer.	
The	 DNA	 is	 constantly	 challenged	 by	 exogenous	 and	 endogenous	 damaging	 agents,	 such	 as	 UV	
irradiation,	water	or	reactive	oxygen	species	that	threaten	the	integrity	of	DNA.	The	resulting	lesions	
are	addressed	by	base	excision	repair	(BER)	and	mismatch	repair	(MMR).	The	cell's	repair	pathways	
are,	however,	not	only	needed	to	correct	damage	in	the	DNA	and	mistakes	arising	during	replication,	
but	they	are	also	essential	for	many	physiological	processes.	BER	and	MMR	were	shown	to	play	a	role	
in	 antibody	 diversification	 during	 adaptive	 immune	 response	 and	 BER	 is	 implicated	 in	 DNA	
methylation	dynamics	to	control	gene	expression.	
In	 the	 first	 part	 of	 the	 thesis,	 we	 set	 out	 to	 investigate	 the	 role	 of	 BER	 and	MMR	 in	 class	 switch	
recombination	 (CSR),	 a	 process	 that	 enables	 B-cells	 to	 produce	 antibodies	 with	 different	 effector	
functions.	Using	DNA	substrates	containing	defined	nicks	and	uracils,	we	mimicked	the	intermediates	
arising	during	CSR	by	the	action	of	activation	 induced	cytidine	deaminase	(AID).	We	found	that	the	
creation	of	DNA	double	strand	breaks,	a	step	that	 is	essential	 for	CSR,	heavily	depends	on	the	BER	
enzyme	uracil	DNA	glycosylase	(UNG)	and	on	the	MMR	protein	MutSα.	
In	 the	 second	 part	 of	 the	 thesis,	 I	 aimed	 to	 gain	 insights	 into	 the	 dynamic	 metabolism	 of	 DNA	
modifications	 that	 control	 gene	 expression	 by	 investigating	 the	 chromatin	 dynamics	 at	 the	
vitellogenin	 (VTG)	 gene	 regulatory	 region.	The	VTG	 gene	 represents	a	valuable	model	 to	 study	 the	
events	on	chromatin	 leading	 to	expression	of	 the	gene,	as	 it	 is	well-characterized	and	 inducible	by	
estradiol	 treatment.	 Demethylation	 events	 have	 been	 observed	 in	 the	 enhancer	 region	 in	 rooster	
DNA	upon	hormone	treatment.	In	our	cell	line	system,	we	saw	no	demethylation,	but	an	increase	in	
5-hydroxymethylation,	 a	 product	 of	 oxidation	mediated	 by	 the	 Ten-eleven	 Translocation	 proteins,	
implicated	 in	 DNA	 demethylation.	 In	 addition,	 the	 estrogen	 receptor	 α	 binding	 to	 its	 response	
element	 in	 the	VTG	 enhancer	 was	 not	 altered	 by	 the	 presence	 of	 5mC	 or	 5hmC,	 but	 a	 shift	 of	 a	
methylation-sensitive	 factor	 was	 observed	 in	 nuclear	 extracts.	 In	 vitro	 methylation	 of	 a	 reporter	
plasmid	 under	 the	 control	 of	 the	 VTG	 regulatory	 region	 inhibited	 transcription,	 confirming	 an	
important	role	of	methylation	dynamics	in	the	control	of	VTG	expression.	We	found	evidence	that	a	
CpG	 residing	 outside	 of	 the	 estrogen	 response	 element	 in	 an	 E-box	 in	 the	 VTG	 promoter	 is	
responsible	for	the	methylation-sensitivity.		
The	data	presented	in	this	thesis	illustrate	the	diverse	functions	of	eukaryotic	repair	pathways.	They	
show	the	great	potential	of	these	versatile	mechanisms,	but	also	point	out	the	danger	they	pose	to	
cells	 and	 multicellular	 organisms.	 If	 they	 are	 not	 processed	 correctly,	 the	 DNA	modifications	 and	
rearrangements	can	 lead	to	tumorigenesis,	highlighting	the	 importance	of	a	deep	understanding	of	
the	mechanisms	involved.		
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ZUSAMMENFASSUNG	
Streng	kontrollierte	Zellteilung	ist	sehr	wichtig	für	multizelluläre	Organismen,	damit	sie	wachsen	und	
über	 längere	 Zeit	 überleben	 können.	 Der	 anspruchsvollste	 Schritt	 dabei	 ist	 die	 zuverlässige	
Verdoppelung	des	Genoms.	Wenn	eine	Zelle	ihr	DNS	Molekül	nicht	fehlerfrei	kopieren	kann,	können	
die	resultierenden	genetischen	Veränderungen	zum	Zelltod	oder	noch	schlimmer,	zu	unkontrollierter	
Zellteilung	führen.	Dies	wiederum	kann	in	Genominstabilität	und	Krebs	resultieren.	
DNS	wird	konstant	von	exogenen	und	endogenen	schädlichen	Wirkstoffen	angegriffen,	zum	Beispiel	
UV-Strahlung,	Wasser	 oder	 reaktive	 Sauerstoffverbindungen,	 die	 die	 Integrität	 der	 DNS	 bedrohen.	
Die	 resultierenden	 Läsionen	 werden	 von	 der	 Basen-Exzisions-Reparatur	 (BER)	 und	 der	
Fehlpaarungsreparatur	(MMR)	adressiert.	
Die	zellulären	Reparaturmechanismen	werden	jedoch	nicht	nur	gebraucht,	um	Schäden	und	Fehler	in	
der	Replikation	zu	korrigieren,	sondern	sind	auch	wichtig	für	viele	physiologische	Prozesse.	BER	und	
MMR	 spielen	 eine	 Rolle	 in	 der	 Diversifizierung	 von	 Antikörpern	 während	 der	 adaptiven	
Immunreaktion,	und	BER	ist	verwickelt	in	der	Dynamik	von	DNS-Methylierungen,	um	Genexpression	
zu	kontrollieren.	
Im	ersten	Teil	der	These	wollten	wir	die	Rollen	von	BER	und	MMR	in	Klassenwechsel-Rekombination	
(CSR)	 untersuchen,	 einem	 Prozess,	 der	 es	 B-Zellen	 ermöglicht,	 Antikörper	 mit	 unterschiedlichen	
Effektor-Funktionen	zu	produzieren.	
Der	Einsatz	von	DNS-Substraten,	die	definierte	Strangbrüche	und	Uracil-Basen	enthalten	-	Läsionen,	
die	 von	der	 aktivierungsabhängigen	Cytidin-Deaminase	 (AID)	 erzeugt	werden	 -	 ermöglichte	es	uns,	
die	 Zwischenprodukte	 von	CSR	nachzuahmen.	Wir	haben	herausgefunden,	dass	die	 Erzeugung	 von	
DNS-Doppelstrangbrüchen,	 ein	 essentieller	 Schritt	 in	 CSR,	 vom	 BER-Enzym	 Uracil-DNS-Glykosylase	
(UNG)	und	vom	MMR	Protein	MutSα	abhängt.	
Im	zweiten	Teil	dieser	Arbeit	wollte	 ich	einen	Einblick	 in	den	dynamischen	Metabolismus	von	DNS-
Modifikationen	 in	 der	 Kontrolle	 von	Genexpression	 gewinnen,	 indem	 ich	die	 Chromatindynamik	 in	
der	 regulierenden	Region	des	Vitellogenin	 (VTG)-Gens	untersuchte.	Das	VTG	Gen	 ist	ein	wertvolles	
Modellsystem,	um	die	Ereignisse	am	Chromatin	zu	erforschen,	die	zur	Expression	des	Gens	 führen,	
da	 das	 System	 gut	 charakterisiert	 ist	 und	 ausserdem	mit	 Estradiol	 induzierbar	 ist.	 Demethylierung	
wurde	in	der	Enhancer	Region	in	der	DNS	von	Hähnen	nach	einer	Hormonbehandlung	beobachtet.	In	
unserer	 Zelllinie	 konnten	 wir	 keine	 Demethylierung	 sehen,	 aber	 einen	 Anstieg	 von	
Hydroxymethylierung,	 einem	 Produkt	 der	 Ten-eleven	 Translocation	 Proteine,	 die	 eine	 Rolle	 in	 der	
DNS-Demethylierung	spielen.	Zusätzlich	haben	wir	herausgefunden,	dass	der	Östrogenrezeptor	seine	
Bindungsstelle	im	Enhancer	des	VTG-Gens	unabhängig	von	Methylierung	oder	Hydroxymethylierung	
bindet,	 aber	wir	 fanden	 einen	methylierungsempfindlichen	 Faktor	 in	 nuklearen	 Extrakten.	 In-vitro-
Methylierung	 eines	 Reporter-Plasmids	 unter	 der	 Kontrolle	 der	 VTG-regulativen	 Region	 führte	 zur	
Verhinderung	 der	 Transkription,	was	 die	 Bedeutung	 von	Methylierungsdynamiken	 in	 der	 Kontrolle	
der	 VTG	 Expression	 hervorhebt.	 Wir	 fanden	 Hinweise,	 dass	 ein	 CpG,	 ausserhalb	 des	
hormonreagierenden	 Elements	 in	 einer	 E-Box	 Sequenz	 des	VTG	 Promotors,	 für	 die	Methylierungs-
Sensitivität	verantwortlich	ist.	
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Die	 in	 dieser	 These	 präsentierten	 Daten	 zeigen	 die	 verschiedenen	 Funktionen	 der	 eukaryotischen	
Reparaturwege.	 Sie	 zeigen	 das	 grosse	 Potenzial	 dieser	 vielseitigen	 Mechanismen,	 aber	 auch	 die	
Gefahr	 für	 die	 Zellen	 und	multizellulären	Organismen.	 Die	 DNS-Modifikationen	 und	Umordnungen	
können	zu	Krebsentstehung	 führen,	wenn	sie	nicht	korrekt	prozessiert	werden,	was	die	Bedeutung	
eines	detaillierten	Verständnisses	der	involvierten	Mechanismen	hervorhebt.		
																																																																																																																																																																																																																																			.																																																																																																																																																																																																				
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INTRODUCTION	
	
GENOME	STABILITY	
All	multicellular	organisms	face	the	challenging	task	of	controlled	cell	division	in	order	to	be	able	to	
grow	 and	 survive	 over	 long	 periods	 of	 time.	 The	 most	 critical	 step	 in	 this	 process	 is	 the	 faithful	
replication	of	the	genome.	When	a	cell	 fails	 to	copy	 its	DNA	molecule	 in	an	error-free	manner,	the	
genetic	changes	in	the	DNA	sequence	can	lead,	in	the	best	case,	to	the	controlled	death	of	the	cell,	
called	 apoptosis,	 but	 they	 can	 also	 lead	 to	 uncontrolled	 division	 of	 the	 cell,	 resulting	 in	 genome	
instability	 and	 cancer	 [1-3].	 It	 is	 therefore	 of	 critical	 importance	 for	 the	 cell	 to	 ensure	 error-free	
replication	 of	 the	 genetic	 information	 and	 prevent	 any	 unintended	 changes	 in	 the	 DNA	molecule.	
Cells	possess	several	repair	pathways	that	ensure	the	stability	of	the	DNA	sequence	and	 its	 faithful	
duplication	and	propagation	to	the	following	generations,	some	of	which	will	be	discussed	below.		
Adding	 even	more	 complexity	 to	 the	metabolism	 of	 DNA,	 the	 cell's	 repair	 pathways	 are	 not	 only	
needed	 to	 correct	 damage	 in	 the	 DNA	 and	 mistakes	 arising	 during	 replication,	 but	 they	 are	 also	
essential	 for	many	physiological	processes	 in	 the	cell.	 It	 is	of	outmost	 importance	for	example	that	
the	DNA	molecule	 can	be	dynamically	modified	 for	 the	 regulation	and	 control	 of	 gene	expression.	
This	 occurs	 on	 an	 epigenetic	 level,	 meaning	 one	 level	 above	 the	 genetic	 code,	 but	 nevertheless	
involves	transient	modifications	of	the	DNA.	Even	more	striking,	 in	addition	to	modifications	of	the	
DNA	 necessary	 for	 epigenetic	 regulation	 of	 gene	 expression,	 there	 are	 some	 examples	where	 the	
DNA	 sequence	 itself	 is	 deliberately	 and	 irreversibly	 changed.	 In	 vertebrates	 for	 example,	DSBs	 are	
introduced	 in	 a	 controlled	 manner	 into	 DNA	 during	 adaptive	 immune	 response,	 where	 extensive	
parts	of	the	DNA	sequence	are	excised	[4,	5].	The	role	of	DNA	repair	pathways	in	these	physiological	
processes	will	be	addressed	extensively	in	this	thesis.	
Genome	stability	does	therefore	not	imply	that	the	DNA	molecule	is	a	rigid	molecule	that	must	not	
be	changed.	It	rather	describes	the	controlled	and	well-regulated	dynamics	of	the	DNA	and	proteins	
associated	with	it	that	enable	a	cell	to	divide	many	times	without	losing	its	characteristics.		
In	 summary,	 the	 requirements	 of	 DNA	metabolism	 are	 extremely	 high,	 ranging	 from	dynamic	 and	
flexible	DNA	transactions	to	its	long-term	overall	stability	and	error-free	duplication.	
	
DNA	METABOLISM	AND	REPAIR	
DNA	is	a	remarkably	stable	molecule	due	in	part	to	numerous	inter-strand	hydrogen	bonds	along	the	
polymer.	 The	 polar	 amidino,	 guanidino	 and	 carbonyl	 groups	 of	 the	 complementary	 bases	 form	 a	
complex	network	consisting	of	hydrogen	bonds	with	neighboring	water	molecules.	Stability	depends	
on	 the	DNA	sequence,	 as	G/C	base	pairs	 are	held	 together	by	 three	hydrogen	bonds	 compared	 to	
only	two	in	A/T	pairs	[6,	7].	But	inter-strand	hydrogen	bonds	are	not	the	only	factors	contributing	to	
the	stability	of	DNA;	stacking	interactions	between	bases	and	base	pairs	were	found	to	be	the	most	
important	factors	for	the	stability	of	the	duplex	[8].	They	depend	on	the	aromatic	rings	of	the	bases	
that	 form	 hydrophobic	 and	 electrostatic	 interactions.	 The	 degree	 of	 stability	 conferred	 by	 base	
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stacking	also	depends	on	the	base	sequence,	as	some	combinations	of	base	pairs	form	more	stable	
interactions	than	others.	
The	high	stability	of	DNA	in	a	cell	is	somewhat	unexpected,	considering	that,	apart	from	exogenous	
sources	like	UV	irradiation,	there	are	also	numerous	endogenous	agents	that	constantly	attack	DNA.	
The	 most	 important	 and	 most	 abundant	 ones	 are	 oxygen	 and	 water.	 Their	 contact	 with	 DNA	 is	
inevitable,	but	can	lead	to	modifications	that	threaten	the	integrity	of	the	DNA	and	the	genome.	
Molecular	oxygen	can	react	with	unpaired	electrons	that	escape	the	electron	transfer	chain,	leading	
to	 the	 formation	 of	 reactive	 oxygen	 species	 (ROS).	 1-2%	 of	 the	 electrons	 traveling	 through	 the	
respiratory	chain	are	estimated	to	leave	the	chain	that	way.	ROS	are	therefore	generated	frequently	
in	metabolizing	cells	[9].	The	most	reactive	species	is	the	superoxide	anion	that	is	readily	converted	
to	hydrogen	peroxide	(H2O2).	H2O2	is	either	decomposed	to	water	or	further	converted	to	the	strong	
oxidant	hydroxyl	 radical	 [10,	11].	ROS	 impose	an	 immense	 threat	 to	DNA,	because	 they	 react	with	
the	bases	and	 the	deoxyribosyl	backbone	causing	mutagenic	 lesions,	DNA	breaks	and	DNA-protein	
cross-links	[12,	13].	The	formation	of	7,8-dihydro-8-oxoguanine	(8-oxo-dG)	is	particularly	mutagenic	
in	 DNA,	 because	 its	 base	 pairing	 properties	 mimic	 those	 of	 a	 thymidine,	 causing	 the	 frequent	
misincorporation	of	adenine	into	the	opposite	strand	[14,	15].	This	leads	to	transversions	from	C/G	to	
A/T,	 which	 are	 among	 the	 predominant	 somatic	 mutations	 in	 lung,	 breast	 and	 colorectal	 cancers	
[16].	It	is	therefore	of	outmost	importance	for	the	cell	to	remove	8-oxo-dG	before	replication.	
	 	
Figure 1: Oxidation of guanosine by ROS leading to the formation of 8-oxo-dG.  
	
The	 other	 prevalent	 endogenous	 DNA	 damaging	 agent,	 water,	 also	 causes	 a	 variety	 of	mutagenic	
DNA	lesions.	It	hydrolyzes	cytosine	to	uracil	[17,	18]	and	5-methylcytosine	(mC)	to	thymine	[19-21].	
The	latter	reaction	causes	more	complex	problems,	as	the	product	is	a	bona	fide	DNA	base	and	not	
an	obvious	damage	product.	 In	addition,	adenine	can	be	hydrolyzed	 to	hypoxanthine,	causing	 it	 to	
mispair	with	 cytosine	 leading	 to	 A/T	 to	G/C	 transitions	 [22,	 23].	Water	 also	 causes	 protonation	 of	
guanine,	 eventually	 leading	 to	 its	 spontaneous	 loss	 through	 depurination	 [24]	 and,	 together	 with	
oxygen,	 it	can	generate	thymine	glycol	and	a	plethora	of	other,	minor,	aberrant	bases	that	need	to	
be	repaired	by	the	cell	to	ensure	the	stability	of	DNA.	
The	 third	 agent	 that	 spontaneously	 modifies	 DNA	 is	 S-adenosylmethionine	 (SAM);	 it	 acts	 as	 a	
gratuitous	 methyl	 group	 donor	 in	 a	 range	 of	 reactions,	 but	 it	 also	 gives	 rise	 to	 non-canonical	
modifications,	such	as	3-N-methyladenine,	7-N-methylguanine	and	6-O-methylguanine	[24,	25].	
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Figure 2: Alkylated purines generated in DNA by aberrant methylation. From left to right: 3-N-
methyladenine, 7-N-methylguanine and 6-O-methylguanine. 
		
Apart	 from	arising	 through	endogenous	DNA	damaging	agents,	 cells	also	deliberately	modify	bases	
for	 regulatory	 purposes	 or	 to	 selectively	modify	 the	 genome	 in	 a	 highly	 controlled	manner.	 Some	
examples	relevant	for	this	work	are	mentioned	briefly	and	will	be	discusses	in	detail	later.	SAM	is	not	
only	 a	 mutagenic	 agent	 in	 cells,	 but	 is	 also	 used	 to	 attach	 methyl	 moieties	 to	 the	 5-position	 of	
cytosines,	 forming	 5-methylcytosine	 (5mC)	 [26].	 This	 so-called	 fifth	 base	 plays	 an	 essential	 role	 in	
many	 regulatory	 processes.	 In	 2009,	 a	 family	 of	 oxidases,	 the	 Ten-eleven	 Translocation	 (TET)	
enzymes	were	discovered	to	oxidize	5mC	to	5-hydroxymethylcytosine	(5hmC),	5-formylcytosine	(5fC)	
and	5-carboxycytosine	 (5caC)	 [27,	 28].	 The	exact	 role	of	 these	 additional	 cytosine	 species	 is	 under	
intense	investigation.		
	 	
Figure 3: Spontaneous or enzymatic (by AID/APOBEC) hydrolytic deamination of cytosine (top 
row) gives rise to uracil. 5-Methylcytosine can be either deaminated directly to thymine (middle row), 
or enzymatically converted in a stepwise manner to hydroxymethylcytosine, formylcytosine and 
carboxycytosine by TET dioxygenases. When opposite G in double-stranded DNA, T, fC and caC 
can be excised by thymine DNA glycosylase. 
Figure 1: Spontaneous hydrolytic deamination of cytosine (top row) gives rise to uracil. 5-
Methylcytosine can be either deaminated directly to thymine (middle row), or enzymatically 
co verted in stepwise manner to hydroxymethylcytosine, formylcytosine and carboxycytosine 
by TET dioxygenases. When opposite G in double-stranded DNA, T, fC and cC can be 
excised by TDG.     
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Another	 enzyme	 family	 shown	 to	 deaminate	 cytosines	 in	 DNA	 consists	 of	 the	 APOBEC1/AID	
deaminases.	Originally	described	 to	edit	RNA,	 they	were	 later	 shown	 to	also	modify	DNA	 [29,	 30].	
Activation-induced	cytidine	deaminase	(AID)	 is	used	by	the	cell	 to	deaminate	cytosines	to	uracils	 in	
the	 immunoglobulin	 locus	 in	activated	B-cells,	 to	facilitate	somatic	hypermutation	(SHM)	and	class-
switch	recombination	(CSR).		
Cellular	 repair	 pathways	 address	 all	 of	 the	 mentioned	 lesions,	 no	 matter	 whether	 they	 occurred	
spontaneously	as	damaging	events	or	whether	they	were	introduced	by	the	cellular	machinery.	With	
the	notable	exception	of	6-O-methylguanine,	which	is	converted	back	to	guanine	by	methylguanine	
methyltransferase	(MGMT)	by	a	process	referred	to	as	damage	reversal	[31],	the	above	modifications	
are	detoxified	by	base	excision	repair	(BER),	the	resulting	mismatches	by	mismatch	repair	(MMR),	in	
the	 best	 case	 before	 the	 damage	 is	 converted	 to	 single	 strand	 breaks	 (SSBs)	 or,	 even	 worse,	 to	
double	strand	breaks	(DSBs)	or	fixed	in	the	genome	as	mutations.	The	repair	pathways	involved	are	
discussed	in	more	detail	below.	
																	 	
Figure 4: Damage reversal by MGMT, restoring guanine from 6-O-methylguanine generated for 
example by the alkylating chemotherapeutic Temozolomide. 
	Base	Excision	Repair	
BER	removes	damaged	bases	arising	from	oxidation,	alkylation	and	deamination	and	can	also	act	on	
abasic	sites	resulting	from	non-enzymatic	hydrolysis,	as	mentioned	above.	Damage	on	bases	occurs	
very	 frequently,	 as	 it	 arises	 from	 spontaneous	 events	 caused	 by	 endogenous	 agents	 abundantly	
present	 in	 all	 cells.	 Most	 of	 these	 lesions	 cause	 severe	 problems	 when	 encountering	 replication,	
either	because	they	cause	mispairings	that	are	turned	into	mutations	during	replication	or	because	
they	block	the	replicative	polymerases.		A	highly-efficient	and	sensitive	process	is	therefore	required	
to	protect	the	genome	from	different	kinds	of	DNA	modifications.	Damage-specific	DNA	glycosylases	
scan	the	DNA	for	lesions	as	they	move	along	the	double	helix.	More	than	ten	different	glycosylases	
are	known	in	mammals,	each	recognizing	a	set	of	related	lesions.	The	first	one	discovered	was	uracil	
DNA	glycosylase	(UNG)	that	efficiently	excises	uracils	from	single-	and	double-stranded	DNA	[32-34].	
This	 lead	to	 the	discovery	of	many	other	damage-specific	glycosylases	 that	were	grouped	 into	 four	
structurally	 distinct	 superfamilies;	 the	 uracil	 DNA	 glycosylases	 (UDGs),	 the	 helix-hairpin-helix	
glycosylases	(HhH),	the	3-methyl-purine	glycosylases	and	the	endonuclease	VIII-like	glycosylases	[35].	
Although	the	glycosylases	differ	 in	 their	structure	and	substrate	specificities,	 they	share	a	common	
mode	of	action.	They	recognize	damaged	bases	by	flipping	them	out	of	the	helix	into	their	respective	
active	site	pockets	[36].	If	fitting	is	successful,	the	damaged	base	is	processed	further.	Despite	being	
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highly-specialized	 enzymes,	 many	 of	 the	 glycosylases	 have	 overlapping	 functions	 leading	 to	
redundancies,	as	indicated	by	the	mild	phenotypes	of	single	knockouts	of	the	different	glycosylases	
[37,	 38].	 The	 notable	 exception	 is	 thymine	 DNA	 glycosylase	 (TDG)	 that	 has	 been	 shown	 to	 be	
essential	for	embryonic	development	[39].	
The	minimal	BER	requires	a	monofunctional	DNA	glycosylase	or	a	bifunctional	DNA	glycosylase/lyase,	
an	 AP	 endonuclease,	 a	 DNA	 polymerase	 and	 a	 DNA	 ligase	 [38,	 40].	 First,	 the	 damaged	 base	 is	
recognized	and	removed	by	the	glycosylase,	leaving	behind	an	apurinic	or	apyrimidinic	(AP)	site,	or,	
in	 the	 case	 of	 a	 bifunctional	 glycosylase,	 a	 3'	 nicked	 AP	 site.	 The	 AP	 site	 is	 then	 processed	 by	 AP	
endonuclease	1	(APE1)	that	creates	a	single-stranded	DNA	nick	5'	to	the	AP	site	or	a	single	nucleotide	
gap	 when	 acting	 downstream	 from	 a	 glycosylase/lyase.	 Polymerase	 b	 then	 inserts	 the	 excised	
nucleotide.	 In	 the	 last	 step,	 the	 nick	 is	 sealed	 by	 XRCC1/ligaseIII	 [38].	 The	 basic	 repair	 pathway	 is	
shown	in	figure	5,	exemplified	on	UNG.	
The	 excised	 nucleotide	 can	 be	 replaced	 either	 by	 short-	 or	 long-patch	 base	 excision	 repair.	While	
short	 patch	 BER	 involves	 the	 replacement	 of	 a	 single	 nucleotide	 by	 polymerase	 b,	 followed	 by	
XRCC1/ligaseIII-dependent	ligation	of	the	nick,	long	patch	BER	is	slightly	more	complex	[41,	42].	It	has	
been	shown	to	additionally	depend	on	proliferating	cell	nuclear	antigen	(PCNA)	and	the	flap	structure	
specific	 endonuclease	 1	 (FEN1)	 [43,	 44],	 and	 involves	 the	 replacement	 of	 2-6	 nucleotides	 by	
polymerase	b,	 ε	 or	 δ,	 via	 a	 strand	displacement	mechanism.	 The	nicks	 in	 long-patch	base	excision	
repair	are	sealed	by	Ligase	I.	Due	to	the	additional	factors	required,	long-patch	BER	is	mainly	active	in	
proliferating	cells	[45-47].	
	
	 	
	
	
	
	
Figure 5: The basic base excision repair pathway exemplified on 
uracil DNA glycosylase. In a first step, the lesion, here a uracil, is 
recognized by the glycosylase. The base is excised, leaving behind an 
AP site that is addressed by an AP endonuclease, nicking the AP 
site 5'. Polymerase b inserts the missing nucleotide and removes the 
deoxyribose 5-phosphate using its lyase activity. Ligase III seals the 
nick. Taken from Robertson et al., 2009 [38]. 
	 ! 	
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Uracil	DNA	glycosylase	superfamily	
The	UDGs	are	a	big	family	of	glycosylases	consisting	of	six	subfamilies,	three	of	which	are	present	in	
eukaryotes;	 the	 UNG	 subfamily,	 the	 mismatch-specific	 uracil	 DNA	 glycosylases	 (MUGs)	 and	 the	
single-strand-specific	 monofunctional	 uracil	 DNA	 glycosylases	 (SMUGs)	 [35,	 48].	 There	 are	 four	
mammalian	 uracil	 DNA	 glycosylases;	 UNG,	 SMUG1,	methyl	 domain	 binding	 protein	 4	 (MDB4)	 and	
TDG	that	diverge	considerably	 in	their	amino-acid	sequence,	but	show	similarity	 in	the	structure	of	
their	catalytic	domains	[49,	50].	They	all	excise	deaminated	Cs	and	incorporated	Us	from	DNA	[20].	
	
Uracil	DNA	glycosylase	
UNG	efficiently	excises	uracils	 in	double-	as	well	as	single-stranded	DNA	and	acts	 independently	of	
the	 base	 opposite	 the	 uracil	 [33].	 UNG	 has	 an	 exceptionally	 high	 turnover	 rate	 of	 up	 to	 1000	 U	
excised	 per	 minute	 [51].	 It	 possesses	 a	 very	 narrow	 catalytic	 cavity	 that	 provides	 high	 specificity	
towards	 uracils	 and	 the	 chemotherapeutic	 uracil	 analog	 5-fluorouracil	 [52,	 53].	 Highly	 conserved	
amino-acid	residues	in	the	active	pocket	ensure	this	specificity.	The	N-glycosidic	bond	of	the	bound	
uracil	 is	polarized	by	a	conserved	histidine	and	thus	marked	for	nucleophillic	attack.	 In	addition,	an	
aspartate	deprotonates	a	water	molecule	that	then	attacks	the	deoxyribose,	leading	to	the	hydrolysis	
of	the	N-glycosidic	bond	[54].	Steric	hindrance	prevents	purines	from	entering	the	active	site	pocket	
and	the	side	chain	of	a	 tyrosine	residue	blocks	 the	entry	of	 thymine.	Cytosine	can	enter	 the	active	
site,	but	is	not	processed	further	due	to	unfavorable	positioning	[55].	
There	are	two	UNG	isoforms	in	mammals,	the	mitochondrial	form	UNG1	and	the	nuclear	form	UNG2,	
arising	from	alternative	splicing	 [56].	UNG1	 is	highly	expressed	 in	mitochondria-rich	tissues	 like	the	
heart	or	 skeletal	muscle	 [57].	Considering	 that	most	ROS	arise	during	mitochondrial	metabolism,	 it	
makes	sense	for	the	cell	 to	have	a	specialized	glycosylase	 in	mitochondria.	The	nuclear	 form	UNG2	
has	been	more	extensively	studied.	Whereas	UNG1	is	ubiquitously	expressed,	UNG2	expression	is	cell	
cycle	regulated,	the	highest	levels	being	observed	in	late	G1/S.	It	has	additionally	been	shown	that	in	
B-cells,	UNG2	mRNA	 is	 only	 present	 after	 activation	 [58].	 The	differential	 expression	 levels	 can	be	
explained	 by	 the	 usage	 of	 two	 different	 promoters	 for	 the	 transcription	 of	 the	 two	 isoforms	 [57].	
Consistent	with	its	high	expression	in	S	phase,	UNG2	has	been	shown	to	bind	to	PCNA	and	partly	co-
localizes	with	replication	foci	[59].	Besides	being	the	predominant	glycosylase	to	repair	U/A	mispairs	
arising	during	replication,	UNG2	is	also	the	major	repair	enzyme	addressing	U/G	mismatches	arising	
through	deamination	of	cytosines	[33,	60].	Moreover,	knockout	studies	have	revealed	a	role	of	UNG2	
in	the	adaptive	immune	response	of	B-cells.	
UNG-deficient	mice	are	viable	and	show	only	a	slight	 increase	 in	mutation	frequency	[61],	but	they	
are	susceptible	to	developing	B-cell	lymphomas	[62],	hinting	towards	an	important	role	of	UNG	in	B-
cell	 development.	 An	 altered	mutational	 pattern	 in	 somatic	 hypermutation	 (SHM)	was	 found.	 The	
ratio	 of	 nucleotide	 transition	 versus	 transversion	 at	 C/G	 sites	 was	 shifted	 significantly	 towards	
transition	 in	 the	absence	of	UNG,	whereas	 the	 ratio	at	A/T	sites	was	unchanged.	This	 is	 consistent	
with	the	fact	that	unrepaired	uracils	lead	to	transitions	from	C/G	to	T/A,	whereas	replication	through	
UNG-generated	 abasic	 sites	 yields	 more	 transversions	 [63].	 Rada	 et	 al.	 also	 observed	 an	
accumulation	of	IgM	in	Ung-/-	mice,	hinting	towards	a	defect	in	CSR.	Consequently,	in	vitro	activated	
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B-cells	deficient	of	UNG	showed	drastic	 reduction	 in	CSR	 [64].	Humans	with	mutations	 in	 the	UNG	
gene	 display	 the	 Hyper-IgM-syndrome	 (HIGM),	 characterized	 by	 increased	 serum	 IgM	 levels	
combined	 with	 low	 or	 absent	 serum	 IgG,	 IgA	 and	 IgE	 [58,	 65].	 HIGM	 is	 additionally	 linked	 to	
mutations	 in	 activation-induced	 cytidine	 deaminase	 [66],	 different	 cluster	 of	 differentiation	 (CD)	
genes	[67]	and	mismatch	repair	proteins.		
Both	SHM	and	CSR	are	 initiated	by	AID	that	 locus-specifically	deaminates	cytosines	 to	uracils.	UNG	
and	MMR	proteins	 seem	 to	be	 the	main	 repair	 factors	 involved	 in	 the	processing	of	 these	uracils.	
How	 the	 interplay	 of	 these	 two	 repair	 pathway	 leads	 to	 extensive	 mutagenesis	 and	 genomic	
rearrangements	is	still	not	well	understood	and	is	the	focus	of	the	first	part	of	this	thesis.	
	
Thymine	DNA	glycosylase	
The	 correction	 of	 G/T	mismatches	 arising	 from	 deamination	 of	 5mC	 in	 the	 CpG	 context	 has	 been	
debated	[68-71].	Although	the	repair	seems	to	be	inefficient,	depicted	by	a	loss	of	CpG	dinucleotides	
in	evolution,	 it	was	clear	that	there	had	to	be	a	way	to	faithfully	repair	G/T	to	G/C.	Repair	activity,	
directed	 towards	 a	 bona	 fide	 deoxyribonucleotide	 uncoupled	 from	 replication	 however,	 demands	
careful	 regulation.	 A	 repair	 activity	 on	 G/T	 mismatches	 has	 first	 been	 described	 in	 simian	 cells	
transfected	 with	 SV40	 bearing	 mismatches.	 A	 bias	 of	 G/T	 repair	 was	 found,	 favoring	 correction	
towards	G/C	by	90% [72].	Further	investigations	with	HeLa	nuclear	extracts	showed	a	similar	bias	and	
provided	evidence	for	a	glycosylase-mediated	repair,	involving	the	formation	of	abasic	sites	[73,	74].	
The	enzyme	responsible	was	subsequently	purified	from	HeLa	extracts	and	found	to	be	thymine	DNA	
glycosylase	 [75].	 TDG	 also	 catalyzes	 the	 removal	 of	 uracil	 in	 G/U	mismatches,	 supporting	 UNG	 in	
protecting	 the	DNA	 from	accumulating	 uracils	 [76,	 77].	Other	 than	UNG,	 TDG	 is	mismatch-specific	
and	therefore	does	not	address	A/U	pairs	arising	from	wrongly	incorporated	uracils,	but	only	uracils	
in	 the	G/U	 context,	 resulting	 from	deaminated	 cytosines.	 Its	mismatch	 specificity	 also	 implies	 that	
TDG	only	 acts	on	dsDNA,	 in	 contrast	 to	UNG	 that	processes	 also	 ssDNA	 substrates.	 The	enzymatic	
activities	of	UNG	and	TDG	can	be	readily	separated	by	the	use	of	UGI,	an	inhibitory	peptide	specific	
for	 UNG	 [78].	 Despite	 their	 overlapping	 substrate	 specificities,	 TDG	 was	 assigned	 into	 a	 new	
subfamily	of	UDGs,	the	MUGs.	
Unlike	UNG,	MUGs	have	 spacious,	 rather	non-discriminating	active	 site	pocket,	 allowing	a	broader	
range	 of	 substrates.	 TDG	 is	 able	 to	 excise	 a	wide	 variety	 of	modified	 and	 damaged	 bases	 (Fig.	 6),	
among	many	others	5-bromo-	and	5-formyluracil,	 as	well	 as	hypoxanthine	and	 thymine	glycol	 [79-
81].	TDG	uses	its	N-terminus	to	make	a	non-specific	contact	with	the	DNA,	scanning	for	non-Watson-
Crick	base	pairing,	therefore	involving	the	opposite	base	in	lesion	recognition.	Upon	encountering	a	
mismatch,	the	N-terminus	clamp	structure	flips	the	base	to	be	removed	out	of	the	double	helix	and	
stabilizes	 the	 G	 in	 the	 opposite	 strand	 [82-84].	 An	 asparagine	 (Asn	 140	 in	 humans)	 acts	 as	 the	
catalytic	 residue,	 coordinating	 the	 nucleophilic	 attack	 on	 the	 N-glycosidic	 bond.	 TDG	 stays	 firmly	
bound	to	the	resulting	abasic	site,	translating	in	a	low	turnover	rate	[85].	TDG	dissociates	only	upon	
modification	with	small	ubiquitin-like	modifier	(SUMO)	on	its	C-terminus,	leading	to	a	conformational	
change	that	relaxes	the	binding	of	the	N-terminal	clamp	to	DNA	[86,	87].	
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Figure 6: TDG substrate spectrum. 
	
TDG	displays	 an	 opposite	 regulation	 to	UNG2	during	 cell	 cycle,	with	 the	 highest	 expression	 in	G1-
phase	and	the	lowest	in	S-phase	[88].	Considering	its	activity	towards	thymine	in	G/T	mismatches	the	
importance	of	its	absence	during	S-phase	is	obvious.	It	is	not	able	to	distinguish	which	nucleotide	has	
been	wrongly	incorporated	during	replication	in	a	G/T	mismatch.	It	was	found	that	TDG	is	specifically	
degraded	 during	 S-phase	 through	 a	 conserved	 PCNA-interacting	 peptide	 (PIP)-degron	 [89],	 first	
described	 in	 chromatin	 licensing	 and	 DNA	 replication	 factor	 1	 (CDT1).	 CDT1	 and	 other	 degron-
containing	proteins	are	marked	for	degradation	by	the	E3	ubiquitin	 ligase	CRL4Cdt2	upon	interaction	
with	PCNA.	This	depicts	an	efficient	way	to	couple	DNA	synthesis	and	proteolysis,	thereby	preventing	
re-replication	 [90,	 91]	or	 in	 the	 case	of	 TDG,	 erroneous	 repair	 of	G/T	mismatches	 arising	 from	Gs,	
incorporated	opposite	Ts.	
Aside	from	its	important	role	in	DNA	repair,	TDG	has	been	repeatedly	linked	to	gene	regulation	and	
DNA	demethylation	 [92,	 93],	 especially	 since	 the	discovery	of	 the	TET	proteins	 and	 their	oxidation	
activity	towards	5mC.	TDG	displayed	glycosylase	activity	towards	the	TET	products	5fC	and	5caC	[27,	
94-97].	 Interestingly,	 TDG	 is	 the	 only	 glycosylase	 with	 a	 lethal	 phenotype	 in	 KO	 mice	 that	 is	
dependent	on	its	catalytic	activity,	but	not	linked	to	canonical	base	damage.	This	affirms	an	essential	
role	 of	 TDG	 aside	 from	 its	 known	 DNA	 repair	 activity	 [39,	 98].	 The	 involvement	 of	 TDG	 in	
transcriptional	regulation	and	DNA	demethylation	will	be	discussed	below.	
	
Methyl-CpG	binding	domain	protein	4	
Although	structurally	distinct	from	the	UDG	family,	the	HhH	gylcosylase	methyl-CpG	binding	domain	
protein	4	(MBD4)	 is	mentioned	here	briefly,	due	to	 its	overlapping	substrate	specificities	with	UNG	
and	TDG	and	to	its	role	in	methylation	dynamics.	
MBD4	was	discovered	 in	a	database	 search	 for	proteins	with	a	methyl-CpG-binding	domain	 (MBD)	
resembling	MeCP1	 (=MBD1)	and	2,	 together	with	MBD2	and	3	 [99].	All	 of	 the	mentioned	proteins	
bind	methylated	DNA.	MBD1,	MBD2	and	MBD4	proteins	 specifically	bind	methylated	DNA	 in	 vitro,	
NH
N
O
O
N
N
NH2
O
NH
N
O
O
N
N
NH2
O
H3C
H3C NH
N
O
O
Br
NH
N
O
O
C
O
H
HO
NH
N
O
O
HO
N
N
NH2
O
O
HN
N
NH2
O
O
HON
N
NH2
O
HO
NH
NN
N
O
N
N
N
O
NH
N
O
O
HO
H
H3C
HO
T (5-methyl-U) 5-bromo-U 5-formyl-U 5-hydroxy-U 5-hydroxymethyl-U
5-carboxy-C 5-formyl-C
hypoxanthine
thymine glycol 5-methyl-C
cytosine (C)
5-hydroxy-C3,N4-etheno-C
hTDG substrates not substrates
																																																																																																																																																																																																												INTRODUCTION	
	
	_______________________________________________________________________________________________________________________________________	21	
preferably	 double-stranded,	 symmetrically	 methylated	 DNA.	 Reduced	 binding	 of	 MBD4	 to	
hemimethylated	 oligonucleotides	 was	 observed.	 The	 binding	 of	 MBD3	 to	 methylated	
oligonucleotides	was	shown	to	be	unspecific.	MBD3	was	found	to	lack	a	functional	MBD,	but	it	is	an	
important	 component	 of	 the	 nucleosome	 remodeling	 and	 deacetylase	 (NuRD)	 repressor	 complex	
[100,	101].	MBD1	binds	methylated	DNA	in	cells,	but	it	was	shown	to	bind	the	same	regions	in	DNMT	
KO	cells,	indicating	nonspecific	binding	in	vivo.	The	murine	Mbd	genes	were	expressed	in	all	somatic	
tissues	tested	and	all	members,	except	MBD1,	were	present	in	embryonic	stem	cells	(ESC).	
MBD4	is	the	only	known	MBD	protein	that	possesses	another	functional	domain	at	the	C-terminus,	in	
addition	 to	 the	 N-terminal	 MBD.	 This	 C-terminal	 domain	 was	 described	 to	 be	 homologous	 to	
bacterial	 DNA	 repair	 enzymes,	 linking	 DNA	 repair	 and	 methylation	 [99].	 Subsequently	 MBD4	 was	
shown	to	efficiently	excise	thymine	and	uracil	from	mismatches,	similar	to	TDG.	Despite	the	similar	
substrate	specificities,	TDG	and	MBD4	show	no	amino-acid	sequence	homology,	 indicating	that	the	
proteins	 evolved	 from	 two	 different	 ancestors.	 MBD4	 shows	 preference	 for	 the	 binding	 of	
5mCpG/TpG	 mismatches.	 These	 mismatches	 are	 the	 main	 products	 of	 hydrolytic	 deamination	 of	
5mCpG,	hinting	towards	a	role	for	MBD4	in	minimizing	mutations	at	5mCpGs	[102].	
Consistent	with	the	fact	that	MBD4	is	endowed	with	5mC	binding-	and	glycosylase	activities,	there	is	
evidence	for	a	role	of	MBD4	in	DNA	demethylation	in	chicken	[103]	and	zebrafish	[104].	Interestingly,	
despite	its	obvious	connection	to	DNA	methylation,	MBD4	is,	unlike	TDG	and	MeCP2,	not	embryonic	
lethal.	Nevertheless,	analysis	of	MBD4-deficient	mice	revealed	elevated	levels	of	C	to	T	transitions	at	
CpG	sites	translating	into	increased	tumor	susceptibility	[105].		
	Mismatch	Repair	
MMR	 is	 a	 highly-conserved	 bidirectional	 process	 that	 repairs	 nucleotide	 incorporation	 errors	 and	
insertion-deletion	 loops	(IDLs)	occurring	during	DNA	replication.	MMR	improves	the	fidelity	of	DNA	
replication	 by	 several	 orders	 of	 magnitude	 [106].	 Cells	 deficient	 in	 MMR	 display	 greatly	 elevated	
mutation	rates	and	microsatellite	repeat	instability,	a	hallmark	of	MMR	deficient	cancers	(reviewed	
in	 [107]).	 Inherited	defects	 in	 the	MMR	system	underlie	 the	disease	hereditary	nonpolyposis	colon	
cancer	(HNPCC),	also	called	Lynch	Syndrome,	one	of	the	most	prevalent	cancer	syndromes	in	humans	
[108,	109].	
In	contrast	to	BER	and	other	repair	pathways,	the	substrate	for	MMR	is	undamaged	DNA	persisting	
only	 transiently	 in	 the	 DNA.	 In	 case	 the	 mismatches	 are	 not	 repaired	 before	 the	 next	 round	 of	
replication,	half	of	the	newly-synthesized	strands	will	acquire	a	mutation	that	is	no	longer	recognized	
as	a	lesion.	It	is	therefore	of	great	importance	that	MMR	acts	fast	and	that	it	is	directed	to	the	newly-
synthesized	 strand	 to	 avoid	 mutagenesis.	 Apart	 from	 correcting	 nucleotide	 incorporation	 errors,	
MMR	 also	 has	 an	 important	 role	 in	 the	 protection	 against	 oxidative	 stress	 [110]	 and	
chemotherapeutics	 [111].	 Moreover,	 it	 prevents	 aberrant	 recombination	 between	 non-identical	
sequences	during	meiotic	recombination	and	in	double-strand	break	repair	(DSBR),	as	indicated	by	a	
hyper-recombinogenic	 phenotype	 of	MMR-deficient	 cells	 [112,	 113].	 Operating	 as	 a	 lesion	 sensor,	
MMR	proteins	can	also	induce	apoptosis	and	activate	checkpoints	of	the	cell	cycle	[114].	Surprisingly,	
considering	its	important	function	to	ensure	error-free	replication,	a	non-canonical,	mutagenic	MMR	
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was	implicated	in	antibody	diversification	during	B	cell	development	[115,	116]	as	well	as	 in	kidney	
and	colon	cancer	cells	upon	encounter	with	DNA	lesions	[117,	118].		
	
Canonical	mismatch	repair	
Eukaryotic	 replicative	polymerases	display	an	error	 rate	of	about	10-4-10-5.	The	 fidelity	 is	enhanced	
about	 100-fold	 by	 the	 3'-exonuclease	 proofreading	 activity	 of	 the	 polymerases.	 MMR	 further	
increases	 replication	 fidelity	 by	 additional	 two	 to	 three	 orders	 of	 magnitude	 [106],	 resulting	 in	 a	
highly	 accurate	 process.	 IDLs,	 however,	 generated	 preferentially	 at	 repetitive	 microsatellite	
sequences,	 rely	 entirely	 on	MMR,	 as	 they	 are	 not	 recognized	 by	 the	 proofreading	 activity	 of	 the	
polymerases.	This	translates	 into	high	microsatellite	 instability	 in	the	absence	of	MMR,	the	primary	
phenotype	of	MMR-deficient	cells	[119,	120].	
MMR	 proteins	 are	 highly-conserved	 from	 bacteria	 to	 humans.	 They	 were	 first	 detected	 in	 E.	 coli	
[121],	 where	 the	 mechanism	 shows	 clear	 parallels	 to	 eukaryotic	 MMR,	 but	 also	 important	
differences.	The	first	human	MMR	protein	to	be	purified	was	MutSa.	 It	was	found	in	an	attempt	to	
identify	 enzymatic	 activity	 towards	 deaminated	 5mC	 in	 DNA	 [122,	 123].	 Later,	 a	 minimal	 MMR	
system	was	assembled	from	purified	human	proteins	[124].	
In	a	first	step	in	eukaryotic	MMR,	the	mismatch	or	small	IDL	is	recognized	by	MutSa,	a	heterodimer	
consisting	of	MSH6	and	MSH2.	The	main	substrates	are	1-nucleotide	IDLs	and	G/T	mismatches	[122].	
MutSß,	 consisting	 of	 MSH3	 and	 MSH2,	 recognizes	 larger	 IDLs.	 Upon	 mismatch	 binding,	 MutSa	
changes	 its	 conformation	 into	 a	 sliding-clamp,	 dependent	 on	 Mg2+-	 and	 ATP	 [125].	 MutSa	 then	
recruits	MutLa,	a	heterodimer	of	MLH1	and	PMS2	with	endonucleolytic	activity.	This	complex	then	
moves	along	the	DNA	in	search	of	a	strand-discrimination	signal.	This	step	is	essential	for	successful	
MMR	 and	 has	 long	 posed	 an	 enigma,	 as	 eukaryotes	 lack	 a	MutH	 homologue,	 responsible	 for	 the	
strand	 discrimination	 in	 bacteria.	 To	 date,	 the	 signals	 directing	 MMR	 to	 the	 nascent	 strand	 are	
believed	to	be	the	5'	and	3'	termini	of	Okazaki	fragments	and	the	3'	end	of	the	leading	strand	[126-
128].	 There	 is	 recent	 evidence	 that	 nicks	 resulting	 from	 processed	 ribonucleotides,	 uracils	 and	
oxidized	 bases	 in	 the	 DNA	 act	 as	 supportive	 strand-discrimination	 signals	 [118,	 129,	 130].	 These	
additional	signals	carry	a	 threat	however,	as	 they	may	direct	MMR	to	the	wrong	strand	 if	 they	are	
generated	 in	 the	 DNA	 rather	 than	 being	 mis-incorporated	 during	 replication.	 One	 well-studied	
example	 is	 6-O-methylguanine	 that	 arises	 from	 methylation	 of	 the	 DNA.	 Upon	 encounter	 with	
replication	before	being	 repaired	by	MGMT,	 this	 lesion	either	pairs	with	cytosine	or	 thymine.	Both	
base	pairs	are	addressed	by	MMR	that	 is	 targeted	to	 the	nascent	strand	harboring	 the	unmodified	
base.	This	leads	to	'futile'	cycling	of	MMR-directed	excision	and	resynthesis,	causing	cell	cycle	arrest	
and	apoptosis	([131-134]	and	appendix).		
As	a	next	step	 in	MMR,	the	endonuclease	subunit	PMS2	of	the	MutLa	complex	 is	activated	by	ATP	
and	 MutSa	 [135],	 further	 incising	 the	 nick-containing	 strand	 [136].	 As	 a	 last	 step,	 exonuclease	 1	
(EXO1)	 is	 loaded	 and	 degrades	 the	 strand	 5'	 to	 3'	 past	 the	 mismatch.	 Consistent	 with	 the	
directionality	of	EXO1	it	was	shown	that	MutLa	is	only	required	when	the	strand-discrimination	nick	
resides	3'	of	the	mismatch,	but	is	dispensable	when	the	initial	nick	is	5'	of	the	mismatch	[118,	124].	
The	resulting	single-stranded	gap	is	filled-in	by	polymerase	d	and	the	nick	is	sealed	by	ligase	I.	
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Non-canonical	mismatch	repair	
In	contrast	to	the	canonical,	post-replicative	MMR,	non-canonical	MMR	acts	 independently	of	DNA	
replication	and	therefore	does	not	discriminate	between	the	two	strands.	The	origin	of	substrates	for	
MMR	 acting	 outside	 of	 S-phase	 are,	 similar	 to	 BER,	 damaged	 or	 modified	 bases	 that	 cause	
mismatched	 structures.	 However,	 non-canonical	 MMR	 does	 not	 specifically	 excise	 the	 damaged	
base,	 but	 excises	 a	 long	 stretch	 of	 DNA	 on	 the	 strand	 it	 has	 been	 directed	 to	 by	 a	 nick	 in	 close	
proximity.	 It	 is	 therefore	 difficult	 to	 imagine	 a	 scenario	 where	 MMR	 outside	 of	 S-phase	 would	
efficiently	prevent	mutations.	Due	to	the	fact	that	high-fidelity	replicative	polymerases	able	to	fill	the	
gap	are	scarce	and	dNTP	pools	suboptimal,	 it	 is	 in	fact	much	more	 likely	that	MMR	is	mutagenic	 in	
this	context.		
Genetic	 studies	 implicated	 MMR,	 as	 well	 as	 monoubiquitylated	 PCNA	 (Ub-PCNA)	 and	 DNA	
polymerase	eta	 (pol	η),	 in	 the	mutagenic	processes	somatic	hypermutation	 (SHM)	and	class-switch	
recombination	 (CSR)	 during	 antibody	 diversification	 [137-143].	 This	 non-canonical	MMR,	 linked	 to	
PCNA	 monoubiquitylation	 was	 shown	 to	 be	 activated	 upon	 encounter	 with	 uracils	 or	 alkylation	
damage	 in	 B-cell	 extracts	 as	 well	 as	 in	 human	 embryonic	 kidney	 cells	 [117].	 Ub-PCNA	 led	 to	 the	
recruitment	of	pol	η,	as	shown	in	human	cells	[144].	
SHM	 and	 CSR	 are	 both	 initiated	 by	 activation-induced	 cytidine	 deaminase	 (AID),	 which	 converts	
cytidines	 in	 immunoglobulin	 loci	 to	 uracils	 [145,	 146].	 Those	 uracil-guanine	 mismatches	 are	
substrates	for	BER	and	MMR	and	both	seem	to	play	a	role	in	antibody	diversification,	as	deficiencies	
of	either	process	lead	to	impaired	SHM	and	CSR	[147].	The	involvement	of	an	error-prone	translesion	
polymerase	 in	 combination	 with	 MMR	 acting	 randomly	 on	 both	 DNA	 strands	 represents	 a	 nice	
system	 for	 introduction	 of	 somatic	 mutations	 [148-150].	 Consistent	 with	 this	 it	 was	 found	 that	
mutations	at	A:T	sites	depend	on	MMR	[138]	and	on	pol	η	[151].	However,	the	interplay	of	BER	and	
MMR	 in	CSR	remains	 largely	enigmatic,	as	mentioned	above.	 It	was	hypothesized	earlier	 that	DSBs	
could	be	created	by	the	collision	of	MMR	degradation	tracts	with	single-strand	breaks	(SSBs)	created	
by	BER	at	uracil	sites	[152].	This	hypothesis	will	be	discussed	in	detail	later.	
	Single	Strand	Break	Repair	
Spontaneous	 base	 loss	 (primarily	 depurination)	 or	 incomplete	 BER	 can	 give	 rise	 to	 single-strand	
breaks	 (SSBs).	 SSBs	 occur	 relatively	 frequently,	 but	 are	 usually	 repaired	 by	 a	 rapid	 and	 efficient	
process.	If	left	unrepaired,	they	are	recombinogenic	and	can	lead	to	the	formation	of	double	strand	
breaks	(DBSs).	The	basic	single-strand	break	repair	(SSBR)	pathway	can	be	defined	by	four	steps;	SSB	
detection,	DNA	end	processing,	DNA	gap	filling	and	DNA	ligation	[153].	
Detection	 of	 the	 lesion	 is	 carried	 out	 primarily	 by	 poly	 (ADP-ribose)	 polymerase-1	 (PARP1).	 Upon	
binding	to	DNA,	PARP1	activity	is	stimulated	and	catalyzes	the	generation	of	poly	(ADP)	ribose	chains	
on	 itself	and	other	acceptor	proteins	 in	close	proximity.	This	 first	 recognition	and	activation	step	 is	
fast	 and	 PARP1	 is	 recycled	 to	 its	 de-ribosylated	 state	 by	 poly	 (ADP-ribose)	 glycohydrolase	 (PARG)	
[154,	 155].	 The	 PARylation	 of	 accessory	 proteins	 then	 aids	 in	 recruiting	 further	 factors,	 like	 the	
scaffold	protein	XRCC1,	needed	 to	 complete	 the	 repair.	Depending	on	 its	origin	 the	 SSB	may	have	
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different	termini	that	require	different	accessory	repair	proteins	to	restore	conventional	3'-hydroxyl	
(3'-OH)	and	5'-phosphate	(5'-P)	moieties	needed	for	gap	filling	and	ligation	[153].	Most	ends	of	SSBs	
can	 be	 repaired	 by	 polynucleotide	 kinase/phosphatase	 (PNKP)	 and	 APE1,	 whereas	 termini	 arising	
from	 incomplete	 BER	 typically	 need	 the	 lyase	 activity	 of	 polymerase	 b	 and	 flap	 endonuclease-1	
(FEN1)	in	case	of	a	modified	5'-end	that	the	polymerase	cannot	remove	[156].	Another	type	of	lesion	
addressed	 by	 SSBR	 is	 the	 covalent	 attachment	 of	 topoisomerase	 1	 (Top1)	 to	 DNA.	 These	 lesions	
require	tyrosyl	DNA	phosphodiesterase	1	(TDP1)	to	remove	the	adduct	before	gap	filling	and	ligation	
can	take	place	[157].	
Once	the	termini	of	the	SSB	have	been	repaired,	gap	filling	is	carried	out	mainly	by	pol	β.	Similarly	to	
BER,	this	occurs	by	introducing	a	single	nucleotide	(short-patch)	or	multiple	nucleotides	(long-patch),	
depending	on	the	way	the	ends	were	processed.	Ligase	IIIα	or	ligase	I	seal	the	remaining	nick	in	the	
backbone.	
	Double	Strand	Break	Repair	
In	case	the	above-mentioned	repair	pathways	fail	to	complete	repair,	the	SSBs	will	be	converted	into	
DSBs	 when	 they	 encounter	 replication.	 DSBs	 are	 among	 the	 most	 dangerous	 lesions	 occurring	 in	
cells.	When	unrepaired,	they	can	lead	to	deletions,	translocations	and	chromosomal	fragmentation,	
likely	resulting	in	cell	death	or	tumor	formation	[158].	About	10	DSBs	occur	per	day	in	every	dividing	
human	cell	[159],	highlighting	the	need	for	faithful	repair	mechanisms.	Eukaryotic	cells	evolved	two	
major	 pathways	 to	 deal	 with	 these	 dangerous	 lesions;	 homologous	 recombination	 (HR)	 and	 non-
homologous	end-joining	(NHEJ).	 In	the	absence	of	 factors	needed	for	the	canonical	pathways	NHEJ	
and	HR,	 cells	 can	 choose	 alternative	 repair	mechanisms.	 Single-strand	annealing	 (SSA)	depends	on	
RAD52	and	involves	annealing	at	 long	homologies,	resulting	in	extensive	deletions.	Alternative	end-
joining	(Alt-EJ),	also	called	microhomology-mediated	end	 joining	(MMEJ),	 results	 in	either	deletions	
or	insertions	of	short	microhomologies	(FIg.	7).	
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Figure 7 DNA double strand break repair pathways. Depending on the nature of the break and the 
cell cycle phase, the cells repairs DNA DSBs via canonical NHEJ (A), or it resects the DNA at the 
breaks, channeling the repair into HR (B), SSA (C) or Alt-EJ (D). From [160]. 
	
Homologous	recombination		
HR	 is	essential	 for	highly-accurate	repair	of	DSBs.	 In	addition,	 it	has	a	role	 in	 inter-strand	cross-link	
repair,	supports	telomere	maintenance	and	is	involved	in	the	formation	and	resolution	of	cross-overs	
and	chromosome	segregation	in	meiosis.	
As	the	name	implies,	HR	relies	on	the	presence	of	an	intact	homologous	DNA	molecule	it	can	use	as	a	
template.	This	ensures	a	 faithful	and	error-free	correction	of	 the	 lesion,	but	 it	also	 largely	 restricts	
this	 repair	pathway	to	the	S	and	G2	phases,	where	a	homologous	sister	chromatid	 is	present	 [161,	
162].	Most	HR	genes	were	 identified	by	displaying	hypersensitivity	 towards	DNA-damaging	agents,	
such	as	ionizing	radiation,	when	mutated	[163,	164].		
Upon	DSB	detection	by	the	MRE11/RAD50/NBS1	(MRN)	complex,	histone	H2AX	is	phosphorylated	by	
ataxia	telangiectasia	mutated	(ATM),	or	ataxia	telangiectasia	and	Rad3-related	(ATR)	 in	response	to	
replication	 stress,	 generating	 histone	 γ-H2AX.	 This	 phosphorylation	 serves	 as	 a	 platform	 to	 recruit	
other	repair	proteins	[165].	It	is	followed	by	a	5'	to	3'	end-resection	of	the	broken	DNA	ends,	yielding	
3'	single-stranded	overhangs.	This	resection	step	is	critical	to	channel	repair	towards	HR,	as	opposed	
to	NHEJ	that	is	carried	out	without	extensive	end	resection.	Resected	DNA	ends	are	poor	substrates	
for	the	Ku	proteins,	 the	 initiating	enzymes	 in	NHEJ.	Cells	are	therefore	restricted	to	continue	along	
the	HR-	or	other	homology-mediated	repair	pathways,	such	as	SSA	or	Alt-EJ	[166].	
The	 3'	 single-stranded	 tail	 is	 first	 coated	 by	 replication	 protein	A	 (RPA),	which	 has	 been	 shown	 to	
have	 a	 positive	 as	well	 as	 an	 inhibitory	 effect	 on	HR.	 It	 helps	 to	 stabilize	 ssDNA	 generated	 during	
resection	[167],	but	then	suppresses	the	ATPase	and	recombinase	activities	of	RAD51	if	not	removed	
[168,	169].	Therefore,	RPA	is	replaced	by	RAD51	with	the	help	of	Breast	Cancer	type	2	susceptibility	
protein	 (BRCA2)	 in	 mammals,	 which	 interacts	 physically	 with	 RAD51	 [170,	 171].	 RAD51	 forms	 a	
nucleoprotein	filament,	consisting	of	about	six	molecules	per	18-19	bases	[172-174].	This	presynaptic	
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filament	captures	a	duplex	DNA	molecule	and	searches	for	homology,	followed	by	RAD51-dependent	
strand	invasion	to	form	a	D-loop	intermediate.	RAD51	assembly	and	homology	search	constitute	the	
rate	limiting	steps	of	HR	[174].	DNA	polymerases	extend	the	3'	end	of	the	invading	strand,	followed	
by	 disengagement	 of	 the	 two	 strands.	 This	 process,	 called	 synthesis-dependent	 strand	 annealing	
(SDSA),	 results	 in	 non-crossover	 products	 [175].	 Alternatively,	 double	 Holliday	 junctions	 can	 be	
formed	that	are	resolved	to	form	either	non-crossovers	or	crossovers.		
	
Non-Homologous	End	Joining	
In	contrast	to	HR,	NHEJ	has	no	need	for	a	homologous	template.	It	restores	the	integrity	of	the	DNA	
double-helix	 by	 directly	 re-joining	 the	 two	 ends.	 Due	 to	 its	 applicability	 throughout	 the	 cell	 cycle,	
NHEJ	is	the	more	common	pathway	of	choice	in	higher	eukaryotes,	even	though	it	is	error-prone	and	
can	result	 in	genomic	translocations.	 In	 fact,	most	of	 the	genomic	rearrangements	occurring	 in	our	
genome	and	eventually	causing	cancer	are	induced	by	NHEJ	[176].	Apart	from	fixing	pathogenic	DSBs,	
NHEJ	 is	 important	 for	 the	 processing	 of	 physiologically-induced	 DSB,	 for	 example	 during	 antibody	
diversification	[177].	Patients	lacking	NHEJ	do	not	only	show	sensitivity	to	ionizing	radiation,	but	they	
also	 suffer	 from	 a	 human	 severe	 combined	 immunodeficiency	 (SCID)	 [178,	 179].	 SCID	 is	 an	
autosomal-recessive	disease,	characterized	by	absence	of	circulating	T	and	B	lymphocytes,	indicating	
a	defect	in	V(D)J	recombination	[178,	179].	About	15%	of	SCID	cases	originate	from	defects	in	NHEJ,	
mostly	 in	 Artemis	 [180,	 181].	 CSR	 is	 also	 impaired	 in	 NHEJ-deficient	 cells,	 usually	 masked	 by	 the	
defect	in	V(D)J	recombination	[4].	
NHEJ	proteins	show	great	adaptability,	essential	for	the	repair	of	a	wide	range	of	DNA	end	structures.	
In	the	first	step,	the	proteins	Ku70	and	Ku80,	competing	with	MRN	for	DSBs,	form	a	heterodimer	and	
bind	 to	 free,	 unresected	DNA	 ends,	marked	 by	 γ-H2AX	 [182].	 The	 ends	 are	 thusly	 protected	 from	
degradation	and	the	Ku	proteins	act	as	a	recruiting	platform	for	Artemis	and	DNA-dependent	protein	
kinase	catalytic	subunit	(DNA-PKcs)	[183].	Artemis	has	a	nuclease	activity	and	its	recruitment	leads	to	
resection	 of	 the	 different	 DNA	 end	 configurations.	 The	 DNA-PKcs-Artemis	 complex	 has	 5'	 -and	 3-	
endonuclease,	 as	 well	 as	 hairpin	 opening	 and	 5'	 exonuclease	 activity	 [181,	 184].	 The	 short-range	
resection	of	 the	ends	 is	 followed	by	binding	of	DNA	polymerases	µ	or	l	 that	 repair	 the	ends.	 The	
polymerases	 may	 generate	 small	 deletions	 and	 insertions,	 introducing	 further	 inaccuracy.	
Subsequently,	 the	 XLF/XRCC4/DNA	 ligase	 IV	 complex	 is	 recruited,	 which	 is	 able	 to	 ligate	 also	
incompatible	 ends	 and	 gaps,	 endowing	 the	 process	 with	 high	 flexibility,	 but	 also	 inaccuracy.	
XRCC4/ligase	IV	has	in	fact	been	shown	to	be	the	only	complex	needed	for	repair	of	DSBs	in	case	the	
ends	share	perfect	homology	of	at	 least	4	nucleotides	[185,	186].	 In	case	the	classical	NHEJ	and	HR	
fail,	the	cell	can	switch	to	SSA	that	relies	on	long	homologies	or	an	alternative	end-joining	pathway	
that	relies	on	microhomologies.	
	
Alternative-	and	Microhomology-Mediated	End	Joining	
Alternative	end-joining	is	a	term	that	emerged	recently	to	summarize	the	various	sub-pathways	that	
deviate	in	some	aspects	from	the	classical	NHEJ	pathway.	Alt-EJ	includes	ligase	IV-independent	NHEJ,	
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Ku-independent	 NHEJ	 or	 DNA-PKcs-independent	 NHEJ	 [184].	 It	 is	 also	 frequently	 called	
microhomology-mediated	 end	 joining	 (MMEJ),	 as	 short	 homologous	 sequences	 are	 used	 to	 tether	
the	ends	together	in	most	of	these	sub-pathways.	It	is	discriminated	from	SSA,	which	involves	longer	
resection	 tracts	 and	 the	annealing	at	 long	homologies.	MMEJ	was	 first	described	 in	Ku80-deficient	
yeast	[187]	and	hamster	cells	[188].	Two	studies	in	budding	yeast	provided	further	evidence	for	a	Ku-
independent	repair	mechanism	[189,	190].	In	addition,	they	revealed	a	role	for	MRE11,	most	likely	by	
nucleolytic	processing	of	the	ends.	Involvement	of	Pol	h	and	z	in	the	pathway	was	also	postulated.	In	
fission	yeast,	 the	participation	of	EXO1	 in	nucleolytic	processing	was	shown	and	the	MMR	proteins	
PMS1	and	MSH2	were	attributed	a	role	in	resolving	mismatches	within	the	overlapping	homologous	
tracts,	therefore	counteracting	imperfect	microhomologies	[191].	
For	 ligation,	 the	 MMEJ	 mechanism	 seems	 to	 rely	 more	 on	 DNA	 ligase	 I	 or	 the	 XRCC1/ligase	 III	
complex,	 in	contrast	to	XRCC4/ligase	 IV	acting	 in	NHEJ	[192].	Altered	patterns	of	CSR	bearing	more	
microhomologies	were	observed	 in	human	patients	with	DNA	 ligase	 IV	mutations	 [193].	A	 role	 for	
poly(ADP-ribose)	polymerase-1	 (PARP-1)	was	moreover	postulated	 in	MMEJ	 [194,	195],	where	 it	 is	
believed	to	compete	with	Ku	for	the	binding	of	free	DNA	ends.	Indeed,	it	has	be	shown	that	PARP-1	
binds	DSBs	with	similar	or	even	higher	affinity	than	SSBs	[196,	197].	
	
ANTIBODY	MATURATION	AND	DIVERSIFICATION	
Our	 immune	 system	 is	 steadily	 challenged	 by	 a	 variety	 of	 constantly-evolving	 pathogens.	 The	 vast	
majority	of	 intruders	is	detained	by	the	innate	immune	system.	This	system	is	however	not	specific	
and	cannot	ensure	long-lasting	protective	immunity	to	the	host,	like	the	adaptive	immune	response	
does.	 The	 production	 of	 newly-recombined	 immunoglobulins	 (Igs)	 is	 therefore	 necessary	 for	 an	
efficient	host	defense.		
The	 main	 players	 in	 the	 adaptive	 immune	 system	 are	 T-	 and	 B-lymphocytes	 that	 recognize	 the	
infecting	 pathogens	 in	 a	 highly	 specific	 manner.	 They	 accomplish	 their	 task	 with	 the	 help	 of	
membrane	 receptors	 in	 the	 case	 of	 T-cells	 (cellular	 response)	 or	 with	 soluble	 antibodies	 called	
immunoglobulins	 (Igs)	 in	 the	case	of	B-cells	 (humoral	 response).	This	work	 is	 focused	on	B-cells,	as	
they	are	the	only	cells	making	use	of	SHM	and	CSR	to	increase	the	diversity	of	their	antibodies.	
Each	immunoglobulin	produced	by	B-cells	comprises	two	light	and	two	heavy	chains,	all	four	of	which	
have	a	variable	and	a	constant	 region	 (Fig.	8).	The	variable	 regions,	 containing	 the	antigen-binding	
sites,	 are	 generated	 by	 recombination	 of	 the	 variable	 (V)-,	 diversity	 (D)-	 and	 the	 joining	 (J)-region	
(V(D)J	recombination)	in	progenitor	lymphocytes	of	the	bone	marrow.	The	two	types	of	light	chains	
(λ	 and	κ)	harbor	 several	different	 variable	 regions	 in	 their	 genomic	 locus,	 4,	 respectively	5,	 joining	
regions	 and	 no	 diversity	 regions,	whereas	 the	 heavy	 chains	 are	 assembled	 from	 a	 choice	 of	many	
variable	regions,	6	joining	regions	and	25	diversity	regions.	In	the	case	of	the	heavy	chain,	a	DH	region	
is	 first	 joined	 to	 a	 JH,	 before	 a	 VH	 is	 juxtaposed	 to	 a	 DHJH	 segment.	 The	 recombination	 events	 are	
initiated	by	 the	recombination	activating	genes	1	and	2	 (RAG1	and	RAG2),	expressed	exclusively	 in	
early	 B-	 and	 T-progenitors.	 They	 introduce	 DSBs	 in	 conserved	 non-coding	 DNA	 segments	 located	
adjacent	to	the	coding	sequence	of	the	V,	D	and	J	segments.	The	DNA	breaks	are	rejoined	in	a	highly	
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orchestrated	manner,	involving	NHEJ,	as	mentioned	above.	(Reviewed	in	[198-200]).	
	 	
 
 
 
Figure 8: Structure of an antibody with two light and two 
heavy chains, each comprising a variable and a constant 
region. From [201]. 
	
The	choices	of	V,	D	and	 J	 segments	and	combinations	of	different	 light	and	heavy	chains,	 together	
with	small	 insertions	and	deletions	occurring	during	the	NHEJ-mediated	repair	of	 the	DSBs,	creates	
the	first	 layer	of	diversity.	The	antibodies	expressed	at	this	stage	do	not	yet	have	very	high	affinity	
towards	 antigens,	 but	 it	 is	 high	 enough	 for	 the	 immune	 system	 to	 flexibly	 interact	 with	 many	
different	antigens.	To	neutralize	 the	antigens,	however,	 very	high	affinity	 interactions	are	 required	
[202].	This	 is	achieved	by	SHM	and	CSR,	processes	 that	 follow	V(D)J	 recombination	 in	B-cells,	once	
they	leave	the	bone	marrow	and	migrate	to	peripheral	lymphoid	organs,	where	they	form	germinal	
centers	 ([5],	 FIg.	 9).	 Both	 of	 these	 processes	 are	 initiated	 by	 AID	 upon	 encounter	 with	 antigens.	
Different	mechanisms	of	resolving	the	AID-mediated	lesions	lead	to	very	distinct	outcomes.	
SHM	is	the	process	by	which	B-cells	introduce	point	mutations	into	the	variable	DNA	segments	of	the	
immunoglobulin	genes	to	produce	higher-affinity	Igs	[203].	Mutations	are	generated	at	a	rate	about	
106	 greater	 than	 the	 spontaneous	mutation	 rate	 in	 the	genome	 [204].	Apart	 from	AID,	 this	highly-
mutagenic	process	depends	on	BER	and	MMR,	as	discussed	above.	
CSR	enhances	the	efficiency	of	the	humoral	response	by	changing	the	Ig	isotype	from	IgM	(or	IgD)	to	
the	production	of	IgA,	IgE	and	IgG,	antibodies	with	different	biological	properties,	but	with	the	same	
antigen	specificity	[205].	The	isotype	of	an	Ig	is	defined	by	its	constant	region	and	defines	the	tissue	
distributions	and	effector	 functions	of	 the	antibody.	The	stimulus	provoked	by	the	antigen	dictates	
the	 type	 of	 antibody	 the	 cell	 switches	 to.	 Like	 V(D)J	 recombination,	 CSR	 involves	 the	 deliberate	
formation	of	DSBs.	The	mechanism	 in	CSR	 is	 less	precise,	but	accordingly	more	 flexible.	 It	 involves	
BER	 and	 MMR,	 similarly	 to	 SHM,	 but	 with	 a	 different	 outcome.	 Antibody	 diversification	 is	 an	
excellent	system	to	study	DNA	modification	upon	different	stimuli,	influenced	by	sequence	contexts,	
different	enzymatic	activities	and	interplay	between	repair	pathways.	
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Figure 9 Mechanisms of immunoglobulin diversification schematically represented on the mouse IgH 
locus. One segment of each variable (V), diversity (D) and joining (J) are combined in a process called 
V(D)J recombination. Subsequently, upon activation of the B-cell, AID initiates somatic 
hypermutation of the newly recombined variable region and class switch recombination of the heavy 
chain constant region. From [206]. 
	Activation-induced	Cytidine	Deaminase	
AID	plays	an	essential	 role	 in	adaptive	 immunity	by	 initiating	both	SHM	and	CSR.	 It	 is	a	member	of	
the	 AID/APOBEC	 family	 of	 Zn-dependent	 cytosine	 deaminase-related	 enzymes,	most	 of	 which	 are	
able	 to	 deaminate	 cytosine	 to	 uracil	 in	 RNA	 and	 in	 ssDNA.	 It	 was	 discovered	 in	 a	 cDNA	 screen	
comparing	uninduced	and	induced	lymphoma	cells	[146,	207].		
AID	was	found	to	act	solely	on	ssDNA	[208,	209],	a	fact	that	has	posed	a	challenge	due	to	its	role	in	
targeting	genomic	DNA	and	has	 lead	to	extensive	research.	 It	was	found	that	AID	is	directed	to	the	
target	 sequences	 by	 transcription,	 which	 generates	 transient	 ssDNA	 in	 the	 so-called	 transcription	
bubble	 [210,	 211].	 A	 direct	 interaction	 with	 replication	 protein	 A	 (RPA)	 has	 been	 found,	 possibly	
assisting	in	directing	AID	to	its	target	sequences	[212,	213].	AID	deaminates	cytosines	on	both	ssDNA	
strands	with	a	preference	for	WRC	(W,	A	or	T;	R,	purine;	C,	cytosine)	sequence	motifs	[214,	215].	Its	
cytidine	deaminase	motif	consists	of	two	cysteines	and	a	histidine	residue	for	zinc	coordination	and	a	
glutamic	acid	providing	the	proton	for	deamination	[206,	216].	AID	has	very	high	affinity	for	ssDNA,	
resulting	in	low	turnover	rates.	Another	consequence	of	tight	binding	to	DNA	is	the	long	time	period	
AID	resides	bound	to	DNA.	This	enhances	its	role	as	a	recruiting	platform,	giving	accessory	proteins	
time	to	process	the	deaminated	cytosines	[214,	217].	
Interestingly,	 mutational	 studies	 functionally	 uncoupled	 the	 roles	 of	 AID	 in	 SHM	 and	 CSR.	 It	 was	
shown	that	while	the	catalytic	function	is	essential	for	both	processes,	the	C-terminus	is	additionally	
required	 for	 CSR	 [218,	 219],	 whereas	 the	 N-terminus	 is	 necessary	 for	 SHM	 [220].	 These	 findings	
clearly	 indicate	 that	 the	 steps	 following	 cytosine	 deamination	 are	 critical	 for	 the	 outcome	 of	 the	
process	and	are	controlled,	at	least	partially,	by	AID.	
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Figure 10: AID functional domains showing the naturally occurring mutations in the AID gene that 
are responsible for the autosomal recessive disorder HIGM. These mutations, depending on the 
domain they affect, cause defects in CSR and/or SHM. From [221]. 
 
Loss	of	 function	mutations	 in	AID	abrogate	SHM	and	CSR,	 leading	to	the	HIGM	syndrome	[66,	146,	
222].	 Without	 AID,	 the	 cell	 is	 not	 able	 to	 change	 the	 isotype	 from	 IgM	 to	 another	 class	 of	
immunoglobulin	(Ig),	resulting	in	an	accumulation	of	IgMs	in	those	patients.	Together	with	the	non-
functional	SHM,	this	severely	impairs	the	humoral	immune	response,	leading	to	persistent	infections.	
On	the	other	hand,	AID	activity	can	have	severe	pathological	side	effects.	The	processes	initiated	by	
AID	can	lead	to	potentially	transforming	lesions	such	as	genomic	translocations	provoked	by	the	DSBs	
formed	 as	 CSR	 intermediates.	 Translocations	 involving	 the	 Ig	 locus,	 such	 as	 the	well	 characterized	
IgH-cMyc	 translocation,	were	 found	 	 to	be	a	hallmark	of	Burkitt's	 lymphoma	[223].	But	also	non-Ig	
genes	can	be	targets	of	aberrant	AID	activity	[224].	Elevated	levels	of	AID	were	linked	to	autoimmune	
diseases,	 for	 example	 [225].	 Interestingly,	 ubiquitous	 transgenic	 overexpression	 of	 AID	 has	 more	
severe	 effects	 on	 T-cells	 and	 other	 tissues	 than	 on	 B-cells,	 suggesting	 that	 B-cells	 have	 evolved	
protective	mechanisms	[226].		
The	sensitive	balance	of	AID	 levels	 in	B-cells	has	 likely	evolved	as	a	 trade-off	between	an	effective	
and	 highly	 adaptive	 immune	 response	 and	 the	 risk	 of	 cancer	 or	 autoimmune	 diseases	 [202].	 The	
regulation	 of	 AID	 is	 therefore	 essential	 and	 takes	 place	 on	 various	 levels.	 Apart	 from	 its	
transcriptional	regulation,	there	 is	complex	post-transcriptional	regulation.	The	AID	mRNA	is	bound	
by	two	miRNAs,	miR-155	[223]	and	miR-181b	[227],	negatively	regulating	AID	levels.	To	further	limit	
its	activity	on	DNA,	AID	is	kept	predominantly	cytoplasmic	(>90%),	where	it	is	very	stable.	After	being	
transported	 into	 the	nucleus	 [228-230],	AID	 is	 constantly	 targeted	 to	 the	proteasome.	 In	 addition,	
AID	 is	 regulated	 through	phosphorylation	on	 five	 residues	 that	 affects	 its	 localization	 and	 catalytic	
activity	[231-234].	
AID	is	a	B-cell	specific	enzyme	and	therefore	only	B-cells	and	not	T-cells	are	able	to	undergo	SHM	and	
CSR.	 Nevertheless,	 low	 levels	 of	 AID	 have	 been	 reported	 in	 the	 ovary,	 heart,	 prostate,	 lung	 and	
primordial	germ	cells,	where	the	function	of	AID	remains	unclear	[202].		
Apart	from	converting	cytosine	to	uracil,	AID	is	also	able	to	deaminate	5-methylcytosine	to	thymine,	
although	 with	 much	 lower	 efficiency	 [209,	 235,	 236].	 This	 finding	 led	 to	 the	 very	 controversial	
discussion	about	the	involvement	of	AID	in	DNA	demethylation	and	epigenetic	reprogramming	[237,	
238]	that	will	be	discussed	later.	
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	Class-Switch	Recombination	
In	order	to	switch	antibody	isoform	and	guarantee	an	efficient	immune	response	in	different	tissues,	
CSR	of	the	constant	heavy	chain	(CH)	region	takes	place.	Each	isotype	possesses	one,	or	in	the	case	of	
IgG	four,	constant	region;	Cμ	for	IgM,	Cd	for	IgD,	different	Cγ	for	IgG3,	1,	2a	and	2b,	Cɛ	for	IgE	and	Cα	
for	 IgA.	 IgD	 is	 produced	 through	alternative	 splicing	of	 the	 IgM	 transcript.	 Before	CSR	 takes	place,	
IgM	and	IgD	isoforms	are	produced.	Five	IgM	molecules	interact	to	form	pentamers	that	can	activate	
the	complement	system,	but	have	low	affinity	for	antigens.	They	are	secreted,	but	cannot	leave	the	
vessels	due	to	their	large	size.	The	switch	from	IgM/IgD	to	the	high	affinity	antibodies	is	enabled	by	
the	 joining	 of	 the	 chosen	 downstream	 CH	 region	 to	 the	 previously-assembled	 VDJ	 region,	 and	 the	
excision	of	the	intervening	DNA	fragment	(Fig	11).		
The	different	CH	regions	are	cytokine-inducible	transcription	units	each	consisting	of	a	promoter,	IH-
exons,	a	switch	(S)	region	important	for	the	mechanism	of	switching	and	CH-exons.	Specific	cytokine-
activated	transcription	factors	(TFs)	initiate	the	transcription	through	the	Sµ	(IgM)	and	the	respective	
downstream	 S	 region,	 producing	 non-coding	 germline	 transcripts.	 S	 regions	 are	 1-10	 kb	 long,	
repetitive	sequences	5'	of	every	CH	region,	except	for	Cd	(IgD)	[205].	S	regions	display	a	high	density	
of	the	AID	targeting	sequence	WRC.	Additionally,	they	consist	of	tandem	repeats	of	20-80	bp	G-rich	
sequences,	 resulting	 in	the	generation	of	ssDNA	R-loop	structures	that	are	more	easily	attacked	by	
AID	 [49,	 239].	 This	 contributes	 to	 an	 accumulation	 of	 uracils	 in	 the	 S	 regions,	 whose	 processing	
results	in	DSBs.	The	DNA	fragment	between	two	breaks	is	spliced	out	as	an	extrachromosomal	circle	
(Fig.	11).	The	exposed	CH	terminus	is	then	joined	to	the	VDJ	region,	preferentially	by	NHEJ,	but	if	need	
be	 also	 by	 the	 poorly-characterized	 alternative-NHEJ	 pathway	 that	 depends	 on	 microhomologies	
[240-242].	
After	successful	class	switching,	the	mono-	or	dimeric	IgE,	IgG	and	IgA	are	distributed	systemically	to	
tissues,	 where	 they	mediate	 different	 biological	 effector	 functions	 [243].	 The	 effectiveness	 of	 the	
humoral	 response	 is	 greatly	 increased	 after	 CSR,	 even	 though	 the	 antigen-binding	 sites	 of	 the	
antibodies	remain	unaltered.	
																																																																																																																																																																																																												INTRODUCTION	
	
	_______________________________________________________________________________________________________________________________________	32	
	 	
Figure 11: CSR from IgM- to IgA-expression. A promoter upstream of the VDJ region initiates 
transcription of the IgH locus yielding IgM (or IgD if alternativley spliced) antibodies before CSR 
had occurred. To enable CSR in activated B-cells, two DSBs have to be introduced with the help of 
AID; one in the very first S region (Cµ) and one in the specific S region the cell switches to (here Cα). 
The DNA in between is spliced out as a circular DNA fragment and the new immunoglobulin isotype 
can be transcribed. From [49]. 
 
The	factors	and	pathways	involved	in	CSR	are	well	defined,	being	AID	[66],	BER	with	UNG	[64,	244],	
MMR	 with	 MutSα	 [137,	 139,	 140,	 142],	 and	 to	 a	 lower	 extent	 MutLα	 [245],	 and	 NHEJ	 factors,	
although	 the	 latter	 are	not	 essential	 [4,	 246].	 Still,	 the	exact	mechanism	of	DSB	 induction	and	 the	
specificity	 towards	 S	 regions	 in	 B-cells	 remain	 enigmatic.	 The	 current	model	 postulates	 that	MMR	
helps	 create	DSBs	when	 the	uracils	 are	 less	dense,	by	EXO1-mediated	degradation	of	DNA	 regions	
between	 two	 BER-created	 nicks,	 resulting	 in	 a	 DSB	 [152,	 247].	 Although	 widely-accepted,	 this	
mechanism	has	never	been	characterized	biochemically.	With	the	present	study,	we	attempt	to	 fill	
this	gap	and	investigate	the	mechanism	of	DSB	induction	in	detail.	
	
EPIGENETICS	
Epigenetics	entails	a	variety	of	processes	that	modify	DNA	'in	addition'	(Greek:	epi-:	over,	above,	 in	
addition	 to,	 around)	 to	 the	 base	 sequence	 and	 chromatin	 structure,	 leading	 to	 transient	 or	 stable	
changes	in	gene	expression.		
In	addition	to	the	direct	modification	of	DNA	with	covalently-attached	methyl	groups	on	cytosines	(or	
adenines),	 also	 the	 building	 blocks	 of	 nucleosomes,	 the	 histones,	 can	 become	 altered	 by	 a	 large	
variety	 of	 post-translational	 modifications	 (PTMs).	 DNA-	 and	 histone	 modifications	 affect	 the	
structure	 of	 chromatin	 not	 only	 directly,	 but	 also	 indirectly,	 through	 bringing	 about	 alterations	 of	
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interactions	with	other	factors.	Which	of	these	processes	plays	the	primary	role	in	the	modulation	of	
gene	expression	has	been	the	subject	of	 intense	debate	during	the	past	several	decades.	Mounting	
evidence	 points	 towards	 a	 complex	 interplay	 that	 depends	 on	 the	 stimulus	 and	 the	 type	 and	
developmental	stage	of	the	cell.	
In	 eukaryotes,	 genomes	 are	 packaged	 into	 two	 main	 types	 of	 chromatin:	 the	 relaxed	 or	 "open"	
euchromatin	 and	 the	 densely-packed	 heterochromatin.	 The	 differences	 are	 established	 by	 a	
combination	of	DNA	methylation	and	the	type	and	modifications	of	the	associated	proteins.	Actively-
transcribed	 genes	 are	 generally	 located	 in	 euchromatic	 regions,	 whereas	 other	 genomic	 regions,	
containing	mostly	 inactive	 genes,	 are	 packed	 into	 heterochromatin.	 The	 latter	 can	 be	 divided	 into	
two	different	 types:	 facultative	 and	 constitutive.	An	example	of	 facultative	heterochromatin	 is	 the	
inactive	X-chromosome,	marked	extensively	with	histone	H3	trimethylated	on	lysine	27	(H3K27me3)	
and	 the	 Polycomb	 Repressor	 Complex	 (PRC),	 responsible	 for	 transcriptional	 silencing	 during	
development	 [248].	 Constitutive	 heterochromatin	 contains	 permanently-silenced	 genes.	 Examples	
are	chromatin	of	 the	centromeres	or	 telomeres	 that	are	characterized	by	high	abundance	of	H3K9	
trimethylation	 and	 binding	 of	 heterochromatin	 protein	 1	 (HP1)	 that	 recruit	 other	 chromatin	
remodeling	proteins	and	DNA	methyltransferases,	leading	to	DNA	compaction	[249].	
Increasing	 attention	 in	 the	 field	 of	 epigenetics	 is	 given	 to	 different	 kinds	 of	 RNAs	 that	 influence	
transcription,	among	others	long-noncoding	RNAs	and	micro	RNAs	(reviewed	in	[250-253]).	This	topic	
will	not	be	addressed	here.	
	Histone	modifications	
Eukaryotic	 DNA	 is	 organized	 and	 packed	 into	 nucleosomes,	which	 consist	 of	 five	main	 histones	 in	
eukaryotic	cells:	H1,	H2A,	H2B,	H3	and	H4	and	several	minor	specialized	histone	variants.		Two	H2A-
H2B	dimers	and	one	H3-H4	tetramer	form	the	nucleosome	core	that	is	stabilized	by	the	linker	histone	
H1	[254].	A	diverse	array	of	modifications	of	the	histones	controls	chromatin	organization.		
The	two	main	and	largely	opposing	histone	modifications	are	acetylation	and	methylation	of	lysines	
and	 arginines	 on	 the	 histone	 N-terminal	 tails.	 Acetylation	 of	 lysines	 has	 a	 positive	 effect	 on	 RNA	
synthesis	 [255]	 by	 largely	 neutralizing	 the	 positive	 charge	 of	 the	 histone,	 thereby	 weakening	 the	
interaction	 with	 the	 negatively-charged	 DNA.	 The	 resulting	 less-tightly	 packed	 chromatin	 is	 more	
accessible	 to	 the	 transcription	 machinery.	 Histone	 acetylation	 is	 regulated	 by	 histone	
acetyltransferases	(HATs)	and	deacetylases	(HDACs).	Acetylated	lysines	are	bound	by	bromodomains,	
often	found	in	chromatin-remodeling	complexes	that	function	to	open	the	chromatin	structure	[256].		
Methylation	 of	 histones	 is	 more	 complex,	 as	 there	 are	 different	 combinations	 of	 modifications.	
Lysines	for	example	can	be	mono-,	di-	or	tri-methylated	and	depending	on	the	histone	type	and	the	
site	modified,	methylation	can	lead	to	activation	or	repression	of	transcription.	Methylation	patterns	
on	histones	are	established	by	histone	methyltransferases	that	use	S-adenosyl	methionine	(SAM)	as	
the	methyl	group	donor	and	removed	by	histone	demethylases. Specialized	domains	of	chromatin-
associated	 factors	 can	 bind	 methylated	 lysines,	 among	 others	 zinc	 finger	 plant	 homeodomains	
(PHDs),	 chromodomains,	 PWWP	 (proline-tryptophan-tryptophan-proline)	 motifs,	 Tudor	 or	 MBT	
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(malignant	 brain	 tumor)	 domains	 [257].	 Some	methylation	marks	 on	 histone	 3	 that	 are	 especially	
important	for	gene	regulation	will	be	discussed	in	more	detail.	
A	histone	mark	strongly	linked	to	active	genes	is	H3K4	methylation.	Enhancers	responsible	for	active	
transcription	contain	high	levels	of	H3K4me1	[258],	whereas	transcriptional	start	sites	(TSS)	of	active	
genes	are	marked	by	enrichment	of	H3K4me3	[259,	260].		
H3K4me3	is	bound	by	tandem	chromodomains	within	chromodomain-helicase-DNA-binding	protein	
1	 (CHD1),	 an	 ATP-dependent	 remodeling	 enzyme	 capable	 of	 repositioning	 nucleosomes	 [261].	 In	
addition,	 H3K4me3	 prevents	 binding	 of	 the	 nucleosome	 remodeling	 and	 deacetylase	 (NuRD)	
repressor	 complex	 to	 the	 H3	 N-terminal	 tail	 [262].	 Both	 these	 interactions	 lead	 to	 chromatin	
opening.	H3K36me3	is	also	associated	with	active	chromatin,	but	it	is	highly	enriched	throughout	the	
entire	transcribed	region	[263].	
H3K27	methylation,	the	mark	of	facultative	heterochromatin	as	mentioned	above,	 is	established	by	
the	 PRC,	 specifically	 by	 the	 lysine	 methyltransferase	 EZH2,	 leading	 to	 compaction	 of	 chromatin	
during	development,	for	example	on	the	inactive	X	chromosome	[264].	
H3K9me3	is	bound	by	HP1	and	also	correlates	with	repressive	chromatin	environment.	HP1	binds	to	
H3K9me3	via	its	N-terminal	chromodomain	and	this	interaction	is	important	for	the	overall	structure	
of	heterochromatin	 [265,	266].	HP1	has	also	been	 shown	 to	 recruit	 the	DNA	methyltransferase	3B	
(DNMT3B),	thereby	linking	histone	and	DNA	methylation	[267].	DNA	methylation	in	contrast	can	also	
inhibit	 protein	 binding	 to	 specific	 histone	 modifications.	 An	 example	 is	 lysine	 demethylase	 2A	
(KDM2A)	 that	 is	 only	 able	 to	 bind	 nucleosomes	 bearing	H3K9me3	when	 the	DNA	 is	 unmethylated	
[268].	
The	 two	 methylation	 systems	 interact	 to	 form	 stable	 heterochromatic	 subdomains	 and	 thereby	
protect	genome	integrity.	
To	 make	 the	 story	 even	 more	 complex,	 histones	 can	 also	 be	 ADP	 ribosylated,	 phosphorylated,	
ubiquitylated,	 or	 SUMOylated,	 enabling	 the	 recruitment	 of	 a	 large	 variety	 of	 modulating	 proteins	
(reviewed	in	[269,	270]).	
	DNA	methylation	
The	 modification	 of	 adenines	 and	 cytosines	 with	 a	 covalently-attached	 methyl	 group	 can	 alter	
protein/DNA	 interactions.	 In	 bacteria,	 this	 forms	 the	 basis	 of	 restriction/modification	 systems;	 a	
primitive	 immune	system	 in	which	 invading	DNA	molecules	 (e.g.	phage	genomes)	are	degraded	by	
nucleases	that	cleave	unmethylated	DNA.	
This	 phenomenon	 was	 first	 reported	 by	 Werner	 Arber	 in	 the	 early	 1960s.	 He	 hypothesized	 that	
enzymes	 in	bacteria	 cut	 foreign	DNA	 into	pieces	at	defined	 sequences	and	 that	 this	 is	 impeded	by	
methylases	 of	 the	 host	 [271-277].	 Confirmation	 of	 this	 process	 came	 from	 Hamilton	 Smith,	 who	
discovered	 the	 endonuclease	 HindII	 in	 1969.	 He	 showed	 that	 cleavage	 depended	 on	 a	 specific	
sequence	 of	 6	 base	 pairs	 [278,	 279].	 Daniel	 Nathans	 then	 used	 Smith's	 and	 others'	 restriction	
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enzymes	 to	 create	 a	 map	 of	 simian	 virus	 40	 (SV40),	 by	 cutting	 it	 into	 defined	 pieces,	 applying	
restriction	 enzymes	 to	 genetics	 for	 the	 first	 time	 [280-285].	 The	 discovery	 of	 this	
restriction/modification	system	opened	a	whole	new	field	of	molecular	biology	and	helped	to	solve	
various	problems	in	genetics,	not	only	in	bacteria,	but	also	in	eukaryotes.	
Apart	from	host	protection,	methylation	in	bacteria	was	shown	to	have	another	important	purpose,	
namely	to	act	as	a	strand-discrimination	signal	in	MMR	[121,	286-289].	E.coli	strains	either	lacking	or	
overexpressing	 the	 Dam	 methylase	 responsible	 for	 post-replicative	 methylation	 of	 GATC	 motifs	
exhibit	a	hypermutator	phenotype	[288,	290-293],	similar	to	MMR	mutants	[294,	295].	
DNA	methylase	activity	 is	 also	present	 in	mammals	 [296,	297],	where	 it	 serves	different	purposes.	
While	the	main	modified	bases	in	bacteria	are	both,	6-methyladenine	and	5-methylcytosine,	only	the	
latter	plays	a	role	in	higher	eukaryotes.	In	plants	and	vertebrates,	DNA	methylation	of	cytosines	plays	
a	 key	 role	 in	 development	 through	 controlling	 gene	 expression.	 Physiological	 DNA	 methylation	
occurs	in	CpG,	CpHpH	or	CpHpG	(H	describes	a	non-guanine	residue)	sequence	context	in	plants	[298,	
299],	but	mainly	in	CpG	dinucleotides	in	vertebrates	[300].	This	work	will	focus	on	DNA	methylation	
in	vertebrates,	where	the	majority	of	CpGs	(70-90%)	are	methylated	[301].	
Nearest-neighbor	 sequencing	 studies	 revealed	 many	 years	 ago	 that	 the	 frequency	 of	 CpG	
dinucleotides	in	DNA	is	much	lower	than	expected	from	random	distribution	[302].	This	phenomenon	
was	 suggested	 to	 be	 linked	 to	DNA	methylation,	 as	 there	was	 a	 correlation	between	deficiency	 in	
CpGs	and	high	methylation	 levels	 in	different	 species.	An	explanation	came	 from	studies	 in	E.	 coli,	
where	 sites	 of	 cytosine	 methylation	 were	 shown	 to	 be	 hotspots	 of	 C	 to	 T	 transition	 mutations,	
believed	to	be	associated	with	spontaneous	deaminations	of	5mC	to	T	that	are	not	repaired	[303].	To	
confirm	 this	 phenomenon,	 TpG	 and	 CpA	 dinucleotide	 frequencies	 were	 assessed	 and	 found,	 as	
expected,	to	be	above	average	in	frequency	[304].	Several	groups	set	out	to	calculate	the	mutation	
rate	of	methylated	CpGs.	Depending	on	the	gene	investigated	and	the	exact	formula	applied,	values	
from	10	to	42	times	higher	mutation	rates	at	5mC	than	at	other	sites	were	found	[305-307].	Several	
intriguing	questions	arose	from	these	findings,	concerning	the	role	and	the	consequences	of	5mC	and	
its	mutability.	Are	there	repair	mechanisms	counteracting	the	high	mutation	frequency?	Might	this	
phenomenon	 be	 just	 a	 way	 to	 increase	 mutation	 rate	 beneficial	 for	 evolution?	 Or	 is	 there	 an	
important	function	of	5mC,	outweighing	the	disadvantage	of	high	mutability?		
In	an	attempt	to	identify	repair	pathways	acting	on	5mC	deamination	that	results	in	G:T	mismatches,	
the	MMR	 protein	MutSα	 [122,	 123]	 and	 the	 BER	 enzyme	 TDG	 [73,	 75]	 were	 found,	 as	 discussed	
above.	
A	role	of	5mC	mutability	in	evolution	seemed	unlikely,	because	it	brings	about	only	a	limited	number	
of	amino	acid	changes	and	would	gradually	lose	significance	through	the	progressive	loss	of	mutable	
sites.	The	notion	that	cytosine	methylation	played	an	important	biological	role	outside	of	evolution,	
counterbalancing	its	mutability,	gained	support	with	the	discovery	of	CpG	islands.	
Apart	 from	a	significant	underrepresentation	of	 the	CpG	dinucleotide,	an	asymmetrical	distribution	
of	CpGs	was	found	[308].	In	the	5'	region	of	many	genes	there	was	an	accumulation	of	CpGs.	Due	to	
this	 pattern,	 a	 role	 for	 5mC	 in	 gene	 expression	was	 postulated	 [309].	 A	 study	 in	 Chinese	 hamster	
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confirmed	this	hypothesis.	Two	housekeeping	genes,	possessing	dense	CpG	regions	at	the	5'	region,	
were	analyzed	using	methylation-sensitive	restriction	enzymes	and	found	to	be	unmethylated	at	the	
CpGs.	 In	 vitro	 methylation	 caused	 the	 silencing	 of	 the	 genes,	 directly	 linking	methylation	 to	 gene	
expression	 [310].	 Similar	 findings	 were	 obtained	 from	 a	 study	 on	 human	 gamma-globin	 gene	
expression	[311].	Further	evidence	for	the	inhibitory	effect	of	methylation	at	CpG-islands	came	from	
studies	 of	 the	 hypoxanthine	 phosphoribosyltransferase	 (HPRT)	 gene	 on	 the	 X	 chromosome.	 It	was	
found	to	be	inactive	when	methylated	and	could	be	induced	with	5-azacytidine,	a	cytosine	analogue	
whose	incorporation	into	DNA	leads	to	demethylation	[312-314]. 
In	 the	 following	 years,	 more	 examples	 of	 primarily	 housekeeping	 genes	 with	 unmethylated	 CpG	
islands	 in	 the	 5'	 region	were	 found	 [315,	 316].	 The	 generally	 unmethylated	 state	 of	 these	 regions	
explains	the	accumulation	of	CpGs,	as	unmethylated	cytosines	are	more	resistant	to	deamination	and	
if	still	deaminated,	extremely	efficiently	repaired	by	BER,	which	prevents	their	loss	from	DNA.	
Studies	on	 the	X	chromosome	[317]	and	on	 imprinted	genes	 [318,	319]	showed	however	 that	CpG	
islands	 are	 not	 inherently	 resistant	 to	 methylation.	 Moreover,	 many	 cancers	 exhibit	 CpG	
hypermethylation	 of	 tumor	 suppressor	 genes	 [320,	 321].	 One	 prominent	 example	 is	 aberrant	
methylation	 of	 the	 MLH1	 promoter,	 leading	 to	 inactivation	 of	 the	 gene	 and	 tumorigenesis	 in	
endometrium	and	colon	[322-325].	It	is	therefore	of	interest	to	investigate	the	mechanism	by	which	
CpG	 islands	 are	 selectively	 kept	 free	 of	methylation.	 Several	 hypotheses	 are	 under	 consideration.	
There	 is	 evidence	 that	 the	 de	 novo	 methylation	 capacity	 of	 adult	 tissues	 is	 very	 weak	 [326].	 This	
would	 guarantee	 the	 maintenance	 of	 unmethylated	 sites	 after	 methylation	 patterns	 have	 been	
established	 during	 development.	 Another	 idea	 is	 that	methylation	 is	 a	 secondary	 consequence	 of	
gene	inactivity.	As	long	as	a	gene	is	active,	its	CpG	island	might	be	bound	by	transcription	factors	or	
other	 accessory	 proteins,	 preventing	 access	 for	 methylases.	 There	 is	 accumulating	 evidence	 for	
proteins	 binding	 unmethylated	 CpG	 islands,	 therefore	 protecting	 them	 from	methylation	 or	 even	
constantly	 demethylating	 them.	 Accordingly,	 the	 TET1	 protein	 has	 been	 shown	 to	 localise	 to	 CpG	
islands	via	its	CXXC	domain	[327,	328]	and	depletion	of	TET1	resulted	in	increased	CpG	methylation	
[329].	In	addition,	experiments	in	TDG	knockout	mice	suggested	that	the	glycosylase	may	play	a	role	
in	 protecting	 CpG	 islands	 from	de	 novo	methylation	 [39,	 98].	 These	 pathways	will	 be	 discussed	 in	
more	detail	later.	
The	study	of	CpG	islands	received	a	great	deal	of	attention,	but	also	single	CpGs	have	been	linked	to	
gene	 silencing	 and	 shown	 to	 be	 modified	 dynamically.	 One	 example	 is	 the	 thymidine	 kinase	
promoter,	where	one	CpG	was	enough	to	significantly	downregulate	transcription	when	methylated	
[330].	In	this	thesis,	the	focus	lies	on	the	vitellogenin	system,	discussed	later,	where	methylation	of	
few	CpGs	impaired	transcription	[331,	332].	
	DNA	methylation	and	chromatin	structure	
The	effect	of	DNA	methylation	on	gene	expression	was	found	to	be	mediated	by	altered	DNA-protein	
interactions	 leading	 to	 changes	 in	 chromatin	 structure	 as	 mentioned	 already	 in	 'histone	
modifications'.	Studies	using	DNaseI	and	micrococcal	nuclease	 (MNase)	 showed	that	unmethylated	
DNA	 stretches	 assume	 a	 DNase	 I-sensitive	 conformation	 that	 was	 prevented	 by	 CpG	methylation,	
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rendering	 the	 sequence	 DNase	 I-insensitive.	 These	 findings	 led	 to	 the	 conclusion	 that	 DNA	
methylation	modifies	 specific,	as	well	as	nonspecific	 interactions	between	DNA	and	proteins	 [333].	
Support	for	these	findings	came	from	studies	of	an	upstream	region	of	the	tyrosine	aminotransferase	
(TAT)	 gene,	 where	methylation	 prevented	 specific	 factor	 binding	 in	 cells	 that	 do	 not	 express	 TAT	
[334].	 Another	 example	 is	 the	 methylation	 of	 the	 cAMP-responsive	 element	 that	 was	 shown	 to	
suffice	 to	 abolish	 transcriptional	 activation	 by	 inhibiting	 transcription	 factor	 binding	 [335].	 In	 the	
following	 years,	 many	 transcription	 factors	 were	 found	 to	 be	 prevented	 from	 binding	 DNA	 when	
their	 recognition	site	was	methylated	[336-341].	Specific	 transcription	 factor	binding	often	 initiates	
the	 changes	 in	 chromatin	 leading	 to	 the	 establishment	 of	 a	 transcription-friendly	 environment.	
Inhibiting	 their	 binding	 therefore	 prevents	 recruitment	 of	 chromatin	 remodelers,	 impeding	
transcription.	
The	discovery	of	a	group	of	proteins	binding	specifically	to	methylated	CpGs	added	another	layer	of	
complexity	to	the	control	of	chromatin	dynamics	by	DNA	methylation.	The	first	methyl-CpG	binding	
domain	 (MBD)	 protein	 discovered	was	MeCP1	 [342].	 It	was	 shown	 to	 bind	DNA	 stretches	with	 an	
accumulation	of	symmetrically-methylated	CpGs,	leading	to	inhibition	of	transcription	[343].	MeCP2,	
detected	shortly	thereafter,	displayed	similar	properties,	but	was	able	to	bind	a	single	5mCpG	pair	in	
vitro	 [344].	 In	 vivo	 it	 was	 shown	 to	 localize	 to	 centromeric	 heterochromatin	 in	 a	 methylation-
dependent	manner	[345].	It	has	an	important	role	in	embryonic	development,	but	was	dispensable	in	
embryonic	stem	cells	(ESCs)	[346].	MeCP2	binding	leads	to	repression	of	transcription	in	vitro	as	well	
as	 in	 vivo,	 displaying	 a	 direct	 correlation	 with	 the	 density	 of	 5mCpGs	 [347].	 Three	 additional	
members	of	 the	MBD	 family	were	 found	 in	a	database	 search	 for	proteins	with	an	MBD	similar	 to	
MeCP1	 and	 2,	 as	 mentioned	 earlier	 [99].	 MBD	 proteins	 recruit	 chromatin	 remodelers,	 histone	
deacetylases	and	DNA	methyltransferases,	leading	to	compaction	of	chromatin	[348,	349].	Deletions	
of	MBD1,	MBD2	and	MBD4	show	only	mild	developmental	phenotypes,	pointing	towards	redundant	
functions.	Mbd3-/-	mice	are	embryonic	lethal,	most	likely	due	to	the	important	role	of	MDB3	as	part	
of	the	NuRD	repressor	complex	[350,	351].	Mutations	of	MeCP2,	however,	are	mostly	lethal	in	males	
and	 cause	 Rett	 Syndrome,	 a	 neurological	 disorder,	 in	 females	 [352-354].	 Rett	 syndrome	 is	 not	 a	
neurodegenerative	disorder,	accordingly,	symptoms	have	been	successfully	reversed	in	mutant	mice	
by	re-expression	of	the	protein	[355].	
DNA	methylation	 acts	 through	 recruitment	 of	 a	 combination	 of	 unspecific	 and	 specific	 interacting	
proteins.	MBD	proteins	play	a	major	role	in	silencing	regions	with	a	high	density	of	methylated	CpGs,	
such	as	methylated	CpG	islands.	Cell	type-specific	genes,	however,	often	have	only	few	CpGs	in	their	
regulatory	 regions.	 In	 that	 case,	 specific	 transcription	 factor	binding	 seems	 to	be	 inhibited	by	DNA	
methylation.	These	events	often	occur	in	enhancers	instead	of	promoters,	complicating	the	analysis.	
	Chromatin	and	transcription	
The	 compaction	 of	 DNA	 into	 chromatin,	 guided	 by	 histone	 and	 DNA	 modifications	 as	 mentioned	
above,	 is	 necessary	 to	 fit	 the	 large	 DNA	molecule	 into	 the	 limited	 space	 of	 the	 nucleus.	 It	 brings	
about	a	 flexible	and	versatile	way	of	controlling	gene	expression,	but	also	a	number	of	challenges,	
due	to	limited	accessibility	of	the	DNA.	
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Gene	 expression	 is	 controlled	 primarily	 by	 regulatory	DNA	 elements	 and	 chromatin	 structure.	 The	
minimal	elements	defining	a	gene	on	DNA	are	a	promoter	 region,	containing	sequence	motifs	 that	
bind	transcription	factors	(TFs),	and	a	transcription	start	site	(TSS),	defined	by	these	sequence	motifs.	
Most	genes	have	additional	regulatory	elements,	called	enhancers,	often	distal	from	the	gene	itself.	
Promoters	can	be	broadly	divided	into	CpG-poor	and	CpG-rich,	the	latter	containing	CpG	islands,	as	
discussed	in	'DNA	methylation'.	Most,	if	not	all,	housekeeping	genes	are	associated	with	CpG	islands	
and	 therefore	 'open'	 chromatin,	 whereas	 only	 around	 half	 of	 tissue-specific	 genes	 display	 this	
feature.	 A	 ubiquitous	 TF	 that	 binds	 the	 consensus	 sequence	 GGGCGG	 (or	 CCGCCC),	 a	 sequence	
prominent	 in	 CpG	 islands,	 is	 Specificity	 Protein	 1	 (SP1).	 Most,	 but	 not	 all	 promoters	 additionally	
possess	a	TATA-box	~30	nt	upstream	of	the	TSS	that	is	bound	by	a	TATA-box	binding	(TBP)	protein.	
Transcription	factors	are	responsible	for	communicating	the	gene-specific	DNA	sequence	information	
to	 the	 transcription	 machinery.	 They	 consist	 of	 two	 main	 domains:	 a	 DNA	 binding	 domain	 that	
"reads"	 the	 binding	 site	 sequence,	 and	 a	 transactivation	 domain.	 The	 DNA	 binding	 domain	 can	
assume	 different	 forms.	 One	 group	 of	 TFs	 possesses	 helix-turn-helix	 motifs	 consisting	 of	 two	 α-
helices	connected	by	a	short	amino-acid	stretch.	The	C-terminal	helix	is	placed	in	the	major	groove	of	
the	DNA,	where	it	can	make	base-specific	contacts.	The	members	of	this	group	bind	DNA	as	dimers.	
Other	DNA	binding	proteins	contain	so-called	zinc	fingers,	domains	that	coordinate	one	or	more	zinc	
ion	 to	 stabilize	 their	 structure	 [356].	 Leucine	 zippers	 constitute	 a	 special	 case	 of	 DNA	 binding	
domains,	 as	 they	 mediate	 -	 in	 addition	 to	 DNA	 binding	 -	 also	 protein-protein	 interactions	 via	
extended	 contacts	 along	 their	 α-helices	 [357,	 358].	 A	 related	 DNA-binding	motif	 is	 the	 helix-loop-
helix	 (HLH)	 structure.	 It	 also	 mediates	 dimerization	 in	 addition	 to	 DNA	 binding.	 A	 HLH	 motif	 is	
composed	of	a	short	α-helix	connected	to	a	longer	one	via	a	flexible	loop	[359].		
The	 different	 TF	 motifs	 “read”	 specific	 nucleotide	 sequences,	 primarily	 through	 hydrophobic	
interactions	in	the	major	grove	of	DNA,	but	also	with	the	help	of	base-specific	interactions	defined	by	
combinations	 of	 hydrogen	 bond	 donor	 and	 acceptor	 sites.	 Some	 TF	 recognize	 their	 cognate	 DNA	
sequences	with	the	help	of	other	characteristics,	such	as	base-stacking	or	helical	twist.	Depending	on	
the	 flexibility	of	 the	DNA	stretch,	DNA	binding	proteins	can	cause	distortions	of	 the	helix,	enabling	
them	better	access.	Some	TFs	show	moreover	sensitivity	to	cytosine	methylation	in	their	recognition	
sites,	 as	 mentioned	 above,	 while	 other	 DNA	 binding	 factors,	 containing	 MDB	 domains,	 bind	
specifically	to	methylated	DNA	as	transcriptional	repressors	[360-363].	
The	 other	 domain	 defining	 a	 transcription	 factor	 can	 also	 assume	 different	 forms.	 Generally	
speaking,	 the	 activation	 domain	 mediates	 the	 effector	 function	 of	 the	 TF.	 This	 happens	 via	
interactions	with	other	proteins,	for	example	RNA	polymerase	II.	This	represents	the	most	direct	way	
of	activating	transcription.	Many	TF	also	act	via	chromatin	remodeling	interactors,	thereby	preparing	
the	 chromatin	 environment	 for	 gene	 expression.	 There	 are	 three	main	motifs	 characteristic	 of	 TF	
activation	domains:	acidic-,	 glutamine-rich-	and	proline-rich	motifs.	Acidic	activation	domains	were	
shown	 to	 assemble	 in	 an	 amphipathic	 helical	 structure,	 where	 one	 side	 contains	 the	 acidic,	
hydrophilic	 residues,	 whereas	 the	 other	 side	 is	 hydrophobic	 [364].	 Glutamine-rich	 domains	 have	
been	most	 extensively	 studied	 in	 SP1,	where	 they	mediate	 the	 interaction	with	 TBP,	 a	 subunit	 of	
TFIID	 [365-367].	 Regardless	 of	 whether	 the	 activation	 domain	 of	 a	 TF	 interacts	 with	 other	 TFs	 or	
directly	with	RNA	polymerase,	the	ultimate	goal	is	recruitment	of	the	latter	enzyme	to	the	TSS.	
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Eukaryotes	 possess	 three	 different	 nuclear	 RNA	 polymerases	 that	 are	 responsible	 for	 the	
transcription	of	distinct	 classes	of	 genes	 [368].	 The	most	 extensively-studied	 is	RNA	polymerase	 II,	
which	transcribes	all	protein-coding	genes	into	messenger	RNAs	(mRNAs)	and	a	variety	of	non-coding	
RNAs.	 RNA	 polymerase	 I	 is	 responsible	 for	 the	 synthesis	 of	 the	 long	 ribosomal	 RNAs	 (rRNAs)	 and	
polymerase	III	for	transcription	of	the	small	rRNA	and	transfer	RNAs	[369].	The	three	enzymes	consist	
of	several	subunits,	some	of	which	are	shared,	resulting	in	common	characteristics.	In	contrast	to	the	
prokaryotic	enzyme,	eukaryotic	RNA	polymerases	rely	on	TFs	for	the	 initiation	of	transcription.	The	
factors	that	are	absolutely	needed	to	enable	basic	transcriptional	activity	and	are	 involved	 in	every	
transcription	event,	are	called	general	TFs.	They	help	recruit	the	transcription	machinery,	consisting	
of	an	RNA	polymerase	and	chromatin	remodelers.	There	are	five	general	TFs	needed	for	transcription	
of	protein-coding	genes	by	 the	eukaryotic	RNA	polymerase	 II.	 The	 first	 step	 is	 the	binding	of	TFIID	
(containing	TBP)	to	the	TATA-box.	TBP	was	shown	to	have	a	relatively	broad	sequence	specificity	and	
binds	also	to	promoters	lacking	a	TATA-box.	TBP	then	binds	TFIIB	and	together	they	recruit	TFIIF	and	
RNA	polymerase	 II.	 Then,	 TFIIE	 and	H,	 important	 for	 initiation	of	 transcription,	 can	bind.	 TFIIH	 is	 a	
multi-subunit	 protein	 with	 several	 enzymatic	 activities.	 It	 comprises	 helicases	 to	 open	 DNA	 for	
transcription	 and	 a	 kinase	 that	 phosphorylates	 the	 C-terminal	 domain	 (CTD)	 of	 the	 largest	 RNA	
polymerase	 subunit	 [370].	 	 The	 CTD	 has	 many	 essential	 functions	 in	 transcription,	 not	 only	 in	
initiation,	 but	 also	 in	 elongation,	 processing	 of	mRNAs	 and	 in	 termination.	 It	 consists	 of	 up	 to	 52	
copies	 of	 the	 heptad	 repeat	 Tyr-Ser-Pro-Thr-Ser-Pro-Ser.	 Phosphorylation	 of	 CTD	 by	 the	 kinase	
subunit	of	TFIIH	helps	to	release	the	polymerase	from	the	transcription	initiation	complex,	enabling	it	
to	start	elongating	the	RNA.	A	complex	interplay	of	different	kinases	and	phosphatases	modifies	the	
CTD	 while	 it	 travels	 along	 the	 gene,	 enabling	 efficient	 transcription,	 as	 well	 as	 orchestrating	 5'-
capping,	splicing	and	3'-polyadenylation	[371].	
This	 complex	general	mechanism	of	gene	expression	 is	 further	modulated	and	 fine-tuned	by	many	
additional	 factors,	especially	 in	 the	case	of	 tissue-specific	genes,	but	also	 in	ubiquitously	expressed	
housekeeping	genes.	
To	account	for	the	different	tissue-	and	developmental	stage-specific	expression	patterns	in	the	cells	
of	 higher	 eukaryotes,	 a	 wide	 array	 of	 additional	 TFs	 is	 needed.	 Gene-specific	 transcriptional	
regulation	 is	 generally	 governed	 by	 the	 binding	 of	 transcriptional	 activators	 or	 repressors	 to	
upstream	regulatory	sequences,	the	so-called	enhancers.	They	recruit	chromatin-modifying	enzymes,	
preparing	a	transcription-permissive	environment	for	the	general	TFs	and	the	RNA	polymerase	[372].	
Often,	 these	 tissue-specific	 transcription	 factors	 react	 to	 intra-	 or	 extracellular	 stimuli,	 such	 as	
cellular	metabolites,	 interleukins	or	hormones.	They	are	thereby	able	to	merge	a	variety	of	signals,	
translating	 them	 into	 cell	 type-specific	 gene	 expression.	 Hormone-dependent	 transcription	 factors	
belonging	to	the	superfamily	of	nuclear	receptors,	will	be	discussed	in	more	detail	below.	
	DNA	methyltransferases	
DNA	methyltransferases	 (DNMTs)	 are	 a	 highly	 conserved	 family	 of	 proteins.	 In	 jawed	 vertebrates,	
there	 are	 three	major	 DNMTs	 displaying	 robust	methyltransferase	 activity:	 DNMT1,	 DNMT3A	 and	
DNMT3B.	DNMT2	has	only	weak	enzymatic	activity	and	is	not	well	described	[373].	Another	member	
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of	 the	 family,	DNMT3L	 [374],	 has	 no	 enzymatic	 activity,	 but	was	 shown	 to	 increase	 activity	 of	 the	
other	DNMT3s	[375,	376].	
The	C-terminal	catalytic	domain	of	the	DNMTs	consists	of	10	conserved	amino	acids	forming	a	prolyl-
cysteinyl	 active	 site	 that	 catalyzes	 the	 attachment	 of	 a	methyl	 group	 to	 the	 5-position	 of	 cytosine	
through	 a	 complex	 process	 first	 described	 in	 bacterial	 homologs	 of	 the	 DNMTs	 [377-379].	 A	
conserved	cysteine	residue	 initiates	the	reaction	by	attacking	the	carbon	at	the	6-position,	 forming	
an	covalent	 intermediate	between	 the	cytosine	and	 the	enzyme	 (Fig	12).	 This	produces	a	negative	
charge	 at	 position	 5	 and	 activates	 the	 usually	 inert	 carbon	 that	 can	 now	 interact	with	 the	methyl	
donor	 S-adenosyl	methionine	 (SAM).	 The	product,	 S-adenosyl-homocysteine	 (SAH),	 is	 released	and	
the	 proton	 at	 position	 5	 removed	 by	 a	 basic	 amino	 acid	 on	 the	 enzyme.	 A	 β-elimination	 step	
completes	the	reaction,	releasing	an	active	enzyme	and	5mC	that	returns	into	the	double	helix	[380-
382].	
The	demethylating	agent	5-aza-deoxycytidine	 (5-AzaC)	 is	a	cytosine	analog	that	bears	a	nitrogen	at	
position	5,	instead	of	a	carbon.	This	leads	to	the	formation	of	a	covalent	bond	with	the	enzyme	that	
cannot	be	β	-eliminated	[377,	378],	thereby	trapping	the	DNMT	on	the	DNA.	
	
Figure 12 Mechanism of cytosine methylation in DNA, catalyzed by DNA methyltransferases. 
	
The	first	mammalian	relative	of	bacterial	restriction	methyltransferases,	DNMT1,	was	cloned	in	1988	
[383].	 It	 was	 shown	 to	 have	 5-	 to	 30-fold	 preference	 for	 hemimethylated	 substrates,	 strongly	
implicating	 it	 in	maintenance	of	methylation	during	DNA	replication	 [384].	 It	 shares	 the	C-terminal	
catalytic	domain	with	DNMT3A	and	B,	but	has	an	additional,	large	N-terminal	domain,	implicated	in	
regulation	and	 targeting.	 The	 interaction	with	Ubiquitin	 Like	With	PHD	And	Ring	Finger	Domains	1	
(UHRF1,	also	nuclear	protein	95)	mediates	the	selectivity	for	hemimethylated	site	recognition,	via	the	
SRA	(SET	and	RING	finger	associated)	domain	of	UHRF1	[385-387].	In	addition,	DNMT1	contains	a	zinc	
finger	 CXXC	 domain	 that	 is	 characteristic	 of	 proteins	 binding	 unmethylated	 CpGs.	 Other	 proteins	
containing	 this	domain	 include	the	 lysine	demethylases	KDM2A/B	and	the	 ten-eleven-translocation	
(TET)	proteins	1	and	3.	DNMT1	also	possesses	a	PCNA	interacting	peptide	(PIP)	module	responsible	
for	 targeting	 the	 protein	 to	 replication	 foci	 during	 S	 phase.	 This	 interaction	 has	 been	 shown	 to	
increase	the	enzyme	efficiency	two-fold,	but	the	recruitment	to	the	replication	fork	is	not	absolutely	
necessary	to	maintain	global	methylation	levels	[388,	389].		
The	N-terminal	domain	of	DNMT1	was	shown	to	 inhibit	de	novo	methylation	activity	of	 the	C-term	
[390-392],	further	increasing	the	specificity	towards	maintenance	methylation.	
Evidence	 for	 the	 existence	 of	 further	 DNA	 methyltransferases	 came	 from	 knockout	 studies	 of	
DNMT1.	Dnmt1-/-	embryos	die	during	development,	but	ESCs	grow	normally	and	retain	basal	levels	of	
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methylation	 [393],	 pointing	 towards	 a	 backup	 system	 for	 methylation	 of	 cytosine.	 Dnmt1-/-	 ESCs	
undergo	apoptosis	when	induced	to	differentiate	however,	leading	to	the	conclusion	that	the	backup	
system	 is	 specific	 for	 embryonic	 development	 [394].	 A	 database	 search	 for	 5-cytosine	
methyltransferase	motifs	performed	following	these	finding	revealed	the	existence	of	DNMT3A	and	
B	[326].	Apart	from	the	C-terminal	catalytic	domain,	they	show	little	sequence	similarity	to	DNMT1.	
They	are	highly	expressed	in	undifferentiated	ESCs.	DNMT3A	levels	in	adult	tissues	are	very	low	and	
DNMT3B	 is	 barely	 detectable.	 They	 show	 robust	 methyltransferase	 activity	 on	 hemi-	 as	 well	 as	
unmethylated	DNA,	assigning	them	a	role	as	de	novo	DNA	methyltransferases	[395].	
While	DNMT1	is	uniformly	expressed	in	all	cell	types	and	developmental	stages,	DNMT3A	and	B	show	
distinct	 cellular	 localizations	 during	 embryogenesis	 hinting	 towards	 separate	 roles.	 Like	 DNMT1,	
knockouts	 of	 DNMT3A	 and	 B	 lead	 to	 early	 lethality.	 Dnmt1-/-	 	 and	 Dnmt3B-/-	 do	 not	 survive	 the	
embryonic	stage,	whereas	Dnmt3A-/-	mice	appear	normal	at	birth,	but	die	at	around	4	weeks	of	age	
[396].		
DNMT3B	is	required	for	de	novo	methylation	of	pericentromeric	repetitive	DNA	sequences	and	CpG	
islands	on	the	inactive	X	chromosome.	Mutations	in	both	alleles	of	DNMT3B	lead	to	the	development	
of	 the	 ICF	 (immunodeficiency,	 centromeric	 region	 instability,	 and	 facial	 anomalies)	 syndrome	 in	
humans	[397-400].	Consistent	with	the	fact	that	DNMT3B	loss	is	embryonic	lethal,	it	was	found	that	
at	least	one	mutation	in	ICF	patients	has	residual	catalytic	activity	[401].	One	hallmark	of	this	genetic	
disorder	 are	 low	 methylation	 levels	 in	 pericentromeric	 satellite	 regions	 [402]	 and	 the	 disease	
translates	into	genomic	instability	and	fatal	immunodeficiency.	
Deregulation	of	all	major	DNMTs	is	associated	with	cancer	development	[403,	404],	assigning	them	a	
role	 as	 potential	 anti-cancer	 targets.	 Methyltransferase	 inhibitors	 that	 competitively	 bind	 to	 the	
catalytic	 site	 of	 DNMT	 have	 been	 used	 in	 clinical	 trials	 to	 treat	 different	 kinds	 of	 hematopoietic	
malignancies.	 5-AzaC	 (Decitabine,	 trade	 name:	 Dacogen)	 is	 approved	 for	 the	 treatment	 of	
myelodysplasic	 syndromes,	 including	 different	 kinds	 of	 anemias	 and	 chronic	 myelomonocytic	
leukemia	[405-408].	
	DNA	demethylation	
DNA	 demethylation	 can	 be	 divided	 into	 two	major	 mechanisms:	 passive	 demethylation,	 involving	
replication-dependent	 dilution	 of	 the	 methyl	 marks,	 and	 active	 demethylation	 that	 is	 replication-
independent	and	needs	 the	action	of	 specialized	proteins.	 The	most	 studied	demethylation	events	
occur	in	the	paternal	pronucleus	after	fertilization	[409,	410]	and	during	primordial	germ	cell	(PGC)	
development	[411,	412].	Both	were	described	to	involve	active	demethylation	events,	as	they	occur	
rapidly,	before	DNA	replication	takes	place.		
Most	studies	to	date	described	genome-wide	changes	in	methylation	during	development,	involving	
CpG-rich	 regions,	 such	 as	 CpG	 islands.	 The	 sensitivity	 of	 the	 applied	 methods	 does	 not	 allow	
conclusions	on	specific	single	CpGs.	As	mentioned	earlier,	however,	demethylation	of	single	CpGs	can	
also	have	a	profound	effect	on	expression	of	certain	genes	in	somatic	cells.	The	proteins	involved	in	
the	 drastic	 demethylation	 events	 occurring	 during	 development	 and	 the	 subtle	 changes	 in	
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methylation	 in	somatic	cells	are	not	clearly	defined.	There	are	several	hypotheses	under	discussion	
that	will	be	presented	briefly.	
The	direct	removal	of	the	methyl	group	would	be	the	simplest	mechanism	of	demethylation	and	has	
been	 shown	 to	 occur	 during	 the	 repair	 of	 6-O-methylguanine	where	MGMT	 removes	 the	O-linked	
methylation	on	damaged	DNA,	 thereby	 irreversibly	 inactivating	 itself.	 But,	 in	 contrast	 to	 the	 latter	
alkylated	 base,	 the	methyl	 group	 on	 5mC	 is	 attached	 via	 a	 carbon-carbon	 bond.	 Breakage	 of	 this	
bond	is	thermodynamically	very	unfavorable,	rendering	this	mechanism	unlikely.	
If	the	damage	cannot	be	reversed	directly,	the	next	idea	would	be	to	remove	the	entire	nucleotide.	
Enzymes	capable	of	carrying	out	this	reaction	have	been	found	in	plants.	The	Demeter/repressor	of	
silencing	 1	 (ROS1)	 family	 of	 glycosylase/lyases	 can	 initiate	 the	 active	 demethylation	 process	 by	
excising	 5mC,	 leaving	 behind	 an	 incised	 abasic	 site	 that	 can	 be	 repaired	 by	 BER	 [413].	 Although	
described	in	several	reports	[93,	103,	414,	415],	no	enzyme	with	robust	glycosylase	activity	towards	
5mC	has	actually	been	purified	from	animal	cells.		
Another	highly-debated	hypothesis	involves	enzymatic	deamination	of	5mC	to	T.	It	is	a	very	tempting	
model,	 because	 -	 as	 already	 described	 -	 there	 are	 several	 possibilities	 to	 repair	 the	 resulting	 G:T	
mismatches,	leading	to	demethylation.	The	main	player	described	for	this	pathway	is	AID.	Although	
mainly	 expressed	 in	 activated	 B-cells,	 low	 levels	 of	 AID	 have	 been	 detected	 among	 others	 in	
primordial	 germ	 cells	 [202],	 which	 undergo	 a	 wave	 of	 rapid,	 active	 demethylation.	 The	 cytidine	
deaminase	displays	activity	on	5mC,	albeit	much	weaker	than	on	unmethylated	cytosine	[235,	236].	
This	 raises	 the	 question	 of	 how	 the	 cell	would	 protect	 the	 cytosines	 in	 an	 environment	with	 high	
levels	 of	 AID	 activity.	 Despite	 this	 caveat,	 genome-wide	 studies	 found	 a	 correlation	 between	 AID	
activity	and	demethylation	in	PGCs	[237,	238,	416]	and	in	embryogenesis	[98,	104,	417].	
With	 the	discovery	of	 the	Ten-Eleven-Translocation	 (TET)	enzymes,	 the	 field	of	DNA	demethylation	
got	another	interesting	twist.	It	proposes	a	way	of	demethylation	involving	oxidation	of	5mC,	instead	
of	deamination,	and	the	excision	of	the	oxidation	products	by	a	glycosylase.	It	is	the	most	supported	
hypothesis	at	the	moment	and	will	be	discussed	in	more	detail.	
	
Ten	eleven	translocation	proteins	in	demethylation	
Ten-eleven	 translocation	 (TET)	 proteins	 constitute	 a	 new	 family	 of	 Fe2+	 and	 2-oxoglutarate	 (2OG)	
dependent	dioxygenases.	Their	existence	was	 first	mentioned	 in	2002,	when	a	 translocation	of	 the	
H3K4	 methyltransferase	 mixed	 lineage	 leukemia	 (MLL)	 gene	 on	 chromosome	 11	 to	 a	 gene	 on	
chromosome	10	 encoding	 a	 protein	with	 a	CXXC	domain	was	observed	 in	 acute	myeloid	 leukemia	
(AML)	[418,	419].	
It	was	only	several	years	 later	 that	the	enzyme	was	purified	and	characterized.	 It	was	shown	to	be	
one	of	three	enzymes	in	mammals	that	catalyze	the	oxidation	of	5mC	to	5hmC	[28]	and	further	to	5-
formylcytosine	 (5fC)	 and	 5-carboxylcytosine	 (5caC)	 [27]	 in	 vitro	 and	 in	 cells.	 5fC	 and	 5caC	 are	
substrates	 for	 TDG,	 providing	 an	 attractive	model	 for	 sequential	 demethylation	 [97,	 420].	 All	 five	
cytosine	species	are	known	to	be	present	in	numerous	mammalian	tissues.	5hmC	is	present	at	1-5%	
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of	5mC	in	most-cell	types	[421,	422],	up	to	10%	in	ESCs	[28]	and	as	high	as	40%	in	Purkinje	neurons	
[423].	5fC	and	5caC	 levels	are	much	 lower	 (0.03	and	0.01%	respectively)	compared	to	5mC	 in	ESCs	
[27,	97].	
The	family	of	TET	dioxygenases	 is	widely	distributed	among	eukaryotes,	 from	the	amoeboflagellate	
Naegleria	gruberi	to	mammals.	In	jawed	vertebrates,	the	TET	gene	underwent	triplication,	giving	rise	
to	 TET1,	 2	 and	 3.	 Chromosomal	 inversion	 of	 TET2	 detached	 the	 CXXC	 domain,	 which	 became	 an	
independent	gene	that	is	translated	into	IDAX	(inhibition	of	the	DvI	and	axin	complex,	also	known	as	
CXXC4).		
	
	 	 	
Figure 13 Schematic representation of the three TET proteins present in jawed vertebrates. They 
share a highly conserved catalytic region at their C-terminus. The TET2 locus underwent inversion, 
resulting in the detachment of the DNA binding domain CXXC. From [424]. 
	
The	 core	 catalytic	 domain	 of	 the	 TET	 enzymes	 forms	 a	 double-stranded	 β-helix	 (DSBH)	 fold,	
characteristic	of	Fe2+	-and	2OG-dependent	dioxygenases.	It	contains	a	triad	of	two	histidines	and	one	
aspartate	 or	 glutamate	 that	 cooperate	 to	 bind	 Fe2+.	 The	 iron	 center	 then	 binds	 oxygen	 and	 2OG,	
together	with	 a	 conserved	 arginine	 and	 a	 serine	 residue.	 TET	 enzymes	 are	 dioxygenases,	 because	
they	incorporate	both	atoms	of	molecular	oxygen,	coordinated	by	the	iron,	into	their	products;	one	
into	the	co-factor	2OG,	resulting	in	the	release	of	CO2	and	succinate,	and	one	into	5mC,	5hmC	or	5fC	
[425-428].	Ascorbate	was	shown	to	enhance	TET	catalytic	activity	[429],	likely	by	acting	as	a	reducing	
agent	to	return	the	metal	center	iron	to	its	active	state	[430,	431].	
Studies	 on	 a	 Naegleria	 TET-like	 dioxygenase	 (NgTET1)	 reveal	 that	 5mC	 is	 strongly	 preferred	 as	
substrate	 over	 5hmC	 and	 5fC.	 It	 was	 further	 shown	 that	more	 5caC	 was	 formed	when	 the	 initial	
substrate	was	5mC,	then	when	the	reaction	was	started	with	DNA	containing	5hmC	or	5fC.	This	led	
the	authors	to	the	conclusion	that	the	three	oxidation	steps	might	be	carried	out	processively	by	TET,	
without	 releasing	 the	 DNA	 [432,	 433].	 After	 every	 oxidation	 step,	 however,	 succinate	 has	 to	 be	
released	to	make	space	for	a	new	2OG.	Structural	studies	on	human	TET2	revealed	that	the	hydrogen	
abstraction	 leading	 to	 the	 oxidation	 of	 the	 cytosine	 species	 is	 likely	 to	 be	 inefficient	 from	 the	
hydroxyl	 and	 carbonyl	 groups	 of	 5hmC	 and	 5fC.	 This	 results	 in	 low	 catalytic	 efficiency	 [434].	 The	
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crystal	structures	of	NgTET1	and	TET2	revealed	a	base	flipping	mechanism	to	carry	out	the	oxidation	
of	their	substrates,	indicating	that	only	one	cytosine	in	a	symmetrical	CpG	is	addressed	at	a	time.		
TET1	and	3	contain	a	CXXC	motif	in	the	N-terminal	domain,	known	from	other	DNA	binding	proteins	
and	 implicated	 in	binding	of	unmethylated	CpG-rich	regions	[435,	436].	Metazoan	TETs	additionally	
possess	a	cysteine	(cys)-rich	domain	in	the	catalytic	region	at	the	C-terminus,	adjacent	to	the	DSBH	
domain.	The	cys-rich	region	chelates	two	or	more	zinc	ions	and	is	postulated	to	bind	DNA	and	help	in	
target	 recognition.	Crystal	 structure	of	a	TET2	complex	with	methylated	DNA	showed	that	 the	cys-
rich	 domain	 wraps	 around	 the	 DSBH	 and	 together	 they	 coordinate	 3	 zinc	 ions	 thus	 stabilizing	
important	structures	for	catalysis	and	DNA	binding	[437].	
The	different	TETs	 in	 jawed	vertebrates	carry	out	 the	same	catalytic	 reaction,	but	are	expressed	 in	
different	tissues	and	developmental	stages.	
TET1	levels	are	barely	detectable	in	early	zygotic	stages,	but	increase	at	later	pre-implantation	stages	
and	are	high	 in	ESCs,	 together	with	TET2	 [438,	439].	There	 is	 limited	expression	of	TET1	 in	 several	
adult	 tissues	 [418].	 TET1	 localizes	 predominantly	 to	 CpG	 islands,	 keeping	 them	 methylation-free,	
presumably	by	 inhibiting	de	novo	methylation	by	DNMTs	or	by	 active	demethylation.	Depletion	of	
TET1	 leads	 to	 increased	 levels	 of	 5mC	 at	 many	 TET1-enriched	 regions.	 	 These	 experiments	 also	
revealed	a	dual	 role	of	TET1	 in	gene	 regulation,	as	 similar	number	of	genes	were	upregulated	and	
downregulated	in	the	absence	of	TET1.	This	points	towards	a	complex	 interplay	of	different	factors	
and	complicates	the	analysis	on	a	genome-wide	scale	[329,	440,	441].	
Tet1	 knockout	mESCs	 show	a	decrease	 in	5hmC	 levels	of	 approximately	35%,	but	maintain	normal	
morphology	 and	 support	 embryonic	 development.	 Tet1-null	 mice	 are	 viable,	 but	 the	 number	 of	
progenies	 is	 reduced	 indicating	 that	 either	 a	 fraction	 of	 embryos	 die	 or	 germ	 cell	 development	 is	
impaired	[442].	Tet1-	and	-2	double	knockout	mice	are	also	viable	and	develop	all	three	germ	layers,	
indicating	that	the	two	TETs	have	modulatory,	but	not	essential	functions	in	development	[443].	
TET1	 and	 2	 have	 been	 implicated	 in	 the	 rapid	 demethylation	 event	 occurring	 in	 PGCs.	 The	
demethylation	is	accompanied	by	conversion	of	5mC	to	5hmC	[444,	445].	Kinetics	of	removal	of	5mC	
and	5hmC	indicate	a	passive	mechanism	involving	DNA	replication,	after	rapid	conversion	of	most	of	
the	 methylation	 to	 hydroxymethylation.	 TET1	 and	 TET2	 therefore	 seem	 to	 enhance	 passive	
demethylation,	but	they	are	not	the	only	factors	responsible,	 in	agreement	with	the	 largely	normal	
phenotypes	of	the	surviving	progenies	from	Tet1-/-	Tet2-/-	mice	[443].	
TET2	 levels	 are,	 similarly	 to	 TET1,	 high	 in	 later	 stage	 embryos	 and	 in	 ESCs.	 TET2	 is	 additionally	
ubiquitously	expressed	in	adult	tissues	[418],	including	high	levels	in	hematopoietic	stem	cells	(HSCs).	
Accordingly,	 loss	 of	 TET2	 was	 observed	 to	 promote	 HSC	 self-renewal,	 proliferation,	 and	
differentiation,	 leading	 to	 a	 number	 of	 hematopoietic	 malignancies	 [446-449].	 TET2	 displays	
haploinsufficieny,	 as	 already	 TET2-/+	 HSCs	 show	 a	 growth	 advantage	 for	 populating	 hematopoietic	
lineages	 [450].	 Although	 there	 are	 also	 low	 levels	 of	 TET1-	 and-	 3	 expressed	 in	 the	 hematopoietic	
system,	loss	of	TET2	alone	causes	significant	loss	of	5hmC	and	results	in	tumorigenesis,	assigning	it	a	
role	as	 tumor	suppressor	 in	HSCs	[446].	As	TET2	 lacks	a	CXXC	DNA	binding	domain,	 its	 targeting	to	
DNA	is	likely	to	be	mediated	differently	from	TET1	and	3,	probably	by	interacting	proteins.	
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TET3	is	enriched	in	oocytes	and	early	zygotes	[451].	It	has	been	postulated	to	be	responsible	for	the	
rapid	demethylation	events	taking	place	after	fertilization	in	the	paternal	pronucleus.	Appearance	of	
5hmC	 coincides	with	 the	 disappearance	 of	 5mC	 from	 the	 paternal	 pronucleus.	 [439],	 where	 TET3	
appears	 to	 be	 specifically	 enriched	 [452].	 Further	 evidence	 for	 this	 pathway	 was	 provided	 by	
knockdown	studies	showing	impeded	conversion	of	5mC	to	5hmC	in	the	absence	of	TET3	[439].	In	a	
recent	 study,	 however,	 it	 was	 found	 that	 the	 initial	 loss	 of	 paternal	 5mC	 does	 not	 require	 TET3-
dependent	 5hmC	 formation	 [453],	 pointing	 towards	 a	 more	 complex	 mechanism	 likely	 involving	
other,	 yet	 unknown,	 factors.	 In	 addition,	 the	 observation	 was	 made	 that	 5hmC	 and,	 to	 a	 lesser	
extent,	 5fC	 and	5caC,	 persist	 in	 embryos	 and	only	 gradually	 decline	until	 the	eight-cell	 stage	 [438,	
454,	455],	consistent	with	passive	dilution	during	replication.	The	intriguing	question	arises	how	the	
TET	activity	 is	halted	mostly	at	5hmC.	The	oxidation	of	5mC	by	TET3	nevertheless	has	an	important	
role,	as	mice	produced	from	TET3	knockout	oocytes	are	not	viable,	regardless	of	the	genotype	of	the	
male	[452].	
Apart	 from	 the	 role	 of	 the	 TET	 enzymes	 in	 active	 DNA	 demethylation,	 its	 oxidized	 products	
themselves	 might	 also	 play	 important	 roles	 in	 DNA.	 One	 well-established	 example	 concerns	
maintenance	methylation.	DNMT1	strongly	prefers	hemi-methylated-	over	hemi-hydroxymethylated	
sites	 [456].	 This	 results	 in	 passive,	 replication-coupled	 demethylation,	 following	 a	 first	 active	
enzymatic	step.	Also	the	MBD	proteins	were	shown	to	have	reduced	binding	affinity	towards	5hmC,	
as	compared	to	5mC	[457].	The	binding	properties	of	specific	transcription	factors,	such	as	hormone	
receptors,	 towards	 the	 oxidized	 cytosine	 species	 remain	 to	 be	 analyzed	 and	 will	 provide	 further	
information	about	the	regulatory	capabilities	of	the	TETs	and	their	products.	
	
Thymine	DNA	glycosylase	in	demethylation	
TDG	was	 first	 implicated	 in	 chromatin	dynamics	 and	 transcriptional	 control	via	 its	 interaction	with	
hormone	receptors	[458-460]	and	the	histone	acetyltransferase	CBP/p300	[461].	Knockouts	of	both	
CBP	[462]	and	p300	[463]	display	similar	defects	as	TDG	knockout	mice,	indicating	that	TDG	knockout	
lethality	is	connected	to	chromatin	dynamics,	rather	than	its	canonical	repair	activity.	
The	 first	 evidence	 that	 TDG	 might	 play	 a	 role	 in	 DNA	 demethylation	 was	 obtained	 when	 it	 was	
purified	 from	a	 chicken	 'demethylation	 complex'	 and	 shown	 to	have	5mC	glycosylase	 activity	 [93].	
This	 activity	 was	 however	 extremely	 low	 compared	 to	 the	 activity	 against	 G/T	 mismatches	 and	
therefore	most	 likely	 not	physiologically	 relevant,	 unless	 unknown	auxiliary	 factors	would	 increase	
the	activity	substantially.	
The	connection	between	TDG	and	demethylation,	however,	received	further	support	in	the	following	
years.	Overexpression	of	TDG	in	human	kidney	cells	lead	to	demethylation	of	a	hormone-responsive	
reporter	 gene	 that	 was	 necessary	 for	 its	 expression	 [460].	 TDG	 was	 also	 linked	 to	 myoblast	
differentiation	 that	 was	 accompanied	 by	 genome-wide	 DNA	 demethylation	 [464].	 In	 a	 functional	
genomics	screen	aimed	to	identify	proteins	involved	in	demethylation	of	a	reporter	gene,	the	SUMO-
dependent	 ubiquitin	 E3-ligase	 RING	 finger	 protein	 4	 (RNF4)	 was	 found	 [465].	 RNF4	 deficiency	 is	
embryonic	lethal	and	Rnf4-/-	mouse	embryonic	fibroblasts	(MEFs)	present	higher	levels	of	5mC.	RNF4	
was	 shown	 to	 interact	 with	 TDG	 and	 APE1	 and	 the	 interaction	 enhanced	 demethylation	 of	 the	
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reporter.	RNF4	increased	the	enzymatic	activities	of	TDG	and	APE1	as	shown	on	a	G/T	mismatch.	The	
authors	postulated	an	involvement	of	a	deaminase,	but	detected	no	involvement	of	AID	or	APOBEC1.	
Another	study	saw	no	RNF4-mediated	demethylation,	but	found	that	RNF4	is	responsible	for	MeCP2	
turnover,	thereby	activating	transcription	of	methylated	genes	[466].	
Tdg	knockout	mice,	shown	to	be	embryonic	lethal,	shed	more	light	on	the	role	of	TDG	in	methylation	
dynamics.	TDG	was	shown	to	protect	unmethylated	regions	from	aberrant	de	novo	methylation,	as	
Tdg-/-	 MEFs	 display	 hypermethylation	 at	 regions	 normally	 unmethylated	 and	 bound	 by	 TDG	 [39].	
Another	 group	 that	 also	 established	 a	 TDG	 knockout	 model	 showed	 that	 two	 site-specific	
demethylation	events	described	earlier	[467,	468]	are	dependent	on	TDG.	They	proposed	a	pathway	
involving	AID	and	GADD45a	 (Growth	Arrest	and	DNA	Damage-inducible	45)	 [98],	based	on	the	 fact	
that	AID	 interacts	with	TDG	and	GADD45a.	 The	 involvement	of	GADD45a	 in	DNA	demethylation	 is	
controversial.	Some	groups	support	its	role	[104,	469],	whereas	others	do	not	[470].	
With	the	discovery	of	the	TET	enzymes	and	the	ability	of	TDG	to	excise	their	oxidation	products,	the	
connection	 between	 TDG	 and	DNA	demethylation	was	 further	 strengthened	 [27,	 28,	 97,	 420].	 5fC	
and	 5caC	 accumulate	 in	 proximal	 and	 distal	 regulatory	 elements	 in	mESCs	 upon	 depletion	 of	 TDG	
[471]	 and	 a	 connection	 between	 5fC,	 TDG	 and	 the	 p300	 histone	 acetyltransferase	 was	 found	 at	
enhancers	[472].	Recombinant	TET1	and	TDG	were	shown	to	interact	physically	and	to	process	5mC	
and	5hmC	in	vitro,	resulting	in	alkaline	labile	AP-sites	[95].	
Despite	extensive	research	on	the	pathway	of	active	DNA	demethylation	via	 the	TET-TDG	pathway,	
the	exact	mechanism,	the	targeting	and	the	genomic	regions	involved	remain	to	be	investigated.	
	
NUCLEAR	RECEPTOR	SUPERFAMILY	
A	potential	 site-specific,	active	DNA	demethylation	machinery	must	be	 targeted	 reliably	 to	defined	
CpGs	 in	 regulatory	 sequences.	 In	 the	 case	 of	 hormone-induced	 demethylation	 events,	 a	 likely	
candidate	 is	 the	 hormone-activated	 receptor.	 Consistently,	 nuclear	 hormone	 receptors	 have	 been	
linked	to	several	demethylation	events	[332,	468,	473-475]	and	found	to	interact	with	TDG	[458-460]	
and	GADD45	[476].	
Nuclear	hormone	receptors	are	a	class	of	ligand-activated	proteins	that	translate	extracellular	signals	
into	transcriptional	responses.	Four	different	classes	are	defined	to	date;	steroid	receptors	(class	I),	
RXR	 heterodimers	 (class	 II),	 homodimeric	 orphan	 receptors	 (class	 III)	 and	 monomeric	 orphan	
receptors	 (class	 IV).	 Nuclear	 hormone	 receptors	 consist	 of	 three	 main	 domains;	 a	 central	 DNA	
binding	 domain	 (DBD),	 a	 C-terminal	 ligand	 binding	 domain	 (LBD)	 and	 a	 variable	 transactivation	
domain.	
The	DBD	of	nuclear	receptors	consists	of	two	highly	conserved	zinc	fingers	[477,	478].	Since	they	act	
as	 transcription	 factors,	 nuclear	 receptors	 rely	 on	 specific	 sequence	motifs	 for	 binding,	 known	 as	
hormone	response	elements.	Except	for	the	monomeric	orphan	receptors,	they	bind	as	dimers	to	a	
sequence	 motif	 with	 two	 half	 sites,	 separated	 by	 random	 spacer	 sequences	 of	 defined	 length	
depending	on	the	receptor.	Steroid	receptors	typically	bind	to	palindromic	 inverted	repeats	spaced	
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by	3	base	pairs	[479],	whereas	retinoic	acid	receptors	(RAR)	preferentially	bind	to	direct	repeats	with	
a	5	base	pair	spacer	[480].		
The	 LBD	 works	 as	 a	 switch,	 changing	 the	 conformation	 and	 the	 properties	 of	 the	 receptor	 upon	
ligand	binding,	 thereby	 activating	 the	 transcription	 factor	 [481,	 482].	 The	majority	 of	NRs	 has	 two	
activation	 function	 (AF)	 domains.	 The	 N-terminal	 AF1	 mediates	 ligand-independent	 activation,	
whereas	AF2	at	the	C-terminus	is	responsible	for	ligand-mediated	effects	[483].	The	two	AF	domains	
cooperate	to	ensure	full	transcriptional	activity	of	the	receptor.	
Steroid	receptors	are	bound	by	heat	shock	proteins	in	the	cytoplasm	that	dissociate	upon	hormone	
binding	enabling	 the	 receptors	 to	 translocate	 in	 the	nucleus,	where	 they	bind	 to	DNA	 [484].	Most	
NRs	are	induced	to	dimerize	upon	ligand	binding	and	then	either	directly	recruit	general	transcription	
factors	or	bind	co-activating	accessory	factors,	such	as	members	of	the	p160	family	[485].		
					 								 	
Figure 14 Structure of a typical nuclear receptor with the two activation domains (AF-1 and AF-2), 
the DNA binding domain (DBD) and the ligand binding domain (LBD). Below the general principle 
of activation of class I and class II NRs; lipophilic hormones pass the lipid bilayer of the cell and bind 
to their cognate receptors, causing their dissociation from heat shock proteins (HSPs) in the 
cytoplasm, in the case of NRs from class I. The receptors dimerize and translocated into the nucleus 
to exert their effector functions on target genes. In the case of NRs from class II (and III/IV), the 
hormones bind their receptors directly in the nucleus (class II, III, IV). From [486]. 	Estrogen	receptors	
Estrogens	 are	 involved	 in	 the	 regulation	of	 gene	expression	 in	 vertebrate	 females	 and,	 to	 a	minor	
extent,	in	males.	They	are	fat-soluble	steroid	hormones	able	to	pass	through	the	lipid	bilayer	of	the	
cell	membrane.	They	act	through	binding	their	cognate	receptors,	converting	them	to	an	active	state	
through	dissociation	from	the	heat	shock	protein	they	are	bound	to	in	the	cytoplasm.	There	are	two	
estrogen	receptors	 (ERs)	 in	vertebrates,	ERα	 [487]	and	ERβ	 [488],	encoded	by	 two	different	genes.	
They	are	highly	conserved	in	the	DBD,	resulting	in	similar	affinities	towards	the	consensus	estrogen	
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response	element	 (ERE)	GGTCANNNTGACC	 [489].	They	are	59%	homologous	 in	 the	LBD,	explaining	
the	similar	affinities	to	E2	and	other	ligands	[490].	However,	ligands	with	distinct	affinities	and	ligand	
binding	 characteristics	 for	 the	 two	 receptors	 have	 been	 described	 [491,	 492].	 	 One	 prominent	
example	is	the	chemotherapeutic	Tamoxifen.	It	acts	as	a	selective,	partial	agonist/antagonist	of	ERα,	
but	has	a	pure	antagonistic	effect	when	binding	 to	ERβ	 [493].	 The	 two	ERs	display	different	 tissue	
distributions.	 ERβ	 is	 expressed	primarily	 in	 thymus,	 testis	 and	ovary,	 but	 absent	 in	 liver	 [488,	 494,	
495],	whereas	ERα	is	highly-expressed	in	liver,	uterus	and	muscles	[496].	
ERα	can	be	activated	by	a	variety	of	different	stimuli,	but	its	response	to	E2	is	best	studied.	Binding	of	
estradiol	causes	the	receptor	to	translocate	into	the	nucleus,	where	it	exerts	its	effector	functions	by	
binding	to	palindromic	EREs	as	a	head-to-head	dimer	[497].	Besides	the	sequence	motif,	binding	of	
ERα	 to	 DNA	 also	 depends	 on	 the	 chromatin	 context.	 Similarly	 to	 other	 transcription	 factors,	 it	
preferably	 binds	 to	 open	 chromatin	 regions	 [498].	 It	 was	 shown	 that	 ERα	 is	 recruited	 mostly	 to	
regulatory	 elements	 distant	 from	 promoters	 and	 mediates	 loop	 formation	 to	 interact	 with	
promoters.	 Its	depletion	results	 in	 loss	of	chromatin	 loops	 [499].	Once	bound	to	DNA,	ERα	recruits	
co-activators	to	enhance	the	transcriptional	response.	One	of	the	first	chromatin	modifying	enzymes	
found	to	interact	with	ERα	was	the	histone	acetyltransferase	p300	[500]	that	had	also	been	shown	to	
interact	with	TDG.	
ERα	plays	an	important	role	in	cancer	development	of	estrogen-responsive	tissues,	such	as	mammary	
tissue.	 ERα-positive	 breast	 cancers	 are	 treatable	 with	 hormonal	 therapy,	 such	 as	 the	 selective	
estrogen	 receptor	 modulator	 (SERM)	 Tamoxifen.	 ERα	 overexpression	 therefore	 correlates	 with	 a	
better	 initial	 prognosis,	 development	 of	 resistances	 is	 frequent,	 however,	 limiting	 the	 overall	
prognostic	value	of	the	level	of	ERα	in	breast	cancer	(Reviewed	in	[501,	502]).	
	
THE	VITELLOGENIN	SYSTEM	
Vitellogenin	proteins	are	large	egg	yolk	precursors	produced	in	the	liver	in	response	to	estradiol.	The	
precursor	proteins	are	released	into	plasma	and	taken	up	by	the	oocyte,	where	they	are	cleaved	into	
lipovitellin	 and	 phosvitin	 that	 serve	 as	 nutritional	 reserves	 in	 the	 egg.	 There	 are	 two	 minor	
vitellogenin	genes	and	one	major	vitellogenin	gene,	vitellogenin	II.	
The	chicken	vitellogenin	II	(VTG)	gene	is	ideally	suited	to	study	the	connection	between	methylation,	
chromatin	 dynamics	 and	 gene	 activity,	 because	 it	 is	 rapidly	 induced	upon	β-estradiol	 treatment	 in	
terminally-differentiated	 hepatocytes,	 concomitantly	 with	 chromatin	 rearrangements.	 It	 is	 well	
studied	 and	 several	 sites	 in	 the	 proximal	 enhancer	 and	 promoter	 that	 play	 a	 role	 in	 the	
transcriptional	control	are	described.		
A	 site-specific	 DNA	 demethylation	 event	 was	 observed,	 as	 assessed	 by	 digests	 with	 HpaII,	 a	
methylation-sensitive	 restriction	enzyme	 [503].	 The	hormone-dependent	demethylation	 took	place	
in	 hepatocytes	 that	 express	 ERα	 and	 also	 in	 the	 oviduct	 that	 expresses	 ERα,	 but	 no	 VTG.	 In	 ERα-
negative	 erythrocytes,	 there	 was	 no	 demethylation	 of	 the	 specific	 site.	 The	 responsible	 factor	
therefore	 seems	 to	be	estrogen-responsiveness	 in	 general	 and	not	 transcription	per	 se	 [503].	DNA	
replication	was	suggested	not	to	play	an	important	role	in	the	demethylation,	but	only	based	on	slow	
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cell	 division	 [504].	 The	 next	 observation	made	was	 the	 appearance	 of	 DNaseI	 hypersensitive	 sites	
with	different	 characteristics.	Two	sites	 close	 to	 the	TSS	were	 stable,	while	one	was	only	 transient	
and	 disappeared	 after	 hormone	 removal	 [505].	 Further	 studies	 confirmed	 the	 independence	 from	
DNA	synthesis	by	using	arabinose	and	hydroxyurea	(HU)	and	showed	15%	undermethylation	of	the	
HpaII	 site	 after	 24h	 treatment.	 The	 same	 group	 showed	 in	 addition	 a	 relatively	 uniform	 VTG	
expression	 in	 the	 cells	 analyzed,	 excluding	 that	 the	 effect	 came	 from	 only	 a	 few	 cells	 within	 the	
population	[506].	
The	DNA	sequencing	protocol	developed	by	Maxam	and	Gilbert	 [507]	and	modified	by	Church	and	
Gilbert	 [508]	opened	new	possibilities	 to	 also	 analyze	CpGs	methylation	 status	outside	of	HpaII	 or	
other	 methylation-sensitive	 restriction	 enzyme	 recognition	 sites.	 Additionally,	 it	 was	 only	 now	
possible	to	distinguish	hemimethylated	sites	from	fully-methylated	ones.	
A	 key	 study	 in	 1986	 made	 use	 of	 this	 method	 and	 observed	 the	 site-	 and	 strand-specific	
demethylation	 of	 four	 CpGs	 in	 the	VTG	 enhancer	 in	 liver	 nuclei	 of	 immature	 chickens.	 The	 coding	
(upper)	strand	became	demethylated	with	kinetics	parallel	to	those	of	mRNA	synthesis,	whereas	the	
lower	 strand	 followed	 only	 after	 24	 h	 of	 hormone	 treatment.	 This	 re-opened	 the	 possibility	 that	
demethylation	 preceded	 transcription,	 which	 was	 disputed	 earlier	 because	 HpaII	 cleaves	 DNA	
unmethylated	 on	 both	 strands.	 Another	 interesting	 observation	 concerned	 a	 CpG	 lying	 in	 a	
glucocorticoid	response	element.	 It	was	found	to	be	unmethylated	in	the	upper	strand	in	the	basal	
state,	 but	 50%	methylated	 in	 the	 lower	 strand.	 Stable	 presence	 of	 hemimethylated	 CpGs	was	 not	
considered	possible,	because	of	the	maintenance	methyltransferase	DNMT1.	The	same	behavior	of	
the	 gene	 in	 oviduct	 cells	 and	 erythrocytes,	 already	 described	 by	Wilks	 et	 al.,	 1982,	 was	 observed	
here.	Demethylation	was	taking	place	 in	 liver	and	oviduct,	expressing	ERα,	but	not	 in	erythrocytes.	
The	authors	made	two	essential	conclusions	from	these	findings:	transcription	of	VTG	is	not	needed	
for	demethylation	and	binding	of	ERα	seems	to	be	a	prerequisite	for	demethylation,	therefore	ERα	is	
likely	able	to	bind	methylated	DNA.	Moreover,	they	revealed	in	preliminary	results	the	presence	of	
strand-specific	DNA	breaks	in	the	region	of	the	CpGs	studied	[332].	The	follow-up	study	observed	the	
binding	 of	 two	 non-histone	 proteins	 (NHP1	 and	 2)	 to	 the	 estrogen-responsive	 element	 (ERE)	 that	
were	different	from	ERα	and	seemed	to	increase	its	binding	efficiency	to	the	ERE	[509].	Another	ERE	
was	 found	 in	 the	VTG	enhancer,	but	 it	has	an	 imperfect	consensus	sequence	and	contributed	only	
mildly	to	estrogen-responsiveness	[510].	
We	decided	to	use	this	experimental	system	to	shed	light	on	the	chromatin	dynamics	of	the	chicken	
VTG	enhancer/promoter	region,	with	a	special	focus	on	DNA	methylation	and	the	newly-discovered	
players	in	5mC	metabolism.	
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It	is	of	outmost	importance	for	multicellular	organisms	to	ensure	the	long-term	stability	and	faithful	
duplication	of	their	genomes.	Simultaneously,	a	wide	range	of	dynamic	transactions	to	replicate	and	
repair	DNA,	and	to	flexibly	regulate	gene	expression	has	to	be	possible.	Disturbances	in	this	delicate	
balance	 readily	 lead	 to	 uncontrolled	 cell	 division,	 enhanced	 apoptosis	 or	 altered	 behavior	 of	 cells,	
resulting	in	cancer,	degenerative-	or	autoimmune	diseases,	respectively.	The	detailed	understanding	
of	 the	DNA	modifying	 processes	 and	 their	 regulation	 in	 cells	 is	 therefore	 of	 critical	 importance	 to	
prevent	and	treat	a	wide	spectrum	of	diseases	in	humans.	
Cellular	 repair	processes	counteracting	DNA	damage	arising	 from	endogenous	metabolites,	such	as	
reactive	oxygen	species	or	evoked	by	exogenous	agents,	such	as	tobacco	smoke	or	UV	irradiation,	are	
undoubtedly	 important	 for	 the	 survival	 of	 higher	 eukaryotes.	 This	 is	 exemplified	 by	 a	 variety	 of	
diseases	 caused	 by	 mutations	 in	 key	 DNA	 repair	 proteins	 [511,	 512].	 However,	 in	 addition	 to	
repairing	damage	arising	 in	DNA,	cells	sometimes	use	the	same	pathways	to	generate	physiological	
DNA	 modifications	 during	 development	 or	 in	 circumstances	 when	 the	 organism	 has	 to	 react	 to	
changes	in	the	environment,	such	as	infections.	
This	work	focuses	on	these	latter	DNA	modifying	processes	that	are	used	by	the	cellular	machinery	
for	physiological	purposes.	
In	the	first	part	of	this	thesis	we	aimed	to	unravel	the	mechanism	of	class-switch	recombination	and	
the	repair	pathways	involved.	CSR	is	a	very	intriguing	example	of	physiological	genome	editing	that	is	
still	poorly	understood.	 It	 is	essential	for	organisms	possessing	adaptive	immunity,	but	also	poses	a	
high	risk,	as	it	involves	substantial	DNA	rearrangements.	Paradoxically,	several	DNA	repair	pathways	
are	 involved	in	this	DNA	modifying	process	that	are	normally	 important	to	restore	 intact	DNA	after	
damage.	In	this	interesting	case,	they	are	used	to	create	transient	damage	and	irreversible	changes	in	
the	DNA	sequence.	
The	second	part	of	this	thesis	focuses	on	the	DNA	modification	5mC	and	its	metabolism	in	DNA.	5mC	
has	 a	 very	 important	 role	 in	 the	 control	 of	 gene	 expression	 in	 development,	 as	well	 as	 in	 somatic	
cells.	Methylation	patterns	are	highly	deregulated	in	most	cancers,	further	stressing	their	importance	
in	genomic	stability.	To	find	new	interventions	for	cancer	therapy	without	causing	side	effects,	it	is	of	
great	 importance	 to	 understand	 how	 cells	 maintain	 the	 sensitive	 balance	 between	 maintaining	
methylation	 patterns	 and	 retaining	 the	 flexibility	 to	 react	 to	 stimuli.	We	 study	 the	metabolism	 of	
5mC,	its	modifications	in	DNA	and	its	effect	on	transcription	on	the	example	of	the	chicken	VTG	gene.	
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ABSTRACT
During class switch recombination (CSR), antigen-
stimulated B-cells rearrange their immunoglobulin
constant heavy chain (CH) loci to generate antibodies
with different effector functions. CSR is initiated by
activation-induced deaminase (AID), which converts
cytosines in switch (S) regions, repetitive sequences
flanking the CH loci, to uracils. Although U/G mi-
spairs arising in this way are generally efficiently
repaired to C/Gs by uracil DNA glycosylase (UNG)-
initiated base excision repair (BER), uracil process-
ing in S-regions of activated B-cells occasionally
gives rise to double strand breaks (DSBs), which trig-
ger CSR. Surprisingly, genetic experiments revealed
that CSR is dependent not only on AID and UNG,
but also on mismatch repair (MMR). To elucidate the
role of MMR in CSR, we studied the processing of
uracil-containing DNA substrates in extracts of MMR-
proficient and –deficient human cells, as well as in
a system reconstituted from recombinant BER and
MMR proteins. Here, we show that the interplay of
these repair systems gives rise to DSBs in vitro and
to genomic deletions and mutations in vivo, partic-
ularly in an S-region sequence. Our findings further
suggest that MMR affects pathway choice in DSB re-
pair. Given its amenability to manipulation, our sys-
tem represents a powerful tool for the molecular dis-
section of CSR.
INTRODUCTION
Antigen-dependent antibody diversification occurs in two
stages: somatic hypermutation (SHM) and class switch
recombination (CSR) (1,2). During SHM, antibody-
expressing B cell clones that bind antigens are stimulated to
proliferate and the variable regions of their immunoglobulin
(Ig) genes acquire a large number of mutations. Cell clones
expressing mutated immunoglobulins with higher affini-
ties for the antigen undergo positive selection and further
rounds of maturation. In contrast to SHM, which yields
antibodies with higher affinity through altering the variable
region, CSR gives rise to antibodies of a different isotype
through an irreversible rearrangement of the heavy chain
(CH) locus. The human CH locus consists of several genes
(C!, C", C# 3, C# 1, C$1, C# 2, C# 4, C% and C$2), but ma-
ture B cells express on their surface initially only IgM or
IgD (the latter arising through alternative splicing). During
CSR, the antigen/cytokine combination in the environment
of the B cell activates transcription of specific switch (S) re-
gions, highly-repetitive sequences flanking the 5′ termini of
the CH genes. Transcription then triggers a recombination
process during which the Ig variable region is joined to one
of the downstream constant genes with a concomitant loss
of the intervening DNA. In this way, the B-cell switches
from expressing the high-avidity IgM to producing high-
affinity IgG, IgA or IgE with different biological effector
functions (3).
SHM and CSR are initiated by activation-induced cy-
tidine deaminase (AID), a protein expressed in antigen-
activated B cells (4,5). AID converts numerous cytidines
within the Ig locus to uracils, in a reaction that is depen-
dent on transcription (6). In the absence of AID, both SHM
and CSR are abrogated (7,8). In humans, CSR malfunc-
tion causesHyper-IgM syndrome, characterized by elevated
IgM levels and a concomitant decrease or complete absence
of IgG, IgA and IgE (9).
That SHM and CSR depend not only on the genera-
tion of uracils but also on their metabolism was demon-
strated by the finding that ageing mice lacking uracil-DNA
N-glycosylase (UNG), an enzyme that excises uracil from
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DNA (10), develop B-cell lymphomas (11) and that SHM
and CSR are severely attenuated in these animals (12). In
humans, recessive mutations in theUNG gene cause Hyper-
IgM syndrome (13).
Genetic evidence implicated also the mismatch repair
(MMR) pathway in these processes: disruption of the
mouse MMR genes Msh2, Msh6, Mlh1, Pms2 or Exo1 led
to altered SHMand to a reduction in CSR that ranged from
2- to 7-fold, depending on the gene and the Ig serotype (14–
21). Similarly, patients lacking PMS2 or MSH6 were di-
agnosed with a profound CSR defect (22,23). These find-
ings were unexpected. Deamination of deoxycytidine, both
AID-catalyzed and spontaneous (24), gives rise to U/G
mispairs in DNA, however, even though these structures
are recognized and bound by the human mismatch bind-
ing factor MutS! (heterodimer of MSH2 and MSH6) (25),
they should not be addressed by MMR. Postreplicative
MMR has evolved to remove mispaired nucleotides from
the newly-synthesized strand during replication. To achieve
this goal, MMR proteins need not only detect the mis-
pair, but also direct its repair to the nascent strand. In eu-
karyotes, this strand is distinguished from the template by
pre-existing termini, such as gaps between Okazaki frag-
ments, where EXO1 initiates the degradation of the error-
containing nascent strand up to and ∼150 nucleotides past
the mispair (26). Because AID-induced U/Gmispairs arise
in G1 phase of the cell cycle, i.e. in DNA devoid of EXO1
loading sites, they should not trigger MMR. Instead, they
should be repaired to C/G by base excision repair (BER)
(27).
In all organisms, short-patch BER of uracil is initiated
by the removal of this aberrant base, catalyzed primar-
ily by UNG (10), although mammalian cells encode also
the uracil-processing enzymes TDG (28), SMUG1 (29) and
MBD4 (30). The resulting apyrimidinic (AP) site is then in-
cised at its 5′ phosphate by an AP-endonuclease (APE1 in
humans), which thus provides an entry site for polymerase-
" (pol-") that extends the 3′-OH terminus of the break by a
single dCMP and concurrently removes the baseless sugar-
phosphate residue by "-elimination. The remaining nick is
then sealed byDNALigase III/XRCC1.Uracils can also be
addressed by long-patch BER, which differs from the short-
patch process in that the repair synthesis catalyzed by pol-
", pol-# or pol-$ generates repair tracts of 2–6 nucleotides
through stand displacement. This process requires, in addi-
tion to the BER enzymes, also the replication factors RFC,
PCNA and FEN1 (31–33). BER-mediated repair of uracils
is generally extremely efficient, possibly also due to the re-
dundancy betweenUNG,TDG, SMUG1 andMBD4, how-
ever, only UNG has to date been implicated in SHM/CSR.
BER and MMR are highly-effective guardians of ge-
nomic integrity. So why are these processes linked to mu-
tagenesis and chromosomal deletions at the Ig locus? One
possible reason could be the high density of uracils gener-
ated byAID at its preferred target sequencesWRCY (where
the underlined C is the target of deamination and W = A
or T; R = A or G; Y = C or T) in the regions undergoing
SHM and CSR. In an earlier study, we were able to demon-
strate that MMR can interfere with BER-mediated uracil
repair on substrates containing a U/G and a G/T mispair
in close proximity (34). We could also show that processing
of substrates containing two U/G mispairs in close prox-
imity activated PCNAmonoubiquitylation and recruitment
to chromatin of the error-prone DNA pol-% (35), events re-
quired for SHM (36–38). It was proposed that a similar in-
terference between BER and MMR might give rise to the
double-strand breaks (DSBs) that arise in the switch regions
during the G1 phase of the cell cycle and that are necessary
for CSR (39,40), but experimental evidence supporting this
hypothesis is not available to date.
In an attempt to gain novel insights into the CSR pro-
cess, wemade use of a series of circular phagemid substrates
containing uracil residues in one strand and a nick at a de-
fined site in the other strand, the latter representing an inter-
mediate of BER-catalyzed uracil repair and an entry point
for MMR. We then studied the appearance and location
of DSBs upon incubation of these molecules with MMR-
proficient or -deficient extracts of human cells, as well as
with purified recombinant BER and MMR proteins. We
now show that DSBs can arise through processing of a com-
bination of uracils and nicks situated on opposite strands.
We also show that DSB induction is absolutely dependent
on UNG, but that the dependence on MutS! is limited to
substrates in which the uracils and the nick are separated
by more than∼50 nucleotides. MutL! was required only in
a subset of events and this function required its endonucle-
olytic activity. We also provide evidence that processing of
these substrates in vivo gives rise to deletions delineated by
the uracil and/or strand break sites, and that this process is
not limited to B-cells.
MATERIALS AND METHODS
Antibodies and reagents
The rabbit polyclonal anti-TDG antibody was a generous
gift of Primo Scha¨r, MSH2 antibody was from Calbiochem
and the MSH6 and Lamin B antibodies were from Abcam.
Restriction enzymes (NotI, XmnI, AclI and Nt.BstNBI),
UDG, APE1 and the UDG inhibitor Ugi were obtained
from New England Biolabs and the Protein A Dynabeads
were obtained from Dynal Biotech. The purified recombi-
nantMutL!D699N protein was a generous gift of Farid A.
Kadyrov; additionally, MutL! and MutS! wt and MutS!
KR (41), RPA and EXO1 were purified in our laboratory.
Cell culture
Burkitt lymphoma cells (BL2) were cultured in RPMI
medium 1640 (GIBCO) with 10% fetal calf serum
(GIBCO), 10 000 U/ml penicillin and 10 mg/ml strep-
tomycin (Gibco-BRL). LoVo cells were grown in 50%
DMEM (GIBCO), 50% F12 (GIBCO) supplemented with
10% fetal calf serum and penicillin-streptomycin, 293T
L! were cultured in DMEM supplemented with 10% Tet
System-approved fetal calf serum (Clontech), 300 &g/ml
hygromycin B (Roche) and 100 &g/ml zeocin (InvivoGen).
To abrogateMutL! expression, 50 ng/ml doxycyclin (Clon-
tech) was added to the media. siRNA transfections were
carried out using the calcium phosphate transfection. Syn-
thetic siRNA oligonucleotides sequences (all 5′ to 3′) were
as follows: siLuc sequence CGTACGCGGAATACTTC-
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GATT, siMSH2 UCCAGGCAUGCUUGUGUUGAATT
and MSH6 CGCCATTGTTCGAGATTTA (Microsynth).
DNA substrates and DSB/mismatch repair assays
Isolation of the supercoiled homo- and heteroduplex sub-
strates and the MMR assays were carried out as previously
described (42). A heteroduplex DNA substrate (referred
to as ‘304’, Figures 1A, and 3A) containing a U/G-U/G
mismatch (one within an AclI restriction site) in the 89-bp
polylinker of a pGEM13Zf(+) derivative pRichi was con-
structed by primer extension, using the primer
CCAGTGAATTGTAATA U GAACACTATA
GGGCGAATTGGCGGCCGCGATCTGATCAGA
TCCAGACGTCTGTCAAUGTTGGGAAGCTTGAG.
In this substrate, the distance between the nick and the
closest uracil was 304 nucleotides. In order to create a
substrate with a distance of 58 nucleotides between the
nicking site and the closest uracil in the top strand (referred
to as ‘58’, Figure 3B), the following primer was used:
U/G-U/G 235–306 GCCCGCTTTCUAGTCGGGA
AACCTGTCGTGCCAGCTGCATTAATG
AATCTGCCAACGCG U GGGGAGAGGCGG
To assess the impact of sequence context, a 95-mer
oligonucleotide containing nucleotides 267–344 sequence
of the human S! region (GenBank/EMBL/DDBJ
accession no. X54713) was cloned into the PshAI
site of the polylinker of plasmid pRichi. The S!
substrate was then generated by primer extension
on the phagemid ssDNA, using the oligonucleotide
CCAGACGTGGGCTAAGTTGUACCAGGTGAGCTGA
GCTGAGCTAGGGCTTGGCTGCACTAACTGGGCTG
AGUTGGGCAGGGCTGGGCCTGTCAACG. (The S!
region sequence is shown in italics.) In this substrate, the
Us are mispaired with Gs in the complementary strand.
To generate substrates with abasic sites, the following
primers were used: U/G-ab: CCA GTG AAT TGT AAT
AUG AAC ACT ATA GGG CGA ATT GGC GGC CGC
GAT CTG ATC AGA TCC AGA CGT CTG TCA AXG
TTG GGA AGC TTG AG and ab-U/G: CCA GTG AAT
TGT AAT AXG AAC ACT ATA GGG CGA ATT GGC
GGC CGC GAT CTG ATC AGA TCC AGA CGT CTG
TCA AUG TTG GGA AGC TTG AG. In all sequences,
uracils are shown in bold. X represents the abasic site ana-
log inserted with using dSpacer CE phosphoramidite (Glen
Research, 10–1914–90). The desired supercoiled substrates
were purified on a CsCl gradient by standard methods. The
nick was introduced by incubation with Nt.BstNBI.
TheDSB assays were carried out using 100 ng (47.5 fmol)
heteroduplexDNA substrate and 100!g of nuclear extracts
from BL2, 293TL"+ (MLH1+), 293TL"− (MLH1−) or
LoVo cells in a total volume of 25 !l in a buffer contain-
ing 20 mM Tris HCl pH 7.6, 110 mM KCl, 5 mM MgCl2,
1 mM glutathione, 1.5 mM ATP, 50 !g/ml BSA. The re-
actions were incubated for 25 min at 30◦C, followed by 60
min incubation with a stop solution (final concentrations:
0.5 mmol/l EDTA, 1.5% SDS, 2.5 mg/ml proteinase K).
The DNA was purified using Qiagen MinElute Reaction
Cleanup Kit followed by digestion with XmnI and treat-
ment with 200 !g/ml RNase A (Sigma-Aldrich, Germany).
MMR efficiency was estimated as described previously
(34), by digestion of the recovered DNAwith AclI. In order
to be able to visualize the repair tracts, the nuclear extracts
were supplemented with ["-32P]dATP. The DNA fragments
were then separated on 1% agarose gels containing GelRed
and visualized on a UV trans-illuminator. The gels were
then dried and exposed to PhosphoImager screens or X-ray
films.
UDG inhibition and immunodepletions
Where indicated, UDG was inhibited by the addition of
Ugi peptide (4.8 units) per 100 !g nuclear extract and pre-
incubation for 10 min at 37◦C. Immunodepletions were car-
ried out as described previously (34).
Primer extension reactions
Phagemid DNA recovered from the DSB assay was
subjected to primer extension reactions, using the 5′-
labeled ‘Blue’ GCCTCCCTCGCGCCATCAGCTTAAT-
GCGCCGCTACAGGG or ‘Red’ CTCATTAGGCACC-
CCAGGC primers (Figure 5). The reactions were per-
formed by adding 0.2 !M5′-labelled primer to 50 ng DNA,
1 mM dNTPs, 1x thermobuffer and 0.3 !l Taq polymerase.
The following parameters were used for the annealing and
extension reactions: 15 min at 95◦C, 15 min at 50◦C and 35
min at 72◦C. The reaction products were admixed with an
equal volume of formamide and separated on 5% denatur-
ing polyacrylamide gels. The gels were fixed in 50% EtOH,
40% H2O and 10% acetic acid, dried and exposed to Phos-
phoImager screens.
Transfection/transformation experiments
HEK 293 cells were grown to 60% confluence and trans-
fected with 1 !g U/G-U/G or C/G-C/G (ccc or nicked 5′
from the mispaired Us) plasmids (Amp resistant) and 500
ng of a control plasmid (Kan resistant) using calcium phos-
phate transfection. Twenty four hours post transfection,
the plasmids were recovered using a DNA extraction kit
(Qiagen). As DSB generation and religation was expected
to be rare, we used positive selection. Half of the recov-
ered plasmid DNAwas digested with PshAI, the restriction
site of which is situated in the vicinity of the uracils. Dele-
tions were expected to eliminate this cleavage site and hence
render the plasmid refractory to cleavage, while making it
also unable to form colonies. DH10B bacteria were trans-
formed with the digested or undigested plasmid DNA and
plated on kanamycin or ampicillin plates. Single ampicillin-
resistant colonies were picked and taken forward to colony
hybridization.
Colony hybridization
The colony hybridizations were performed essentially as de-
scribed (43). The colonies picked from the agar plate (see
above) were streaked on a fresh plate as shown in Figure 6B.
The bacteria were then transferred to a nitrocellulose mem-
brane by placing the membrane on top of the agar plate for
30 s. The membrane was then denatured and fixed as de-
scribed (43). The bacterial plate was kept at 4◦C. The clones
identified as mutated or deleted were then sequenced.
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Figure 1. Processing of the U/G-U/G substrate in vitro gives rise to DSBs. (A) Schematic representation of the circular heteroduplex substrates carrying
two U/Gmispairs, one located in the recognition site of AclI endonuclease at nucleotide 47 and the other at position 3182. The positions of the Nt.BstNBI
sites at nucleotide 351 (5′ substrate) or 2865 (3′ substrate), where a nick can be introduced selectively into the inner strand, and the position of the XmnI
cleavage site are indicated. Digestion of the phagemid DNA with XmnI resulted in its linearization (3194 bp). Upon incubation of the substrates (either
covalently-closed or nicked as shown in the respective figures) with the nuclear extracts, recovery and enzymatic digestion, appearance of DSBs in the
vicinity of the uracils (mimicked here by additional restriction with NotI that cuts between the two uracils) gave rise to two smaller fragments of about
1900 bp and 1300 bp. The efficiency of DSB induction was estimated by ImageQuant from scans of GelRed-stained agarose gels. (B) Minimal requirements
for DSB induction, analyzed by incubation of substrates containing two uracils in one strand and, where indicated, a nick either 3′ or 5′ from the mispaired
Gs with BL2 nuclear extracts (NE). The upper panel shows UV shadowing of an agarose gel stained with GelRed. Black arrows indicate the fragments
arising due to the presence ofDSBs. (C) DSBs arising in theU/G-U/Gsubstrate nicked 3′ from themispairedGs upon incubationwith extracts of BL2 cells,
LoVo extracts supplemented with recombinant MutS! or HEK 293TL!+ (MMR-proficient) extracts. Quantifications of three independent experiments
are shown in the lower panels. Error bars show mean +/− S.D. (n = 3).
Reconstituted DSB assay
For the in vitro DSB-assay, the reaction contained 100 ng
of the substrate, 375 fmol human MutS!, 460 fmol human
MutL!, 478 fmol human RPA, 26 fmol human EXOI, 1.2
fmol bacterial Uracil-DNA glycosylase and 0.378 fmol hu-
man AP Endonuclease. Briefly, the substrates were incu-
bated with the indicated proteins in the presence of 20 mM
Tris-HCl (pH 7.6), 3 mM ATP, 1 mM glutathione, 5 mM
MgCl2, 0.05 mg/ml BSA and 100 mM KCl. After incuba-
tion at 37◦C for 20 min, the samples were heat-inactivated
for 10 min at 80◦C, digested with XmnI and analyzed on a
1% agarose gel containing GelRed.
RESULTS
U/G processing in B-cell extracts promotes DSB formation
AID was reported to act in a processive manner (44) and
to target both strands in switch regions, albeit with dif-
ferent efficiencies (45). In an attempt to mimic the sub-
strates that might arise in vivo in our in vitro assays, we
set out to generate circular plasmids containing uracils in
bothDNA strands.However,U/Gmispairs arising through
AID-catalyzed deamination of cytosines are substrates for
both BER and MMR and processing of substrates carry-
ing several such mispairs could therefore potentially initiate
at any uracil residue, which would complicate the analysis
of the products. In order to simplify the situation, we gen-
erated substrates containing two U/G lesions in the same
strand, representing the processive action of AID, and a
nicking site for Nt.BstNBI on the opposite strand, either 3′
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or 5′ from the uracils (Figure 1A, left panel), representing
a cleaved abasic site generated upon removal of a uracil by
UNG and hydrolysis by APE1 that would provide an entry
site for MMR as shown in our earlier work (34). Restric-
tion digest of these substrates with XmnI gives rise to the
linearized full-length plasmid molecule of 3193 bp (Figure
1A, top right panel), but a DSB arising in the vicinity of
the uracils would give rise to fragments migrating close to
the 1923 and 1270 bp fragments generated by XmnI/NotI
cleavage (Figure 1A, bottom right panel). When we in-
cubated the closed-circular U/G-U/G substrates (which
should be addressed by BER but not by MMR due to the
absence of a pre-existing nick) with nuclear extracts (NE) of
BL2 (human Burkitt lymphoma) B cells and subjected the
recovered DNA to XmnI digest, only the full-length frag-
ment was detectable (Figure 1B, lane 1). Introduction of
a single nick (MMR entry site) in the opposite strand ei-
ther 5′ or 3′ from the U/G mispairs prior to incubation of
the substrates with the extracts yielded ∼10% of molecules
cleaved by XmnI into two fragments of ∼2000 and ∼1200
bp in size, indicative of the presence of DSBs in the vicinity
of the uracil residues (Figure 1B lane 1 versus lanes 2, 3).
Induction of DSBs in the nicked U/G-U/G substrate is not
limited to B-cell extracts
In order to learn whether theDSBs arising as a consequence
of uracil processing require B-cell specific factors, we com-
pared the processing of the above substrates in B-cell ex-
tracts to that in extracts of LoVo and HEK293T-L! cells.
The former is a MMR-deficient human colon cancer cell
linemutated inMSH2, but the extracts can bemadeMMR-
proficient by complementation with purified recombinant
MutS!. The latter cells are of human embryonic kidney ori-
gin. The MLH1 MMR gene is silenced by methylation in
these cells, but we have modified them to express exogenous
MLH1 upon treatment with doxycycline (46). As shown
in Figure 1C, DSBs were generated in nuclear extracts de-
rived from BL2 cells as shown previously (lane 1), and even
somewhat more efficiently in the MMR-proficient extracts
of LoVo cells supplemented with recombinantMutS! (lane
2) or in HEK293T-L!+ extracts expressing MLH1 (lane 3).
This finding demonstrates that DSB generation in this sys-
tem is not limited to B-cell extracts.
UNG and MutS! play key roles in DSB induction
As mentioned above, genetic evidence showed that both
BER and MMR participate in CSR. We therefore wanted
to test whether the induction of DSBs in our system was de-
pendent on these repair pathways. MMR-deficient extracts
of LoVo cells generated noDSBs in theU/G-U/Gsubstrate
containing a single nick in the G strand 5′ from the mispairs
(Figure 2A, lane 1) and addition of the uracil DNA glycosy-
lase inhibitor Ugi did not alter the situation (lane 2). When
the MMR defect in these extracts was complemented with
MutS!, DSBs were formed (lane 3), but their formation
was effectively inhibited by Ugi (lane 4). This showed that
the breaks were generated by a process requiring uracil ex-
cision. Similar observations were made when the substrate
contained a nick in the G strand 3′ from the mispairs (Fig-
ure 2A, lanes 5–8). In order to test whether DSB induction
required enzymatically-activeMutS!, we supplemented the
LoVo extract with the MutS! KR variant, which is mu-
tated in the ATP binding motifs of bothMSH2 andMSH6.
This variant is unable to undergo the ATP-driven transition
to a sliding clamp and hence remains bound at the mis-
match (47). Unlike the wild type protein (Figure 2A, lane
7), MutS!KR failed to restore DSB induction in LoVo ex-
tracts (lane 9). The generation of DSBs thus requires not
only the binding of MutS! to DNA, but also its ATPase
activity.
We next studied the requirement for MutL! (a het-
erodimer of MLH1 and PMS2). When the nick was posi-
tioned 5′ from the mispaired guanines, DSBs were induced
independently of MutL! (Figure 2B, lanes 1 and 3). As
above, their formation was inhibited by Ugi (lanes 2 and
4). In contrast, MutL! was indispensable for the induction
of DSBs in a substrate containing the nick 3′ from the mis-
paired guanines (Figure 2B, lane 9). No DSBs were formed
when the extracts were supplemented with aMutL! variant
lacking endonuclease activity (lane 7). These results con-
form to our understanding of MMR mechanism (see also
Discussion), in which excision initiated at a 3′ nick displays
an absolute requirement forMutL!, whereas excision start-
ing at a 5′ nick does not (48). The requirement for UNG
showed that DSB formation in these substrates required
an intermediate of uracil processing, most likely a strand
break arising through APE1-mediated cleavage of the aba-
sic site generated by the UNG-catalyzed removal of one of
the uracils. DSBs might then arise through the collision of a
U/G-activatedMMR-catalyzed excision tract in the nicked
strand with a cleaved abasic site in the other strand.
The requirement for MMR in DSB formation is dependent
on the distance between the nick and the U/G mispairs
In the Ig loci of activated B-cells, AID carries out multi-
ple deaminations (44) in both strands (45). In an attempt
to gain further insight into the criteria necessary to give
rise to BER- and MMR-dependent DSBs in vivo, we var-
ied the distance between the uracils and the nick in the op-
posite strand. By using uracil-containing oligonucleotides
in the primer extension reaction that annealed closer to
the Nt.BstNBI site, we were able to generate an additional
substrate (Figure 3B), in which the nicking site was 58 nu-
cleotides 5′ from the G of the nearest U/G mispair rather
than 304 (Figure 3A). When the nick was 58 nucleotides
away, the DSBs were formed with similar efficiency as in the
substrate where it was 304 nucleotides away (Figure 3C).
[NB: In the ‘58’ substrate, a DSB generated close to the
uracils and XmnI cleavage generate two fragments of simi-
lar size, hence only a single band is seen in the agarose gel,
as opposed to two different size bands generated from the
‘304’ substrate.]
Because CSR efficiency is only decreased and not abol-
ished in MMR-deficient cells, we wanted to test whether
the DSBs generated in the ‘58’ substrate were MMR-
dependent, like those detected in the ‘304’ substrate (Fig-
ure 2). As shown in Figure 3D, incubation of the former
substrate with MMR-deficient extracts of LoVo cells re-
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Figure 2. UNG and MutS! play key roles in DSB induction. (A) Lanes 1–4: DSB formation in a U/G-U/G substrate, nicked 5′ from the mispaired Gs,
upon incubation with NE of LoVo cells supplemented with recombinant MutS! and pretreated with Ugi where indicated. Lanes 5–10: Incubation of the
U/G-U/G substrate, nicked 3′ from the mispaired Gs, with LoVo extracts supplemented either with wild type MutS! or the ATPase-dead KR mutant,
and pretreated with Ugi where indicated. (B) Lanes 1–4: DSB formation in a U/G-U/G substrate, nicked 5′ from the mispaired Gs, upon incubation with
MMR-proficient (HEK 293T-L!+) and -deficient (HEK 293T-L!-) extracts. UNG was inhibited by the addition of Ugi where indicated. Lanes 5–10:
DSB formation in a U/G-U/G substrate, nicked 3′ from the mispaired Gs, upon incubation with MMR-proficient (HEK 293T-L!+) or -deficient (HEK
293T-L!−) extracts. The MMR-deficient extracts were supplemented with either wild type MutL! or its endonuclease-deficient mutant (DN). Extracts
were pretreated with Ugi where indicated. Quantifications of three independent experiments are shown in the lower panels. Error bars show mean +/−
S.D. (n = 3).
sulted in the generation of DSBs when the extract was sup-
plemented with purified recombinant MutS! (lane 3), but
were detectable, albeit only weakly, even in the unsupple-
mented extract (lane 1). Because DSB formation was still
absolutely dependent on UNG (lanes 2,4), we postulated
that they must have arisen byMMR-independent exonucle-
olytic degradation between the nick and the cleaved abasic
site(s) in the opposite strand. This was substantiated by the
finding that no DSBs were detected upon incubation of this
substrate with extracts of EXO1-deficient cells (Supplemen-
tary Figure S1).
The DSB formation is dependent on sequence context
As mentioned in the Introduction, deletions occurring at
the Ig locus during CSR initiate and terminate at the in-
tergenic S regions. In order to learn whether these repet-
itive sequence elements affect the efficiency of DSB for-
mation, we cloned a fragment of the S"-region into our
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phagemid and positioned the U/G mispairs 52 nucleotides
apart within this sequence (see Materials and Methods).
As shown in Figure 3E, DSB induction in the switch re-
gion sequence context was more efficient than in the orig-
inal phagemid (compare lanes 1,3,5,7 with lanes 2,4,6,8).
This result suggested that the S regions might be highly
recombinogenic in vivo not only because they contain nu-
merousAID consensus sequences, but possibly also because
the highly-repetitive sequences might form secondary struc-
tures upon degradation of one strand. This would hinder re-
pair synthesis and thus increase the time window for a col-
lision of the MMR and or BER degradation tracts, which
could result in DSB formation.
MMR involvement in DSB generation requires U/Gmispairs
Exonucleolytic degradation of the error-containing strand
during postreplicative MMR is initiated by loading of
EXO1 at the nick by mismatch-activated MutS!. We
wanted to confirm that the MMR-dependent DSB forma-
tion observed in our assays was indeed triggered by MutS!
binding to the U/G mispairs. We also wondered whether
the low efficiency of DSB formation was linked to the rapid
removal of the uracils by UNG, which would convert our
U/G-U/G substrate into a DNA molecule carrying two
abasic sites, which are not substrates for MutS!. We there-
fore generated a substrate carrying only a single U/G mis-
pair and a synthetic abasic site (a tetrahydrofuran ring) in
place of the second uracil. This substrate mimics the U/G-
U/G substrate from which one uracil had been removed
by UNG. When a nick was introduced 3′ or 5′ from the
mispair into the unmodified G strand, DSBs arose only in
the MMR-proficient extract and upon inhibition of UNG
with Ugi (Figure 3F, lanes 4,8). This suggested that UNG-
catalysed removal of the uracil was more rapid than recog-
nition of the U/G mispair by MutS!. Once the uracil was
removed, the substrate contained either two abasic sites (in-
tact or cleaved), or two C/G pairs generated by success-
ful BER (see next section). As neither abasic sites nor C/G
pairs are substrates for MMR, the strand degradation pro-
cess was not activated.
U/G mispairs are processed by BER more rapidly than by
MMR
We could test the above hypothesis directly. The 3′ uracil in
the U/G-U/G substrate is situated in an AclI site such that
it renders the substrate refractory to cleavage by this enzyme
(Figure 4A). Correction to C/G, which can be mediated ei-
ther by BER or by MMR directed to the uracil-containing
strand, restores the AclI site (35). Because the repaired plas-
mid contains three AclI sites as opposed to only two in the
U/G-U/G substrate, digestion of the repaired plasmid with
AclI gives rise to three fragments of 1515, 1305 and 373 bp,
whereas the unrepaired plasmid is cleaved into only two, of
2820 and 373 bp. As shown in Figure 4B (lane 1), incubation
of the U/G-U/Gplasmid nicked in the G strand 5′ from the
mismatch in the AclI site with MMR-proficient extracts of
HEK293TL!+ cells resulted in ∼60% repair to C/G. Im-
portantly, much of this repair was mediated by BER, as its
efficiency was reduced by maximally 50% (lanes 2,3) in the
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presence of aphidicolin, an inhibitor of DNA polymerase
! that carries out repair synthesis in the in vitro MMR re-
action (26). Moreover, the MMR-mediated events were di-
rected into the U-containing strand, most likely through re-
pair tracts initiating at the cleaved abasic site generated by
BER at the 5′ uracil (34), because only U/G to C/G repair
restores the AclI site. This was further confirmed by the in-
corporation of ["-32P]dAMP into the 1515 and 1305 bpAclI
fragments that only arise upon U/G to C/G repair (Figure
4C, lane 1).
In contrast, inhibition of UNG with Ugi inhibited AclI
cleavage almost completely (Figure 4B, lanes 4–6). Impor-
tantly, MMR was activated on this substrate more effi-
ciently than in the absence of Ugi, as witnessed by the
greater incorporation of ["-32P]dAMP into the phagemid
molecules (Figure 4C, lane 4). Moreover, this process was
mostly directed to the G-strand, given that the labeled
molecules were refractory to AclI cleavage. This is indica-
tive of U/G-activated MMR repair tracts initiating at the
Nt.BstNBI nicking site, which would convert the U/G mi-
spairs into U/A pairs.
Taken together, the latter evidence helps explainwhyDSB
incidence in our system is relatively low. First, to generate
a DSB, the MMR repair tract must collide with a BER
intermediate in the opposite strand. Second, in order for
MMR to be activated, some U/G mispairs must remain in
theDNA, which is likely to occur only rarely due to the high
efficiency of BER.
In vitro-generated DSBs cluster mostly in the proximity of
the uracil sites
Using primer extension assays, we mapped the position of
the DSBs arising in the U/G-U/G substrate nicked 3′ from
the mispairs in the G-strand upon incubation with extracts
of MMR-proficient HEK 293TL"+ cells. The most promi-
nent breakpoint in the G-strand (mapped with the ‘blue’
primer) was located in close proximity of the AclI site con-
taining the distal (3′) uracil residue (Figure 5A, lane 1).
Upon inhibition of UNG with Ugi (lane 2), several weaker
bands were detected, which were most likely generated by
the MutL" heterodimer (49) upon MMR activation by the
U/G mismatch.
The major breakpoint in the uracil-containing strand,
mapped by extension of the ‘red’ primer, also resided at or
close to the uracil within the AclI site (Figure 5B, lane 1). As
addition of Ugi to the extract substantially reduced the in-
cidence of this breakpoint (lane 2), we propose that it arose
through APE1-catalyzed cleavage of the abasic site gener-
ated byUNG.Under the latter conditions, a second, slightly
shorter, product was also detected. This fragment might
represent an intermediate of uracil processing by long-patch
BER initiated by other glycosylases present in the extracts
(MBD4, SMUG1 or undepleted TDG).
DSBs in the U/G-U/G substrate are induced also in vivo
The sizes of the plasmid fragments generated from the
U/G-U/G substrates in our in vitro assay indicated that the
DSBs were occurring in close proximity to the uracils. We
wanted to learn whether these findings reflected the process-
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Figure 5. Breakpoints in the U/G-U/G substrate are at or near the uracil
residues. U/G-U/G substrate nicked 5′ from the mispaired Gs was incu-
batedwithHEK293T-L"+/− extracts pretreatedwithUgiwhere indicated.
The DNA was recovered and subjected to primer extension using 5′ la-
beled primers ‘blue’ and ‘red’ (see Materials and Methods). The reaction
products were separated on 5% denaturing polyacrylamide gels. Markers
were products of primer extensions on plasmids digested with AclI (A) or
NotI (N). The ‘blue’ primer was complementary to the G strand (A), the
‘red’ primer was complementary to the uracil-bearing strand (B) as shown
schematically between the panels. The figure shows representative autora-
diographs from four independent experiments.
ing of these substrates in vivo. DSBs arising upon transfec-
tion of the U/G-U/G plasmids into human cells should be
repaired by non-homologous end-joining (NHEJ), a pro-
cess that generally leads to a small loss of genetic informa-
tion at the break (50,51). We therefore designed a proto-
col that enabled us to identify the mutated plasmids among
the large excess of molecules that were corrected by BER
to C/G-C/G without mutations. We carried out these ex-
periments in human kidney 293 (HEK 293) cells, because
they can be transfected with very high efficiency. Moreover,
we showed above that DSBs form in uracil-containing sub-
strates also in non-B cell types, and ectopic expression of
AID in non-B cells was shown to trigger both SHM and
CSR (52–54), suggesting that AID is the only B-cell-specific
factor required for these processes.
We transfected the U/G-U/G or the control C/G-C/G
substrate into the HEK293 cells, either wild-type or de-
pleted of MutS" with siRNAs targeting MSH2 and MSH6
(Figure 6A), recovered the plasmid DNA 24 h later and
used it to transform competent E. coli after digestion with
PshAI. The cleavage site of this enzyme is situated in close
proximity of the uracils and it was therefore anticipated that
all plasmid molecules carrying the wild-type sequence at
this site would be linearized and thus made transformation-
incompetent. [NB: The enrichment for mutant molecules
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Figure 6. In vivo repair ofDSBs in theU/G-U/Gsubstrate leads tomutations and deletions. (A)Western blot of extracts ofHEK293 cells showing efficiency
of knock-down of MSH2 and MSH6 with siRNA. (B) Autoradiograph of a representative filter carrying plasmid DNA recovered from transfections of
HEK 293 cells with the U/G-U/G substrate nicked 5′ from the mispaired Gs, hybridized with a radiolabeled oligonucleotide complementary to the wild
type (unmodified) plasmid sequence flanking the uracil residues. (C) Mutated and deleted plasmids recovered from multiple transfections of HEK 293
cells with the listed substrates. (D) As in C, but the substrates were transfected into HEK 293 cells depleted of MutS!. (E) As in C, but the substrates were
transfected intoHEC59+ chr2 cells (MMR-proficient). (F) As inC, but the substrates were transfected intoHEC59 cells. (G) Incidence ofmicrohomologies
in plasmids recovered from transfections of the indicated substrates into HEK 293 cells depleted or not of MutS!. (H) Incidence of microhomologies in
plasmids recovered from transfections of the indicated substrates into HEC 59 + chr2 or HEC 59 cells.
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by digestion with PshAI was necessary, because the forma-
tion of DSBs and/or uracil misrepair in vivo are extremely
rare.] In six independent experiments, we generally obtained
∼20 times more colonies from transformations with the re-
covered PshAI-digested U/G-U/G plasmid than with the
C/G-C/G homoduplex control (data not shown). How-
ever, DNA sequencing revealed that the majority of these
molecules in both populations were devoid of mutations,
which implied that the PshAI digest was not quantitative.
We therefore introduced a second screening step for the
mutants: colony hybridization with a radiolabeled oligonu-
cleotide complementary to the sequence flanking the PshAI
site. We then sequenced only those colonies that indicated
the presence of point mutations or deletions (Figure 6B).
As shown in Figure 6C and Supplementary Figure S2A,
of 326 sequenced colonies from control transformations
of HEK 293 cells with the covalently-closed circular (ccc)
C/G-C/Gplasmid, 7 (2.1%) contained pointmutations and
7 (2.1%) contained deletions. Because the mutants were se-
lected with a probe located between the two uracil residues,
all examined deletion mutants lost this site. DNA sequenc-
ing revealed that these very rare deletions in the unnicked
C/G-C/G substrate were several hundred base pairs long
and did not share their end points. The presence of a nick
in the G strand of this substrate trebled the occurrence of
these large deletions to 6.3% and, as anticipated, one end
point of these deletions was often (∼30%) close to the posi-
tion of the nick. Transfection of the cccU/G-U/Gsubstrate
yielded both mutations (8.5%) and deletions (7%), which
were generally short, mostly <200 bp. Transfection of the
nicked U/G-U/G substrate yielded plasmids containing a
similar amount of mutations (8.7%), but substantially more
deletions (16%), largely spanning the distance between the
position of the uracils and the Nt.BstNBI nick. Most of the
end-joining events occurred at sequences with no apparent
homologies. This resembled analysis of hybrid S-S junctions
in immunoglobulin switch regions, which showed that the
sequences were fused at or very close to AID hotspots (40).
We also detected several translocation events between the
U/G-U/G plasmid substrate and genomic DNA (Supple-
mentary Figure S2A, yellow lines). This finding shows that
DSBs arising through the interplay ofMMR and BER dur-
ing the processing of proximal uracil residues in our sub-
strate are recombinogenic and provides independent sup-
port for the hypothesis that chromosomal translocations
arising in activated B cells (55) might have arisen through
a similar mechanism.
We next wanted to study the effect of the MMR sys-
tem on the above events. To this end, we treated the HEK
293 cells with siRNA targeting MSH2 and MSH6 to de-
plete MutS! (Figure 6A). Transfections of the above sub-
strates into these cells yielded some unanticipated results
(Figure 6D, Supplementary Figure S2B), inasmuch as the
proportion of deletions was similar in all four substrates
(8% for ccc C/G-C/G, 9.5% for nicked C/G-C/G, 5.3% for
ccc U/G-U/G and 9.3% for nicked U/G-U/G), but––most
remarkably––the number of point mutants was substan-
tially reduced (0.8% for ccc C/G-C/G, 1% for nicked C/G-
C/G, 1.9% for ccc U/G-U/G and 2.7% for nicked U/G-
U/G). In all these mutants, the deletions were large and the
influence of the nick was much less pronounced, which con-
firms that the nick is a specific signal for MMR-catalyzed
strand degradation events.
We then transfected these substrates into the MMR-
deficient human endometrial cancer cell lineHEC 59, which
is mutated in MSH2, or HEC 59 + chr2 cells, in which
the MMR defect was corrected by transfer of chromosome
2 that carries the wild type MSH2 gene. Unexpectedly,
the number of point mutants identified in both cell lines
was very low, but the number of deletions in the MMR-
proficient cells (Figure 6E, Supplementary FIgure S2C) was
more than 2.5-fold higher than in the MMR-deficient line
(Figure 6F, Supplementary FIgure S2D), particularly in the
nicked U/G-U/G substrate. Their size and end-points re-
flected those observed in HEK 293 cells. Interestingly, se-
quence analysis of the clones revealed an increase in the
number of microhomologies around the break points in the
plasmids recovered from MMR-deficient MutS!-depleted
HEK 293 (Figure 6G) andHEC 59 cells (Figure 6H), which
suggests that the molecular mechanism of DSB repair is af-
fected by theMMRstatus of the cells. [N.B.: The sequencing
data are not shown due to space limitations, but are avail-
able upon request.]
DSBs arise in the nicked U/G-UG substrate in a system re-
constituted from purified proteins
Based on the results of the above experiments and on pub-
lished biochemical (34,35) and genetic (40,56,57) data, we
postulated that the DSBs in the nicked U/G-U/G substrate
might arise by a mechanism outlined in Figure 7. To sub-
stantiate that the DSBs in our system arose by this mech-
anism and that the process did not involve additional, as
yet unidentified, factor(s) present in human cell extracts,
we reconstituted the repair process from purified recombi-
nant UNG, APE1, MutS!, MutL!, RPA (required to sta-
bilize the single-stranded DNA gap) and EXO1. As shown
in Figure 8, DSB generation in the substrate nicked in the
G-strand 5′ from the mispairs was rather efficient.
DISCUSSION
Antigen-induced B cell activation leads to the expression of
AID, which is targeted to the Ig loci, where it deaminates
a subset of cytosines in its preferred recognition sequences
to uracils. Metabolism of the AID-generated uracils then
triggers SHM, during which the rearranged VDJ regions
undergo extensive mutagenesis, and CSR that affects the
switch regions between the constant genes. Here, uracil pro-
cessing results in the generation of not only mutations, but
also DSBs that trigger non-homologous end-joining and
cause an irreversible loss of the interveningDNA sequences.
Genetic evidence implicated BER and, to a lesser extent,
alsoMMR in both these processes, even though the absence
of UNG resulted in a substantially more severe phenotype
thanMMRdeficiency. However, the absence of bothMMR
and BER abolishes CSR completely (58,59).What is the na-
ture of themolecular transactions that allowSHMandCSR
to subvert antimutator DNA repair processes such as BER
andMMR to give rise tomutations and genomic rearrange-
ments?
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Figure 7. Putative scheme of BER- and MMR-dependent DSB induction in Ig loci. The first step of CSR is the active recruitment to the Ig locus of AID,
which deaminates several cytosines in both DNA strands. The U/Gmispairs generated at these sites are substrates for both BER andMMR. In a scenario
explored in the present study, removal of a uracil in the bottom strand by UNG followed by APE1-mediated cleavage of the abasic site would generate
the substrate shown in (A). Recognition of one of the remaining U/G mispairs by MutS!/MutL! causes activation of the complex and its translocation
along the DNA contour. Interaction with PCNA loaded at the cleaved abasic site (B) activates the endonuclease activity of MutL!, which, upon complex
formation with PCNA, introduces additional nicks into the discontinuous (bottom) strand (C). One of these is used as an entry site for EXO1, which
commences to degrade the DNA in a 5′ to 3′ direction (D). If the remaining Us in the upper strand were in the meantime addressed by UNG (E), APE1
will cleave the abasic sites (F). Collision of the EXO1-catalyzed excision tract in the lower strand with the APE1-induced break in the upper strand will give
rise to a DSB and EXO1 dissociation (G). [N.B. In this scenario, DSB formation is absolutely dependent on MutL!, which has to introduce additional
nicks into the bottom strand, some of which must be situated 5′ from the mispaired Gs. Only then will EXO1 be able to degrade this strand toward the U/G
mispairs. Had the process been initiated by the removal of a uracil residue 5′ from the two mispaired Gs, the process would have been largely independent
of MutL!.]
We argued that one answer to this question might lie in
the processive action of AID. Because this enzyme is tar-
geted to the variable and switch regions of the Ig locus (60),
uracils arise at these sites frequently and are clustered to-
gether, rather than being dispersed and rare, as is the case
when they arise through spontaneous hydrolytic deamina-
tion. This unique situation provides both BER and MMR
with substrates in the same region of DNA and, because
the two repair systems do not normally encounter each
other, it is likely that there are no evolutionary safeguards
in place that prevent them from interfering with one an-
other. Our experiments suggest that the incidence of DSBs
arising through BER and MMR interference is rather low,
even in our system that was designed to increase the likeli-
hood of their detection. In vivo, the mutagenic events trig-
gering SHM/CSR also occur rather infrequently, but they
are detectable due to a process of positive selection of the
mutated and/or rearranged clones. Moreover, CSR can be
triggered by only a few breaks, providing that they occur at
sites conducive to recombination, such as the Ig switch re-
gions. Experimental evidence in support of the hypothesis
that strategically-placed DSBs are sufficient for CSR was
provided by replacement of the switch regions with yeast
I-SceI endonuclease cleavage sites (61).
The finding that CSR-associated DSBs arise outside of
S-phase (40) rules out the possibility that these DSBs are
generated when replication forks encounter single-strand
breaks arising through APE1-mediated cleavage of abasic
sites left behind after uracil removal. In this study, we pro-
vide evidence supporting this hypothesis, inasmuch as the
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Figure 8. Reconstitution of the minimal BER/MMR interference system.
The minimal mismatch repairosome was assembled from purified recom-
binant MutS!, MutL!, RPA, EXO1, RFC and PCNA. Uracil process-
ing was mediated by purified recombinant UNG and APE1. Following
incubation of the U/G-U/G and nicked U/G-U/G substrates with the
indicated protein combinations, the recovered plasmids were subjected to
electrophoresis on 0.8% agarose gels. The panel shows an image of a repre-
sentative gel stained with GelRed. Bar graph shows quantification of three
independent experiments. Error bars show mean +/− S.D. (n = 3).
DSBs arising in our in vitro assay arise in DNA molecules
that do not replicate and that therefore lack strand dis-
crimination signals (such as Okazaki fragment termini) that
MMR uses to direct excision to the nascent DNA strand.
Indeed, no DSBs were generated in the covalently-closed
U/G-U/G substrate even when BER was active (Figure 1),
nor were they formed in the same substrate when BER was
blocked by the addition of Ugi, even though a nick was
present in the G-strand (Figures 2–4). In contrast, when
BERwas active, DSBs were readily detected, providing that
the substrate was nicked and that MMR was also active.
This shows that the breaks in our system were generated
by interplay of the two pathways, where MMR-dependent
strand excision initiated at the nick in one strand collided
with a cleaved abasic site arising after uracil removal and
in the opposite strand. This hypothesis is experimentally
substantiated by our break- and deletion-mapping exper-
iments, which showed that the DSBs were predominantly
positioned at or close to one of the uracils (Figure 5) and
that the deletions most often spanned the distance between
the nick and the closest uracil (Supplementary Figure S2).
It should be remembered that the nick in our model sub-
strates acts as a surrogate for an APE1-cleaved abasic site
arising through UNG-catalyzed uracil removal, which we
could show previously to act as a loading site for MMR-
activated EXO1 (34).
During processive AID-catalyzed cytosine deamination
of the Ig loci, uracil residues would be generated in both
strands in close proximity. Although BER is normally ex-
tremely efficient, uracil repair in antigen-activated B cells
appears to be sluggish. This leads on the one hand to muta-
tions caused probably to Rev1/pol-" -catalyzed error-prone
by-pass of a subset of abasic sites arising at the sites of
deamination upon uracil removal by UNG and, on the
other hand, to strand breaks generated by APE1-catalyzed
cleavage of another subset of these abasic sites. Thus, AID-
deaminated S region might contain intact U/G and G/U
mispairs, as well as incised and intact abasic sites. The intact
mispairs would activate MMR, which would load EXO1 at
the strand discontinuities to generate a single-stranded ex-
cision tract that could be up to a kilobase long. If this tract
were to collide with a cleaved abasic site or indeed with a
MMR-activated EXO1-catalyzed excision tract in the op-
posite strand, a DSB would arise.
Our transfection experiments yielded also an unexpected
finding, in that the frequency of microhomologies was
higher in MMR-deficient cells compared to the MMR-
proficient controls (Figure 6). The requirement for MMR
in the control of HR fidelity has long been known (62), but
its involvement in NHEJ or microhomology-mediated end-
joining (MMEJ) has to our knowledge not been reported to
date in recombination-proficient cells.
DSBs are a frequent cause of chromosomal rearrange-
ments that play a key role in cancer, particularly in in-
stances where recombination is disrupted, such as in case
of BRCA1/2 mutations that cause breast cancer predispo-
sition (63). In B-cells, deregulation of AID expression and
its aberrant targeting induces translocations and results in
lymphomagenesis (64), and it would appear highly likely
that the latter chromosomal rearrangements are triggered
by DSBs arising through MMR- and BER-mediated pro-
cessing of AID-generated uracils. As shown above, the in-
terference of MMR and BER is neither specific to B-cells,
nor to U/G processing. We therefore posit that this phe-
nomenon could come into play in instances where DNA
modifications, such as U/G mispairs, addressed by both
systems are generated at high density. One analogous ex-
ample is methylation damage induced by SN1 type methy-
lating agents, such as the cancer therapeutics temozolo-
mide, dacarbazine or streptozotocin, which generate sub-
strates for both BER andMMR and which are highly toxic
to MMR-proficient, but not –deficient cells (46). It is also
possible that the interference of MMR and BER may be
the cause of the MMR-dependent DNA damage-induced
chromosomal instability in colon cancer cells (65). Indeed,
MMR-deficient colon cancer cell lines are generally diploid,
in contrast to MMR-proficient cells, which are frequently
aneuploid (8).
DNA repair processes are generally thought of as
guardians of our genome. In this work we demon-
strate that their canonical roles can––under certain
circumstances––cause genomic instability. In this particu-
lar case, mutagenesis and genetic deletions that accompany
SHM/CSR are beneficial to the organism, given that they
protect it from infections. Moreover, these processes affect
B cells that are programmed to die, which minimizes the
possibility of deleterious side effects. Thus, even though
aberrant recombination linked to antibody diversification
may in rare instances cause cancer, the benefits offered
by SHM/CSR in evolutionary terms far outweigh the
drawbacks. It is our hope that an understanding of the
molecular mechanisms of the latter processes will help us
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find the Achilles heel of cells in which antibody diversi-
fication went awry and, in the long run, identify ways of
eliminating them.
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Figure S1. DSB induction in the “58” substrate is EXO1-dependent 
The U/G-U/G substrate “58” nicked 5’ from the mispaired Gs was incubated with 
extracts of HEK293 cells pretreated with siRNA targeting EXO1 mRNA and 
supplemented where indicated with Ugi and/or recombinant purified EXO1. As shown, 
no DSBs are formed in the absence of EXO1, even though the nick in the bottom strand 
and the nearest UNG/APE1-cleaved abasic site in the upper strand are only 58 base 
pairs apart. The figure is a UV-shadowing image of a 0.8% agarose gel stained with 
GelRed.  
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Figure S2. Graphic representation of  in vivo deletions detected in the U/G-U/G “304” 
substrate nicked 5’ from the mispaired Gs.  
A. Deletion in plasmids recovered from multiple transfections of HEK 293 cells with the listed 
substrates. B. As in A, but the substrates were transfected into HEK 293 cells depleted of MutSα. 
C. As in A, but the substrates were transfected into HEC 59 + chr2 cells (MMR-proficient). D. 
As in A, but the substrates were transfected into HEC 59 cells. Vertical red lines indicate the 
positions of the uracils and the triangle shows the position of the nick. 
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A	methylation-responsive	E-box	binding	protein	controls	estrogen-dependent	transcription	of	the	chicken	vitellogenin	gene			Lia	Kallenberger1,3,	Rachel	Erb1,3,	Josef	Jiricny1,2,3		
1Institute	of	Molecular	Cancer	Research,	University	of	Zurich,	Winterthurerstrasse	190,	
CH-8057	Zurich,	Switzerland	
2Department	of	Biology,	Swiss	Federal	Institute	of	Technology	(ETH)	Winterthurerstrasse	190,	
CH-8057	Zurich,	Switzerland	
3Present	address:	Department	of	Biology,	Institute	of	Biochemistry,	Swiss	Federal	Institute	of	
Technology	(ETH)	Winterthurerstrasse	190,	CH-8057	Zurich,	Switzerland			Abstract		The	regulation	of	vitellogenin	(VTG)	transcription	has	been	extensively	studied.	The	hormone-inducible	expression	of	the	gene	was	shown	to	be	accompanied	by	extensive	 chromatin	 remodeling	 and	 strand-specific	 DNA	 demethylation.	 The	pathways	involved	in	the	selective	removal	of	5-methylcytosine	(5mC)	remained	elusive,	 as	 there	 was	 no	 plausible	 mechanism	 described	 for	 active	 DNA	demethylation,	 despite	 the	 common	 consensus	 of	 its	 existence.	 With	 the	discovery	 of	 the	 ten-eleven	 translocation	 (TET)	 proteins	 and	 their	 oxidizing	activity	 towards	 5mC,	 a	 persuasive	 way	 to	 actively	 demethylate	 DNA	 was	emerging.	We	set	out	to	investigate	the	dynamics	of	5mC	metabolism	in	the	VTG	regulatory	region	in	a	hepatoma	cell	line.	We	saw	no	demethylation,	despite	the	fact	 that	 the	 gene	was	 efficiently	 induced	 upon	 β-estradiol	 treatment.	We	 did,	however,	 observe	 increased	 levels	 of	 5-hydroxymethylcytosine	 (5hmC),	 a	product	of	the	TET	enzymes.	Estrogen	receptor	α	binding	to	its	response	element	in	 the	 VTG	 enhancer	 was	 not	 altered	 by	 the	 presence	 of	 5mC	 or	 5hmC,	 as	assessed	 by	 electrophoretic	 mobility	 shifts.	 In	 nuclear	 extracts	 of	 different	origins,	however,	we	saw	 the	binding	of	a	methylation-sensitive	 factor.	 In	vitro	methylation	of	a	reporter	plasmid	under	the	control	of	the	VTG	regulatory	region	inhibited	transcription,	confirming	an	important	role	of	methylation	dynamics	in	the	control	of	VTG	expression.	We	have	evidence	that	another	CpG,	residing	in	an	E-box	 in	 the	 VTG	 promoter,	 is	 responsible	 for	 the	 observed	 methylation-sensitivity.	The	 factor(s)	 involved	 in	the	methylation-dependent	transcriptional	regulation	of	VTG	remain	to	be	characterized	and	will	provide	valuable	insights	into	the	role	of	methylation	and	its	removal	in	the	control	of	gene	expression.			Introduction		Methylation	of	 the	5-position	of	cytosines	 in	 the	CpG	sequence	context	 is	a	key	epigenetic	modification	of	DNA	in	higher	eukaryotes.	In	vertebrates,	around	90%	of	CpGs	are	methylated,	primarily	 in	the	bodies	of	genes	(Eckhardt	et	al.,	2006;	Rakyan	et	 al.,	 2004).	Unmethylated	CpGs	are	 found	 in	gene	 regulatory	 regions,	promoters	 and	 enhancers.	 Methylation	 patterns	 are	 established	 during	 early	embryogenesis	by	the	DNA	methyltransferases	DNMT1,	DNMT3a	and	DNMT3b.	DNMT3a/b	are	believed	to	be	the	major	de	novo	methyltransferases	that	modify	unmethylated	DNA,	while	DNMT1	 is	 believed	 to	 be	 the	 enzyme	 that	maintains	
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the	 methylation	 patterns	 following	 replication	 or	 repair	 (Bacolla	 et	 al.,	 1999;	Bestor,	1992;	Hsieh,	1999;	Okano	et	al.,	1998;	Pradhan	et	al.,	1999).	The	essential	nature	 of	 DNA	methylation	 is	 demonstrated	 by	 the	 fact	 that	 knock-out	mouse	models	show	early	lethality	(Li	et	al.,	1992;	Okano	et	al.,	1999).	While	 the	 establishment	 of	methylated	 cytosines	 is	 relatively	well	 understood,	little	 is	 known	 about	 the	 active	 erasure	 of	 methylation	 patterns.	 With	 the	discovery	of	the	ten-eleven	translocation	(TET)	enzymes,	a	new	attractive	model	of	active	DNA	demethylation	emerged	(Tahiliani	et	al.,	2009).	TET	enzymes	are	capable	 of	 oxidizing	 5-methylcytosine	 (5mC)	 to	 5-hydroxymethylcytosine	(5hmC),	5-formylcytosine	(5fC)	and	5-carboxylcytosine	(5caC)	and	the	latter	two	have	been	shown	to	be	excised	by	TDG	and	replaced	with	unmodified	cytosine	(He	 et	 al.,	 2011;	 Ito	 et	 al.,	 2011;	 Zhang	 et	 al.,	 2012).	 Nevertheless,	 there	 are	numerous	 remaining	 open	 questions	 concerning	 targeting	 of	 a	 possible	demethylation	 complex	 to	 specific	 loci,	 the	 exact	mechanism	 of	 action	 and	 the	consequences	on	gene	transcription.	DNA	 methylation	 in	 gene	 regulatory	 sequences	 has	 been	 generally	 associated	with	transcriptional	silencing.	Many	housekeeping	genes	have	CpG-rich	regions,	the	 so-called	 CpG	 islands,	 flanking	 their	 transcription	 start	 sites,	 which	 are	generally	unmethylated	and	transcriptionally	active	(Bird	et	al.,	1985;	Cooper	et	al.,	 1983).	 Their	 methylation	 is	 mainly	 described	 in	 imprinting,	 retroviral	silencing	 and	 X	 chromosome	 inactivation,	 where	 it	 is	 accompanied	 by	 gene	silencing	(Liu	et	al.,	1994;	Walsh	et	al.,	1998;	Woodcock	et	al.,	1997).	There	are	also	few	examples	of	CpG	island	methylation	at	selected	loci	in	a	highly	cell	type	specific	manner	during	development	(De	Smet	et	al.,	1996;	De	Smet	et	al.,	1999).	Established	 methylation	 patterns	 of	 CpG	 islands	 are	 thought	 to	 be	 relatively	stable	 in	 somatic	 cells	 after	 development	 is	 completed.	 Aberrant	 changes	 are	reported	in	aging	and	during	tumorigenesis,	leading	to	deregulated	expression	of	the	affected	genes	(Baylin	et	al.,	1986;	Gama-Sosa	et	al.,	1983;	Goelz	et	al.,	1985;	Noreen	et	al.,	2014;	Toyota	et	al.,	1999).	Research	on	DNA	methylation	has	been	heavily	focusing	on	CpG	islands,	but	evidence	pointing	towards	more	flexible	and	dynamic	 changes	 of	 DNA	methylation	 apart	 from	 CpG	 islands	 is	 accumulating.	These	changes	are	reported	to	occur	in	somatic	cells	upon	exogenous	stimuli	and	are	 also	 linked	 to	 the	 transcriptional	 silencing	 of	 genes	 (Amenya	 et	 al.,	 2016;	Kangaspeska	et	al.,	2008;	Metivier	et	al.,	2008;	Thomassin	et	al.,	2001;	Toker	et	al.,	2013).	A	relatively	well-studied	example	 is	 the	chicken	vitellogenin	 (VTG)	gene	 that	 is	expressed	in	the	liver	of	mature	hens,	but	not	roosters.	This	difference	correlates	with	 methylation	 of	 the	 enhancer	 sequence,	 which	 contains	 the	 estrogen-response	 element	 (ERE).	 Interestingly,	 the	 VTG	 gene	 in	 rooster	 liver	 could	 be	transcriptionally	 activated	 by	 a	 single	 β-estradiol	 (E2)	 injection,	 followed	 by	demethylation	of	a	Hpa	II	site	at	the	5'	end	region	of	the	gene	(Wilks	et	al.,	1982).	This	was	accompanied	by	 the	appearance	of	DNaseI	hypersensitive	sites	 in	 the	enhancer	 and	 promoter	 (Burch	 and	 Weintraub,	 1983).	 Church	 &	 Gilbert	sequencing	 of	 the	 genomic	 DNA	 showed	 that	 the	 transcription	 was	 activated	after	6	h	and	that	this	event	coincided	with	the	demethylation	of	four	CpGs	in	the	non-transcribed	strand	close	to	the	ER	binding	site.	After	24	h,	both	strands	were	demethylated.	 Passive	 demethylation	 through	 replication	 was	 excluded	 at	 the	early	 time	point	 (Saluz	et	 al.,	 1986).	The	molecular	mechanism	underlying	 this	
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phenomenon	has	not	been	elucidated	to	date.	In	1986,	the	molecular	machinery	involved	in	DNA	demethylation	had	not	been	characterized	yet.	We	 therefore	 wanted	 to	 make	 use	 of	 this	 inducible,	 well-studied	 system	 to	address	 the	 enzymology	 behind	 the	 DNA	 methylation	 and	 demethylation	 in	hormone-dependent	gene	activation	and	the	effects	on	transcription.			Material	and	Methods		
Cell	culture	LMH/2A	cells	were	grown	 in	Williams'	E	medium	(GIBCO)	without	phenol	red,	supplemented	 with	 10%	 FCS,	 streptomycin/penicillin	 (100	 U/ml)	 and	 L-Glutamine	(2.4	mM).	MCF-7	cells	were	grown	in	DMEM	(GIBCO)	with	phenol	red,	supplemented	 with	 10%	 FCS,	 streptomycin/penicillin	 (100	 U/ml)	 and	 insulin	(Sigma-Aldrich,	10	µg/ml).	Cell	lines	were	grown	at	37°C	in	a	6%	CO2	humidified	atmosphere.	Where	 indicated,	 cells	 were	 treated	with	 100	 nM	 β-estradiol	 (E2,	Sigma-Aldrich)	 or	 an	 equivalent	 volume	 of	 ethanol,	 or	 with	 8	 µM	 aphidicolin	(aph,	ready	made	solution,	Sigma-Aldrich)	or	an	equivalent	volume	of	DMSO.	E2	and	aphidicolin	were	added	freshly	every	12	h,	because	of	instability	under	cell	culture	 conditions.	 For	 the	 TET2	 overexpression	 experiments,	 cells	 were	transfected	 with	 the	 mouse	 TET2	 expression	 vector	 (FH-Tet2-pEF	 a	 kind	 gift	from	Anjana	Rao	 (Addgene	 plasmid	#	 41710)(Ko	 et	 al.,	 2010))	 24	 h	 before	 E2	treatment.		
Western	Blot	(WB)	Cells	 were	 collected	 using	 trypsin,	 washed	 in	 phosphate-buffered	 saline	 (PBS)	and	 lysed	 in	 RIPA	 buffer	 (50	 mM	 Tris	 pH	 8,	 1	 mM	 EDTA,	 1%	 NP-40,	 0.5%	deoxycholate	(DOC),	0.1%	SDS,	150	mM	NaCl).	Lysates	were	sonicated	(18	s,	50	cycles,	 70%	 amplitude;	 in	 a	 Bandelin	 Sonoplus	 GM70)	 and	 protein	concentrations	 were	 measured	 using	 the	 Bradford	 assay.	 1	 µl	 of	 sample	 was	diluted	in	800	µl	H2O	and	200	µl	of	Bradford	solution	(BioRad)	and	absorbance	was	 measured	 at	 595	 nm	 (Varian-Cary	 50	 Scan	 spectrophotometer).	 Protein	concentration	 was	 calculated	 using	 a	 calibration	 curve	 with	 increasing	concentrations	of	bovine	serum	albumin	(BSA).	30-80	µg	of	protein	were	boiled	in	1x	SDS	loading	buffer	(50	mM	Tris,	pH	6.8,	10%	glycerol,	1.6%	SDS,	0.1	M	DTT,	0.01%	bromophenol	blue)	and	separated	on	polyacrylamide	gels	(6-10%)	using	the	Mini	Trans-Blot	Electrophoretic	Transfer	Cell	(BioRad)	in	10%	SDS-running	buffer	 at	 130	 V.	 Proteins	 were	 transferred	 onto	 activated	 PVDF	 membranes	(Amersham	Pharmacia	Biotech)	from	1.5	h	to	overnight	in	25	mM	Tris,	192	mM	glycine	 and	 10%	methanol.	Membranes	were	 stained	with	 Ponceau	 S	 solution	(5%	acetic	 acid,	 0.1%	Ponceau	S,	Applichem)	 for	5	min	 to	 check	equal	 loading	and	successful	transfer,	and	blocked	for	1	h	in	5%	non-fat	dry	milk	in	1x	TBS-T	(20	mM	Tris	pH	7.4,	150	mM	NaCl,	0.1%	Tween-20).	Membranes	were	incubated	with	primary	antibody	overnight	at	4°C	in	5%	milk,	washed	3x	with	TBS-T	and	incubated	 for	 1	 h	 at	 RT	 in	 a	 secondary	 antibody	 (horseradish	 peroxidase-conjugated	 sheep	 anti-mouse	 or	 donkey	 anti-rabbit	 IgG,	 GE	 Healthcare).	Membranes	 were	 washed	 3x	 in	 TBS-T,	 incubated	 in	 WesternBright	Chemiluminescent	Detection	Reagent	(Advansta)	for	2	min	and	analyzed	with	a	Fusion	 Solo	 (Vilber	 Lourmat).	 Antibodies	 used	 were	 mouse	 Anti-Vtg	 (Abcam,	
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ab36794),	 rabbit	 Anti-TFIIH	 p89	 (Santa	 Cruz,	 sc-293),	 mouse	 Anti-ERα	(ThermoFisher,	 MA5-13065),	 mouse	 Anti-TET2	 (Abiocode,	 M1086-1),	 mouse	Anti-Flag	M2	(Sigma,	F3165),	mouse	Anti-HA	Tag	(GenScript,	A01244).		
Real-time	quantitative	PCR	(RT-qPCR)	Cells	 were	 harvested	 using	 trypsin	 and	 RNA	 was	 extracted	 according	 to	manufacturer's	 instructions	 (RNeasy,	 Qiagen).	 2	 µg	 of	 the	 extracted	 RNA	 was	reverse	 transcribed	 using	 the	 high	 capacity	 cDNA	 reverse	 transcription	 kit	(Applied	 Biosystems)	 according	 to	 manufacturer's	 instructions.	 125	 ng	 of	 the	cDNA	was	used	for	the	PCR	using	the	platinum	SYBR	green	qPCR	superMix-UDG	kit	 (Invitrogen)	 according	 to	 manufacturer's	 instructions,	 except	 that	 the	reaction	was	scaled	down	from	50	µl	to	20	µl.	The	standard	cycling	program	for	ABI	 instruments	was	used	(50°C	 for	2	min,	95°C	 for	2	min,	40x	(95°C	 for	15	s,	60°C	for	30	s)	and	melting	curve	analysis	at	65°C	for	15s,	heating	to	97°C	with	continuous	 acquisition	 per	 5°C,	 40°C	 for	 30	 s).	 The	 RT-qPCR	 was	 run	 on	 a	LightCycler	 480	 (Roche).	 GapDH	 primers	 were	 used	 as	 an	 internal	 control.	Technical	triplicates	were	made	for	every	sample	and	primer.	The	primers	used	are	listed	in	Table	S1	(SI).		
Chromatin	immunoprecipitation	75	Mio	 LMH/2A	 cells	were	 harvested	 after	 24	h	 treatment	with	 100	nM	E2	 or	EtOH.	 Cells	 were	 washed	 twice	 with	 PBS	 and	 fixed	 for	 10	 min	 in	 1%	formaldehyde	at	RT.	Fixation	was	quenched	with	125	mM	glycine	at	RT	 for	10	min.	Cells	were	collected	by	centrifugation	at	300	x	g	for	5	min	at	4°C.	Cells	were	washed	 twice	with	PBS	and	 the	pellet	was	 resuspended	 in	 cell	 lysis	buffer	 (10	mM	Tris,	pH	8,	1	mM	EDTA,	0.5%	IGEPAL,	protease	inhibitors)	and	incubated	on	ice	for	10	min.	Lysate	was	centrifuged	at	2000	x	g	at	4°C	for	5	min.	The	pellet	was	resuspended	in	nuclear	lysis	buffer	(10	mM	Tris,	pH	8,	1	mM	EDTA,	0.5	M	NaCl,	1%	 Triton	 X-100,	 0.5%	 sodium	 dexycholate,	 0.5%	 lauroylsarcosine,	 protease	inhibitors)	and	incubated	on	ice	for	10	min	with	repeated	vortexing.	Lysate	was	centrifuged	at	3000	x	g	for	5	min	at	4°C.	The	pellet	was	resuspended	in	PBS,	split	for	different	immunoprecipitations	and	centrifuged	at	3000	x	g	for	10	min	at	4°C.	Pellets	were	resuspended	in	300	µl	lysis	buffer	(10	mM	Tris,	pH	8,	1	mM	EDTA,	150	mM	NaCl,	 0.1%	 sodium	 deoxycholate,	 0.1%	 SDS,	 protease	 inhibitors)	 and	sonicated	 at	 maximum	 power	 for	 10	 min	 with	 30	 s	 intervals	 in	 a	 Bioruptor	(Diagnode).	 Samples	were	 centrifuged	at	16'000	x	 g	 for	10	min	at	4°C	and	 the	supernatant	was	 collected.	 Input	 samples	 (15%)	were	 frozen	and	 the	 rest	was	made	up	to	1	ml	with	IP	buffer	(16.7	mM	Tris,	pH	8,	1.2	mM	EDTA,	300	mM	NaCl,	1.1%	Triton	X-100,	protease	inhibitors).	5	µg	of	the	respective	antibodies	(Anti-ERα;	ThermoFisher	MA5-13065	or	Anti-Flag;	 Sigma	F3165)	were	added	 to	 the	lysate	and	incubated	on	a	rotating	wheel	at	4°C	overnight.		Beads	(G	protein	Sepharose,	GE	Healthcare)	were	washed	twice	in	IP	buffer	and	centrifuged	for	2	min	at	2700	x	g	before	being	blocked	with	1	mg/ml	BSA	in	IP	buffer	for	1	h.	After	one	additional	wash,	50	µl	of	beads	were	added	to	1	ml	lysate	with	 antibody.	 The	mixture	was	 incubated	 for	 3	 h	 on	 a	 rotating	wheel	 at	 4°C.	Mixtures	 were	 centrifuged	 for	 2	 min	 at	 2000	 x	 g	 and	 the	 supernatant	 was	removed.	 The	 beads	were	washed	 successively	 in	 1	ml	 of	 four	 different	 wash	buffers	for	5	min	on	the	rotating	wheel	(wash	buffer	1:	20	mM	Tris,	pH	8,	2	mM	EDTA,	0.1%	SDS,	1%	Triton	X-100,	300	mM	NaCl;	wash	buffer	2:	like	wash	buffer	
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1,	 but	with	 500	mM	NaCl;	wash	 buffer	 3:	 10	mM	Tris,	 pH	 8,	 1	mM	EDTA,	 1%	sodium	deoxycholate,	500	mM	LiCl,	1%	NP-40;	wash	buffer	4:	10	mM	Tris,	pH	8,	1	mM	EDTA).	 One	 additional	wash	with	wash	 buffer	 4	was	 performed,	 during	which	the	beads	were	split	 for	DNA	and	proteins.	For	proteins:	the	beads	were	taken	up	 in	2x	SDS	 loading	dye	(100	mM	Tris,	pH	6.8,	20%	glycerol,	3.2%	SDS,	0.2	mM	DTT,	 0.04%	 bromophenol	 blue),	 the	mixture	was	 vortexed	 vigorously	and	incubated	for	30	min	at	100°C	(denaturing	and	de-cross-linking).	The	beads	were	spun	down	and	the	supernatant	was	loaded	on	an	SDS-PAGE	together	with	inputs.	Gels	were	processed	further	according	to	general	WB	protocol.	For	DNA:	beads	and	inputs	were	taken	up	in	100	µl	crosslink	reversal	buffer	(20	mM	Tris,	pH	8,	 0.5	mM	EDTA,	0.1	M	NaHCO3,	 1%	SDS,	RNase	 at	 10	µg/ml	 (Roche))	 and	incubated	at	65°C	overnight.	The	next	day,	the	DNA	was	purified	using	the	PCR	purification	kit	 from	Qiagen	and	eluted	in	10	µl	of	H2O.	RT-PCR	was	performed	on	 3.5	 µl	 of	 DNA	 using	 the	 platinum	 SYBR	 green	 qPCR	 superMix-UDG	 kit	(Invitrogen)	 according	 to	manufacturer's	 instructions,	 except	 that	 the	 reaction	was	scaled	down	to	20	µl	and	1	mM	of	MgCl2	were	added.	The	following	protocol	was	used	for	amplifications:	50°C	for	2	min,	95°C	for	2	min,	50x	(95°C	for	15	s,	57°C	for	30	s)	and	melting	curve	analysis	at	65°C	for	15	s,	heating	to	97°C	with	continuous	 acquisition	 per	 5°C,	 40°C	 for	 30	 s).	 The	 qPCR	 was	 run	 on	 a	LightCycler	 480	 from	 Roche	 with	 the	 following	 primers:	 fwd	 5'-TAAGCAAAGCTTTGGCTGCATTTTGTATTTGGTTCTGTAGGAAATG-3',	 rev	 5'-TAAGCAGCTAGCCTGCAGGCCAGAGGCTAATCCAGATAAACC-3'.		
Labeling	of	oligos	Fill-in	reaction	(3'-labeling):	2	pmoles	of	ds	5'-overhanged	DNA	were	incubated	for	 15	 min	 at	 RT	 with	 0.2	 µl	 of	 the	 respective	 [α-32P]-dNTP	 (2	 µCi,	 Hartman	Analytic),	1	mM	of	each	of	the	other	three	dNTPs	and	5	U	Klenow	fragment	(3'—>5'	exo-,	NEB)	in	the	corresponding	buffer.	The	enzyme	was	heat-inactivated	for	20	min	 at	 75°C	 and	 slowly	 cooled	 down	 to	 re-anneal	 the	 strands.	 Free	 dNTPs	were	removed	on	a	Sephadex	G-25	column	(GE	Healthcare).		Kinase	reaction	(5'-labeling):	2	pmoles	of	ssDNA	were	phosphorylated	with	0.7	µl	of	[γ-32P]-ATP	(7	µCi,	Hartman	Analytic)	using	T4	polynucleotide	kinase	(10	U,	NEB).	 The	 reaction	was	 supplemented	with	 10	mM	DTT	 and	 incubated	 for	 30	min	 at	 37°C.	 The	 reaction	 was	 heat-inactivated	 for	 5	 min	 at	 95°C	 and	 free	nucleotides	 were	 removed	 on	 a	 Sephadex	 G-25	 column	 (GE	 Healthcare).	 The	oligo	 was	 annealed	 to	 a	 1.5x	 excess	 of	 unlabeled	 complementary	 strand	 by	heating	 for	5	min	 to	80°C	and	slowly	cooled	down	 in	annealing	buffer	 (50	mM	Hepes,	pH	7.5,	100	mM	NaCl).		
Nuclear	extracts	All	 nuclear	 extracts	 were	 prepared	 according	 to	 Dignam	 et	 al.	 (Dignam	 et	 al.,	1983),	with	or	without	pretreatment	of	the	cells	with	E2.		
Electrophoretic	Mobility	Shift	Assay	(EMSA)	All	EMSA	reactions	were	carried	out	in	binding	buffer	(10	mM	Tris-HCl,	pH	7.6,	50	mM	NaCl,	 1	mM	DTT,	 1	mg/ml	BSA,	 5%	 glycerol	 (Hyder	 et	 al.,	 1999))	 in	 a	volume	of	5	µl	using	the	unspecific	competitor	poly(dI-dC)	 	(Sigma-Aldrich).	20	ng	of	poly(dI-dC)	was	used	for	100	ng	of	recombinant	ERα	(ThermoFisher,	RP-
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310)	and	1	µg	 for	10	µg	of	nuclear	 extracts.	 For	 all	EMSAs,	10	 fmol	of	 [α-32P]-dNTP	labeled,	or	[γ-32P]-ATP	phosphorylated	oligos	were	used.	Where	indicated,	an	 excess	 of	 unlabeled	 competitor	 DNA	 or	 100	 nM	 of	 E2	 were	 added.	 For	 the	supershift	 assays,	 200	 ng	 of	 antibody	 (Anti-ERα;	 ThermoFisher	 MA5-13065)	were	added	 together	with	 the	proteins.	Proteins,	 and	 competitor	or	 antibodies	where	 indicated,	 were	 incubated	 for	 20	min	 on	 ice	 in	 binding	 buffer.	 Labeled	DNA	was	added	and	the	mixture	was	left	at	RT	for	another	20	min	before	loading	on	a	5%	polyacrylamide	gel	(Acryl/	Bis	29:1,	Amresco)	eluted	with	1x	TAE	(40	mM	Tris,	20	mM	acetate,	1	mM	EDTA).	The	gels	were	run	at	200	V	for	1	h	in	1x	TAE	and	dried	in	a	gel	dryer	for	1	h.	The	gels	were	exposed	to	phosphor	screens	and	the	autoradiographs	were	developed	in	a	typhoon	FLA	9500	(GE	Healthcare	Life	Sciences).	The	oligonucleotides	used	are	listed	in	Table	S2	(SI).		
SDS-PAGE	of	cross-linked	binding	reactions	EMSAs	were	performed	as	described	and	cross-linked	for	5	min	(~720	mJoules)	in	a	UV	Stratalinker	1800	(Stratagene).	Samples	were	taken	up	in	2x	SDS	loading	buffer	 and	boiled	 for	5	min	before	being	 loaded	on	 a	7.5%	polyacrylamide	 gel	and	run	for	1-2	h	in	10%	SDS-running	buffer	at	130	V.	Gels	were	dried	for	1	h,	exposed	 to	 phophor	 screens	 and	 developed	 in	 a	 typhoon	 FLA	 9500	 (GE	Healthcare	Life	Sciences).		
CpGL	cloning	and	Luciferase	assay	The	 enhancer/promoter	 region	 of	 the	 chicken	 vitellogenin	 gene	 spanning	nucleotides	 -638	 to	 -1	 was	 cloned	 into	 a	 CpG-free	 firefly	 luciferase	 plasmid	(pCpGL-basic,	InvivoGen)	using	HindIII	and	NcoI.	The	enhancer	promoter	region	was	amplified	from	genomic	DNA	of	LMH/2A	cells	using	the	forward	primer	5'-TAAGCAAAGCTTTGGCTGCATTTTGTATTTGGTTCTGTAGGAAATG-3'	 and	 the	reverse	 primer	 5'-ATTCGTCCATGGCGAAGGTGAATAGGGCTCTGCC-3'.	 The	plasmid	 was	 further	 cut	 with	 HindIII	 and	 HpaII	 to	 excise	 the	 intervening	sequence	and	the	annealed	upper	5'-AGCTTAAAAATATTCCTGGTCAGCGTGAC-3'	and	 lower	 5'-CGGTCACGCTGACCAGGAATATTTTTA-3'	 ds-oligo	 was	 ligated	 into	the	plasmid	to	translocate	the	HindIII	site	closer	to	the	ERE	for	further	ligations	of	the	ERE.	On	the	other	side	of	the	ERE	a	KpnI	site	was	created	by	mutagenesis	using	 the	 following	 primers:	 new	 KpnI	 fwd	 5'-CCGGAGCTGAAAGAACACATGGTACCCGTGATTTCAATAAATAC-3';	 new	 KpnI	 rev	5'-GTATTTATTGAAATCACGGGTACCATGTGTTCTTTCAGCTCCGG-3'.	 Another	
KpnI	site	 in	the	plasmid	had	to	be	destroyed	by	mutagenesis:	destroy	KpnI	site	fwd	 5'-CATGTTCACAACACTGGGGTATCTGATCTGTGGCTTCAGAG-3';	 destroy	KpnI	site	rev	5'-CTCTGAAGCCACAGATCAGATACCCCAGTGTTGTGAACATG-3'.	The	 resulting	 VTG-CpGL	 plasmid	 was	 co-transfected	 with	 a	 Renilla	 luciferase-expressing	plasmid	(pRL-SV40,	Promega)	into	LMH/2A	cells	using	Lipofectamine	2000	 (Invitrogen)	 according	 to	 manufacturer's	 instructions.	 Cells	 were	 re-seeded	the	next	day	in	technical	triplicates	both	for	E2	and	ethanol	treatment	and	treated	 for	 24	 h.	 Cells	 were	 subsequently	 lysed	 directly	 in	 firefly	 luciferase	substrate	 from	 Promega	 (Dual-Glo	 Luciferase	 kit)	 for	 30	 min,	 with	 vigorous	shaking.	 Cell	 lysates	 were	 processed	 further	 according	 to	 manufacturer's	instructions	 and	 luminescence	was	measured	on	 the	SpectraMax	 i3	 (Molecular	Devices)	plate	reader.	Relative	luciferase	units	(RLU)	were	calculated	as	the	ratio	between	firefly	and	Renilla	signals.	
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Mutagenesis	of	VTG-CpGL	200	ng	of	vector	DNA	were	mixed	with	50pmoles	forward	and	reverse	primers,	250	µM	dNTPs,	2%	DMSO	and	1	U	phusion	high	 fidelty	polymerse	(NEB)	 in	1x	buffer	 provided	 by	 the	 manufacturer.	 Extension	 was	 performed	 in	 50	 µl	according	to	the	following	protocol:	95	°C,	2	min;	30x	(95	°C,	1	min,	55	°C,	1	min,	63	°C,	30	min);	68	°C,	20	min;	15	°C	hold.	Extension	reaction	was	digested	twice	with	20	U	DpnI	for	1	h	at	37°C	followed	by	heat	inactivation	of	the	enzyme	for	20	min	at	80°C.	The	reaction	mix	was	then	transformed	into	electro-competent	Pir1	bacteria	(R6K	gamma	ORI,	Invitrogen)	after	being	desalted	by	incubating	for	15	min	on	a	0.025	µm	Millipore	nitrocellulose	filter	on	H2O.	Bacteria	were	shaken	at	37°C	 for	 40	 min	 and	 plated	 onto	 Zeocin	 (25	 µg/ml,	 InvivoGen)	 agar	 plates.	Clones	were	picked	the	next	day,	grown	in	liquid	culture	overnight	and	plasmids	were	extracted	using	the	NucleoSpin	Plasmid	Kit	(Macherey-Nagel)	according	to	manufacturer's	 instructions.	 Plasmids	 were	 sequenced	 at	 Microsynth	 to	 check	for	 successful	mutagenesis.	The	primers	 for	mutagenesis	are	 listed	 in	Table	S3	(SI).	 For	 sequencing,	 the	 following	 primers	were	 used:	 VTG	 enhan	 seq	 fwd	 5'-GCAATCAATATTGAAAACCAC-3';	 CpGL	 seq	 luc1	 fwd	 5'-CGTGAAGAGAATTTATGATTGC-3';	 CpGL	 seq	 luc2	 fwd	 5'-CCCTGACACTGCCATCCTG-3'.		
Ligation	of	modified	ERE	into	VTG-CpGL	50	µg	of	 the	plasmid	DNA	were	 cut	with	HindIII-HF	 (NEB)	 in	Cut	 Smart	buffer	with	100	U	of	enzyme	for	1.5	h	at	37°C	in	50	µl.	Linearization	was	verified	on	a	1%	agarose	gel	and	enzyme	was	heat-inactivated	for	20	min	at	80°C.	For	the	first	ligation	 step,	 10	 µg	 of	 linearized	 DNA	 and	 20x	 excess	 of	 annealed	 oligo	 with	different	 modifications	 at	 the	 CpGs	 (Upper:	 5'-AGCTGAAAAATATTCCTGGTCAGCGTGACCGGAGCTGAAAGAACACATGGTAC-3';	Lower:	 5'-CATGTGTTCTTTCAGCTCCGGTCACGCTGACCAGGAATATTTTTC-3')	were	incubated	for	2	h	at	RT	in	T4	ligase	buffer	with	400	U	of	T4	ligase	(NEB)	in	a	 total	 volume	of	100	µl.	 Ligase	was	 inactivated	by	heating	 to	65°C	 for	10	min	and	 efficient	 ligation	 was	 verified	 on	 an	 agarose	 gel.	 Reaction	 volume	 was	increased	to	200	µl	with	1x	Cut	Smart	buffer,	40	U	of	KpnI-HF	(NEB)	were	added	and	 incubation	was	 continued	 for	 additional	 1.5	 h	 at	 37°C.	 20	U	 of	HindIII-HF	were	 then	 added,	 the	 mixture	 was	 incubated	 for	 an	 additional	 hour	 and	subsequently	 cleaned-up	 on	 MinElute	 columns	 (5µg	 per	 column,	 Qiagen)	 and	eluted	in	20	µl	H2O.	20	reactions	of	the	first	ligation	were	pooled	for	the	second	ligation.	12.5	µg	of	DNA	from	the	first	ligation	were	incubated	in	10	ml	of	1x	T4	ligase	buffer	with	4000	U	of	ligase	for	1	h	at	RT.	Recircularization	was	verified	on	an	agarose	gel.		
n,	nicked.	l,	linear.	sc,	super-coiled	
s.c 
n 
l 
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	The	 resulting	mix	was	concentrated	by	EtOH	precipitation	and	 the	 supercoiled	form	 of	 the	 plasmid	 was	 extracted	 on	 a	 CsCl	 gradient	 and	 purified	 further	 as	described	(Baerenfaller	et	al.,	2006).	
	
In	vitro	methylation	1	µg	of	plasmid	DNA	was	 incubated	in	1x	NEB	buffer	2,	160	µM	freshly	diluted	SAM	 (NEB)	 and	 4	 U	 of	 SssI	 (NEB)	 for	 1	 h	 at	 37°C.	 Reaction	 was	 stopped	 by	heating	to	65°C	for	20	min.		
EdU	incorporation	and	Click-iT	Reaction	Cells	were	grown	on	coverslips	and	treated	with	8	µM	aphidicolin	or	DMSO,	100	nM	E2	or	ethanol	and	10	µM	of	5-ethynyl-2'-deoxyuridine	(EdU,	 Invitrogen)	 for	24h.	Medium	was	removed,	cells	were	washed	once	with	PBS	and	1	ml	of	3.7%	formaldehyde	in	PBS	was	added.	Cells	were	fixed	for	15	min	at	RT	before	being	washed	twice	with	1	ml	of	3%	BSA	in	PBS.	1	ml	of	0.5%	Triton	X-100	in	PBS	was	added	and	cells	were	 incubated	 for	20	min	at	RT.	Click-iT	 reaction	master	mix	was	 prepared	 (for	 5	 slides):	 129	 µl	 1x	 Click-iT	 reaction	 buffer	 (freshly	 diluted	1:10	in	H2O),	6	µl	CuSO4,	0.36	µl	Alexa	Fluor	azide,	15	µl	reaction	buffer	additive	(freshly	 diluted	 1:10	 in	 H2O).	 Permeabilization	 buffer	 was	 removed	 and	 cells	were	washed	twice	with	1	ml	3%	BSA	in	PBS.	30	µl	of	Click-iT	reaction	mix	were	pipetted	onto	Parafilm	and	the	coverslips	were	put	cells-down	onto	the	mix	and	incubated	for	30	min	at	RT,	protected	from	light.	Coverslips	were	washed	once	with	1	ml	of	3%	BSA	in	PBS	and	then	washed	well	with	1x	PBS	to	remove	BSA.	After	one	final	wash	with	H2O,	cells	were	fixed	with	mounting	media	containing	4',6-diamidino-2-phenylindole	 (DAPI,	 VectaShield).	 Slides	were	 analyzed	 on	 an	Olympus	IX81	fluorescence	microscope.	
	
DNA	extraction,	oxidation	of	hmC	and	bisulfite	conversion	Genomic	 DNA	 was	 extracted	 from	 cells	 using	 the	 Wizard	 Genomic	 DNA	Purification	Kit	(Promega).	DNA	was	eluted	with	water	and	digested	with	EcoRV	overnight.	EtOH	precipitation	was	performed	and	DNA	was	additionally	cleaned	up	on	Micro	Bio-Spin	6	chromatography	columns	in	SSC	(BioRad)	as	purity	was	essential	for	oxidation	of	5hmC.	Samples	were	split	and	one	half	was	subjected	to	oxidation.	 Selective	 oxidation	 of	 5hmC	 to	 5C	 was	 achieved	 using	 potassium	perruthenate	(KRuO4,	Sigma-Aldrich)	as	described	(Booth	et	al.,	2012;	Booth	et	al.,	2013).	In	short,	0.5-2	µg	of	DNA	were	incubated	in	50	mM	NaOH	in	24	µl	for	30	min	at	37°C	after	vigorous	vortexing	to	denature	DNA.	1	µl	of	15	mM	KRuO4	solution	in	50	mM	NaOH	was	added	and	oxidation	was	incubated	on	ice	for	1	h	with	vortexing	every	5	min.	Reaction	was	cleaned	up	on	polyacrylamide	columns	(89849,	ThermoScientific)	and	processed	further	with	the	rest	of	the	sample	for	bisulfite	 conversion.	 Bisulfite	 conversion	 was	 achieved	 using	 the	 EZ	 DNA	Methylation-Gold	 Kit	 from	 Zymo	 Research	 according	 to	 manufacturer's	instructions.	 The	 cycling	 protocol	 was	 adapted	 because	 of	 the	 slightly	 less	efficient	conversion	of	fC	as	compared	to	unmodified	cytosine	(95°C	for	5	min;	2x	(60°C	for	25	min,	95°C	for	5	min,	60°C	for	85	min,	95°C	for	5	min,	60°C	for	175	min,	95°C	for	5	min);	20°C	hold).		
	
																																																																																																																																																																																								RESULTS		
	____________________________________________________________________________________________________________________	77	
	
Polymerase	chain	reaction	on	bisulfite	converted	DNA	100	ng	of	bisulfite-converted	DNA	was	used	as	 template	 for	 the	PCR	using	 the	ZymoTaq	DNA	polymerase	(Zymo	Research).	The	reaction	was	carried	out	 in	a	total	 volume	 of	 40	 µl	 in	 the	 reaction	 buffer	 provided	 by	 the	 manufacturer	supplemented	with	of	1	mM	dNTPs,	1.5	mM	MgCl2,	500	mM	each	primer	and	2	U	of	polymerase.	The	cycling	protocol	was	as	follows:	10	min	95°C;	5x	(30	s	94°C;	30	s	52°C;	90	s	72°C);	5x	(30	s	94°C;	30	s	52°C;	90	s	72°C);	35x	(30	s	94°C;	30	s	55°C;	90	s	72°C);	7	min	72°C.	The	primers	used	were:	Upper	strand	forward	5'-TAAGCAAAGCTTTTTGTTTATTTAAAAATATTTTTGGTTAG-3';	 Upper	 strand	reverse	 5'-TAAGCAGCTAGCCCTCAACTTTAATTTATAACCATTC-3';	 Lower	 strand	forward	 5'-TAAGCAAAGCTTAGTTTTGGTTTATGGTTATTTTTGTA-3';	 Lower	strand	 reverse	 5'-TAAGCAGCTAGCCAAAATACTTATAAAACCTTTATTCATTTA-3'.	The	 forward	 primers	 were	 only	 added	 after	 the	 first	 5	 cycles	 to	 reduce	 the	formation	of	primer	dimers.	The	PCR	fragments	were	purified	using	a	BluePippin	(Sage	 Science)	 on	 a	 2%	 agarose	 gel	 according	 to	 manufacturer's	 instructions,	before	being	bar-coded	for	PacBio	sequencing.		
PacBio	sequencing	and	analysis	Pacific	 Biosciences	 developed	 a	 new	 sequencing	 approach	 that	 uses	 single-molecule	 real-time	 technology	 (SMRT),	 referred	 to	 as	 PacBio	 sequencing.	 The	converted	RSII	sequencers	allow	time-resolved	single-molecule	studies	based	on	custom	experimental	design	(in	manual	operation	mode).	Any	desired	probe	can	be	immobilized	on	the	surface	of	the	SMRT	cell,	which	consists	of	150'000	zero-mode	 waveguide	 (ZMW)	 nanostructures	 allowing	 to	 work	 with	 up	 to	 50'000	single	 molecules	 in	 parallel.	 The	 nanostructures	 allow	 for	 discrimination	between	 single	 molecule	 binding	 events	 and	 fluorescent	 background	 even	 at	high	analyte	concentration.	SMRT	 is	 a	 fluorescence-based	 method.	 For	 each	 of	 the	 150'000	 ZMW	nanostructures,	traces	in	four	wavelength	channels	are	stored.	Software	for	data	evaluation	 was	 created	 by	 informaticians	 at	 the	 Functional	 Genomic	 Center	Zurich	 (FGCZ).	 The	 technology	 is	 able	 to	 produce	 long	 reads	 via	 a	 strand-displacement	mechanism	of	 the	polymerase.	The	resulting	high-quality	circular	consensus	 reads	 faithfully	 correct	 the	 high	 error-rate	 of	 the	 polymerase,	resulting	in	very	accurate	sequencing	results.			Results		
The	 vitellogenin	 enhancer	 is	 methylated	 and	 the	 gene	 silenced	 in	 LMH/2A	 cells	
prior	 to	 exposure	 to	 β-estradiol	 and	 is	 induced	 upon	 hormone	 treatment,	
independently	of	DNA	replication.	In	a	first	step,	we	wanted	to	test	whether	the	phenomenon	described	by	Saluz	et	al.	 (Saluz	 et	 al.,	 1986)	 was	 reproducible	 and	 whether	 E2	 would	 activate	 the	silenced	VTG	gene	also	in	a	system	more	amenable	to	manipulation.	We	decided	to	 use	 chicken	 LMH/2A	 cells,	 a	 Leghorn	 rooster	 hepatocellular	 carcinoma	 cell	line	 stably	 expressing	 estrogen	 receptor	 alpha	 (ERα).	 We	 could	 show	 by	bisulphite	 sequencing	 that	 the	 four	 CpGs	 in	 the	 VTG	 enhancer	 (a-d,	 Fig.	 1	 A),	described	by	Saluz	et	al.,	are	about	90%	methylated,	except	 for	CpG	b,	which	is	54%	methylated	in	both	strands	(Fig.	1	B).	This	is	in	line	with	the	results	of	Saluz	
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et	al.	 from	 rooster	 liver,	where	 the	 four	 CpGs	were	 also	methylated	 except	 for	CpG	 b	 that	 was	 described	 to	 be	 50%	 hemimethylated.	With	 our	 approach	 we	cannot	say	with	certainty	whether	all	of	CpG	b	is	hemimethylated	or	half	is	un	-and	half	is	fully-methylated,	but	the	latter	is	much	more	likely,	pointing	towards	a	loss	of	hemimethylation	in	the	cell	line.	Using	RT-qPCR,	we	could	show	that	the	VTG	gene	is	not	transcribed	in	LMH/2A	cells	 prior	 to	 exposure	 to	 estrogen,	 but	 is	 efficiently	 induced	 already	 6	 h	 after	addition	of	100	nM	E2	and	expression	increases	further	after	24	h	(Fig.	1	C).	The	increase	in	transcription	continues	up	to	72	h	as	shown	by	RT-PCR	and	Western	Blot	 (Supp.	 Fig.	 1	 A),	 at	 least	 partly	 due	 to	 a	 positive	 feedback	 resulting	 in	increased	transcription	of	estrogen	receptor	α	(Supp.	Fig.	1	B).	Activation	of	VTG	 transcription	occurs	 in	a	 replication-independent	manner,	 as	inhibition	 of	 DNA	 replication	 by	 addition	 of	 the	 B-family	 polymerase	 inhibitor	aphidicolin	 to	 the	 experiment	 does	 not	 impede	 transcription,	 but	 rather	enhances	 it	 (Fig.	 1	 D).	 A	 possible	 explanation	 for	 this	 observation	 is	 that	 any	interference	 of	 replication	 with	 the	 transcription	 process	 is	 inhibited	 by	 the	addition	 of	 aphidicolin.	 The	 successful	 inhibition	 of	 DNA	 synthesis	 was	confirmed	 with	 a	 5-ethynyl-2'-deoxyuridine	 (EdU)	 incorporation	 assay	 (Supp.	Fig.	1	C).		
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Fig 1: VTG mRNA expression is induced upon `<estradiol (E2) treatment in LMH/2A cells, independently of DNA 
synthesis. A Sequence of the enhancer/promoter region of the chicken VTG gene. The ERE binding site (violet), the 
CpGs (green) and the translation start site (yellow) are highlighted. The  four CpGs (a-d) analyzed in Saluz et al. are 
indicated . B Bisulfite sequencing results of the four CpGs in the VTG enhancer region for the lower and the upper DNA 
strand.  C VTG mRNA levels were measured with qPCR after 6 and 24 hours of 100 nM E2 treatment and with additional 
treatment with 8 µM aphidicolin or DMSO for 24h (D). Data are represented as mean ± SD. Significance was assessed 
using Sidak’s multiple comparisons test.
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Estrogen	receptor	alpha	binds	to	the	ERE	of	VTG	upon	treatment	with	β-estradiol.	Next	 we	 checked	 whether	 the	 estrogen	 receptor	 physically	 interacts	 with	 the	ERE	 in	 the	 VTG	 enhancer	 upon	 E2	 treatment.	 To	 this	 end	 we	 performed	 a	chromatin	 immunoprecipitation	 experiment	 using	 an	 ERα	 antibody	 or	 a	 flag	antibody	as	a	control.	We	could	retrieve	ERα	in	the	chromatin	fraction	only	with	the	 ERα	 antibody	 and	 with	 E2	 treatment	 (Fig.	 2,	 upper	 panel).	 Moreover,	 we	
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could	confirm	its	binding	to	the	VTG	ERE	using	RT-qPCR	on	the	recovered	DNA	(Fig.	2,	 lower	panel).	Only	very	little	signal	was	apparent	without	E2	treatment,	confirming	the	widely	accepted	model	that	estrogen	receptors	bind	DNA	in	vivo	only	in	response	to	hormone	treatment	(Carroll	et	al.,	2005;	Klinge,	2001).		
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The	four	CpGs	in	the	enhancer	region	of	VTG	are	not	demethylated	in	LMH/2A	cells,	
but	there	is	evidence	for	elevated	levels	of	5hmC	upon	E2	treatment.	After	showing	that	VTG	expression	is	induced	upon	hormone	treatment	and	ERα	binds	 to	 the	 enhancer,	 we	 set	 out	 to	 investigate	 if	 demethylation	 or	 TET-mediated	 oxidation	 of	 the	 involved	 CpGs	 took	 place.	 Therefore,	we	 performed	PCR	on	the	bisulfite-converted	DNA	to	distinguish	C,	5fC	and	5caC	from	5mC	and	5hmC.	To	separate	mC	from	hmC	signals,	bisulfite	conversion	was	preceded	by	an	oxidation	step	using	KRuO4,	which	selectively	oxidizes	5hmC	to	5fC,	resulting	in	its	conversion	to	uracil	following	bisulfite	treatment.	The	PCR	products	were	then	sequenced	using	the	PacBio	approach,	which	is	able	to	provide	information	on	single	molecules.	5hmC	levels	were	assessed	as	the	difference	in	the	amount	of	converted	cytosines	between	bisulfite	only	-	and	oxidizing-bisulfite	converted	DNA.	Using	 this	 approach,	 we	 could	 show	 that	 the	 promoter/enhancer	 was	 not	demethylated	during	the	course	of	the	induction,	but	that	a	small	percentage	of	5mCs	were	oxidized	to	5hmCs,	indicating	an	involvement	of	one	or	several	of	the	TET	enzymes	(Fig.	3	A	and	Supp.	Fig.	2).	TET	1	and	2	were	shown	to	be	present	in	LMH2A	cells	as	assessed	by	qPCR	and	WB,	as	well	as	all	cytosine	modifications	as	 assessed	by	Dot	Blot	 (data	not	 shown).	We	next	 checked	 the	 effect	 of	TET2	overexpression	in	LMH/2A	cells	on	the	induction	of	VTG	expression	and	found	a	significant	 increase	 in	 the	 level	 of	 induction	upon	mouse	TET2	overexpression	(Fig.	3	B).	Successful	overexpression	was	confirmed	by	Western	Blot	using	Anti-TET2,	-Flag	and	-HA	antibodies	(Fig.	3	C).		 	
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Fig 3:  CpGs a-d are not demethylated, but E2 treatment brings about conversion of 5mC to 5hmC.
A Representative bisulfite and oxidated-bisulfite sequencing result of CpG a. The numbers below the 
upper panel indicate the total amount of analyzed reads per condition. The percentage of 5hmC (lower 
panel) was calculated as the difference of converted Cs between the oxidated-bisulfite converted DNA 
and the only-bisulfite converted DNA. B Induction of VTG mRNA with mock treatment or mTET2 overex-
pression measured by qPCR (left panel). Data are represented as mean ± SD. C Western Blot showing 
overexpression of Flag-HA-tagged mTET2.
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Binding	 of	 ERα	 to	 the	 ERE	 is	 insensitive	 to	 different	 cytosine	 modifications	 and	
hormone	treatment.	Since	 it	 was	 published	 that	 transcriptional	 activation	 goes	 hand	 in	 hand	 with	demethylation	of	the	ERE	and	we	saw	elevated	levels	of	hmC,	we	next	wanted	to	assess	whether	binding	of	the	ERα	was	dependent	on	the	methylation	status	of	the	ERE.	EMSA	assays	using	synthetic	oligonucleotides	containing	the	VTG	ERE	wt	 or	ΔG,	missing	 one	 nucleotide	 in	 the	 3-nt	 spacer	 between	 the	 palindromic	repeats	 (Fig.	 4	 A)	 and	 recombinant	 ERα	 (ThermoFisher,	 RP-310) showed	 that	the	recombinant	protein	was	able	to	bind	the	ERE	sequence	with	similar	affinity	in	presence	and	absence	of	E2,	on	unmethylated	 (Fig.	4	B	&	C)	and	methylated	oligos	 (Fig.	 4	 B,	 lower	 panel).	 Moreover,	 the	mutant	 ERE	ΔG	 bound	 ERα	with	significantly	reduced	affinity	(Fig.	4	B,	last	lanes).	The	binding	of	ERα	to	the	ERE	was	 competed	 with	 a	 100-fold	 excess	 of	 specific	 competitor,	 but	 not	 with	 a	scrambled	 sequence	 (Fig.	 4	 C,	 lanes	 4	&	5).	 In	 addition,	 there	was	 a	 change	 in	conformation	upon	addition	of	E2,	 resulting	 in	 altered	mobility,	 confirming	 the	functionality	of	 the	receptor	(Fig.	4	C	&	Supp.	Fig.	3	A).	Supershift	experiments	using	an	ERα	antibody	further	confirmed	the	specificity	of	the	shift	(Fig.	4	D)	
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The	binding	of	ERα	could	be	shown	to	be	 insensitive	to	methylation	of	 the	two	CpGs	 within	 the	 ERE	 at	 different	 receptor	 concentrations	 (Fig.	 4	 E).	Hemimethylation	(Supp.	Fig.	3	B	&	C),	as	well	as	hydroxy-	(Supp.	Fig.	3	B	&	D)	and	hemihydroxymethylation	(Supp.	Fig.	3	B	&	E),	of	the	ERE	also	failed	to	affect	ERα	 binding.	 Also	 formylcytosine	 and	 carboxycytosine	 in	 the	 ERE	 had	 no	influence	on	receptor	binding	(Supp.	Fig.	3	B).	To	confirm	the	specificity	of	 the	binding,	another	mutant	missing	all	three	nucleotides	of	the	spacer,	resulting	in	direct	 palindromic	 repeats,	 was	 included	 and	 competition	 assays	 were	performed	on	the	45	bp	oligos	and	additionally	on	shorter,	25	bp	oligos	(Supp.	Fig.	 3	 F	 &	 G).	 The	 methylated	 and	 the	 hydroxymethylated	 oligos	 successfully	competed	with	the	unmethylated	oligos,	whereas	the	mutants	did	not.		
A B
D
0 5 10 20 30 40 80 20
0
0
20
40
60
80
ng ER
%
 b
ou
nd
 o
lig
o
C/C
mC/mC
C
C
mC
mC
ΔG ΔG- -rec. ER_
ERE wt
ΔG
C
- -100nM E2 - +
100x comp - - uns
pe
c
spe
c
oligo
only
Fig 4: Binding of recombinant ER_ to the ERE is methylation- and hormone-insensitive. A Oligos used for radioac-
tive EMSAs, showing the ERE (violet) and the CpGs (green). B Upper panel: Representative EMSA with increasing 
concentrations of recombinant ER_ (0, 5, 10, 20, 30, 40, 80 and 200 ng) on unmethylated ERE wt oligo and ΔG oligo in 
the last lanes with 40 ng of ER_- (left panel) /+ (right panel) E2. Quantification of percentage bound oligo on unmeth-
ylated (middle panel) or methylated (lower panel) oligo of three independent experiments. Data are represented as 
mean ± SD. C EMSA with 60 ng recombinant ER_ and unmethylated ERE wt oligo, with or without E2 or competitor. 
D EMSAs showing a supershift with ER_ antibody with unmethylated oligo. E Upper panel: Representative EMSA with 
increasing concentrations of recombinant ER_ (0, 5, 10, 20, 30, 40, 80 and 200 ng) and unmethylated (left panel) or 
methylated (right panel) ERE wt oligo and ΔG oligo in the last lanes with 40 ng of ER_. Lower panel: Quantification of 
percentage bound oligo of three independent experiments. Data are represented as mean ± SD.
E
0 5 10 20 30 40 80 20
0
0
20
40
60
80
ng ER
%
 b
ou
nd
 o
lig
o
C/C
- E2
+ E2
C/C
 - E2  + E2
ΔG ΔG- -rec. ER_
0 5 10 20 30 40 80 20
0
0
20
40
60
ng ER
%
 b
ou
nd
 o
lig
o
mC/mC
- E2
+ E2
+
C
C
200ng AB-
	
																																																																																																																																																																																								RESULTS		
	____________________________________________________________________________________________________________________	82	
	
	
In	vitro	methylation	of	a	luciferase	reporter	plasmid	under	the	control	of	the	VTG	
enhancer/promoter	inhibits	transcription.	In	 the	study	performed	by	Saluz	et	al.,	 transcriptional	activation	with	hormone	treatment	 was	 accompanied	 by	 changes	 in	methylation	 of	 the	 enhancer.	 Even	though	we	saw	no	evidence	of	 a	direct	 impact	of	ERE	methylation	on	 receptor	binding,	we	were	interested	to	check	the	impact	of	different	methylation	states	on	 transcription.	 We	 generated	 a	 reporter	 plasmid	 in	 a	 CpG-free	 backbone,	expressing	 firefly	 luciferase	 under	 the	 control	 of	 the	 VTG	 enhancer/promoter	(Fig.	 5	 A).	 We	 than	 replaced	 the	 ERE	 with	 synthetic	 oligonucleotides	 either	unmethylated	 or	methylated	 at	 the	 two	CpGs	 or	 in	vitro	methylated	 the	whole	construct,	resulting	in	methylation	of	all	CpGs	in	the	enhancer/promoter	region.	The	substrates	were	transfected	into	LMH/2A	cells	and	cells	were	treated	with	either	100	nM	E2	or	EtOH	for	24h.		The	analysis	of	unmethylated	and	in	vitro	methylated	wt	and	ΔG	plasmid	showed	impaired	 expression	 when	 the	 ERE	 is	 mutated,	 but	 the	 plasmid	 was	 still	inducible	by	E2	(Fig.	5	B).	Both	plasmids	show	very	weak	transcriptional	activity	and	hormone-inducibility	when	 in	 vitro	 methylated	 (Fig.	 5	 B).	 Next	 we	 wanted	 to	 check	 whether	methylation	 of	 the	 CpGs	 in	 the	 ERE	 was	 responsible	 for	 the	 inhibition	 of	transcription.	Therefore,	we	 included	a	plasmid	 in	vitro	methylated	with	HpaII,	affecting	only	CpG	c	 (according	 to	Saluz	et	al.)	 in	 the	ERE,	and	saw	no	effect	of	this	 methylation	 (Fig.	 5	 C).	 Using	 a	 ligation-mediated	 approach,	 we	 then	exchanged	 the	 ERE	 region	 containing	 two	 CpGs	 (c	 and	 d)	 with	 an	 oligo	containing	mC	or	hmC	at	both	CpGs.	The	luciferase	assay	showed	no	difference	in	transcriptional	activity	between	these	different	modifications	(Fig.	5	D).	This	 is	in	 line	 with	 the	 EMSA	 results	 showing	 that	 binding	 of	 ERα	 is	 unaffected	 by	different	modifications,	 but	 it	 opens	 the	 question	why	 the	 in	 vitro	 methylated	plasmids	have	impaired	transcriptional	activity	even	though	ERα	is	able	to	bind	to	its	response	element.	The	next	steps	therefore	were	to	investigate	whether	the	binding	 behavior	 of	 ERα	 is	 different	 in	 nuclear	 extracts	 compared	 to	 the	recombinant	 protein	 and/or	 if	 methylation	 of	 another	 CpG	 in	 the	 enhancer/	promoter	is	responsible	for	the	inhibition	of	transcription.		
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Fig 5: Transcription of a luciferase reporter is inhibited upon methylation of the VTG enhancer/promoter region. 
A Scheme of the CpG-free luciferase reporter under the control of the VTG enhancer/promoter. B Luciferase expression 
of unmethylated and in vitro methylated (SssI) CpG-free plasmid with wt ERE (C/C) and a single nucleotide deletion in 
the spacer of the ERE (ΔG). C As B, additionally with a plasmid methylated with HpaII, only present in one CpG in the 
ERE. D Luciferase expression from the plasmid with different cytosine modifications only in the two CpGs in the ERE.  
Relative luciferase units (RLU) are defined as ratio between firefly and Renilla signal. The graphs show the mean ± SD of 
three independent experiments.
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Another	protein	binds	the	ERE	wt	and	ΔG	in	nuclear	extracts	In	 order	 to	 investigate	 whether	 the	 binding	 characteristics	 of	 ERα	 in	 nuclear	extracts	are	the	same	as	of	the	recombinant	ERα,	we	prepared	nuclear	extracts	(NEs)	according	to	Dignam	et	al.	(Dignam	et	al.,	1983)	of	LMH/2A	cells	as	well	as	MCF-7	 and	 Hela	 cells	 and	 carried	 out	 EMSAs	 with	 the	 ERE	 oligos.	 We	 could	detect	 a	 shifted	 double	 band	 with	 the	 unmethylated	 wt	 oligo	 in	 LMH/2A	 NE,	which	was	even	stronger	with	the	ΔG	oligo.	The	band	with	higher	electrophoretic	mobility	was	methylation-sensitive.	The	two	bands	migrated	slightly	faster	than	the	 complex	 formed	by	 recombinant	ERα	and	 there	was	no	 change	 in	mobility	when	 E2	was	 added	 to	 the	mixture	 (Fig.	 6	 A).	 The	 same	 behavior	was	 seen	 in	MCF-7	 NE	 (Fig.	 6	 B).	 Hemi-methylated	 oligos	 retained	 the	 band	 with	 higher	electrophoretic	mobility,	whereas	hemi	-and	fully-hydroxymethylated	oligos	lost	it	 similar	 to	 fully	methylated	oligos	 (Supp.	Fig.	4	A).	Supershift	assays	using	an	ERα	 antibody	 had	 no	 effect	 on	 the	 shifts	 (Supp.	 Fig.	 4	 B).	 These	 observations	prompted	us	 to	 conclude	 that	 the	protein	binding	 the	wt	and	mutant	ERE	was	not	ERα,	but	another,	yet	unknown	protein	(referred	to	as	factor	X).	To	narrow	down	 the	binding	sites	 for	additional	proteins,	 shorter	oligos	were	used	 for	all	further	experiments	(Supp.	Fig.	3	G	&	Fig.	6	C).	The	shifts	on	the	shorter	oligos	showed	 slightly	 altered	 mobility,	 but	 the	 methylation-sensitivity	 was	 still	detectable.	 Direct	 comparison	 of	 binding	 to	 ERE	 of	 recombinant	 ERα	 and	 NE	clearly	showed	the	different	behavior,	most	strikingly	on	the	ΔG	oligo	that	bound	ERα	with	strongly	reduced	affinity	and	factor	X	with	higher	affinity	as	compared	to	wt	ERE	(Fig.	6	C).	Retinoic	acid	(RA)	and	retinoic	X	(RX)	receptors	are	known	
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to	 bind	 to	 similar	 sequences	 as	 the	 ERs	 (Mader	 et	 al.,	 1993).	 To	 check	 this	possibility	we	used	a	competitor	oligo	shown	to	bind	RAR	and	RXR	and	saw	no	competition	in	contrast	to	competition	with	ΔG	(Supp.	Fig.	4	C).	Since	we	were	not	able	to	see	an	ERα	shift	 in	the	NEs,	we	wanted	to	assess	the	effect	 of	 proteins	 present	 in	 the	 NE	 on	 binding	 of	 the	 recombinant	 ERα.	Therefore	 we	 titrated	 recombinant	 ERα	 into	 the	 binding	 reactions	 with	 NE.	Recombinant	 ERα	 bound	 wt	 ERE	 unmethylated	 and	 methylated	 also	 together	with	NEs,	 but	with	 reduced	 affinity,	most	 likely	 due	 to	 competition	with	 other	proteins	such	as	factor	X	(Fig.	6	D).	ΔG	that	was	bound	very	strongly	by	factor	X	did	not	bind	any	ERα	titrated	to	the	reaction.	Quantification	of	the	binding	of	ERα	versus	factor	X	of	 three	 independent	experiments	revealed	that	the	methylated	oligo	bound	ERα	with	higher	affinity	compared	to	factor	X	than	the	unmethylated	oligo	 (Fig.	 6	D	 lower	 panel)	 also	 pointing	 towards	 a	 competition	 of	 binding	 of	ERα	versus	factor	X	rather	than	a	synergy.	We	 then	 set	 out	 to	 characterize	 factor	 X	 further.	 Therefore	 binding	 reactions	with	NEs	were	performed	on	oligos	containing	one	BrdU	on	each	strand	(Fig.	6	E)	 and	 cross-linked	 by	UV.	 Reactions	were	 then	 resolved	 on	 SDS-PAGE	 gels	 to	assess	the	exact	size	of	the	bound	proteins.	We	were	able	to	detect	the	expected	band	of	the	ERα-oligo	complex	of	about	80	kDa	in	LMH/2A	NE	on	un-,	hemi-	and	fully-methylated	 oligos,	 which	 displayed	 similar	mobility	 like	 the	 recombinant	protein	cross-linked	to	the	oligo	(Fig.	6	E).	 In	addition,	there	was	another	band	visible	at	around	50	kDa	on	all	oligos	and	a	band	at	around	170	kDa	if	the	upper	(labeled)	 strand	was	methylated.	 Subtracting	 the	weight	of	 the	 single	 stranded	oligo	 (roughly	 15	 kDa)	 this	 corresponded	 to	 proteins	 of	 about	 30-40	 kDa	 and	150-160	kDa.	When	we	titrated	the	recombinant	receptor	into	the	reaction	with	NE	we	saw	a	weak,	but	reproducible	competition	with	the	smaller	protein	(Fig.	6	F).	 The	 binding	 of	 recombinant	 ERα	 on	 the	 unmethylated	 oligo	 could	 be	outcompeted	with	specific,	but	not	with	unspecific	competitor	(Fig.	6	F,	last	three	lanes).	There	was	no	effect	upon	addition	of	E2	on	 the	binding	affinities	or	 the	ratios	 of	 binding	 of	 the	 different	 proteins	 (Fig.	 6	 G).	 Also	 the	 ERα	 band	 was	unchanged,	 confirming	 that	 the	 shift	 with	 estradiol	 in	 the	 EMSA	 was	 a	conformational	change	that	is	not	visible	in	the	denaturing	conditions	of	the	SDS	gel.	The	pattern	of	the	bound	proteins	 looks	similar	in	MCF-7	NE,	except	for	an	additional	low	molecular	weight	band	around	55	kDa	(Fig.	6	H).		
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A B C
Fig 6: A methylation-sensitive shift on ERE wt and ΔG that is not mediated by ER_A EMSA with LMH/2A nuclear 
extracts (NEs) pretreated for 24 h with EtOH (LMH/2A-) or 100 nM E2 (LMH/2A+) and recombinant ER_ (last lane). Where 
indicated, reaction mixtures were supplemented with EtOH (-), 100 nM E2 (+) or 100 x excess of specific (spec) or unspe-
cific (unspec) competitor. B EMSA comparing binding of LMH/2A and MCF-7 NEs on unmethylated and methylated ERE 
oligo, -/+ E2. C EMSA comparing  recombinant protein with LMH/2A NEs on shorter oligos (ERE short) unmethylated 
(C/C) and methylated (mC/mC) and a shorter ΔG oligo (ΔG short). D Upper panel: EMSA with LMH/2A NE with titration 
of indicated amounts of recombinant ER_on different oligos. Lower panel: Quantification of ratio of bound oligo by 
ER_ and factor X of three independent experiments. Data are represented as mean ± SD. Significance was assessed 
using the Holm-Sidak test. For A and B oligos from Fig 4 A were used. For C and D oligos depicted in C were used. 
E-H UV-crosslinked binding reaction using 60 µg of LMH/2A or MCF-7 (H) NE and recombinant ER_ and short oligos 
containing BrdU (E, lower panel). Where indicated, 100 nM E2, recombinant ER_ or competitor was added to the 
reaction mix. Crosslinked complexes were resolved on an 8% polyacrylamide gel and visualized on phosphor screens.
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CpG7	shows	a	methylation-sensitive	shift	in	LMH/2A,	MCF-7	and	HeLa	extracts.	Since	 we	 observed	 a	 strong	 inhibitory	 effect	 of	 methylation	 in	 the	enhancer/promoter	 region	 of	 VTG	 that	 was	 shown	 to	 be	 independent	 of	methylation	of	the	ERE,	we	set	out	to	investigate	the	other	CpGs	in	this	region	to	find	 the	 CpG	 conferring	 methylation-dependent	 inhibition.	 The	 eight	 CpGs	(following	 the	 two	 in	 the	ERE)	were	numbered	 from	one	 to	 eight,	 CpG	b	 from	Saluz	et	al.	being	CpG1,	CpG	a	being	CpG2	(Fig.	1	A).	CpG5	and	6	were	analyzed	together	as	they	lie	very	close	to	each	other.	We	performed	EMSAs	with	NEs	on	these	CpGs	and	were	surprised	to	see	the	same	shift	with	different	intensities	on	the	ERE,	CpG1,	2	and	7	(Fig.	7	A).	Another	molecular	mobility	shift	was	seen	on	CpG3	 (Supp.	 Fig.	 4	D)	 and	no	 shifts	 on	CpG4,	5/6	and	8	 in	LMH/2A	as	well	 as	MCF-7	NEs	(Fig.	7	A	and	Supp.	Fig.	4	E).	Interestingly,	the	shift	of	seemingly	the	same	protein	on	the	ERE,	CpG1,	2	and	7	showed	distinct	methylation	sensitivities	
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on	the	different	sequences.	The	methylation	sensitivity	on	the	ERE	has	been	seen	before	and	also	on	CpG1	there	was	an	influence	of	methylation,	but	not	on	CpG2.	The	strongest	effect	of	methylation	however,	could	be	seen	on	CpG7.	The	same	behavior	was	visible	in	MCF-7	(Supp.	Fig.	4	E)	and	in	HeLa	extracts	(Supp.	Fig.	4	F).	 SDS	 gels	 with	 cross-linked	 binding	 reactions	 showed	 a	 band	 with	 similar	mobility	on	CpG7	as	on	the	ERE	and	an	additional	band	migrating	slightly	slower	in	LMH/2A	(Fig.	7	B)	and	in	HeLa	NE	(Fig.	7	C).			
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Fig 7: CpG 7 shows strong methylation-sensitivity of a complex migrating at the same height as on the ERE. 
A Left panel: EMSA with LMH/2A nuclear extracts on four different CpG-containing regions bearing different cyto-
sine combinations. Right panel: Quantification of percentage bound oligo of three independent experiments. Data 
are represented as mean ± SD. Significance was assessed using the Tukey test for multiple comparisons. 
B & C UV-crosslinked binding reaction using 60 µg of LMH/2A (B) or HeLa (C) NE and recombinant ER_ (first lanes) 
and short oligos containing BrdU (Fig. 6 E, lower panel). Oligo Δ3 misses the 3nt of the spacer region in the ERE. 
Crosslinked complexes were resolved on an 8% polyacrylamide gel and visualized on a phosphor screen.
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CpG7	 plays	 an	 important	 role	 in	 the	 methylation-sensitivity	 of	 the	 expression	 of	
luciferase	under	control	of	the	VTG	enhancer/promoter.	We	next	set	out	to	characterize	the	behavior	of	the	different	CpGs	further	using	the	luciferase	assay.	Since	it	is	very	elaborate	to	introduce	methylated	oligos	for	all	CpGs	using	ligation,	we	decided	to	mutate	the	CpGs	one	by	one	from	CpG	to	TpG,	 therefore	 inhibiting	 their	methylation	by	SssI	 (Fig.	 8	A).	 First	we	 checked	whether	 the	 C	 to	 T	 transition	 itself	 influenced	 the	 expression	 of	 luciferase,	impeding	the	investigation	of	methylation-sensitivity.	We	found	that	mutation	at	the	ERE	 (mut	ERE)	 and	CpG7	 (C594T)	were	 the	only	 ones	negatively	 affecting	luciferase	expression	absolutely	(Fig.	8	B	&	C	&	Supp.	Fig.	5	A	&	B)	as	well	as	fold	
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induction	upon	E2	treatment	(Supp.	Fig.	5	C).	They	had	to	be	kept	unchanged	and	were	as	a	consequence	always	methylated	when	the	plasmids	were	treated	with	
SssI.	To	check	whether	the	mutation	in	CpG7	directly	affects	factor	X	binding,	we	performed	an	EMSA	on	the	mutant	oligo	and	saw	reduced	binding	as	compared	to	the	wt	unmethylated	oligo	bearing	CpG7,	but	still	stronger	binding	than	with	wt	methylated	CpG7	(Fig.	8	D).	This	translated	directly	to	luciferase	expression,	where	 the	 mutant	 CpG7	 showed	 intermediate	 expression	 between	 wt	unmethylated	and	wt	methylated,	hinting	towards	an	important	role	of	factor	X	binding	in	transcriptional	activation.	The	expression	in	all	the	other	mutants	was	still	 inhibited	 when	 methylated	 with	 SssI,	 showing	 that	 these	 individual	 sites,	when	unmethylated,	had	no	influence	on	transcription	(Fig.	8	E	&	Supp.	Fig.	5	D).				
A B
C
Fig 8: CpG7 is responsible for the methylation-sensitivity of the VTG enhancer/promoter. A Scheme of experimental 
setup. B Luciferase assay of different mutants. One representative experiment is shown. Data are represented as mean of 
technical triplicates ± SD. C Luciferase assay of wt unmethylated plasmid (wt), C to T mutations in the ERE (mut ERE) and 
mutation of CpG7 (C594T). Data are represented as mean of three independent experiments ± SD. D EMSA showing bind-
ing of factor X to unmethylated (7), methylated (7 mC) and mutant CpG7 (C594T) in LMH/2A and HeLa nuclear extracts. E 
Same as B but mutants are methylated with SSSI. F Luciferase assay of wt CpGL, of the CpGL with all CpGs mutated except 
for the ERE, CpG7 and CpG8 (ERE/7/8 wt) and the CpGL with all mutated except for the ERE and CpG7(ERE/7 wt), unmethyl-
ated and methylated (+SSSI). Data are represented as mean of three independent experiments ± SD.  
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Since	CpG7	seems	to	play	an	important	role	in	the	control	of	VTG	transcription,	but	we	could	not	analyze	the	mutant,	we	had	to	use	a	different	approach.	We	set	out	to	mutate	all	CpGs	together,	except	for	CpG	c	and	d	in	the	ERE	and	CpG7.	We	tested	the	combined	mutants	successively	to	exclude	that	 interactions	between	different	sites	had	any	additional	 influence	on	transcription,	which	was	not	the	case.	All	combinations	tested	were	still	active	when	unmethylated	and	inhibited	when	 methylated	 (Supp.	 Fig.	 5	 E).	 Analysis	 of	 the	 final	 plasmid	 (ERE/7	 wt)	unmethylated	and	methylated	confirmed	that	methylation	of	CpG7	and	possibly	the	 combination	with	methylated	 ERE	 (even	 though	methylation	 of	 ERE	 alone	had	no	effect,	Fig.	5	D),	was	conferring	the	inhibition	(Fig.	8	F).	This	prompted	us	to	 conclude	 that	 proteins	 binding	 to	 CpG7	 were	 key	 to	 the	 regulation	 of	expression	 of	 VTG	 and	 that	 their	 binding	 was	 methylation-sensitive.	 Figure	 9	shows	 a	 summary	 of	 the	 results	 obtained	 with	 the	 luciferase	 experiments,	highlighting	again	the	importance	of	CpG7	(arrows).			
Fig 9: CpG7 is responsible for the 
methylation-sensitivity of the VTG 
enhancer/promoter. Summary scheme of 
luciferase assays with the different CpGLs. 
White circles represent unmethylated, black 
circles methylated and blue circles hydroxym-
ethylated CpGs. Ticks indicate induction of 
expression, crosses indicate inhibited expres-
sion. The first five lines show plasmids prepared 
with ligation of short oligos bearing the ERE 
with different cytosine modifications. The 
others were in vitro methylated using SssI, the 
unmethylated CpGs were mutated. 				Discussion		We	 could	 show	 that	 vitellogenin	 expression	 is	 induced	 upon	 β-estradiol	treatment	 in	 LMH/2A	 cells,	 but	 that	 this	 is	 happening	 independently	 of	detectable	 changes	 in	 DNA	 methylation.	 The	 four	 CpGs	 reported	 earlier	 to	become	 demethylated	 upon	 hormone	 treatment	 (Saluz	 et	 al.,	 1986)	 remained	resistant	to	bisulfite	conversion.	We	did,	however,	see	accumulation	of	the	TET	oxidation	product	5hmC,	 already	6	h	 after	E2	 treatment	 and	 increasing	 further	with	 longer	 exposure	 to	E2.	 In	our	 system,	we	 cannot	distinguish	between	 low	expression	 of	 VTG	 in	 all	 cells	 or	 high	 expression	 in	 a	 subset	 of	 cells	 that	underwent	 demethylation,	 possibly	 escaping	 our	 analysis,	 or	 expression	resulting	from	oxidation	of	5mC	to	5hmC	in	some	cells.	The	question	why	we	are	unable	to	detect	demethylation	remains	unresolved,	especially	because	proteins	
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with	 an	 assigned	 role	 in	 demethylation,	 namely	 the	 TETs	 and	 thymine	 DNA	glycosylase	(TDG),	and	that	are	present	in	chicken	embryonic	and	adult	liver,	are	also	 present	 in	 the	 cell	 line.	 The	 involvement	 of	 yet	 unknown	 factors	 in	 the	demethylation	event	at	the	VTG	enhancer	is,	however,	conceivable.	The	finding	that	5hmC	is	enriched	at	the	CpGs	upon	hormone	treatment	and	the	increase	 in	 VTG	 expression	 when	 TET2	 is	 overexpressed,	 points	 towards	 a	functional	 role	 of	 the	 oxidized	 base	 in	 transcription.	 The	 levels	 of	 5hmC	 are,	however,	low	and	there	is	the	possibility	that	TET2	influences	gene	expression	in	a	way	other	than	oxidation	of	5mC.	Another	intriguing	point	is	that	no	oxidation	beyond	 5hmC	 was	 detected.	 5fC	 or	 5caC	 would	 have	 led	 to	 the	 bisulfite-dependent	 conversion,	which	was	 not	 detectable.	 The	 question	 arises	whether	this	 is	 a	 situation	where	 the	TET-mediated	oxidation	cascade	 specifically	 stops	after	 a	 single	 step.	 Another	 possible	 explanation	would	 be	 that	 excision	 of	 5fC	and	 5caC	 and	 re-methylation	 of	 the	 replaced	 cytosine	 are	 extremely	 fast	 and	efficient	 processes.	 Such	 cyclical	 DNA	 methylation	 and	 demethylation	 events	have	been	observed	in	the	pS2	promoter	upon	hormone	treatment	(Kangaspeska	et	al.,	2008;	Metivier	et	al.,	2008).	Even	 though	we	did	not	detect	demethylation	of	 the	enhancer,	 the	observation	that	 we	 can	 shut	 down	 expression	 with	 in	 vitro	 methylation	 of	 the	 gene	regulatory	 region	 points	 towards	 an	 important	 role	 of	 CpG	methylation	 in	 the	regulation	 of	 VTG.	 It	 indicates	 that	 methylation	 in	 this	 system	 is	 more	 than	 a	mere	basal	state,	resulting	as	a	consequence	of	gene	inactivity	before	encounter	with	β-estradiol.	The	fact	that	we	do	not	see	differential	binding	of	the	estrogen	receptor	α	when	the	ERE	is	methylated	or	hydroxymethylated	puzzled	us	at	first,	considering	the	reported	 importance	of	methylation	 at	 this	 locus	 and	our	observations	with	 in	
vitro	methylation.	It	makes,	however,	sense	that	the	ERα	is	able	to	bind	all	forms	of	cytosine	modification,	as	it	is	the	initiating	event	upon	hormone	treatment.	All	chromatin-remodeling	 processes	 follow	 E2	 treatment.	 Since	 several	 nuclear	receptors	(NRs)	were	shown	to	interact	with	chromatin	remodelers	and	proteins	involved	in	demethylation,	such	as	TDG,	stimuli-	and	site-specific	recruitment	of	a	demethylation	complex	by	NRs	would	constitute	an	effective	system.	We	 found	 that	 the	 inducibility	 of	 the	 reporter	 under	 the	 control	 of	 the	 VTG	regulatory	region	was	dependent	on	E2	treatment	and	on	methylation,	also	in	the	ΔG	 ERE	 that	 did	 not	 bind	 ERα	 efficiently.	 Binding	 of	 ERα,	 assessed	 by	 EMSAs,	however,	was	 independent	of	both,	E2	 treatment	and	methylation	status.	 It	has	been	 shown	 previously	 that	 ERα	 binds	 the	 ERE	 independently	 of	 E2	 in	 vitro	(Murdoch	et	al.,	1990).	The	inducibility	in	vivo	seems	to	be	regulated	at	the	level	of	nuclear	import	after	dissociation	from	the	heat	shock	protein.	The	 fact	 that	 the	 reporter	 with	 the	 ΔG	 ERE	 was	 still	 inducible	 by	 E2,	 albeit	roughly	 half	 as	 efficiently,	 seemed	 puzzling.	 For	 all	 we	 know,	 the	 inducibility	upon	E2	 treatment	had	 to	be	mediated	by	 the	ERα.	The	VTG	 regulatory	 region	contains	another,	 imperfect	ERE,	which	could	mediate	the	effect	on	expression.	Moreover,	 there	was	 a	 very	weak	 residual	 binding	 of	 ERα	 to	 the	mutated	ERE	that	possibly	also	contributes.	The	discrepancy	between	methylation	responsiveness	of	the	reporter	and	the	in	
vitro	binding	of	ERα	to	the	ERE	can	have	two	reasons.	The	first	could	be	binding	of	other	proteins	to	the	ERE	 in	vivo	 that	confer	methylation-sensitivity.	Binding	of	two	non-histone	proteins	(NHPs)	to	the	ERE	(NHP1)	and	its	proximity	(NHP2)	
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within	 the	VTG	 enhancer	has	been	described	 (Feavers	et	 al.,	 1987).	We	 indeed	detected	a	methylation-sensitive	mobility	shift	(factor	X)	on	the	ERE	in	nuclear	extracts	 (NEs)	 that	 was	 not	 cell	 type-specific.	 We	 doubt,	 however,	 that	 this	protein	 is	similar	 to	 the	NHPs	published,	due	 to	different	molecular	weights	as	assessed	by	denaturing	SDS	gels.	Additional	evidence	arguing	against	the	NHPs	are	the	strongest	contact	sites	of	NHP1	that	were	found	to	be	the	AGCG,	lying	in	the	spacer	 region	between	 the	palindromic	half	 sites	 (Hughes	et	al.,	1989).	We	see	a	stronger	binding	of	factor	X	on	the	ΔG	substrate	that	misses	the	middle	G	of	this	 sequence.	 Another	 observation	 made,	 concerning	 factor	 X	 binding	 to	 the	ERE,	was	 that	 this	was	 the	 only	 shift	 we	 saw	 in	 NEs.	We	 do	 not	 see	 any	 ERα	binding,	despite	the	presence	of	ERα	in	the	NEs,	arguing	for	a	competition	for	the	ERE	binding	site.		The	second	explanation	for	the	different	methylation	sensitivities	in	the	reporter	and	the	EMSA	could	lie	in	the	regulatory	sequence	downstream	of	the	ERE.	There	are	 six	 additional	 CpGs	 in	 the	 control	 region	 of	 VTG,	 besides	 the	 four	 CpGs	published.	The	inhibitory	effect	of	methylation	was	most	likely	mediated	by	one	or	several	of	these	CpGs.	We	were	able	to	pin	down	the	inhibitory	effect	of	the	in	
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Table	S	1:	RT-qPCR	primers.		
RT-qPCR	primers	GapDH	fwd	 GGCCATCAATGATCCCTTCATCG	GapDH	rev	 GACAGTGCCCTTGAAGTGTCCG	VTG	fwd	 CATACTGGCATTAGTGCTCACCC	VTG	rev	 GGTAACTCCTTCTGCTATTGAATCC	ER1	fwd	 CCAGCAGGTACCCTACTACCTTG	ER1	rev	 GCTGTGGCGCCTATTATCAGAGC		
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Table	S	2:	EMSA	and	pull-down	primers.			
EMSA	and	pull-down	primers	EMSA	comp	scr	 CTCAAGCTTCCCAACGTCGACAGACGTCTGG	EMSA	ERE	long	up	 AGCTGAAAAATATTCCTGGTCAGCGTGACCGGAGCTGAAAGAACACATGGTAC	EMSA	ERE	long	low	 CATGTGTTCTTTCAGCTCCGGTCACGCTGACCAGGAATATTTTTC	EMSA	ERE	long	ΔG	up	 AGCTGAAAAATATTCCTGGTCACGTGACCGGAGCTGAAAGAACACATGGTAC	EMSA	ERE	long	ΔG	low	 CATGTGTTCTTTCAGCTCCGGTCACGTGACCAGGAATATTTTTC	EMSA	ERE	long	Δ3	up	 AGCTGAAAAATATTCCTGGTCATGACCGGAGCTGAAAGAACACATGGTAC	EMSA	ERE	long	Δ3	low	 CATGTGTTCTTTCAGCTCCGGTCATGACCAGGAATATTTTTC	EMSA	ERE	short	up	 TATTCCTGGTCAGCGTGACCGGAGC	EMSA	ERE	short	low	 TTCAGCTCCGGTCACGCTGACCAGGAATA	EMSA	ERE	short	ΔG	up	 TATTCCTGGTCACGTGACCGGAGC	EMSA	ERE	short	ΔG	low	 TTCAGCTCCGGTCACGTGACCAGGAATA	EMSA	ERE	short	Δ3	up	 TATTCCTGGTCATGACCGGAGC	EMSA	ERE	short	Δ3	low	 TTCAGCTCCGGTCATGACCAGGAATA	EMSA	CpG1	up	 GAACACATTGATCCCGTGATTTCAAT	EMSA	CpG1	low	 ATTGAAATCACGGGATCAATGT	EMSA	CpG2	up	 CTTAAATCATGTGCGTTGGTGCACATATGA	EMSA	CpG2	low	 GTATTCATATGTGCACCAACGCACATGATTTAAG	EMSA	CpG3	up	 GTACCAGCAGCCAGCCGTGACCCAATCTAG	EMSA	CpG3	low	 CTAGATTGGGTCACGGCTGGCTGCTG	EMSA	CpG4	up	 ATTGTAAATGCCGTAGTAGAAGTGTTT	EMSA	CpG4	low	 GTAAAACACTTCTACTACGGCATTTACAAT	EMSA	CpG5_6	up	 GATTTTCTTTATTCGCCGTGAAGAGAATTTATG	EMSA	CpG5_6	low	 CATAAATTCTCTTCACGGCGAATAAAGAAA	EMSA	CpG7	up	 GCAGAAAACAGCCACGTGTTCCTGAAC	EMSA	CpG7	low	 GTTCAGGAACACGTGGCTGTTTTC	EMSA	CpG7	mut	up	 GCAGAAAACAGCCATGTGTTCCTGAAC	EMSA	CpG7	mut	low	 GTTCAGGAACACATGGCTGTTTTC	EMSA	CpG8	up	 AGCCCTATTCACCTTCGCTATGAGGGGGATC	EMSA	CpG8	low	 GATCCCCCTCATAGCGAAGGTGAATAGG	EMSA	comp	RAR	 TCGAGGGTAGGGTTCACCGAAAGTTCACTCG	Biotin	oligo	ERE	up	 TTAATATTCCTGGTCAGCGTGACCGGAGC	Biotin	oligo	ERE	low	 TTAAGCTCCGGTCACGCTGACCAGGAATA	Biotin	ΔG	up	 TTAATATTCCTGGTCACGTGACCGGAGC	Biotin	ΔG	low	 TTAAGCTCCGGTCACGTGACCAGGAATA	Biotin	CpG7	up	 TTAAGAAAACAGCCACGTGTTCCTGAAC	Biotin	CpG7	low	 TTAAGTTCAGGAACACGTGGCTGTTTTC		
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Table	S	3:	Mutagenesis	primers.	
	
Mutagenesis	primers	new	KpnI	fwd	 CCGGAGCTGAAAGAACACATGGTACCCGTGATTTCAATAAATAC	new	KpnI	rev	 GTATTTATTGAAATCACGGGTACCATGTGTTCTTTCAGCTCCGG	destroy	KpnI	site	fwd	 CATGTTCACAACACTGGGGTATCTGATCTGTGGCTTCAGAG	destroy	KpnI	site	rev	 CTCTGAAGCCACAGATCAGATACCCCAGTGTTGTGAACATG	C57T	fwd	 GAAAGAACACATGGTACCTGTGATTTCAATAAATACATATG	C57T	rev	 CATATGTATTTATTGAAATCACAGGTACCATGTGTTCTTTC	C119T	fwd	 GCCTCTTAAATCATGTGTGTTGGTGCACATATGAATAC	C119T	rev	 GTATTCATATGTGCACCAACACACATGATTTAAGAGGC	C354T	fwd	 CCATGTACCAGCAGCCAGCTGTGACCCAATCTAGGAAAGC	C354T	rev	 GCTTTCCTAGATTGGGTCACAGCTGGCTGCTGGTACATGG	C410T	fwd	 CAATTTTAAATTTATTGTAAATGCTGTAGTAGAAGTGTTTTACTG	C410T	rev	 CAATTTTAAATTTATTGTAAATGCTGTAGTAGAAGTGTTTTACTG	C509T	fwd	 GTATTATTTGATTTTCTTTATTTGCCGTGAAGAGAATTTATGATTG	C509T	rev	 CAATCATAAATTCTCTTCACGGCAAATAAAGAAAATCAAATAATAC	C512T	fwd	 GATTTTCTTTATTCGCTGTGAAGAGAATTTATGATTGC	C512T	rev	 GCAATCATAAATTCTCTTCACAGCGAATAAAGAAAATC	C594T	fwd	 GAATTCAGCAGAAAACAGCCATGTGTTCCTGAACATTCTTCC	C594T	rev	 GGAAGAATGTTCAGGAACACATGGCTGTTTTCTGCTGAATTC	C655T	fwd	 GCAGAGCCCTATTCACCTTTGCCATGGAGGATGCCAAG	C655T	rev	 CTTGGCATCCTCCATGGCAAAGGTGAATAGGGCTCTGC	EREmut	(C26T	and	C32T)	fwd	 GCTTAAAAATATTCCTGGTCAGTGTGACTGGAGCTGAAAGAACACATGG	EREmut	(C26T	and	C32T)	rev	 CCATGTGTTCTTTCAGCTCCAGTCACACTGACCAGGAATATTTTTAAGC	
ΔG	fwd	 GCTTAAAAATATTCCTGGTCACGTGACCGGAGCTGAAAG	
ΔG	rev	 CTTTCAGCTCCGGTCACGTGACCAGGAATATTTTTAAGC		
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Supplementary Fig. 1: A Upper panel: mRNA levels were measured with qPCR after the indicated lenght of 
treatment with 100 nM E2 . One representative experiment is shown in technical triplicates. Data are repre-
sented as mean ± SD. Lower panel: Western Blot showing VTG protein levels and TFIIH as an internal loading 
control. B Relative ER_ mRNA levels measured by qPCR after 6 and 72 h of E2 treatment. One representative 
experiment is shown in technical triplicates. Data are represented as mean ± SD. C Immunofluorescence of 
EdU incorporation without (left panels) or with 8 µM aphidicolin treatment (right panels) without (upper 
panels) and 24h (lower panels) of E2 treatment.
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Supplementary Fig. 2: Bisulfite and oxidised-bisulfite sequencing result of the CpGs b (A), c (B) and d 
(C). The left panels show the results of the transcribed strand, the right panels show the non-
transcribed strand. The numbers under the upper panels indicate the total amount of analyzed reads 
for every condition. The percentage of 5hmC (lower panels) was calculated as the difference of 
converted Cs between the oxidised bisulfite-converted DNA and only bisulfite-converted DNA. 
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Supplementary Fig. 3: A EMSA showing binding of ER_ to ERE and ΔG substrates of different methylation status, -/+ 
E2 treatment. B EMSA with different cytosine modifications in the ERE, including formylcytosine (fC) and carboxycyto-
sine (caC). C-E EMSA with increasing concentrations of recombinant ER_ (0, 5, 10, 20, 30, 40, 80 and 200 ng) and 
indicated cytosine modifications in ERE wt and ΔG substrates in the last lanes with 40 ng of ER_. Additionally in E right 
panel: Quantification of percentage bound oligo of three independent experiments of fully hemi- and fully-
hydroxymethylated oligos.  Data are represented as mean ± SD.  F & G EMSA on unmethylated ERE with competition 
with increasing amounts of methylated or hydroxymethylated ERE , ΔG or Δ3 oligo (long oligos F, shorter oligos G). 
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Supplementary Fig. 4: A EMSA with LMH/2A nuclear extracts and different combinations of modified oligos, -/+ E2. 
B EMSAs with addition of ER_ antibody with unmethylated (left panel) and methylated (right panel) oligo in LMH/2A 
NEs. C EMSA in LMH/2A with increasing concentrations of a RARE consensus competitor or ΔG competitor on 
unmethylated (C/C) or methlyated (mC/mC) ERE. D EMSAs in LMH/2A NEs on ERE and CpG3 with combinations of 
different cytosine modifications showing complexes with distinct mobilities. E EMSA on CpG4, CpG5_6, CpG7 and 
CpG8 in LMH/2A (left panel) and MCF-7 (right panel) NEs, unmethylated and methylated. F EMSAs in HeLa (left 
panel) and LMH/2A (right panel) NEs on ERE, ΔG, CpG4 and CpG7, each unmethylated and methylated as indicated.
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Supplementary Fig. 5: A Luciferase assays of different mutants, unmethylated. Data are represented as mean of techni-
cal triplicates ± SD. B Luciferase assay of wt unmethylated plasmid (wt), C to T mutations in CpG7 (C594T) and in CpG8 
(C655T). Data are represented as mean of three independent experiments ± SD. C Fold luciferase induction upon E2 
treatment of different mutants. Data are represented as mean of three independent experiments ± SD. D Luciferase 
assays of different mutants, methylated with SssI. Data are represented as mean of technical triplicates ± SD. E Luciferase 
assays of combined mutants, unmethylated and methylated with SssI. Data are represented as mean of technical tripli-
cates ± SD. experiments ± SD.
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Supplementary Fig. 6: EMSA on unmethylated ERE wt of proteins from affinity purification with the ERE wt or ΔG 
from HeLa (A) or LMH/2A (B) nuclear extracts. As a control, beads only eluents were used.
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ADDITIONAL	OBSERVATIONS	
	
TET1	AND	2	AND	MODIFIED	CYTOSINES	ARE	PRESENT	IN	LMH/2A	CELLS	AND	IN	EMBRYONIC	
AND	ADULT	CHICKEN	LIVER	
TET1	 and	 TET2	 could	 be	 detected	 in	 the	 chicken	 hepatoma	 cell	 line	 LMH	 (Fig	 R1	 A)	 and	 in	
embryonic	 and	 adult	 chicken	 liver.	 TET2	 seems	 to	 be	 higher	 expressed	 in	 the	 adult	 tissue,	
whereas	TET1	is	more	abundant	in	the	embryo	(Fig	R1	C).	Moreover,	the	presence	of	5mC	and	
the	TET	oxidation	products	could	be	confirmed	using	Dot	Blots	of	LMH	genomic	DNA	(Fig	R1	B)	
and	embryonic	and	adult	chicken	liver	(Fig	R1	D).	
	
	
Figure R 1: Detection of TETs and cytosine species in LMH/2A and embryonic and adult 
chicken liver. A Western Blots of TET2 (upper panel) and TET1 (lower panel) in different cell 
lines. B Dot Blot of genomic DNA from LMH cells. C As in A, using whole cell extracts (WCE) 
from embryonic (E) and adult (A) chicken liver. TFIIH was used as the loading control. D As in 
B, but using genomic DNA extracted from embryonic and adult liver.  
	
INVESTIGATION	OF	METHYLATION	STATUS	OF	VITELLOGENIN	ENHANCER	AND	VITELLOGENIN	
INDUCIBILITY	IN	CHICKEN	EMBRYOS	
We	 investigated	 the	 site-specific	 and	 inducible	 demethylation	 of	 the	 vitellogenin	 enhancer	 in	
chicken	 embryos,	 in	 addition	 to	 the	 LMH/2A	 cell	 line.	 To	 this	 end,	we	 cut	 a	 "window"	 in	 the	
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shells	of	fertilized	chicken	eggs	(Fig	R2	A,	[513])	and	then	added	E2	or	EtOH	from	day	9	to	day	10	
of	embryonic	development.	 Interestingly,	while	CpGs	a,	c	and	d	were	~90%	methylated	 in	 the	
basal	state,	CpG	b	showed	reduced	methylation	levels	of	70-80%	(Fig	R2	B).	This	phenomenon	is	
comparable	to	the	adult	rooster,	where	one	strand	of	CpG	b	was	unmethylated	already	prior	to	
hormone	 treatment	 and	 the	 other	 strand	 50%	 methylated,	 in	 contrast	 to	 90%	 symmetrical	
methylation	of	the	other	CpGs	[332].	Also,	in	LMH/2A	cells,	CpG	b	was	a	special	case,	being	50%	
methylated	 on	 both	 strands	 (Results	 II,	 Fig	 1	 B).	 We	 could	 show	 a	 weak	 induction	 of	 VTG	
expression	in	10-day	embryos	after	24	h	of	E2	treatment	compared	to	EtOH	mock	treatment	(Fig	
R2	C),	but	no	detectable	demethylation,	similar	to	that	seen	in	the	hepatoma	cell	line	LMH/2A.		
	
	
Figure R 2: Manipulations of chicken embryos in ovo. A Eggs were 'windowed' to enable access 
for manipulations. B Basal methylation states of the four CpGs described by Saluz et al., assessed 
by PacBio single molecule sequencing. C Induction of vitellogenin expression in two individual 
embryos.  
	
MASS	SPECTROMETRIC	IDENTIFICATION	OF	PROTEINS	BINDING	THE	WT	AND	ΔG	VITELLOGENIN	
ERE		
As	we	saw	a	mobility	shift	in	LMH/2A-,	MCF-7-	and	HeLa	NEs	that	was	methylation-sensitive	and	
distinct	from	ERα,	we	set	out	to	identify	the	proteins	binding	the	ERE	wt	and	DG	sequence	using	
an	 approach	 that	 combined	 affinity-enrichment	 and	mass	 spectrometry	 (MS).	 To	 improve	 the	
yield,	 we	 generated	 multimers	 of	 the	 oligonucleotides	 by	 end-to-end	 ligation,	 filled-in	 the	
overhangs	with	bio-dUMP	and	attached	 the	DNA	 to	Streptavidin-derivatised	Dynabeads.	Mass	
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spectrometric	 analysis	 of	 the	 proteins	 bound	 to	 these	 substrates	 upon	 incubation	 with	 HeLa	
extracts	identified	several	proteins	binding	the	ERE	that	were	absent	in	the	control	(Table	1).	A	
candidate	 that	 caught	 our	 attention	 was	 Max-like	 protein	 X	 (MLX).	 MLX	 is	 a	 helix-loop-helix	
transcription	 factor,	 known	 to	bind	 the	E-box	 sequence	CTCGAG.	The	deletion	of	 the	G	 in	 the	
ERE	spacer	in	DG	generates	an	E-box	motif	and	CpG7,	shown	to	bind	the	same	protein	complex	
in	NEs,	is	located	in	an	E-box	(Results	II).	
Table 1: Proteins enriched from HeLa NE. Proteins of the MAX network are marked in green. 
	
We	 performed	 the	 same	 pull-down/	 MS	 experiment	 also	 with	 LMH/2A	 NEs	 and	 could	 also	
retrieve	MLX,	specifically	in	the	affinity	purification	with	ERE	wt	and	DG,	but	not	in	the	control	
(Table	 2).	 We	 could	 also	 detect	 ERα	 in	 the	 enrichment	 from	 LMH/2A	 NEs,	 confirming	 the	
specificity	of	the	method.	
Gene MW 
(kDa) 
Spectrum ΔG Spectrum beads Probability if 
detected 
MLXPL 93 19  >95% 
MLX 33 13  >95% 
NR2F6 43 11  >95% 
MSH6 153 18 4 >95% 
NR2C2 65 20  >95% 
RXRB 57 10  >95% 
MSH2 105 12 6 >95% 
UBP1 60 15  >95% 
MPG 33 12  >95% 
MLXIP 101 19  >95% 
ESRRA 46 9  >95% 
ZBTB9 51 9  >95% 
ZBED1 78 10  >95% 
RFX5 65 8  >95% 
NR2C1 67 9  >95% 
MGA 332 7  >95% 
MAX 18 4  >95% 	
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Table 2: Proteins enriched from LMH/2A NE. Proteins of the MAX network are marked in 
green. 
	
To	verify	 that	MLX	 is	 involved	 in	 the	 complex,	 causing	 the	mobility	 shift	with	ERE	wt,	DG	and	
CpG7	 substrates,	 we	 performed	 EMSA-supershift	 experiments,	 using	 a	 monoclonal	 antibody	
against	MLX	and	other	proteins	 identified	 in	the	MS	analysis.	Only	the	MLX	antibody	caused	a	
supershift	(Fig	R3),	indicating	the	presence	of	MLX	in	the	complex	that	formed	the	mobility	shift	
on	the	substrate.	The	supershift	was,	however,	only	detectable	on	the	DG	and	not	on	the	CpG7	
substrate.	This	unanticipated	finding	thus	needs	further	study.	
Gene MW 
(kDa) 
Spectrum ERE Spectrum ΔG Spectrum beads Probability if 
detected 
Gga 147 64 63  >95% 
SALL4 118 56 58  >95% 
RXRG 51 40 35 2 >95% 
CHD4 219 35 31  >95% 
KIA1958 79 20 20  >95% 
ESR1 67 16 11  >95% 
HNF1A 69 13 8  >95% 
CREBBP 265 13 13  >95% 
RARG 49 8 11  >95% 
NR2C1 62 9 8  >95% 
MPG 30 5 6  >95% 
NR2F1 46 6 7  >95% 
MSH2 95 6   >95% 
TBX3 78 4 4  >95% 
HNF4A 51 5 5  >95% 
CTBP1 47 5 7  >95% 
MSH6 142 6 4  >95% 
TDG 45 4 6  >95% 
LXRA 47 3 4  >95% 
NR2C2 65 5 4  >95% 
MLXIP 89  6  >95% 
ZBTB17 89 3 5  >95% 
MLX 28  4  >95% 
MAX 16  2  >95% 	
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Figure R 3: Supershift experiments show evidence for the role of MLX in factor X shift. 200ng of 
the indicated antibodies were added to the EMSA reaction with LMH/2A NE. The mobility 
shifts were carried out with the DG-  (left panel) or the CpG7 substrate (right panel). 
	
LOCALIZATION	AND	ACTIVITY	OF	EXOGENOUS	TEN-ELEVEN	TRANSLOCATION	PROTEINS	IN	HEK	
293	CELLS	
We	 checked	 the	 localization	 of	 human	 TET1	 and	 mouse	 TET2	 full-length	 proteins	 upon	
expression	in	HEK293	cells.	Both	proteins	were	expressed	in	the	cells	24	h	after	transfection,	as	
assessed	 by	 immunofluorescence	 against	 their	 Flag	 tag	 (Fig	 R4	 A).	 They	 were	 successfully	
targeted	 to	 the	 nucleus	 and	 colocalized	 with	 DAPI	 staining.	 We	 also	 analyzed	 the	 DNA	 of	
transfected	 cells	 to	 assess	whether	 the	 amount	of	 the	oxidized	base	 5hmC	was	 increased.	 To	
this	 end,	 we	 performed	 an	 adapted	 fibre	 assay,	 where	we	 stained	 DNA	 fibres	with	 5mC	 and	
5hmC	 antibodies,	 followed	 by	 staining	 with	 fluorescent	 secondary	 antibodies.	 5hmC	was	 not	
detectable	 in	 mock	 transfected	 cells,	 but	 clearly	 enhanced	 in	 the	 cells	 transfected	 with	 full	
length	human	TET1.	The	5hmC	signal	displayed	nicely	on	the	fibres,	similar	to	5mC	(Fig	R4	B).	
	
	
Figure R 4: A Immunofluorescence using DAPI and Anti-Flag antibody in HEK293 cells 
transfected with full-length human TET1 or mouse TET2. B DNA fibres stained with Anti-
ΔG CpG7
BSA TR2TR4Sin3a Mlx200ng AB BSA TR2TR4Sin3a Mlx
mTET2	
hTET1	
DAPI	 FLAG	 MERGE	A	 CNTR 500ng TET1
B	
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5mC and Alexa Fluor 488 and Anti-5hmC and Alexa Fluor 568 antibodies from DNA of mock 
(CNTR) or human TET1-transfected HEK293 cells. 
	
TET1	CATALYTIC	DOMAIN	PURIFICATION	AND	ENZYMATIC	ACTIVITY	TESTS	
We	purified	active	human	TET1-CD	from	stably-expressing	HEK293	FlpIn	cells	using	a	3x	Flag	tag,	
as	described	in	'Materials	and	Methods	of	Additional	observations'.	Input,	flowthrough	(FT)	and	
elutions	(E1	and	E2)	were	 loaded	on	a	6%	polyacrylamide	SDS	gel	and	stained	with	Coomassie	
blue	to	verify	expression	and	successful	enrichment	with	the	Flag	beads	(Fig	R5	A).	The	TET1-CD	
was	 obtained	 in	 high	 purity.	 The	 faster-migrating	 bands	 on	 the	 gel	 most	 likely	 represent	
degradation	products	and	the	bands	that	migrated	slower	might	be	oxidized	TET1-CD	products,	
as	observed	by	others	 [28].	Activity	of	the	purified	protein	was	assessed	by	carrying	out	a	TET	
reaction	 on	 5mC	 bearing	 substrates,	 as	 described	 in	 'Materials	 and	 Methods	 of	 Additional	
observations'.	The	small-scale-	(26.8.15)	and	the	large-scale	(02.10.15)	purifications	from	100	15	
cm	 dishes	 were	 active	 on	 a	 5mC-containing	 plasmid,	 as	 assessed	 by	 Dot	 blot	 using	 a	 5hmC	
specific	antibody	(Fig	R5	B).	
	
Figure R 5: A Coomassie blue-stained SDS-PAGE of purified TET1-CD small-scale (26.08.15) 
and large-scale (02.10.15) preparations. Input (IN), flow-through (FT), elution 1 (E1) and 
elution 2 (E2) of the large scale and E1 of the small scale were loaded onto a 6% gel. B Activity 
test of purified proteins on 5mC-containing plasmid DNA. Product DNA was loaded onto a Dot 
blot and stained with Anti-5hmC antibody. Lanes marked "+" represent control 5hmC-
containing plasmid DNA. 
	
We	next	addressed	the	question,	at	which	pH	the	TET	reaction	was	most	efficient,	as	there	were	
different	conditions	reported.	We	performed	the	TET	reaction	at	pH	7.9	and	at	pH	6.5	using	our	
purified	 TET1-CD	 and	 oligonucleotide	 substrates.	 A	 Dot	 blot	 assay	 revealed	 that	 5mC	 was	
converted	more	efficiently	to	5hmC	at	pH	6.5	(Fig	R6	A).	5hmC-containing	oligonucleotides	were	
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used	as	a	positive	control.	Also	the	subsequent	oxidation	steps	to	5caC	were	more	efficient	at	
pH	6.5	(Fig	R6	B).	
	
	
Figure R 6: TET reactions using the TET1-CD from the large-scale purification in Fig R5 at 
different pH. A Starting from 5mC-bearing oligonucleotides, reaction products were visualized 
with Anti-5hmC antibodies and HRP-coupled secondary antibodies. 5hmC-containing oligos 
were used as positive controls (hmC CNTR). B Starting from 5mC (mC), 5hmC (hmC) or 5fC 
(fC) oligos, product formation was assessed by staining with an Anti-5caC antibody. 5caC-
containing oligos were used as positive controls (caC CNTR). 
	
To	address	some	of	the	open	questions	concerning	TET	processivity,	we	plan	to	use	our	purified	
active	TET1-CD	and	the	established	reaction	conditions.	Studies	performed	so	far	only	assessed	
average	 product	 formation	 of	 the	 TET	 proteins,	 either	 in	 vivo	 in	 genome-wide	 studies	 or	
biochemically.	No	information	concerning	single	oxidation	steps	at	defined	loci	can	be	retrieved	
from	 these	 studies.	 We	 established	 an	 approach	 on	 covalently-closed	 oligonucleotide	
substrates,	 sequenced	 with	 the	 PacBio	 technology	 that	 provides	 information	 on	 single	
molecules.	This	enables	us	to	assess	whether	the	TET	reaction	yields	asynchronous	oxidations	or	
whether	 they	 primarily	 oxidize	 both	 strands	 symmetrically.	 As	 the	 substrate	 contained	 two	
CpGs,	we	are	also	able	to	get	information	about	processivity	along	the	DNA	on	each	strand	(Fig	
R7).	
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Figure R 7: Schematic representation of the work-flow for the biochemical characterization of 
the TET reaction. 
	
In	preliminary	experiments,	we	obtained	 few	reads	when	starting	with	 short	oligonucleotides,	
confirming	that	the	sequencing	primer	for	the	bisulfite	converted	adapter	works.	The	loss	during	
the	 purification	 steps	 was	 however	 big	 and	 the	 procedure	 needs	 further	 improvement.	 In	
additon,	 the	optimal	TET	 reaction	 incubation	 times	and	protein	concentrations	have	yet	 to	be	
optimised,	so	as	to	enable	us	to	see	single	oxidation	steps.	
	
MATERIALS	AND	METHODS	TO	'ADDITIONAL	OBSERVATIONS'	
	
Antibodies	
Name	 Origin	 Provider	 Dilution	
Anti-TFIIH	 rabbit	 Santa	Cruz	 1:1000	
Anti-TET1	 rabbit	 Abcam	 1:1000	
Anti-TET2	 mouse	 Abiocode	 1:1000	
Anti-5mC	 mouse	 Serotec	 1:500	
Anti-5hmC	 rabbit	 Active	motif	 1:10'000	
Anti-5fC	 rabbit	 Active	motif	 1:2000	
Anti-5caC	 rabbit	 Active	motif	 1:2000	
Anti-rabbit	Alexa	568	 goat	 Molecular	Probes	 1:300	
!
  CATTTAAAAATATTCCTGGTCAG?GTGAC?GGAGCTGAAAGA 
 AGTAAATTTTTATAAGGACCAGTCG?ACTGG?CTCGACTTTC 
!!
   TATTTAAAAATATTTTTGGTTAG?GTGAT?GGAGTTGAAAGA 
 
 
    
  AGTAAATTTTTATAAGGATTAGTTG?ATTGG?TTTGATTTTT !!
TET reaction
Bisulfite conversion
Adapter ligation
PacBio sequencing
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Anti-mouse	Alexa	488	 goat	 Molecular	Probes	 1:300	
Anti-flag	 mouse	 Sigma	 1:1000	
Anti-MLX	 mouse	 Santa	Cruz	 1:1000	
Anti-Sin3a	 mouse	 Santa	Cruz	 1:1000	
Anti-TR2	 mouse	 Santa	Cruz	 1:1000	
Anti-TR4	 mouse	 Santa	Cruz	 1:1000	
Anti-rabbit	IgG	HRP	 goat	 GE	Healthcare	UK	 1:5000	
Anti-mouse	IgG	HRP		 sheep	 GE	Healthcare	UK		 1:5000	
	
Cell	culture	
Human	embryonic	kidney	(HEK)	293	cells	were	grown	in	DMEM	medium	(Gibco),	supplemented	
with	10%	FCS	and	streptomycin/penicillin	(100	U/ml).	Cells	were	grown	at	37°C	in	a	6%	CO2	
humidified	atmosphere.	
	
Dot	Blot	
Samples	were	heated	 for	10	min	at	100°C	 in	a	 total	volume	of	250	µl	 in	0.4	M	NaOH,	10	mM	
EDTA	 and	 transferred	 quickly	 to	 ice	 to	 avoid	 re-annealing.	 An	 equal	 volume	 of	 2	 M	 ice-cold	
ammonium	 acetate	 was	 added.	 After	 pre-soaking	 in	 1	 M	 ammonium	 acetate,	 the	 nylon	
membrane	was	 inserted	 into	 the	Dot	Blot	apparatus	according	 to	manufacturer's	 instructions.	
Wells	were	rinsed	with	water	before	applying	the	samples.	The	vacuum	was	kept	 low	to	avoid	
deforming	 the	membrane.	After	 samples	were	blotted,	 the	wells	were	washed	once	with	1	M	
ammonium	 acetate,	 the	 membrane	 was	 removed	 and	 soaked	 for	 5	 min	 in	 5x	 saline-sodium	
citrate	 (SSC;	 0.75	 M	 NaCl,	 75	 mM	 sodium	 citrate	 pH	 7).	 The	 DNA	 was	 crosslinked	 to	 the	
membrane	by	either	baking	at	80°C	for	2	h	(plasmids)	or	by	irradiating	the	membrane	with	120	
mJ	UV	irradiation	(for	oligos;	Stratalinker	1800,	Stratagene).	The	membrane	was	rinsed	with	5x	
SSC,	followed	by	blocking	in	5%	milk/TBS-T	(20	mM	Tris-HCl	pH	7.4,	150	mM	NaCl,	0.1%	Tween-
20)	 for	 1	 h.	 Incubation	 with	 the	 primary	 antibody	 was	 performed	 overnight	 at	 4°C.	 The	
membrane	was	washed	3x	for	5	min	in	TBS-T,	incubated	with	the	secondary	antibody	for	1	h	at	
RT	 and	 washed	 again,	 before	 being	 developed	 in	 a	 Fusion	 Solo	 (Vilber	 Lourmat)	 using	
WesternBright	Chemiluminescent	Detection	Reagent.	
Oligos	 used	 for	 activity	 tests:	 5'-CCAGACGTCTGTCGACGTTGGGAAGCTTGAG-3',	 with	 the	
underlined	cytosine	carrying	the	modification.	Plasmids	used	for	activity	tests	were	prepared	by	
primer	extensions	with	the	above	oligos	on	pRichi	350t	SalI	phagemid	ssDNA	[514].	
	
Manipulation	of	chicken	embryos	
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Eggs	were	prepared	as	described	 [515,	516].	At	day	10,	eggs	were	treated	with	100	nM	E2	by	
pipetting	~55	µl	 (depending	on	weight	of	egg)	of	a	100	µM	solution	 (10%	EtOH)	 into	 the	egg,	
through	the	window	prepared	at	day	3	of	development	at	39°C.	24	h	later,	the	eggs	were	broken	
and	the	dissected	out	of	the	embryo	for	RNA	and	protein	extraction.	Livers	were	homogenized	
using	a	Tissue	Ruptor	(Qiagen)	in	RIPA	buffer	for	proteins	and	in	RLT	buffer	for	RNA.	Following	
homogenization,	 protein	 samples	 were	 processed	 further	 according	 to	 the	 Western	 Blot	
protocol	as	described	in	Results	II	and	RNA	was	extracted	using	an	RNAeasy	Kit	(Qiagen).	
	
Immunofluorescence	
Cells	were	grown	on	coverslips	in	6-well	plates	and	transfected	with	plasmids	(mTET2;	FH-Tet2-
pEF,	 a	 gift	 from	 Anjana	 Rao	 (Addgene	 plasmid	 #	 41710)[446]	 and	 3x	 Flag	 hTet1-ORF using	
Lipofectamine	 2000	 according	 to	 manufacturer's	 instructions.	 Coverslips	 were	 washed	 in	
phosphate-buffered	 saline	 (PBS)	 and	 cells	 were	 fixed	 in	 3.7%	 formaldehyde/PBS	 for	 15	 min.	
Coverslips	were	washed	3x	in	PBS	before	cells	were	permeabilized	in	0.2%	TritonX-100/PBS	for	5	
min.	Coverslips	were	washed	3x	in	PBS.	50	µl	of	3%	milk/PBS	were	pipetted	onto	Parafilm	and	
the	coverslips	were	put	cells-down	onto	the	mix	and	blocked	for	15	min.	The	same	procedure	
was	applied	with	the	primary	antibody	dilution	in	3%	milk/PBS	and	coverslips	were	incubated	at	
4°C	 overnight.	 The	 coverslips	 were	 washed	 3x	 in	 PBS	 and	 incubated	 with	 the	 secondary,	
fluorescent	antibody	in	3%	milk/PBS	at	37°C	for	1	h,	shielded	from	light.	After	3	washing	steps	in	
PBS,	 cells	 were	 fixed	 with	 mounting	 media	 containing	 4',6-diamidino-2-phenylindole	 (DAPI,	
VectaShield).	Slides	were	analyzed	on	an	Olympus	IX81	fluorescence	microscope. 
	
DNA	Fibre	staining	
Cells	were	washed	and	scraped	off	in	PBS.	2	µl	of	a	cell	suspension,	containing	approximately	1x	
106	 cells/ml,	 were	 pipetted	 onto	 a	 glass	 slide	 (Super	 Frost	 Plus,	 Menzel-Glaser).	 7	 µl	 of	 lysis	
buffer	(200	mM	Tris-HCl	pH	7.4,	50	mM	EDTA,	0.5%	SDS)	were	added,	cells	were	mixed	with	a	
pipette	tip	and	incubated	for	2	min	at	RT	before	glass	slides	were	slightly	tilted	to	let	the	drops	
run	down.	Once	 slides	were	dry,	DNA	was	 fixed	 in	methanol/acetic	acid	3:1	 for	10	min	at	RT.	
Before	staining,	slides	were	washed	twice	in	PBS	and	DNA	was	denatured	in	2.5	M	HCl	for	1	h.	
Slides	were	washed	5x	in	PBS	for	3	min	each	and	blocked	in	2%	bovine	serum	albumin	(BSA)	and	
0.1%	Tween-20	 in	 PBS	 for	 45	min.	 Slides	were	 incubated	 in	 primary	 antibody	 for	 2.5	 h	 at	 RT,	
washed	5x	in	PBS	with	0.2%	Tween-20	(PBS-T)	and	once	in	blocking	solution.	Incubation	with	the	
secondary,	fluorescent	antibody	was	carried	out	at	RT	for	1	h.	Slides	were	washed	again	5x	with	
PBS-T,	before	cells	were	fixed	with	mounting	media	containing	DAPI	(VectaShield).	Slides	were	
analyzed	on	an	Olympus	IX81	fluorescence	microscope.	
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Preparation	of	oligos	for	enrichment	of	proteins	for	MS	
Oligos	with	compatible	5'-overhangs	were	annealed	in	annealing	buffer	(50	mM	Hepes,	pH	7.5,	
100	mM	 NaCl)	 to	 10	 µM	 (ERE	 wt	 upper	 5'-TTAATATTCCTGGTCAGCGTGACCGGAGC-3';	 ERE	 wt	
lower	 5'-TTAAGCTCCGGTCACGCTGACCAGGAATA-3';	 ERE	 ΔG	 upper	 5'-
TTAATATTCCTGGTCACGTGACCGGAGC-3';	 ERE	 ΔG	 lower	 5'-
TTAAGCTCCGGTCACGTGACCAGGAATA-3').	400	pmoles	of	annealed	ds	oligos	were	 ligated	end-
to-end	with	10	U	T4	ligase	(NEB)	overnight	at	16°C.	Efficient	ligation	was	verified	on	an	agarose	
gel	and	the	DNA	was	recovered	by	EtOH	precipitation.	Overhangs	were	filled-in	according	to	the	
protocol	for	3'-labeling,	but	with	only	1	mM	biotin-11-dUTP	(ThermoScientific)	and	2	µl	[α-32P]-
dATP	 in	40	µl.	Reaction	was	 incubated	 for	10	min	at	RT	before	1	µl	of	10	mM	cold	dATP	was	
added	for	another	10	min.	Mixture	was	passed	twice	through	a	Sephadex	desalting	column	to	
get	rid	of	the	free	biotin.	
	
Enrichment	of	binding	proteins	for	MS	
30	 µl	 of	 Dynabeads	 M-280	 Streptavidin	 (ThermoFisher)	 per	 oligo	 were	 washed	 with	 1	 ml	 of	
washing	buffer	(5	mM	Tris,	pH	7.5,	0.5	mM	EDTA,	1	M	NaCl).	The	beads	were	taken	up	in	30	µl	
of	washing	buffer.	The	ligated	oligos	from	above	were	added	and	allowed	to	bind	to	the	beads,	
until	 the	beads	were	saturated,	assessed	by	 the	 lack	of	 radioactive	signal	 in	 the	 flow-through.	
The	beads	were	washed	once	and	taken	up	in	2x	EMSA	binding	buffer	without	BSA	(10	mM	Tris-
HCl,	pH	7.6,	50	mM	NaCl,	1	mM	DTT,	5%	glycerol).	1.5	mg	of	nuclear	extract	were	pre-incubated	
with	 30	 µg	 of	 poly(dI.dC),	 before	 an	 equal	 volume	 was	 added	 to	 the	 beads	 (split	 into	 three	
tubes).	 The	 mixture	 was	 incubated	 for	 15	 min	 with	 gentle	 shaking	 at	 4°C.	 Supernatant	 was	
collected	 and	 beads	 were	 washed	 with	 50	 µl	 of	 1x	 EMSA	 binding	 buffer	 without	 BSA.	Wash	
fraction	was	collected	and	proteins	were	eluted	in	50	µl	(for	all	three	tubes)	of	elution	buffer	(10	
mM	Tris-HCl,	pH	7.6,	500	mM	NaCl,	5%	glycerol)	 for	10	min,	shaking	at	4°C.	7	µl	of	the	eluted	
fraction	were	used	for	EMSA	to	verify	the	presence	of	the	binding	proteins.	
	
Shotgun	LC-MS/MS	
The	 protein	 mixture	 was	 digested	 with	 trypsin	 into	 peptides.	 After	 cleaning	 up,	 the	 peptide	
mixture	 was	 applied	 to	 a	 reversed-phase	 high-performance	 liquid	 chromatography	 (HPLC)	
column	and	separated	prior	 to	 ionization	and	analysis	by	 the	mass	 spectrometer.	The	peptide	
ions,	selected	by	the	instrument,	were	fragmented	and	the	resulting	fragment	ion	spectrum	was	
recorded.	 It	 provided	 a	 set	 of	 peptide	 signatures,	which	were	 used	 to	 identify	 the	 respective	
polypeptides	by	the	database	search	algorithm	MASCOT.	The	factors	were	scored	according	to	
the	average	probability	using	total	spectra	counts.		
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Purification	of	TET1-CD	from	HEK293	cells	stably	expressing	TET1-CD	wt	
Stable	cell	lines	were	established	using	293	TrexFlpIn	cells	that	were	transfected	with	200	ng	of	
pTO-pAIO-FRT-3x	 Flag	 Tet1CD	WT	 (from	 aa	 1418-2136)	 containing	 hygromycin	 resistance	 and	
1.5	µg	of	pOG44	Flp-Recombinase	expression	vector	(ThermoFisher).	When	confluent,	cells	were	
plated	 in	 selection	 medium	 containing	 Hygromycin	 (250µg/ml,	 InvivoGen)	 and	 Blasticidin	
(10µg/ml	 ,	 InvivoGen).	 Once	 visible	 colonies	 formed,	 they	 were	 trypsinized	 and	 re-seeded	 as	
bulk	culture.	
Approximately	 1.2x109	 of	 293	 TrexFlpIn	 pTO-pAIO-FRT-3x	 Flag	 Tet1CD	WT	 bulk	 culture	 were	
treated	with	100	ng/ml	Doxycyclin	 (Clontech)	 for	24	h,	before	being	harvested	at	around	50%	
confluency	directly	in	PBS	on	ice.	Cells	were	spun	for	5	min	at	500	x	g	at	4°C,	washed	in	cold	PBS	
and	spun	again.	Pellets	could	be	snap	frozen	and	stored	at	-80°C	for	later	purification.	
Pellet	was	resuspended	in	12.5	ml	cold	lysis	buffer	(50	mM	Tris	pH	7.5,	1	mM	EDTA,	1%	TritonX-
100,	300	mM	NaCl,	1	mM	PMSF,	2x	protease	inhibitor	cocktail,	Roche)	and	incubated	20	min	on	
ice.	Lysate	was	spun	for	10	min	at	14'000	rpm	at	4°C,	supernatant	was	transferred	to	a	new	tube	
and	diluted	1:1	 in	50	mM	Tris	pH	7.5,	1	mM	EDTA,	1%	TritonX-100,	1	mM	PMSF,	2x	protease	
inhibitor	cocktail.	An	Input	sample	for	the	SDS	gel	was	kept	aside.	
For	 the	 immunopurification	 (IP),	 500	 µl	 Anti-Flag	 M2	 beads	 (Sigma)	 were	 equilibrated	 by	
washing	3x	in	1	ml	of	washing	buffer	(50	mM	Tris	pH	7.5,	150	mM	NaCl)	and	spinning	for	2	min	
at	500	x	g.	All	steps	were	carried	out	at	4°C.	The	lysate	was	added	to	the	beads	and	incubated	on	
a	rotating	wheel	for	3	h.	A	flow-through	(FT)	sample	for	the	SDS	gel	was	kept	aside.	The	beads	
were	washed	3x	in	1	ml	washing	buffer	by	incubating	on	the	rotating	wheel	for	5	min,	followed	
by	 spinning	 for	2	min	at	500	x	g.	Proteins	were	eluted	 in	 two	 rounds	 (E1	and	E2)	with	500	µl	
elution	 buffer	 (50	 mM	 Tris	 pH	 7.5,	 50	 mM	 NaCl,	 1	 mM	 β-mercaptoethanol,	 5%	 glycerol,	
containing	200	ng/ml	Flag	peptide	(3x	Flag	peptide,	Sigma)	by	 incubating	them	for	each	round	
for	30	min	on	a	rotator.	A	sample	was	kept	aside	for	the	SDS	gel	and	the	rest	was	aliquoted	and	
snap	frozen	and	stored	at	-80°C.	
	
TET	enzymatic	reaction	
For	the	TET	reaction,	10	µl	of	the	purified	protein	(E1)	were	used	for	500	ng	of	5mC-containing	
plasmid	in	a	volume	of	15	µl	in	TET	buffer	(prepared	freshly	as	10x:	20	mM	ascorbic	acid,	10	mM	
DTT,	1	mM	ammonium	iron(II)	sulfate	(FAS),	10	mM	2-oxoglutarate,	500	mM	NaCl,	10	mM	ATP,	
500	mM	 Tris	 pH	 6.5	 or	 7.9,	 as	mentioned	 in	 'Additional	 observations',	 Fig	 R6).	 Reaction	 was	
incubated	for	3	h	at	37°C	and	heat	inactivated	for	5	min	at	85°C.	
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Adapter	ligation	for	PacBio	sequencing	of	short	oligonucleotides	
1	 µg	 of	 ds	 oligonucleotides	 were	 mixed	 with	 1	 µl	 of	 20	 µM	 overhang	 adapter	 (Pacific	
Biosciences).	Provided	template	preparation	buffer	was	added	and	supplemented	with	1.5	µl	of	
1	mM	ATP.	30	units	of	provided	ligase	(Pacific	Biosciences)	was	added,	reaction	was	made	up	to	
30	 µl	 and	 incubated	 for	 2	 h	 at	 25°C.	 After	 heat	 inactivation	 at	 65°C	 for	 10	min,	 reaction	was	
treated	with	 exonucleases	 III	 (50	U)	 and	VII	 (5	U)	 to	 get	 rid	 of	 unligated	 oligos	 and	 adapters.	
Reaction	mixture	was	 incubated	 at	 37°C	 for	 1	 h.	 Reaction	was	 purified	 on	AMPure®PB	 Beads	
(Pacific	Biosciences)	according	to	manufacturer's	instructions.	Ligated	oligos	were	now	ready	for	
TET	reactions	and	bisulfite	conversion,	before	being	sequenced	using	the	PacBio	technology.	As	
the	adapters	provided	by	the	company	also	undergo	bisulfite	conversion,	a	different	sequencing	
primer	 had	 to	 be	 added	 (5'-TTTTTTTTTTTTTTTTTTCTCTCAACAACAACAAC-3',	 the	 underlined	
nucleotides	containing	2’-methoxy	modifications	to	increase	stability).	
	
Western	blots,	DNA-	and	RNA	extractions,	PacBio	sequencing,	RT-qPCR	and	EMSAs	were	carried	
out	as	described	in	Results	II.	
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DISCUSSION	
	
DSB	INDUCTION	RESULTING	FROM	AN	INTERPLAY	BETWEEN	BER	AND	MMR		
The	 experimental	 set-up	 developed	 in	 our	 lab,	 using	 defined,	 lesion-containing	 plasmid	
substrates	and	nuclear	 cell	extracts,	 represents	a	very	nice	 system	to	 study	 the	DSB-induction	
step	 in	 class-switch	 recombination.	 The	 plasmids	 do	 not	 replicate,	mimicking	 the	 situation	 in	
germinal	center	B-cells	 that	are	 in	 the	G1-phase	of	 the	cell	 cycle.	The	defined	 locations	of	 the	
lesions	 enable	 us	 to	 draw	 conclusions	 about	 the	 mechanism	 of	 action	 of	 the	 cellular	 repair	
enzymes	acting	on	them.	
Based	 on	 our	 in	 vitro	 and	 in	 vivo	 experiments	 (Results	 I,	 [517]),	 we	 propose	 a	model	 for	 the	
combined	action	of	BER	and	MMR	in	enabling	efficient	CSR	(Results	I	and	Fig	D1).	U/G	mispairs	
are	 substrates	 for	 both	 BER	 and	MMR.	 This	 leads	 to	 a	 competition	 of	 the	 pathways	 for	 the	
lesions,	whose	outcome	depends	on	lesion-density,	sequence	context	and	cell	cycle	phase.	We	
propose	that	DSBs	occur	 through	a	collision	of	 repair	 intermediates	of	BER	and	MMR,	ss	nicks	
and	ss	degradation	tracts,	which	individually	would	not	form	DSBs,	but	-	when	combined	-	very	
efficiently	do	so.	
We	see	an	 important	 contribution	of	MMR,	namely	MutSα,	 in	 the	 induction	of	DSBs	 in	our	 in	
vitro	 and	 in	 vivo	 systems,	 and	 in	 the	 generation	 of	mutations	 in	 vivo.	 The	 break	 formation	 is	
completely	dependent	on	 the	BER	enzyme	UNG,	on	 the	other	hand.	An	explanation	 for	 these	
differences	might	be	that	MMR	alone	lacks	a	strand-discrimination	signal,	necessary	for	efficient	
repair.	 Is	 has	 already	 been	 shown	 that	MMR	 can	make	 use	 of	 sites	 of	 ongoing	 base	 excision	
repair	 [118]	 and	 sites	 of	 ribonucleotide	 excision	 [129]	 to	 start	 EXO1-mediated	 degradation	 of	
one	strand.	It	is	therefore	conceivable	that	CSR	is	highly	dependent	on	these	UNG-created	nicks.	
This	 phenomenon	 has	 also	 been	 observed	 in	 Ung-/-	 mice	 [64].	 The	 milder	 effect	 on	 DSB	
formation	we	see	in	the	absence	of	MMR	is	also	consistent	with	genetic	studies	[137,	139,	245].	
One	 explanation	 could	 be	 that	 repair	 tracts	 generated	 after	 excision	 of	 uracils	 by	 UNG	 could	
result	in	DSBs	in	case	they	are	located	in	close	proximity	on	opposite	strands.	In	these	situations,	
MMR	degradation	tracts	would	not	be	needed.	We	showed	in	our	system,	however,	that	nicks	
on	opposite	strands	have	to	be	very	closely	spaced	to	result	in	melting	of	the	ds	DNA	between	
them.	 A	 stretch	 of	 50	 bp	 between	 the	 uracils	 is	 enough	 to	 keep	 the	 DNA	 stably	 linked.	 It	 is	
imaginable	that	the	sequence	context	in	certain	parts	of	the	S	regions	provides	many	AID	target	
sites	that	could	be	processed	into	MMR-independent	DSB,	whereas	other	regions	might	depend	
on	 MMR	 to	 allow	 formation	 of	 DSBs.	 This	 could	 account	 for	 the	 differences	 in	 Ig	 isoform	
distributions	when	MMR	is	absent.	
																																																																																																																																																																																			DISCUSSION		
	____________________________________________________________________________________________________________________	118	
	
Figure D 1: Model of the interplay of BER and MMR in the processing of uracil lesions in 
DNA. In the case when the MMR system is faster than BER in recognizing and binding a uracil, 
MutSa is activated and recruits MutLa that sets additional nicks into the already-nicked strand. 
EXO1 is loaded at the nicks and starts degrading one strand with its 5' to 3' polarity. In the 
meantime, other uracils generated in the vicinity might have been addressed by the fast UNG 
and APE1, resulting in additional nicks. If the EXO1 degradation tract runs into the BER 
created lesions, DSBs are the consequence. Adapted from [517]. 
	
The	 finding	 that	 the	 absence	 of	MMR	 in	 our	 system	 had	 such	 a	 great	 impact	was	 somewhat	
surprising,	as	the	absence	of	MMR	was	reported	to	result	in	a	less	severe	phenotype	than	BER-
deficiency	in	mice	[64,	137,	139,	245],	as	mentioned	above.	By	providing	a	nick	in	the	substrates,	
we	 do,	 however,	 stress	 the	 involvement	 of	 MMR,	 as	 the	 nick	 can	 be	 used	 as	 a	 strand-
discrimination	 signal	 and	 initiation	 site	 for	 the	 EXO1-mediated	 degradation	 tract.	 A	 more	
physiologically-relevant	substrate	would	contain	uracils	on	both	strands,	instead	of	a	nick	on	one	
strand.	 These	 substrates	were	 extremely	 complex	 to	 prepare	 and	 required	 carefully-designed	
purification	 steps.	 Preliminary	 results	 obtained	with	 those	 plasmids	 gave	 puzzling	 results.	We	
completely	lost	MMR-dependence	in	break	formation	using	this	substrate.	We	did	see	efficient	
break	 formation,	 however,	 dependent	on	UNG	and	on	 catalytically-active	 EXO1.	 These	 results	
support	 the	notion	that	BER,	 initiated	by	UNG	 is	extremely	 fast	and	efficient.	This	could	mean	
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that	MMR	does	not	have	access	 to	 the	uracils	under	normal	circumstances.	However,	MMR	 is	
clearly	involved	in	CSR.	An	explanation	for	this	could	be	that	during	AID-induced	CSR,	there	are	
so	many	uracils	created	in	close	proximity	that	the	capacity	of	BER	is	exceeded,	giving	MMR	the	
chance	to	reach	some	of	the	lesions.	
	
	
Figure D 2: Schematic drawing of the CSR-substrate bearing uracils of both strands. 
	
The	question	why	we	still	see	break	formation	remains.	The	uracils	are	too	far	apart	to	result	in	
melting	of	the	DNA	strands.	This	is	confirmed	by	the	EXO1	dependence.	The	obvious	conclusion	
to	 draw	 here	 is	 that	 EXO1	 is	 loaded	 at	 the	 nicks	 resulting	 from	 BER	 independently	 of	MMR,	
thereby	 assisting	 in	 break	 formation.	Why	 this	 is	 happening	 only	 in	 the	 substrate	 containing	
uracils	on	both	strands	(Fig	D2)	and	not	 in	the	substrate	with	the	nick	 investigated	 in	Results	 I	
cannot	be	answered	conclusively	here.	The	only	difference	between	 the	substrates	 is	 the	nick	
versus	the	uracil	at	a	single	site.	Maybe	the	physical	presence	of	the	BER	or	the	MMR	machinery	
at	the	nick	is	needed	for	loading	of	EXO1	and	their	targeting	might	be	inefficient	in	the	case	of	a	
pre-existing	nick,	as	compared	to	a	uracil.	
	
MUTATIONS	VERSUS	DBS:	SHM	VERSUS	CSR	
An	 interesting	 question	 concerning	 the	mechanisms	of	 SMH	and	CSR	 is	 how	 the	outcomes	of	
lesion	processing	can	be	so	different,	considering	that	the	initial	steps	are	equal.	Both	pathways	
are	 initiated	 by	 AID-induced	 cytosine	 deaminations,	 creating	 uracils	 in	 DNA.	 In	 SHM,	 these	
lesions	 are	 converted	 into	 mutational	 hotspots	 in	 the	 variable	 regions,	 whereas	 in	 CSR	 the	
results	are	targeted	DSBs	involving	loss	of	the	intervening	DNA.	
One	important	point	to	keep	in	mind	is	that	the	outcomes	might	be	less	distinct	from	each	other	
than	might	appear	to	be	the	case	in	B-cells.	We	do	see	a	considerable	amount	of	mutations	in	
our	 CSR	 system,	 highly	 dependent	 on	MMR	 (Results	 I),	 similar	 to	 SHM.	 Although	 cytosines	 in	
WRC	 AID	 targeting	 sites	were	 published	 to	 be	mutational	 hotspots	 [215],	 we	 do	 not	 see	 any	
accumulation	of	mutations	at	our	uracil	 sites	above	 random	 levels.	 It	 is	 therefore	 conceivable	
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that	 the	 same	 non-canonical,	 highly-mutagenic	 MMR	 mechanism	 acting	 in	 SHM	 is	 also	
responsible	for	the	mutations	we	detect	in	our	substrates	[117,	148,	149].	
DSB	formation,	on	the	other	hand,	does	also	occur	during	SHM,	mostly	resulting	in	B-cell	death	
and	 therefore	 not	 easily	measurable.	 Another	 point	 to	 keep	 in	mind	 is	 that	 DSB	 formation	 is	
generally	an	infrequent	even,	not	only	in	SHM,	but	also	in	CSR.	The	power	of	the	process	in	B-
cells	 lies	 in	 the	 efficient	 selection	 and	 elimination	 steps.	 In	 our	 in	 vitro	 system	 that	 was	
optimized	to	assess	DSBs	by	having	a	nick	on	the	opposite	strand	to	the	uracils,	DSB	incidence	
never	exceeded	30%,	reached	by	addition	of	recombinant	proteins.	In	the	in	vivo	system,	we	had	
to	 introduce	 two	 selection	 steps	 in	 order	 to	 be	 able	 to	 detect	 the	DSB	 events.	Moreover,	we	
assume	 that	 many	 DSBs	 escaped	 our	 analysis,	 because	 they	 did	 not	 lead	 to	 efficient	 re-
annealing.	In	B-cells,	these	DSBs,	possibly	also	happening	during	SHM,	would	lead	to	apoptosis.	
Higher	eukaryotes	can	easily	tolerate	high	apoptosis	rates	in	B-cells,	compared	to	other	tissues.	
Nevertheless,	 the	balance	of	DSBs	versus	mutations	 is	 clearly	different	 in	 SHM	versus	CSR.	As	
both	 processes	 occur	 in	 germinal	 center	 B-cells	 and	 therefore	 in	 the	 same	 environments,	 the	
differences	have	 to	come	 from	the	exact	 sequence	contexts	and	 the	 targeting	of	AID	 to	 these	
sites,	as	well	as	 from	the	 re-annealing	step	after	DSB	 induction.	Supporting	 this	notion,	 it	was	
observed	 that	 the	 sequence	 context	 of	 the	 Sµ	 region	 is	 critical	 for	 CSR	 [518,	 519].	 Another	
observation	made	was	that	transcription	targeted	to	S	regions	results	in	the	formation	of	R-loop	
structures,	whereas	these	structures	are	inefficiently	formed	in	the	variable	regions	[116].	
Further	investigations	of	the	differences	in	sequence	context	in	S	regions	versus	variable	regions	
are	needed	and	will	provide	valuable	insights	into	the	mechanisms	of	SHM	and	CSR.	
	
WHY	ARE	REPAIR	PATHWAYS	MUTAGENIC	IN	THIS	PARTICULAR	CASE?	
The	involvement	of	bona	fide	repair	pathways	in	the	mutagenic	pathways	SHM	and	CSR	remains	
puzzling.	 Under	 normal	 circumstances,	 MMR	 and	 BER	 are	 high	 fidelity	 processes	 that	 are	
important	guardians	of	genomic	integrity.	Why	do	they	develop	a	mutagenic	function	in	CSR	and	
SHM,	and	how	can	this	function	be	restricted	to	B-cells?	
Germinal	 center	B-cells	undergoing	SHM	and	CSR	are	mostly	 in	 the	G1	phase	of	 the	cell	 cycle	
[152].	 Canonical	 MMR	 that	 would	 lead	 to	 faithful	 repair	 of	 mismatches	 can	 therefore	 be	
excluded.	 The	 mutagenic	 properties	 of	 non-canonical	 MMR	 outside	 of	 S-phase	 have	 been	
studied	 [117,	 137,	 142].	 Its	 occurrence	 in	 non-B-cells	 seems	 to	 be	 undesirable	 under	 normal	
circumstances.	 Thanks	 to	 alternative	 mechanism	 like	 BER	 that	 addresses	 some	 mismatches	
outside	of	S	phase,	non-canonical	MMR	is	likely	to	play	a	minor	role	in	cells.	In	B-cells,	however,	
the	situation	is	different,	most	likely	because	there	is	a	high	accumulation	of	lesions	that	can	be	
addressed	by	MMR.	
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The	 processing	 of	 uracils	 by	 BER	 is	 a	 highly-efficient	 process.	 There	 are	 four	 glycosylases	 in	
mammals	UNG,	SMUG1,	MDB4	and	thymine	DNA	glycosylase	TDG	[35],	but	only	UNG	has	been	
linked	to	SHM	and	CSR.	As	mentioned	in	the	introduction,	UNG	has	an	extremely	high	turnover	
rate	and	is	therefore	very	efficient	in	removing	uracils	from	DNA.	The	same	explanation	for	the	
mutagenic	 action	 of	MMR	 in	 B-cells	 can	 apply	 here.	 AID	 creates	 an	 unusual	 accumulation	 of	
uracils	 in	 close	 proximity.	 This	 could	 possibly	 lead	 to	 overwhelming	 of	 the	 otherwise	 very	
efficient	BER.		
The	case	of	SHM	and	CSR	constitutes	a	unique	situation,	because	it	involves	an	accumulation	of	
lesions	 that	 can	 be	 addressed	 by	 two	 repair	 pathways	 simultaneously.	 The	 two	 pathways	 are	
normally	 prevented	 from	 encountering	 each	 other,	 as	 MMR	 is	 tightly-coupled	 to	 replication,	
whereas	the	BER	enzyme,	TDG	for	example,	is	specifically	degraded	during	S-phase.		
AID	 is	 the	only	B-cell	 specific	 factor	known	that	 is	 involved	 in	 these	mutagenic	processes.	 It	 is	
therefore	 conceivable	 that	 the	 B-cell	 specific	mutagenicity	 of	 the	 repair	 pathways	 is	 found	 at	
that	step	of	regulation.	Nevertheless,	it	is	still	somewhat	unanticipated	that	the	lesions	are	not	
repaired	faithfully	by	the	two	repair	pathways	involved.	
Several	hypotheses	are	under	discussion	to	explain	the	 inefficient	repair	of	the	uracils	and	the	
induction	 of	 dangerous	 and	 normally-undesirable	 DSBs.	 One	 or	 more	 factors	 of	 the	 repair	
pathways	might	be	absent	or	present	to	a	lesser	extent	in	B-cells.	One	candidate	is	polymerase	
b,	 which	 has	 indeed	 been	 shown	 to	 be	 down-regulated	 in	 activated	 B-cells	 [49].	 B-cells	
completely	lacking	polymerase	b	show	a	slight	increase	in	CSR	to	some	isotypes	[520].	
A	 possible	 explanation	 for	 the	 tolerance	 of	 B-cells	 towards	 DSBs	 came	 from	 the	 Dalla-Favera	
group	 that	 found	 reduced	 p53	 expression	 in	 activated	 B-cells	 [521].	 Limited	 signaling	 of	 the	
important	 tumor	 suppressor	 p53	 in	 an	 environment	 of	 high	 mutagenesis	 and	 frequent	 DNA	
rearrangement	 seems	 very	 dangerous	 though.	 Accordingly,	 the	 incidence	 of	 lymphomas	 is	
particularly	high	in	B-cells.	
	
B-CELL	LYMPHOMAS	
Lymphomas	are	a	group	of	tumors	originating	from	lymphocytes.	95%	of	all	lymphomas	are	of	B-
cell	 origin	 [522].	 The	 biggest	 subgroup	 of	 Non-Hodgkin	 lymphomas	 are	 the	 mature	 B-cell	
lymphomas.	 They	 comprise	 among	 others	 the	 groups	 of	 diffuse	 large	 B-cell	 lymphoma	 and	
Burkitt's	 lymphoma	 (BL).	 Most	 of	 these	 cancers	 are	 initiated	 by	 translocations	 of	 proto-
oncogenes.	Depending	on	the	location	of	the	translocation	and	on	the	type	of	proto-oncogene,	
its	carcinogenic	effect	can	be	due	to	the	removal	of	negative	regulators	or	to	the	addition	of	a	
strong	enhancer	or	active	promoter	[523].	
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A	 hallmark	 of	 mature	 B	 cell	 lymphomas	 is	 the	 involvement	 of	 at	 least	 one	 Ig	 gene	 in	 the	
transformation-initiating	 translocation	 [524-528].	 BL	 for	 example	 is	 characterized	 by	 the	
translocation	of	c-Myc	to	an	immunoglobulin	gene	locus,	in	most	cases	IgH	[523].	This	leads	to	
the	 erroneous	 regulation	 of	 c-Myc	 and	 promotes	 tumor	 formation	 through	 its	 effect	 on	
proliferation	[528].	Other	examples	are	the	translocation	of	the	Ig	locus	to	Bcl-1,	a	controller	of	
the	cell	cycle	or	to	Bcl-2,	an	inhibitor	of	apoptosis	[529].	
The	 frequent	 involvement	 of	 the	 Ig	 locus	 suggests	 an	 involvement	 of	 the	 Ig-modifying	
mechanism	V(D)J	recombination	and	the	mature	B-cell	specific	processes	SHM	and	CSR.	Indeed,	
it	 has	 been	 shown	 that	 deregulated	 expression	 of	 the	 SHM-	 and	 CSR-initiating	 enzyme	 AID,	
together	with	a	p53	mutation,	causes	extensive	genome	instability,	resulting	in	the	induction	of	
B	cell	lymphomas	[224].	AID	has	also	been	shown	to	act	on	off-target	sequences	that	share	AID-
target	 sequence	 similarity	 throughout	 the	 genome.	 It	 has	 been	 shown	 for	 example	 that	 AID	
frequently	attacks	the	c-Myc	sequence	when	it	is	transcribed	[530],	explaining	the	involvement	
of	c-Myc	in	many	translocation	events.		
Apart	 from	AID,	 also	 downstream	 effectors	 of	 SMH	 and	 CSR	 can	 lead	 to	 tumorigenesis	when	
deregulated.	UNG-deficient	mice	show	only	a	slight	increase	in	mutation	frequency,	but	they	are	
susceptible	to	developing	B-cell	lymphomas	[62].		Deficiencies	in	NHEJ	repair	enzymes	have	also	
been	linked	to	malignant	transformations	involving	translocations	[176,	531,	532]	
In	line	with	this,	we	observed	translocations	to	genomic	DNA	and	to	the	GFP	control	plasmid	in	
our	 in	 vivo	 system.	 The	 incidence	 of	 translocations	 was	 higher	 in	 MMR-depleted	 cells.	 This	
indicates	 that	 MMR	 normally	 provides	 some	 protection	 against	 non-compatible	 ligations,	
probably	by	resolving	imperfect	microhomology-mediated	joining	of	the	two	ends.	
A	 better	 understanding	 of	 the	mechanism	 leading	 to	 B-cell	 specific	 DNA	 rearrangements	 and	
mutagenesis	 is	essential	 for	 the	 comprehension	of	 tumorigenesis	 in	B-cells	 and	will	open	new	
ways	to	treat	these	tumors.	
	
THE	ROLE	OF	DNA	METHYLATION	IN	THE	REGULATION	OF	VTG	EXPRESSION	
We	could	 show	 that	 vitellogenin	expression	 is	 induced	upon	β-estradiol	 treatment	 in	 LMH/2A	
cells,	but	that	this	is	happening	independently	of	detectable	changes	in	DNA	methylation	of	the	
four	CpGs	that	were	reported	earlier	to	be	demethylated	upon	hormone	treatment	 [332].	The	
fact	 that	we	 see	 an	 accumulation	of	 the	 TET	oxidation	product	 5hmC	at	 these	CpGs	 confirms	
that	 dynamic	 changes	 at	 the	 level	 of	 chromatin	 are	 taking	 place.	Whether	 the	 appearance	 of	
5hmC	is	a	consequence	of	increased	accessibility	for	different	DNA	binding	proteins	or	actually	
causal	 for	 the	 regulation	 of	 expression	 remains	 to	 be	 determined.	 TET2	 overexpression	
experiments	point	 towards	a	role	 for	 the	dioxygenase	 in	 the	transcriptional	 regulation	of	VTG,	
but	 they	 need	 confirmation	 from	 knockdown	 experiments.	 We	 have	 not	 yet	 succeeded	 in	
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efficiently	 downregulating	 the	 TETs	 at	 the	protein	 level	 using	 specific	 siRNAs,	 despite	 the	 fact	
that	mRNA	levels	were	significantly	reduced.	
The	 observation	 that	 we	 could	 induce	 VTG	 transcription	 without	 affecting	 DNA	 methylation	
puzzled	us	at	first.	One	limitation	to	keep	in	mind	is	the	involvement	of	a	PCR	step	that	can	lead	
to	 distortion	 of	 the	 sequencing	 results.	 Moreover,	 there	 is	 the	 possibility	 that	 the	 VTG	
transcripts	 originated	 from	only	 a	 few	 cells	 that	 underwent	 demethylation;	 the	unmethylated	
sites	of	these	genomes	would	have	escaped	detection	in	sequencing	of	the	entire	cellular	pool.	
Alternatively,	 the	 signal	 could	 have	 arisen	 from	 the	 cells	 that	 acquired	 5hmC.	 The	 question	
remains	why	we	 do	 not	 see	 at	 least	 the	 same	 low	 levels	 of	 demethylation	 as	we	 see	 5hmC-
signal.	If	5hmC	was	just	an	intermediate	step	in	demethylation,	we	should	see	oxidation	events	
that	 go	 further	 than	 hydroxymethylation,	 displaying	 as	 unmodified	 cytosines	 in	 bisulfite-
conversion	assays.	 In	contrast,	 the	oxidation	events	taking	place	at	the	VTG	enhancer	seem	to	
stop	specifically	at	5hmC,	pointing	towards	a	regulatory	role	of	the	base,	beyond	its	function	as	
an	intermediate	in	DNA	demethylation.		
Since	 this	 is	 the	 first	 time	 that	methylation	 dynamics	 of	 the	VTG	 enhancer	were	 analyzed	 by	
bisulfite	 sequencing,	 we	 cannot	 rule	 out	 the	 possibility	 that	 another	 (yet	 uncharacterized)	
modification	 on	 cytosine	 is	 present,	 mimicking	 unmethylated	 cytosine	 in	 HpaII	 digests	 and	
chemical	sequencing,	but	5mC	in	bisulfite	conversion.		
The	possibility	that	DNA	demethylation	is	a	mere	consequence	of	the	activation	of	transcription	
through	other	means	is	still	conceivable.	In	the	early	studies,	this	was	considered	very	likely,	due	
to	the	fact	that	demethylation,	as	assessed	by	HpaII	digests,	was	detectable	only	after	24	h	of	E2	
treatment,	whereas	 transcription	 started	 as	 soon	 as	 4	 h	 after	 hormone	 administration.	 These	
studies,	however,	ignored	the	fact	that	hemi-methylated	DNA	was,	similarly	to	fully-	methylated,	
refractory	 to	 cleavage	 by	 HpaII.	 But,	 hemi-methylation	 of	 DNA	 could	 display	 distinct	
characteristics	 when	 it	 comes	 to	 transcription	 factor	 binding	 or	 chromatin	 remodeling.	 The	
method	established	by	Maxam	and	Gilbert,	and	Church	and	Gilbert	to	chemically	sequence	DNA	
[507,	508],	re-opened	the	discussion	about	the	temporal	sequence	of	transcription	initiation	and	
DNA	 demethylation.	 An	 observation	 made	 when	 different	 tissues	 were	 analyzed	 for	 their	
inducibility	 and	 methylation	 dynamics,	 strongly	 suggests	 a	 causal	 function	 of	 DNA	
demethylation.	 Erythrocytes	 did	 not	 express	 VTG	 when	 treated	 with	 E2	 and	 there	 was	 no	
demethylation	of	the	enhancer.	This	was	not	surprising,	since	erythrocytes	also	do	not	express	
ERs.	 Cells	 of	 the	 oviduct,	 however,	 do	 express	 ERα,	 but	 VTG	 is	 not	 inducible.	 Still,	 the	
demethylation	 event	 was	 observed	 in	 these	 cells.	 This	 indicates	 that	 general	 estrogen-
responsiveness	is	the	key	prerequisite	for	the	demethylation	and	not	transcription	per	se	[332,	
503].	This	phenomenon	also	 implies	that	there	must	be	another	 layer	of	control	 that	prevents	
transcription	in	oviduct	cells,	despite	the	presence	of	ERα	and	E2.	Whether	this	layer	of	control	
involves	methylated	CpGs	at	other	sites	or	other	mechanisms	of	control	is	not	known	to	date.	
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CpG	b	shows	an	interesting	behavior	in	rooster	liver,	 in	that	it	 is	present	in	a	hemi-methylated	
state	prior	to	hormone	treatment.	The	presence	of	hemi-methylated	sites	in	DNA	is	difficult	to	
explain;	first,	they	are	targets	for	DNMT1,	which	should	convert	them	to	fully-methylated	CpGs.	
Second,	 replication	of	hemi-methylated	DNA	would	result	 in	 the	 loss	of	methylation	 in	50%	of	
the	progeny	molecules.	It	is	conceivable	though	that	hemi-methylated	sites	could	persist	in	DNA	
of	non-replicating	cells	when	protected	by	e.g.	specific	binding	proteins.	 In	LMH/2A	cells,	both	
strands	are	50%	methylated,	most	likely	representing	a	CpG	that	is	50%	unmethylated	and	50%	
fully-methylated	 in	 a	 population	 of	 cells.	 The	 factor	 or	 circumstance	 that	 protects	 the	 hemi-
methylated	state	in	rooster	liver	thus	seems	to	be	absent	in	the	cell	line.	The	methylation	state	
at	 CpG	b	 does	 not	 seem	 to	 confer	 any	 advantage	 to	 the	 cell,	 causing	 one	 cell	 population	 to	
outgrow	the	other.		
The	binding	of	 ERα	 to	 its	 response	element	 is	 insensitive	 to	methylation	of	 the	 two	CpG	sites	
present	 in	 the	VTG	 ERE.	Another	 factor	 (X)	 that	 reconises	 the	ERE,	however,	binds	with	 lower	
affinity	 if	 the	 site	 is	methylated.	 The	 reporter	 assay	 revealed	 no	 significant	 influence	 of	 ERE-
methylation	 though,	 arguing	 against	 an	 important	 role	 of	 factor	 X	 binding	 at	 the	 ERE.	
Interestingly,	 we	 detected	 a	 shift	 with	 a	 similar	 mobility	 on	 other	 CpG	 sites	 in	 the	 VTG	
enhancer/promoter	 region	 (CpG	 b,	 a,	 and	 7).	 Moreover,	 we	 observed	 that	 methylation-
responsiveness	of	factor	X	was	different	on	the	different	CpG	substrates,	particularly	on	CpG7.	
We	could	compete	the	binding	of	the	factor	at	the	ERE	with	an	excess	of	CpG7	or	of	ΔG	that	also	
displays	high	affinity	for	factor	X,	but	almost	no	binding	of	ERα.	These	findings	prompted	us	to	
conclude	 that	 it	 is	 indeed	 the	 same	 factor(s)	 that	 binds	different	 sites	with	different	 affinities	
and	binding	behavior.	The	sequences	surrounding	the	different	CpGs	show	no	obvious	similarity,	
but	CpG7	is	located	in	an	E-box	and	the	deletion	of	the	G	in	the	spacer	region	of	the	ERE	gives	
rise	to	in	an	E-box	consensus	sequence	too.	
	
HELIX-LOOP-HELIX	TRANSCRIPTION	FACTORS	
The	 binding	 of	 the	 same	 factor	 to	 several	 CpG-containing	 sequences	 of	 the	 VTG	
enhancer/promoter	 attracted	 our	 interest,	 because	 the	 factor	 displayed	 the	 strongest	 affinity	
for	CpG7	and	ΔG	substrates,	both	of	which	contain	an	E-box	consensus	sequence.	E-box	binding	
proteins	 form	 a	 large	 superfamily	 of	 basic	 helix-loop-helix	 (bHLH)	 factors.	 bHLH	 proteins	 are	
small,	 dimeric	 transcription	 factors	 reported	 to	 be	 important	 regulators	 of	 embryonic	
development.	They	consist	of	an	N-terminal	basic	α-helix,	responsible	for	the	binding	to	the	E-
box	 motif.	 The	 C-terminus	 forms	 the	 HLH	 structure	 that	 facilitates	 interactions	 with	 other	
members	 of	 the	 family	 [533].	 bHLH	 proteins	 are	 known	 for	 their	 versatility,	 due	 to	 many	
different	 combinations	 of	 homo-	 and	 heterodimers	 that	 can	 be	 formed	 depending	 on	 the	
developmental	 stage	and	the	cell	 type.	This	system	enables	 the	cell	 to	 react	 flexibly	 to	stimuli	
with	a	 limited	number	of	proteins.	The	different	combinations	of	bHLH	factors	were	moreover	
shown	to	bind	distinct	E-box	consensus	sequences	with	different	affinities	[534].	
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The	bHLH	proteins	are	subdivided	into	many	families,	depending	on	the	additional	domains	they	
possess.	An	interesting	group	of	bHLH	factors	building	a	network	around	the	transcription	factor	
MAX	contain	an	additional	leucine	zipper	domain	that	assists	in	dimerization	and	DNA	binding.	
Leucine	zippers	contain	an	amphiphilic	α-helical	structure	consisting	of	six	heptad	repeats	with	
leucine	 residues	 in	 the	hydrophobic	 core	of	 the	helix.	Members	of	 this	 group	of	bHLH	 factors	
include	 the	 different	 MYCs,	 MAD	 and	 MLX.	 This	 family	 received	 a	 great	 deal	 of	 attention,	
because	the	MYC	genes	are	very	frequently	mutated	in	cancer	[359],	as	discussed	above	on	the	
example	 of	 B-cell	 lymphomas.	 Depending	 on	 their	 dimerization	 partners,	 MYC	 transcription	
factors	can	promote	transcription	or	inhibit	it.	Methylation-sensitive	DNA	binding	of	c-MYC	has	
been	 reported	 in	 combination	 with	 certain	 bHLH	 proteins,	 but	 plays	 no	 role	 in	 other	
combinations	[535,	536].	
When	we	examined	the	proteins	binding	the	ERE	in	our	nuclear	extracts	on	denaturing	SDS	gels,	
we	 detected	 several	 bands,	 corresponding	 to	 proteins	 of	molecular	 size	 of	 20-50	 kDa.	 This	 is	
consistent	with	the	size	of	most	HLH	proteins	and	considerably	smaller	than	the	NHPs	published	
to	 bind	 to	 the	 ERE	 of	 chicken	 VTG	 [509].	 Even	 more	 evidence	 for	 the	 involvement	 of	 HLH	
proteins	came	from	the	mass	spectrometric	analysis	of	the	proteins	binding	the	wt	and	the	ΔG	
ERE	in	LMH/2A-	,	as	well	as	in	HeLa	NEs.	We	could	identify	several	helix-loop-helix	transcription	
factors	 from	 both	 cell	 lines;	 MLX,	 MLXIP	 and	 MAX,	 in	 HeLa	 NEs	 additionally	 MLXIPL.	 The	
characterization	 of	 the	 role	 of	 these	 factors	 in	 transcriptional	 control	 with	 respect	 to	 their	
methylation-sensitivity	will	be	very	interesting	and	might	lead	to	an	improved	understanding	of	
the	role	of	the	MAX	network	in	development	and	possibly	also	in	malignant	transformation.	
	
TEN-ELEVEN	TRANSLOCATION	PROTEINS	AND	DNA	DEMETHYLATION	
Depletion	 or	 knockout	 of	 TETs	 in	 genome-wide	 studies	 provided	 plausible	 evidence	 for	 an	
important	 role	 of	 the	 dioxygenases	 in	 DNA	 demethylation	 during	 development.	 There	 are,	
however,	 still	 a	number	of	open	questions	 concerning	 their	 role	 in	 somatic	 cells,	 their	precise	
targeting	and	-	last	but	not	least	-	their	exact	mechanism	of	action.	Considering	that	5mC	occurs	
almost	 exclusively	 in	 the	 symmetrical	 CpG	 context,	 a	 global	wave	 of	 demethylation,	 involving	
BER,	seems	to	be	a	very	risky	task.	Each	methylated	CpG	site	could	potentially	be	converted	into	
a	 DSB.	 We	 showed	 in	 our	 study	 (Results	 I,	 [517])	 the	 danger	 of	 an	 accumulation	 of	 BER	
intermediates.	During	CSR,	 closely-spaced	uracils	 processed	by	BER	and	MMR	can	give	 rise	 to	
DSBs.	The	situation	in	the	CpG	context	 is	even	more	acute,	as	the	lesions	are	directly	opposite	
each	other	if	processed	simultaneously.	The	involvement	of	several	oxidation	steps	is	a	genuine	
way	 of	 temporally	 spacing	 the	 base	 excision	 events.	 It	 has,	 however,	 not	 been	 shown	 yet,	
whether	 the	 TET	 enzymes	 act	 symmetrically	 on	 CpGs	 and	 whether	 they	 carry	 out	 the	 three	
oxidation	 steps	 in	 a	 processive	manner,	 from	 5mC	 to	 5caC	 and	 excision,	 without	 leaving	 the	
DNA.	 Crystal	 structures	 of	 NgTET1	 and	 human	 TET2	 bound	 to	 DNA	 suggest	 a	 base	 flipping	
mechanism	reminiscent	of	glycosylases,	which	hints	towards	asymmetrical	oxidations.	The	data	
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present	 evidence	 for	 higher	 turnover	when	 substrates	 are	 oxidized	 processively	 from	 5mC	 to	
5caC	[432-434,	437].	However,	the	relatively	high	levels	of	5hmC	in	cells,	compared	to	5fC	and	
5caC,	 argue	 against	 this.	 Another	 study	 that	 set	 out	 to	 investigate	 if	 TET-mediated	 oxidation	
steps	 occur	 symmetrically	made	 use	 of	 the	 chemical	 reactivity	 of	 the	 formyl	 group	 of	 5fC	 to	
selectively	 attach	 a	 fluorescent	 pyrene	 group.	 The	 authors	 observed	 predominantly	 pyrene	
modification	 of	 both	 strands,	 prompting	 them	 to	 conclude	 not	 only	 that	 the	 oxidation	 is	
symmetrical,	 but	 also	 that	 the	 oxidation	 steps	 are	 non-processive,	 due	 to	 the	 detectable	
presence	of	5fC	[537].	These	studies	were	followed	by	investigations	of	the	mechanism	of	action	
of	the	TETs	using	high	performance	liquid	chromatography	(HPLC)	and	mass	spectrometry	(MS).	
While	 one	 group	 came	 to	 the	 conclusion	 that	 TET2	 carries	 out	 iterative	 oxidations	 to	 5caC	
without	releasing	the	DNA	in	between	[538],	another	group	objected,	postulating	that	TETs	act	
in	a	distributive	manner	[539].	If	symmetrical	5fC	or	5caC	generation	does	indeed	occur	in	DNA,	
it	 is	 	 not	 certain	 that	 their	 processing	 would	 lead	 to	 the	 formation	 of	 a	 DSB,	 as	 there	 is	 an	
additional	 level	of	control	at	 the	BER	step.	The	analysis	of	 symmetrical	5caC	substrates	with	a	
recombinant	 TDG-BER	machinery	 resulted	 in	HpaII	 cleavable	 sites,	 but	 only	marginal	 levels	 of	
DSB,	 indicating	 an	 efficient	 processing	 of	 the	 sites	 without	 critically	 damaging	 the	 DNA.	 The	
group	 concluded	 that	 TDG	 interacts	 tightly	 with	 AP-sites,	 thereby	 inhibiting	 simultaneous	
processing	of	both	strands.	This	finding	 indicates	that	there	 is	an	additional	 level	of	protection	
against	 DSBs	 during	 TET-mediated	 demethylation,	which	 is	 provided	 by	 BER	 [95].	 Despite	 the	
great	research	interest	in	the	field	of	active	DNA	demethylation,	there	are	still	a	number	of	open	
questions	and	contradictory	findings.	The	analysis	of	the	mechanism	of	demethylation	in	vivo	is	
difficult,	because	the	methods	used	to	date,	HPLC,	MS	[540],	antibody-based	[471]	or	using	the	
chemical	reactivity	of	formyl	groups	[537,	541,	542],	cannot	distinguish	single	sites	and	cannot	
draw	 conclusions	 about	 both	 strands	 at	 one	 site.	 They	 yield	 averages,	 making	 it	 difficult	 to	
assess	the	exact	mode	of	action	of	the	enzymes	involved.	More	studies	are	needed	that	would	
differentiate	between	the	two	strands	at	single	sites,	using	for	example	sequencing	methods	on	
hairpin	substrates,	auch	as	suggested	in	'additional	observations'.	
Also,	 the	specific	 targeting	of	 the	demethylation	machinery	 requires	 further	 investigation.	 It	 is	
important	during	 the	global	waves	of	demethylation,	 for	example	 to	protect	 imprinted	genes,	
but	even	more	so	in	somatic	cells,	when	single	CpGs	are	addressed.	Another	layer	of	complexity	
concerns	 the	 finding	 that	 the	 oxidation	machinery	 fails	 to	 proceed	 beyond	 the	 generation	 of	
5hmC	 in	 some	 cases,	 for	 example	 in	 the	 brain,	 where	 levels	 of	 5hmC	 are	 exceptionally	 high,	
while	in	other	cases	a	complete	demethylation	might	be	the	desired	outcome.	
	
TEN-ELEVEN	TRANSLOCATION	PROTEINS	IN	CANCER	
That	TET	proteins	play	a	role	in	cancer	development	has	been	clear	from	the	start,	as	they	were	
discovered	by	being	involved	in	a	translocation	event	in	myeloid	cancer	[418,	446].	Since	then,	a	
substantial	 amount	 of	 evidence	 has	 been	 gathered	 that	 strengthens	 the	 role	 of	 TETs	 (mostly	
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TET2)	 in	hematopoietic	malignancies.	TET2	has	been	found	to	be	the	most	frequently-mutated	
gene	 in	 myelodysplastic	 syndromes	 (MDS),	 with	 up	 to	 30%	 penetrance.	 TET2	 mutations	 are	
found	 in	 the	majority	of	 cells	 in	 the	bone	marrow	of	patients,	 indicating	 that	 these	mutations	
occur	 early	 in	 disease	 development	 [447].	 However,	 no	 reliable	 prognostic	 value	 could	 be	
derived	from	high-throughput	sequencing	of	patients’	DNA	[448].	Also,	the	mechanism	by	which	
TET2	acts	as	a	tumor	suppressor	remains	enigmatic.	
Several	 groups	 studied	 knockout	 mouse	 models	 to	 assess	 the	 role	 of	 TETs	 in	 malignant	
transformation.	 It	 was	 found	 that	 loss	 of	 TET2	 in	 hematopoietic	 cells	 lead	 to	 extensive	
proliferation,	 resulting	 in	an	enlargement	of	 the	hematopoietic	 stem	cell	 compartment	due	 to	
increased	self-renewal.	Also,	heterozygous	HSCs	showed	increased	proliferation,	suggesting	that	
TET2	might	be	haploinsufficient	[450,	543].	A	striking	reduction	of	5hmC	levels	and	concomitant	
increase	of	5mC	were	observed	in	HSCs	of	TET2-deficient	mice	and	differentiation	balances	were	
altered	 towards	 monocytic/granulocytic	 lineages	 [449].	 The	 importance	 of	 TETs	 as	 tumour	
suppressors	 was	 further	 strengthened	 by	 the	 finding	 that	 mutations	 in	 isocitrate	
dehydrogenases	(IDH1/2),	enzymes	that	convert	 isocitrate	to	the	TET	substrate	2-oxoglutarate,	
were	found	to	cause	similar	cancers	as	TET	mutations,	which	were	characterized	by	global	DNA	
hypermethylation.	 IDH1/2	 mutations	 were	 additionally	 shown	 to	 be	 mutually	 exclusive	 with	
TET2	mutations	in	cancer	[544].		
The	observation	that	TET2	mutations	are	more	often	 found	 in	cancers	compared	to	defects	 in	
TET1	or	TET3,	indicates	different	roles	and	distribution	of	the	TETs.	Despite	of	the	considerable	
amount	of	clinical	data	on	the	involvement	of	the	TETs	in	cancer,	the	exact	mechanism	and	the	
key	genes	that	are	deregulated	in	patients	remain	to	be	characterized.	
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CONCLUDING	REMARKS	&	FUTURE	PERSPECTIVES	
The	 involvement	of	 several	 repair	pathways	 in	antibody	diversification	and	 regulation	of	 gene	
expression	 and	 chromatin	 dynamics	 shows	 their	 great	 importance,	 much	 beyond	 repair	 of	
damage	arising	through	endogenous	or	exogenous	agents.	 Instead	of	only	reacting	to	damage,	
they	actively	modulate	cellular	processes,	thereby	enabling	higher	forms	of	life.	The	term	'repair	
pathways'	 clearly	 undervalues	 these	 versatile	 and	 highly	 complex	mechanisms;	 a	 better	 term	
might	be	DNA	modulating	pathways.	
The	 usage	 of	 DNA	 substrates	 containing	 nicks	 and	 uracils	 to	 investigate	 the	 process	 of	 CSR	
enabled	us	 to	gain	 insights	 into	the	exact	way	of	processing	of	 the	 lesions.	By	dispensing	with	
AID,	we	reduced	the	complexity	of	the	events	by	knowing	exactly	where	the	lesions	we	started	
with	 were	 located.	 The	 puzzling	 results	 obtained	 with	 the	 more	 physiological	 substrates	
containing	uracils	on	both	strands	merit	further	attention,	as	they	imply	that	simple	nicks	may	
not	be	identical	to	 intermediates	arising	during	processing	of	damaged	bases.	Thus,	substrates	
containg	 uracils	 rather	 than	 nicks	must	 be	 reexamined	 to	 reveal	 the	 extent	 of	 accessibility	 of	
repair	 intermediates	to	other	pathways,	such	as	MMR.	Experiments	with	substrates	containing	
uracils	on	both	strands	would	moreover	provide	valuable	insights	into	the	mechanism	of	CSR	in	
B-cells,	as	it	mimics	the	situation	present	in	S	regions	acted-upon	by	AID.	
Another	 issue	 worth	 addressing	 in	 the	 future	 is	 the	 reason	 for	 the	 unusually	 inefficient	 BER	
during	antibody	diversification.	The	above-mentioned	 saturation	of	 the	 repair	pathway	by	 the	
creation	 of	 a	 high	 density	 of	 targets	 in	 close	 proximity	 is	 a	 conceivable	 explanation,	 it	 	 has,	
however,	 never	 been	 experimentally	 addressed.	 Downregulation	 or	 modification	 of	 key	
enzymes	of	the	pathway	in	germinal	center	B-cells	is	also	under	discussion.		
There	is	still	a	great	deal	to	learn	about	CSR	and	the	enzymes	and	pathways	involved.	It	is	a	very	
unique	 and	 fascinating	 process	 and	 a	 valuable	 model	 system	 to	 investigate	 the	 interplay	 of	
several	DNA	metabolic	pathways.	The	finding	that	CSR	is	frequently	involved	in	the	formation	of	
malignancies	makes	its	detailed	understanding	particularly	relevant.	
In	 addition	 to	 bona	 fide	 DNA	 repair	 and	 antibody	 diversification,	 BER	 appears	 to	 have	 an	
important	role	in	DNA	demethylation	and	the	control	of	gene	expression.	Epigenetic	processes	
are	extremely	challenging	to	decipher	 in	cells,	as	they	are	complex	and	 involve	many	different	
players	 and	 consecutive	 modifications	 of	 chromatin.	 The	 order	 of	 events	 leading	 to	 the	
activation	or	 shut-down	of	 a	 specific	 gene	 is	 difficult	 to	 address	 and	might	 vary	 from	gene	 to	
gene.	 The	 fact	 that	 methylation	 inhibits	 TF	 binding	 in	 some	 cases,	 either	 directly	 or	 via	 the	
binding	of	MBD	proteins,	argues	for	an	important	causal	role	of	DNA	methylation	in	the	control	
of	gene	expression.	There	are,	however,	also	numerous	examples,	where	DNA	demethylation	is	
reported	to	occur	after	the	onset	of	transcription.	In	hormone-regulated	genes,	as	discussed	in	
this	thesis,	the	binding	of	the	activated	TF	is	very	likely	to	be	the	first	event,	serving	to	target	the	
DNA	modifying	machinery	to	the	specific	site.	The	VTG	gene	represents	a	valuable	model	system	
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to	study	the	events	on	chromatin,	 leading	to	expression	of	the	gene,	as	it	 is	well	characterized	
and	inducible	by	estradiol	treatment.	
The	data	presented	in	this	thesis	illustrate	the	diverse	functions	of	eukaryotic	repair	pathways.	
They	show	the	great	potential	of	these	versatile	mechanisms,	but	also	point	out	the	danger	they	
pose	 to	 cells	 and	 multicellular	 organisms.	 The	 flexibility	 of	 DNA	 modifications	 and	
rearrangements,	 enabling	 an	 efficient	 immune	 protection	 and	 differential	 gene	 expression	 in	
higher	eukaryotes,	goes	at	the	expense	of	an	 increased	risk	for	DNA	damage	and	uncontrolled	
proliferation,	potentially	leading	to	tumor	formation.	A	deep	understanding	of	the	mechanisms	
involved	 and	 their	 regulation	 and	 targeting	 is	 of	 outmost	 importance	 for	 successful	 cancer	
prevention	and	treatment,	without	disturbing	the	beneficial	aspects	of	flexible	DNA	metabolism.	
	
																																																																																																																																																																													REFERENCES		
	____________________________________________________________________________________________________________________	130	
REFERENCES	
	
1.	 Hahn,	W.C.	and	R.A.	Weinberg,	Modelling	the	molecular	circuitry	of	cancer.	Nat	Rev	Cancer,	
2002.	2(5):	p.	331-41.	
2.	 Hanahan,	D.	and	R.A.	Weinberg,	The	hallmarks	of	cancer.	Cell,	2000.	100(1):	p.	57-70.	
3.	 Hanahan,	D.	and	R.A.	Weinberg,	Hallmarks	of	cancer:	the	next	generation.	Cell,	2011.	144(5):	
p.	646-74.	
4.	 Soulas-Sprauel,	P.,	et	al.,	V(D)J	and	immunoglobulin	class	switch	recombinations:	a	paradigm	
to	study	the	regulation	of	DNA	end-joining.	Oncogene,	2007.	26(56):	p.	7780-91.	
5.	 Dudley,	D.D.,	et	al.,	Mechanism	and	control	of	V(D)J	recombination	versus	class	switch	
recombination:	similarities	and	differences.	Advances	in	immunology,	2005.	86:	p.	43-112.	
6.	 Marmur,	J.	and	P.	Doty,	Determination	of	the	base	composition	of	deoxyribonucleic	acid	from	
its	thermal	denaturation	temperature.	J	Mol	Biol,	1962.	5:	p.	109-18.	
7.	 Wartell,	R.M.	and	A.S.	Benight,	Thermal-Denaturation	of	DNA-Molecules	-	a	Comparison	of	
Theory	with	Experiment.	Physics	Reports-Review	Section	of	Physics	Letters,	1985.	126(2):	p.	
67-107.	
8.	 Yakovchuk,	P.,	E.	Protozanova,	and	M.D.	Frank-Kamenetskii,	Base-stacking	and	base-pairing	
contributions	into	thermal	stability	of	the	DNA	double	helix.	Nucleic	Acids	Res,	2006.	34(2):	p.	
564-74.	
9.	 Wei,	Y.H.,	Oxidative	stress	and	mitochondrial	DNA	mutations	in	human	aging.	Proc	Soc	Exp	
Biol	Med,	1998.	217(1):	p.	53-63.	
10.	 Monsalve,	M.,	et	al.,	Mitochondrial	dysfunction	in	human	pathologies.	Front	Biosci,	2007.	12:	
p.	1131-53.	
11.	 Chance,	B.,	H.	Sies,	and	A.	Boveris,	Hydroperoxide	metabolism	in	mammalian	organs.	Physiol	
Rev,	1979.	59(3):	p.	527-605.	
12.	 Dizdaroglu,	M.,	et	al.,	Free	radical-induced	damage	to	DNA:	mechanisms	and	measurement.	
Free	Radic	Biol	Med,	2002.	32(11):	p.	1102-15.	
13.	 Valko,	M.,	et	al.,	Free	radicals,	metals	and	antioxidants	in	oxidative	stress-induced	cancer.	
Chem	Biol	Interact,	2006.	160(1):	p.	1-40.	
14.	 van	Loon,	B.,	E.	Markkanen,	and	U.	Hubscher,	Oxygen	as	a	friend	and	enemy:	How	to	combat	
the	mutational	potential	of	8-oxo-guanine.	DNA	Repair	(Amst),	2010.	9(6):	p.	604-16.	
15.	 Valko,	M.,	et	al.,	Role	of	oxygen	radicals	in	DNA	damage	and	cancer	incidence.	Mol	Cell	
Biochem,	2004.	266(1-2):	p.	37-56.	
16.	 Greenman,	C.,	et	al.,	Patterns	of	somatic	mutation	in	human	cancer	genomes.	Nature,	2007.	
446(7132):	p.	153-8.	
17.	 Frederico,	L.A.,	T.A.	Kunkel,	and	B.R.	Shaw,	A	sensitive	genetic	assay	for	the	detection	of	
cytosine	deamination:	determination	of	rate	constants	and	the	activation	energy.	
Biochemistry,	1990.	29(10):	p.	2532-7.	
18.	 Shapiro,	R.	and	M.	Danzig,	Acidic	hydrolysis	of	deoxycytidine	and	deoxyuridine	derivatives.	
The	general	mechanism	of	deoxyribonucleoside	hydrolysis.	Biochemistry,	1972.	11(1):	p.	23-9.	
19.	 Shen,	J.C.,	W.M.	Rideout,	3rd,	and	P.A.	Jones,	The	rate	of	hydrolytic	deamination	of	5-
methylcytosine	in	double-stranded	DNA.	Nucleic	Acids	Res,	1994.	22(6):	p.	972-6.	
20.	 Duncan,	B.K.	and	J.H.	Miller,	Mutagenic	deamination	of	cytosine	residues	in	DNA.	Nature,	
1980.	287(5782):	p.	560-1.	
21.	 Ehrlich,	M.,	et	al.,	DNA	cytosine	methylation	and	heat-induced	deamination.	Biosci	Rep,	1986.	
6(4):	p.	387-93.	
22.	 Hill-Perkins,	M.,	M.D.	Jones,	and	P.	Karran,	Site-specific	mutagenesis	in	vivo	by	single	
methylated	or	deaminated	purine	bases.	Mutat	Res,	1986.	162(2):	p.	153-63.	
																																																																																																																																																																													REFERENCES		
	____________________________________________________________________________________________________________________	131	
23.	 Karran,	P.	and	T.	Lindahl,	Hypoxanthine	in	deoxyribonucleic	acid:	generation	by	heat-induced	
hydrolysis	of	adenine	residues	and	release	in	free	form	by	a	deoxyribonucleic	acid	glycosylase	
from	calf	thymus.	Biochemistry,	1980.	19(26):	p.	6005-11.	
24.	 Lindahl,	T.	and	B.	Nyberg,	Rate	of	depurination	of	native	deoxyribonucleic	acid.	Biochemistry,	
1972.	11(19):	p.	3610-8.	
25.	 Gates,	K.S.,	An	overview	of	chemical	processes	that	damage	cellular	DNA:	spontaneous	
hydrolysis,	alkylation,	and	reactions	with	radicals.	Chem	Res	Toxicol,	2009.	22(11):	p.	1747-
60.	
26.	 Doerfler,	W.,	DNA	methylation	and	gene	activity.	Annu	Rev	Biochem,	1983.	52:	p.	93-124.	
27.	 Ito,	S.,	et	al.,	Tet	proteins	can	convert	5-methylcytosine	to	5-formylcytosine	and	5-
carboxylcytosine.	Science,	2011.	333(6047):	p.	1300-3.	
28.	 Tahiliani,	M.,	et	al.,	Conversion	of	5-methylcytosine	to	5-hydroxymethylcytosine	in	
mammalian	DNA	by	MLL	partner	TET1.	Science,	2009.	324(5929):	p.	930-5.	
29.	 Harris,	R.S.,	S.K.	Petersen-Mahrt,	and	M.S.	Neuberger,	RNA	editing	enzyme	APOBEC1	and	
some	of	its	homologs	can	act	as	DNA	mutators.	Mol	Cell,	2002.	10(5):	p.	1247-53.	
30.	 Knisbacher,	B.A.,	D.	Gerber,	and	E.Y.	Levanon,	DNA	Editing	by	APOBECs:	A	Genomic	Preserver	
and	Transformer.	Trends	Genet,	2016.	32(1):	p.	16-28.	
31.	 Lindahl,	T.,	B.	Demple,	and	P.	Robins,	Suicide	inactivation	of	the	E.	coli	O6-methylguanine-
DNA	methyltransferase.	EMBO	J,	1982.	1(11):	p.	1359-63.	
32.	 Slupphaug,	G.,	et	al.,	Properties	of	a	recombinant	human	uracil-DNA	glycosylase	from	the	
UNG	gene	and	evidence	that	UNG	encodes	the	major	uracil-DNA	glycosylase.	Biochemistry,	
1995.	34(1):	p.	128-38.	
33.	 Kavli,	B.,	et	al.,	hUNG2	is	the	major	repair	enzyme	for	removal	of	uracil	from	U:A	matches,	
U:G	mismatches,	and	U	in	single-stranded	DNA,	with	hSMUG1	as	a	broad	specificity	backup.	
The	Journal	of	biological	chemistry,	2002.	277(42):	p.	39926-36.	
34.	 Lindahl,	T.,	An	N-glycosidase	from	Escherichia	coli	that	releases	free	uracil	from	DNA	
containing	deaminated	cytosine	residues.	Proc	Natl	Acad	Sci	U	S	A,	1974.	71(9):	p.	3649-53.	
35.	 Jacobs,	A.L.	and	P.	Schar,	DNA	glycosylases:	in	DNA	repair	and	beyond.	Chromosoma,	2012.	
121(1):	p.	1-20.	
36.	 David,	S.S.,	V.L.	O'Shea,	and	S.	Kundu,	Base-excision	repair	of	oxidative	DNA	damage.	Nature,	
2007.	447(7147):	p.	941-50.	
37.	 Friedberg,	E.C.,	et	al.,	DNA	repair:	from	molecular	mechanism	to	human	disease.	DNA	Repair	
(Amst),	2006.	5(8):	p.	986-96.	
38.	 Robertson,	A.B.,	et	al.,	DNA	repair	in	mammalian	cells:	Base	excision	repair:	the	long	and	
short	of	it.	Cellular	and	molecular	life	sciences	:	CMLS,	2009.	66(6):	p.	981-93.	
39.	 Cortazar,	D.,	et	al.,	Embryonic	lethal	phenotype	reveals	a	function	of	TDG	in	maintaining	
epigenetic	stability.	Nature,	2011.	470(7334):	p.	419-23.	
40.	 Kubota,	Y.,	et	al.,	Reconstitution	of	DNA	base	excision-repair	with	purified	human	proteins:	
interaction	between	DNA	polymerase	beta	and	the	XRCC1	protein.	The	EMBO	journal,	1996.	
15(23):	p.	6662-70.	
41.	 Frosina,	G.,	et	al.,	Two	pathways	for	base	excision	repair	in	mammalian	cells.	The	Journal	of	
biological	chemistry,	1996.	271(16):	p.	9573-8.	
42.	 Klungland,	A.	and	T.	Lindahl,	Second	pathway	for	completion	of	human	DNA	base	excision-
repair:	reconstitution	with	purified	proteins	and	requirement	for	DNase	IV	(FEN1).	The	EMBO	
journal,	1997.	16(11):	p.	3341-8.	
43.	 Kim,	K.,	S.	Biade,	and	Y.	Matsumoto,	Involvement	of	flap	endonuclease	1	in	base	excision	DNA	
repair.	The	Journal	of	biological	chemistry,	1998.	273(15):	p.	8842-8.	
44.	 Matsumoto,	Y.,	K.	Kim,	and	D.F.	Bogenhagen,	Proliferating	cell	nuclear	antigen-dependent	
abasic	site	repair	in	Xenopus	laevis	oocytes:	an	alternative	pathway	of	base	excision	DNA	
repair.	Molecular	and	cellular	biology,	1994.	14(9):	p.	6187-97.	
45.	 Podlutsky,	A.J.,	et	al.,	Human	DNA	polymerase	beta	initiates	DNA	synthesis	during	long-patch	
repair	of	reduced	AP	sites	in	DNA.	EMBO	J,	2001.	20(6):	p.	1477-82.	
																																																																																																																																																																													REFERENCES		
	____________________________________________________________________________________________________________________	132	
46.	 Pascucci,	B.,	et	al.,	Long	patch	base	excision	repair	with	purified	human	proteins.	DNA	ligase	I	
as	patch	size	mediator	for	DNA	polymerases	delta	and	epsilon.	J	Biol	Chem,	1999.	274(47):	p.	
33696-702.	
47.	 Sleeth,	K.M.,	R.L.	Robson,	and	G.L.	Dianov,	Exchangeability	of	mammalian	DNA	ligases	
between	base	excision	repair	pathways.	Biochemistry,	2004.	43(40):	p.	12924-30.	
48.	 Haushalter,	K.A.,	et	al.,	Identification	of	a	new	uracil-DNA	glycosylase	family	by	expression	
cloning	using	synthetic	inhibitors.	Curr	Biol,	1999.	9(4):	p.	174-85.	
49.	 Stavnezer,	J.,	J.E.	Guikema,	and	C.E.	Schrader,	Mechanism	and	regulation	of	class	switch	
recombination.	Annual	review	of	immunology,	2008.	26:	p.	261-92.	
50.	 Krokan,	H.E.,	et	al.,	Base	excision	repair	of	DNA	in	mammalian	cells.	FEBS	Lett,	2000.	476(1-
2):	p.	73-7.	
51.	 Kavli,	B.,	et	al.,	Uracil	in	DNA--general	mutagen,	but	normal	intermediate	in	acquired	
immunity.	DNA	repair,	2007.	6(4):	p.	505-16.	
52.	 Pettersen,	H.S.,	et	al.,	UNG-initiated	base	excision	repair	is	the	major	repair	route	for	5-
fluorouracil	in	DNA,	but	5-fluorouracil	cytotoxicity	depends	mainly	on	RNA	incorporation.	
Nucleic	Acids	Res,	2011.	39(19):	p.	8430-44.	
53.	 Fischer,	F.,	K.	Baerenfaller,	and	J.	Jiricny,	5-Fluorouracil	is	efficiently	removed	from	DNA	by	
the	base	excision	and	mismatch	repair	systems.	Gastroenterology,	2007.	133(6):	p.	1858-68.	
54.	 Mol,	C.D.,	et	al.,	Crystal	structure	and	mutational	analysis	of	human	uracil-DNA	glycosylase:	
structural	basis	for	specificity	and	catalysis.	Cell,	1995.	80(6):	p.	869-78.	
55.	 Kavli,	B.,	et	al.,	Excision	of	cytosine	and	thymine	from	DNA	by	mutants	of	human	uracil-DNA	
glycosylase.	EMBO	J,	1996.	15(13):	p.	3442-7.	
56.	 Nilsen,	H.,	et	al.,	Nuclear	and	mitochondrial	uracil-DNA	glycosylases	are	generated	by	
alternative	splicing	and	transcription	from	different	positions	in	the	UNG	gene.	Nucleic	Acids	
Res,	1997.	25(4):	p.	750-5.	
57.	 Haug,	T.,	et	al.,	Regulation	of	expression	of	nuclear	and	mitochondrial	forms	of	human	uracil-
DNA	glycosylase.	Nucleic	Acids	Res,	1998.	26(6):	p.	1449-57.	
58.	 Imai,	K.,	et	al.,	Human	uracil-DNA	glycosylase	deficiency	associated	with	profoundly	impaired	
immunoglobulin	class-switch	recombination.	Nature	immunology,	2003.	4(10):	p.	1023-8.	
59.	 Otterlei,	M.,	et	al.,	Post-replicative	base	excision	repair	in	replication	foci.	EMBO	J,	1999.	
18(13):	p.	3834-44.	
60.	 Akbari,	M.,	et	al.,	Repair	of	U/G	and	U/A	in	DNA	by	UNG2-associated	repair	complexes	takes	
place	predominantly	by	short-patch	repair	both	in	proliferating	and	growth-arrested	cells.	
Nucleic	acids	research,	2004.	32(18):	p.	5486-98.	
61.	 Nilsen,	H.,	et	al.,	Uracil-DNA	glycosylase	(UNG)-deficient	mice	reveal	a	primary	role	of	the	
enzyme	during	DNA	replication.	Molecular	cell,	2000.	5(6):	p.	1059-65.	
62.	 Nilsen,	H.,	et	al.,	Gene-targeted	mice	lacking	the	Ung	uracil-DNA	glycosylase	develop	B-cell	
lymphomas.	Oncogene,	2003.	22(35):	p.	5381-6.	
63.	 Obeid,	S.,	et	al.,	Replication	through	an	abasic	DNA	lesion:	structural	basis	for	adenine	
selectivity.	EMBO	J,	2010.	29(10):	p.	1738-47.	
64.	 Rada,	C.,	et	al.,	Immunoglobulin	isotype	switching	is	inhibited	and	somatic	hypermutation	
perturbed	in	UNG-deficient	mice.	Current	biology	:	CB,	2002.	12(20):	p.	1748-55.	
65.	 Durandy,	A.,	Hyper-IgM	syndromes:	a	model	for	studying	the	regulation	of	class	switch	
recombination	and	somatic	hypermutation	generation.	Biochem	Soc	Trans,	2002.	30(4):	p.	
815-8.	
66.	 Revy,	P.,	et	al.,	Activation-induced	cytidine	deaminase	(AID)	deficiency	causes	the	autosomal	
recessive	form	of	the	Hyper-IgM	syndrome	(HIGM2).	Cell,	2000.	102(5):	p.	565-75.	
67.	 Korthauer,	U.,	et	al.,	Defective	expression	of	T-cell	CD40	ligand	causes	X-linked	
immunodeficiency	with	hyper-IgM.	Nature,	1993.	361(6412):	p.	539-41.	
68.	 Hare,	J.T.	and	J.H.	Taylor,	One	role	for	DNA	methylation	in	vertebrate	cells	is	strand	
discrimination	in	mismatch	repair.	Proc	Natl	Acad	Sci	U	S	A,	1985.	82(21):	p.	7350-4.	
69.	 Modrich,	P.,	Mismatch	correction.	Basic	Life	Sci,	1986.	38:	p.	303-10.	
																																																																																																																																																																													REFERENCES		
	____________________________________________________________________________________________________________________	133	
70.	 Radman,	M.	and	R.	Wagner,	Mismatch	repair	in	Escherichia	coli.	Annu	Rev	Genet,	1986.	20:	
p.	523-38.	
71.	 Wang,	R.Y.,	et	al.,	Heat-	and	alkali-induced	deamination	of	5-methylcytosine	and	cytosine	
residues	in	DNA.	Biochim	Biophys	Acta,	1982.	697(3):	p.	371-7.	
72.	 Brown,	T.C.	and	J.	Jiricny,	A	specific	mismatch	repair	event	protects	mammalian	cells	from	
loss	of	5-methylcytosine.	Cell,	1987.	50(6):	p.	945-50.	
73.	 Wiebauer,	K.	and	J.	Jiricny,	In	vitro	correction	of	G.T	mispairs	to	G.C	pairs	in	nuclear	extracts	
from	human	cells.	Nature,	1989.	339(6221):	p.	234-6.	
74.	 Wiebauer,	K.	and	J.	Jiricny,	Mismatch-specific	thymine	DNA	glycosylase	and	DNA	polymerase	
beta	mediate	the	correction	of	G.T	mispairs	in	nuclear	extracts	from	human	cells.	Proc	Natl	
Acad	Sci	U	S	A,	1990.	87(15):	p.	5842-5.	
75.	 Neddermann,	P.	and	J.	Jiricny,	The	purification	of	a	mismatch-specific	thymine-DNA	
glycosylase	from	HeLa	cells.	J	Biol	Chem,	1993.	268(28):	p.	21218-24.	
76.	 Neddermann,	P.,	et	al.,	Cloning	and	expression	of	human	G/T	mismatch-specific	thymine-DNA	
glycosylase.	J	Biol	Chem,	1996.	271(22):	p.	12767-74.	
77.	 Neddermann,	P.	and	J.	Jiricny,	Efficient	removal	of	uracil	from	G.U	mispairs	by	the	mismatch-
specific	thymine	DNA	glycosylase	from	HeLa	cells.	Proc	Natl	Acad	Sci	U	S	A,	1994.	91(5):	p.	
1642-6.	
78.	 Wang,	Z.	and	D.W.	Mosbaugh,	Uracil-DNA	glycosylase	inhibitor	gene	of	bacteriophage	PBS2	
encodes	a	binding	protein	specific	for	uracil-DNA	glycosylase.	J	Biol	Chem,	1989.	264(2):	p.	
1163-71.	
79.	 Bennett,	M.T.,	et	al.,	Specificity	of	human	thymine	DNA	glycosylase	depends	on	N-glycosidic	
bond	stability.	J	Am	Chem	Soc,	2006.	128(38):	p.	12510-9.	
80.	 Hardeland,	U.,	et	al.,	The	versatile	thymine	DNA-glycosylase:	a	comparative	characterization	
of	the	human,	Drosophila	and	fission	yeast	orthologs.	Nucleic	Acids	Res,	2003.	31(9):	p.	2261-
71.	
81.	 Liu,	P.,	A.	Burdzy,	and	L.C.	Sowers,	Repair	of	the	mutagenic	DNA	oxidation	product,	5-
formyluracil.	DNA	Repair	(Amst),	2003.	2(2):	p.	199-210.	
82.	 Maiti,	A.,	et	al.,	Crystal	structure	of	human	thymine	DNA	glycosylase	bound	to	DNA	elucidates	
sequence-specific	mismatch	recognition.	Proc	Natl	Acad	Sci	U	S	A,	2008.	105(26):	p.	8890-5.	
83.	 Barrett,	T.E.,	et	al.,	Crystal	structure	of	a	G:T/U	mismatch-specific	DNA	glycosylase:	mismatch	
recognition	by	complementary-strand	interactions.	Cell,	1998.	92(1):	p.	117-29.	
84.	 Barrett,	T.E.,	et	al.,	Crystal	structure	of	a	thwarted	mismatch	glycosylase	DNA	repair	complex.	
EMBO	J,	1999.	18(23):	p.	6599-609.	
85.	 Hardeland,	U.,	et	al.,	Separating	substrate	recognition	from	base	hydrolysis	in	human	thymine	
DNA	glycosylase	by	mutational	analysis.	J	Biol	Chem,	2000.	275(43):	p.	33449-56.	
86.	 Hardeland,	U.,	et	al.,	Modification	of	the	human	thymine-DNA	glycosylase	by	ubiquitin-like	
proteins	facilitates	enzymatic	turnover.	EMBO	J,	2002.	21(6):	p.	1456-64.	
87.	 Steinacher,	R.	and	P.	Schar,	Functionality	of	human	thymine	DNA	glycosylase	requires	SUMO-
regulated	changes	in	protein	conformation.	Curr	Biol,	2005.	15(7):	p.	616-23.	
88.	 Hardeland,	U.,	et	al.,	Cell	cycle	regulation	as	a	mechanism	for	functional	separation	of	the	
apparently	redundant	uracil	DNA	glycosylases	TDG	and	UNG2.	Nucleic	Acids	Res,	2007.	
35(11):	p.	3859-67.	
89.	 Slenn,	T.J.,	et	al.,	Thymine	DNA	glycosylase	is	a	CRL4Cdt2	substrate.	J	Biol	Chem,	2014.	
289(33):	p.	23043-55.	
90.	 Zhong,	W.,	et	al.,	CUL-4	ubiquitin	ligase	maintains	genome	stability	by	restraining	DNA-
replication	licensing.	Nature,	2003.	423(6942):	p.	885-9.	
91.	 Havens,	C.G.	and	J.C.	Walter,	Mechanism	of	CRL4(Cdt2),	a	PCNA-dependent	E3	ubiquitin	
ligase.	Genes	Dev,	2011.	25(15):	p.	1568-82.	
92.	 Li,	Z.,	et	al.,	Gadd45a	promotes	DNA	demethylation	through	TDG.	Nucleic	Acids	Res,	2015.	
43(8):	p.	3986-97.	
																																																																																																																																																																													REFERENCES		
	____________________________________________________________________________________________________________________	134	
93.	 Zhu,	B.,	et	al.,	5-methylcytosine-DNA	glycosylase	activity	is	present	in	a	cloned	G/T	mismatch	
DNA	glycosylase	associated	with	the	chicken	embryo	DNA	demethylation	complex.	Proc	Natl	
Acad	Sci	U	S	A,	2000.	97(10):	p.	5135-9.	
94.	 Pidugu,	L.S.,	et	al.,	Structural	Basis	for	Excision	of	5-Formylcytosine	by	Thymine	DNA	
Glycosylase.	Biochemistry,	2016.	55(45):	p.	6205-6208.	
95.	 Weber,	A.R.,	et	al.,	Biochemical	reconstitution	of	TET1-TDG-BER-dependent	active	DNA	
demethylation	reveals	a	highly	coordinated	mechanism.	Nat	Commun,	2016.	7:	p.	10806.	
96.	 Zhang,	L.,	et	al.,	Thymine	DNA	glycosylase	specifically	recognizes	5-carboxylcytosine-modified	
DNA.	Nat	Chem	Biol,	2012.	8(4):	p.	328-30.	
97.	 He,	Y.F.,	et	al.,	Tet-mediated	formation	of	5-carboxylcytosine	and	its	excision	by	TDG	in	
mammalian	DNA.	Science,	2011.	333(6047):	p.	1303-7.	
98.	 Cortellino,	S.,	et	al.,	Thymine	DNA	glycosylase	is	essential	for	active	DNA	demethylation	by	
linked	deamination-base	excision	repair.	Cell,	2011.	146(1):	p.	67-79.	
99.	 Hendrich,	B.	and	A.	Bird,	Identification	and	characterization	of	a	family	of	mammalian	
methyl-CpG	binding	proteins.	Mol	Cell	Biol,	1998.	18(11):	p.	6538-47.	
100.	 Zhang,	Y.,	et	al.,	Analysis	of	the	NuRD	subunits	reveals	a	histone	deacetylase	core	complex	
and	a	connection	with	DNA	methylation.	Genes	Dev,	1999.	13(15):	p.	1924-35.	
101.	 Saito,	M.	and	F.	Ishikawa,	The	mCpG-binding	domain	of	human	MBD3	does	not	bind	to	mCpG	
but	interacts	with	NuRD/Mi2	components	HDAC1	and	MTA2.	J	Biol	Chem,	2002.	277(38):	p.	
35434-9.	
102.	 Hendrich,	B.,	et	al.,	The	thymine	glycosylase	MBD4	can	bind	to	the	product	of	deamination	at	
methylated	CpG	sites.	Nature,	1999.	401(6750):	p.	301-4.	
103.	 Zhu,	B.,	et	al.,	5-Methylcytosine	DNA	glycosylase	activity	is	also	present	in	the	human	MBD4	
(G/T	mismatch	glycosylase)	and	in	a	related	avian	sequence.	Nucleic	Acids	Res,	2000.	28(21):	
p.	4157-65.	
104.	 Rai,	K.,	et	al.,	DNA	demethylation	in	zebrafish	involves	the	coupling	of	a	deaminase,	a	
glycosylase,	and	gadd45.	Cell,	2008.	135(7):	p.	1201-12.	
105.	 Millar,	C.B.,	et	al.,	Enhanced	CpG	mutability	and	tumorigenesis	in	MBD4-deficient	mice.	
Science,	2002.	297(5580):	p.	403-5.	
106.	 Arana,	M.E.	and	T.A.	Kunkel,	Mutator	phenotypes	due	to	DNA	replication	infidelity.	Seminars	
in	cancer	biology,	2010.	20(5):	p.	304-11.	
107.	 Peltomaki,	P.,	Role	of	DNA	mismatch	repair	defects	in	the	pathogenesis	of	human	cancer.	J	
Clin	Oncol,	2003.	21(6):	p.	1174-9.	
108.	 Wimmer,	K.	and	J.	Etzler,	Constitutional	mismatch	repair-deficiency	syndrome:	have	we	so	far	
seen	only	the	tip	of	an	iceberg?	Human	genetics,	2008.	124(2):	p.	105-22.	
109.	 Liu,	B.,	et	al.,	Analysis	of	mismatch	repair	genes	in	hereditary	non-polyposis	colorectal	cancer	
patients.	Nat	Med,	1996.	2(2):	p.	169-74.	
110.	 Colussi,	C.,	et	al.,	The	mammalian	mismatch	repair	pathway	removes	DNA	8-oxodGMP	
incorporated	from	the	oxidized	dNTP	pool.	Current	biology	:	CB,	2002.	12(11):	p.	912-8.	
111.	 Bignami,	M.,	I.	Casorelli,	and	P.	Karran,	Mismatch	repair	and	response	to	DNA-damaging	
antitumour	therapies.	European	journal	of	cancer,	2003.	39(15):	p.	2142-9.	
112.	 Harfe,	B.D.	and	S.	Jinks-Robertson,	DNA	mismatch	repair	and	genetic	instability.	Annu	Rev	
Genet,	2000.	34:	p.	359-399.	
113.	 Paques,	F.	and	J.E.	Haber,	Multiple	pathways	of	recombination	induced	by	double-strand	
breaks	in	Saccharomyces	cerevisiae.	Microbiol	Mol	Biol	Rev,	1999.	63(2):	p.	349-404.	
114.	 Kunkel,	T.A.	and	D.A.	Erie,	DNA	mismatch	repair.	Annual	review	of	biochemistry,	2005.	74:	p.	
681-710.	
115.	 Bardwell,	P.D.,	et	al.,	Altered	somatic	hypermutation	and	reduced	class-switch	recombination	
in	exonuclease	1-mutant	mice.	Nature	immunology,	2004.	5(2):	p.	224-9.	
116.	 Chahwan,	R.,	et	al.,	AIDing	antibody	diversity	by	error-prone	mismatch	repair.	Seminars	in	
immunology,	2012.	24(4):	p.	293-300.	
																																																																																																																																																																													REFERENCES		
	____________________________________________________________________________________________________________________	135	
117.	 Pena-Diaz,	J.,	et	al.,	Noncanonical	mismatch	repair	as	a	source	of	genomic	instability	in	
human	cells.	Molecular	cell,	2012.	47(5):	p.	669-80.	
118.	 Schanz,	S.,	et	al.,	Interference	of	mismatch	and	base	excision	repair	during	the	processing	of	
adjacent	U/G	mispairs	may	play	a	key	role	in	somatic	hypermutation.	Proceedings	of	the	
National	Academy	of	Sciences	of	the	United	States	of	America,	2009.	106(14):	p.	5593-8.	
119.	 Alvino,	E.,	et	al.,	High-frequency	microsatellite	instability	is	associated	with	defective	DNA	
mismatch	repair	in	human	melanoma.	J	Invest	Dermatol,	2002.	118(1):	p.	79-86.	
120.	 Kunkel,	T.A.,	Nucleotide	repeats.	Slippery	DNA	and	diseases.	Nature,	1993.	365(6443):	p.	207-
8.	
121.	 Wagner,	R.,	Jr.	and	M.	Meselson,	Repair	tracts	in	mismatched	DNA	heteroduplexes.	
Proceedings	of	the	National	Academy	of	Sciences	of	the	United	States	of	America,	1976.	
73(11):	p.	4135-9.	
122.	 Jiricny,	J.,	et	al.,	A	human	200-kDa	protein	binds	selectively	to	DNA	fragments	containing	G.T	
mismatches.	Proceedings	of	the	National	Academy	of	Sciences	of	the	United	States	of	
America,	1988.	85(23):	p.	8860-4.	
123.	 Hughes,	M.J.	and	J.	Jiricny,	The	purification	of	a	human	mismatch-binding	protein	and	
identification	of	its	associated	ATPase	and	helicase	activities.	The	Journal	of	biological	
chemistry,	1992.	267(33):	p.	23876-82.	
124.	 Dzantiev,	L.,	et	al.,	A	defined	human	system	that	supports	bidirectional	mismatch-provoked	
excision.	Molecular	cell,	2004.	15(1):	p.	31-41.	
125.	 Cho,	W.K.,	et	al.,	ATP	alters	the	diffusion	mechanics	of	MutS	on	mismatched	DNA.	Structure,	
2012.	20(7):	p.	1264-74.	
126.	 Claverys,	J.P.	and	S.A.	Lacks,	Heteroduplex	deoxyribonucleic	acid	base	mismatch	repair	in	
bacteria.	Microbiological	reviews,	1986.	50(2):	p.	133-65.	
127.	 Holmes,	J.,	Jr.,	S.	Clark,	and	P.	Modrich,	Strand-specific	mismatch	correction	in	nuclear	
extracts	of	human	and	Drosophila	melanogaster	cell	lines.	Proceedings	of	the	National	
Academy	of	Sciences	of	the	United	States	of	America,	1990.	87(15):	p.	5837-41.	
128.	 Thomas,	D.C.,	J.D.	Roberts,	and	T.A.	Kunkel,	Heteroduplex	repair	in	extracts	of	human	HeLa	
cells.	The	Journal	of	biological	chemistry,	1991.	266(6):	p.	3744-51.	
129.	 Ghodgaonkar,	M.M.,	et	al.,	Ribonucleotides	misincorporated	into	DNA	act	as	strand-
discrimination	signals	in	eukaryotic	mismatch	repair.	Molecular	cell,	2013.	50(3):	p.	323-32.	
130.	 Repmann,	S.,	M.	Olivera-Harris,	and	J.	Jiricny,	Influence	of	oxidized	purine	processing	on	
strand	directionality	of	mismatch	repair.	J	Biol	Chem,	2015.	290(16):	p.	9986-99.	
131.	 Karran,	P.,	Mechanisms	of	tolerance	to	DNA	damaging	therapeutic	drugs.	Carcinogenesis,	
2001.	22(12):	p.	1931-7.	
132.	 Bignami,	M.,	et	al.,	Unmasking	a	killer:	DNA	O(6)-methylguanine	and	the	cytotoxicity	of	
methylating	agents.	Mutation	research,	2000.	462(2-3):	p.	71-82.	
133.	 York,	S.J.	and	P.	Modrich,	Mismatch	repair-dependent	iterative	excision	at	irreparable	O6-
methylguanine	lesions	in	human	nuclear	extracts.	The	Journal	of	biological	chemistry,	2006.	
281(32):	p.	22674-83.	
134.	 Olivera	Harris,	M.,	et	al.,	Mismatch	repair-dependent	metabolism	of	O6-methylguanine-
containing	DNA	in	Xenopus	laevis	egg	extracts.	DNA	Repair	(Amst),	2015.	28:	p.	1-7.	
135.	 Shimada,	A.,	et	al.,	MutS	stimulates	the	endonuclease	activity	of	MutL	in	an	ATP-hydrolysis-
dependent	manner.	The	FEBS	journal,	2013.	280(14):	p.	3467-79.	
136.	 Kadyrov,	F.A.,	et	al.,	Endonucleolytic	function	of	MutLalpha	in	human	mismatch	repair.	Cell,	
2006.	126(2):	p.	297-308.	
137.	 Ehrenstein,	M.R.	and	M.S.	Neuberger,	Deficiency	in	Msh2	affects	the	efficiency	and	local	
sequence	specificity	of	immunoglobulin	class-switch	recombination:	parallels	with	somatic	
hypermutation.	The	EMBO	journal,	1999.	18(12):	p.	3484-90.	
138.	 Rada,	C.,	et	al.,	Hot	spot	focusing	of	somatic	hypermutation	in	MSH2-deficient	mice	suggests	
two	stages	of	mutational	targeting.	Immunity,	1998.	9(1):	p.	135-41.	
																																																																																																																																																																													REFERENCES		
	____________________________________________________________________________________________________________________	136	
139.	 Schrader,	C.E.,	et	al.,	Reduced	isotype	switching	in	splenic	B	cells	from	mice	deficient	in	
mismatch	repair	enzymes.	The	Journal	of	experimental	medicine,	1999.	190(3):	p.	323-30.	
140.	 Shen,	H.M.,	et	al.,	Somatic	hypermutation	and	class	switch	recombination	in	Msh6(-/-)Ung(-/-
)	double-knockout	mice.	Journal	of	immunology,	2006.	177(8):	p.	5386-92.	
141.	 Vora,	K.A.,	et	al.,	Severe	attenuation	of	the	B	cell	immune	response	in	Msh2-deficient	mice.	J	
Exp	Med,	1999.	189(3):	p.	471-82.	
142.	 Martomo,	S.A.,	W.W.	Yang,	and	P.J.	Gearhart,	A	role	for	Msh6	but	not	Msh3	in	somatic	
hypermutation	and	class	switch	recombination.	The	Journal	of	experimental	medicine,	2004.	
200(1):	p.	61-8.	
143.	 Phung,	Q.H.,	et	al.,	Increased	hypermutation	at	G	and	C	nucleotides	in	immunoglobulin	
variable	genes	from	mice	deficient	in	the	MSH2	mismatch	repair	protein.	The	Journal	of	
experimental	medicine,	1998.	187(11):	p.	1745-51.	
144.	 Kannouche,	P.L.,	J.	Wing,	and	A.R.	Lehmann,	Interaction	of	human	DNA	polymerase	eta	with	
monoubiquitinated	PCNA:	a	possible	mechanism	for	the	polymerase	switch	in	response	to	
DNA	damage.	Molecular	cell,	2004.	14(4):	p.	491-500.	
145.	 Maizels,	N.,	Immunoglobulin	gene	diversification.	Annual	review	of	genetics,	2005.	39:	p.	23-
46.	
146.	 Muramatsu,	M.,	et	al.,	Class	switch	recombination	and	hypermutation	require	activation-
induced	cytidine	deaminase	(AID),	a	potential	RNA	editing	enzyme.	Cell,	2000.	102(5):	p.	553-
63.	
147.	 Rada,	C.,	J.M.	Di	Noia,	and	M.S.	Neuberger,	Mismatch	recognition	and	uracil	excision	provide	
complementary	paths	to	both	Ig	switching	and	the	A/T-focused	phase	of	somatic	mutation.	
Molecular	cell,	2004.	16(2):	p.	163-71.	
148.	 Zeng,	X.,	et	al.,	DNA	polymerase	eta	is	an	A-T	mutator	in	somatic	hypermutation	of	
immunoglobulin	variable	genes.	Nature	immunology,	2001.	2(6):	p.	537-41.	
149.	 Rogozin,	I.B.,	et	al.,	Somatic	mutation	hotspots	correlate	with	DNA	polymerase	eta	error	
spectrum.	Nature	immunology,	2001.	2(6):	p.	530-6.	
150.	 Wiesendanger,	M.,	et	al.,	Somatic	hypermutation	in	MutS	homologue	(MSH)3-,	MSH6-,	and	
MSH3/MSH6-deficient	mice	reveals	a	role	for	the	MSH2-MSH6	heterodimer	in	modulating	the	
base	substitution	pattern.	The	Journal	of	experimental	medicine,	2000.	191(3):	p.	579-84.	
151.	 Delbos,	F.,	et	al.,	Contribution	of	DNA	polymerase	eta	to	immunoglobulin	gene	
hypermutation	in	the	mouse.	J	Exp	Med,	2005.	201(8):	p.	1191-6.	
152.	 Schrader,	C.E.,	et	al.,	Activation-induced	cytidine	deaminase-dependent	DNA	breaks	in	class	
switch	recombination	occur	during	G1	phase	of	the	cell	cycle	and	depend	upon	mismatch	
repair.	Journal	of	immunology,	2007.	179(9):	p.	6064-71.	
153.	 Caldecott,	K.W.,	DNA	single-strand	break	repair.	Exp	Cell	Res,	2014.	329(1):	p.	2-8.	
154.	 Davidovic,	L.,	et	al.,	Importance	of	poly(ADP-ribose)	glycohydrolase	in	the	control	of	
poly(ADP-ribose)	metabolism.	Exp	Cell	Res,	2001.	268(1):	p.	7-13.	
155.	 Fisher,	A.E.,	et	al.,	Poly(ADP-ribose)	polymerase	1	accelerates	single-strand	break	repair	in	
concert	with	poly(ADP-ribose)	glycohydrolase.	Mol	Cell	Biol,	2007.	27(15):	p.	5597-605.	
156.	 Kim,	Y.J.	and	D.M.	Wilson,	3rd,	Overview	of	base	excision	repair	biochemistry.	Curr	Mol	
Pharmacol,	2012.	5(1):	p.	3-13.	
157.	 Pommier,	Y.,	et	al.,	Tyrosyl-DNA-phosphodiesterases	(TDP1	and	TDP2).	DNA	Repair	(Amst),	
2014.	19:	p.	114-29.	
158.	 Kanaar,	R.,	J.H.	Hoeijmakers,	and	D.C.	van	Gent,	Molecular	mechanisms	of	DNA	double	strand	
break	repair.	Trends	in	cell	biology,	1998.	8(12):	p.	483-9.	
159.	 Lieber,	M.R.,	et	al.,	Mechanism	and	regulation	of	human	non-homologous	DNA	end-joining.	
Nature	reviews.	Molecular	cell	biology,	2003.	4(9):	p.	712-20.	
160.	 Ceccaldi,	R.,	B.	Rondinelli,	and	A.D.	D'Andrea,	Repair	Pathway	Choices	and	Consequences	at	
the	Double-Strand	Break.	Trends	Cell	Biol,	2016.	26(1):	p.	52-64.	
161.	 Hartlerode,	A.,	et	al.,	Cell	cycle-dependent	induction	of	homologous	recombination	by	a	
tightly	regulated	I-SceI	fusion	protein.	PloS	one,	2011.	6(3):	p.	e16501.	
																																																																																																																																																																													REFERENCES		
	____________________________________________________________________________________________________________________	137	
162.	 Takata,	M.,	et	al.,	Homologous	recombination	and	non-homologous	end-joining	pathways	of	
DNA	double-strand	break	repair	have	overlapping	roles	in	the	maintenance	of	chromosomal	
integrity	in	vertebrate	cells.	EMBO	J,	1998.	17(18):	p.	5497-508.	
163.	 Carney,	J.P.,	et	al.,	The	hMre11/hRad50	protein	complex	and	Nijmegen	breakage	syndrome:	
linkage	of	double-strand	break	repair	to	the	cellular	DNA	damage	response.	Cell,	1998.	93(3):	
p.	477-86.	
164.	 Stewart,	G.S.,	et	al.,	The	DNA	double-strand	break	repair	gene	hMRE11	is	mutated	in	
individuals	with	an	ataxia-telangiectasia-like	disorder.	Cell,	1999.	99(6):	p.	577-87.	
165.	 Lee,	J.H.	and	T.T.	Paull,	Activation	and	regulation	of	ATM	kinase	activity	in	response	to	DNA	
double-strand	breaks.	Oncogene,	2007.	26(56):	p.	7741-8.	
166.	 Aylon,	Y.,	B.	Liefshitz,	and	M.	Kupiec,	The	CDK	regulates	repair	of	double-strand	breaks	by	
homologous	recombination	during	the	cell	cycle.	The	EMBO	journal,	2004.	23(24):	p.	4868-75.	
167.	 Sugiyama,	T.,	E.M.	Zaitseva,	and	S.C.	Kowalczykowski,	A	single-stranded	DNA-binding	protein	
is	needed	for	efficient	presynaptic	complex	formation	by	the	Saccharomyces	cerevisiae	Rad51	
protein.	J	Biol	Chem,	1997.	272(12):	p.	7940-5.	
168.	 Haruta,	N.,	et	al.,	The	Swi5-Sfr1	complex	stimulates	Rhp51/Rad51-	and	Dmc1-mediated	DNA	
strand	exchange	in	vitro.	Nat	Struct	Mol	Biol,	2006.	13(9):	p.	823-30.	
169.	 New,	J.H.,	et	al.,	Rad52	protein	stimulates	DNA	strand	exchange	by	Rad51	and	replication	
protein	A.	Nature,	1998.	391(6665):	p.	407-10.	
170.	 Chen,	P.L.,	et	al.,	The	BRC	repeats	in	BRCA2	are	critical	for	RAD51	binding	and	resistance	to	
methyl	methanesulfonate	treatment.	Proc	Natl	Acad	Sci	U	S	A,	1998.	95(9):	p.	5287-92.	
171.	 Sharan,	S.K.,	et	al.,	Embryonic	lethality	and	radiation	hypersensitivity	mediated	by	Rad51	in	
mice	lacking	Brca2.	Nature,	1997.	386(6627):	p.	804-10.	
172.	 Jasin,	M.,	Homologous	repair	of	DNA	damage	and	tumorigenesis:	the	BRCA	connection.	
Oncogene,	2002.	21(58):	p.	8981-93.	
173.	 Ogawa,	T.,	et	al.,	Similarity	of	the	yeast	RAD51	filament	to	the	bacterial	RecA	filament.	
Science,	1993.	259(5103):	p.	1896-9.	
174.	 San	Filippo,	J.,	P.	Sung,	and	H.	Klein,	Mechanism	of	eukaryotic	homologous	recombination.	
Annual	review	of	biochemistry,	2008.	77:	p.	229-57.	
175.	 Ferguson,	D.O.	and	W.K.	Holloman,	Recombinational	repair	of	gaps	in	DNA	is	asymmetric	in	
Ustilago	maydis	and	can	be	explained	by	a	migrating	D-loop	model.	Proc	Natl	Acad	Sci	U	S	A,	
1996.	93(11):	p.	5419-24.	
176.	 Ferguson,	D.O.,	et	al.,	The	nonhomologous	end-joining	pathway	of	DNA	repair	is	required	for	
genomic	stability	and	the	suppression	of	translocations.	Proc	Natl	Acad	Sci	U	S	A,	2000.	
97(12):	p.	6630-3.	
177.	 Nussenzweig,	A.,	et	al.,	Requirement	for	Ku80	in	growth	and	immunoglobulin	V(D)J	
recombination.	Nature,	1996.	382(6591):	p.	551-5.	
178.	 Fischer,	A.,	et	al.,	Naturally	occurring	primary	deficiencies	of	the	immune	system.	Annu	Rev	
Immunol,	1997.	15:	p.	93-124.	
179.	 Stephan,	J.L.,	et	al.,	Severe	combined	immunodeficiency:	a	retrospective	single-center	study	of	
clinical	presentation	and	outcome	in	117	patients.	J	Pediatr,	1993.	123(4):	p.	564-72.	
180.	 Moshous,	D.,	et	al.,	Artemis,	a	novel	DNA	double-strand	break	repair/V(D)J	recombination	
protein,	is	mutated	in	human	severe	combined	immune	deficiency.	Cell,	2001.	105(2):	p.	177-
86.	
181.	 Ma,	Y.,	et	al.,	Hairpin	opening	and	overhang	processing	by	an	Artemis/DNA-dependent	
protein	kinase	complex	in	nonhomologous	end	joining	and	V(D)J	recombination.	Cell,	2002.	
108(6):	p.	781-94.	
182.	 Dynan,	W.S.	and	S.	Yoo,	Interaction	of	Ku	protein	and	DNA-dependent	protein	kinase	catalytic	
subunit	with	nucleic	acids.	Nucleic	acids	research,	1998.	26(7):	p.	1551-9.	
183.	 Gottlieb,	T.M.	and	S.P.	Jackson,	The	DNA-dependent	protein	kinase:	requirement	for	DNA	
ends	and	association	with	Ku	antigen.	Cell,	1993.	72(1):	p.	131-42.	
																																																																																																																																																																													REFERENCES		
	____________________________________________________________________________________________________________________	138	
184.	 Lieber,	M.R.,	The	mechanism	of	double-strand	DNA	break	repair	by	the	nonhomologous	DNA	
end-joining	pathway.	Annual	review	of	biochemistry,	2010.	79:	p.	181-211.	
185.	 Weinstock,	D.M.,	E.	Brunet,	and	M.	Jasin,	Formation	of	NHEJ-derived	reciprocal	chromosomal	
translocations	does	not	require	Ku70.	Nature	cell	biology,	2007.	9(8):	p.	978-81.	
186.	 Gu,	J.,	et	al.,	XRCC4:DNA	ligase	IV	can	ligate	incompatible	DNA	ends	and	can	ligate	across	
gaps.	The	EMBO	journal,	2007.	26(4):	p.	1010-23.	
187.	 Boulton,	S.J.	and	S.P.	Jackson,	Identification	of	a	Saccharomyces	cerevisiae	Ku80	homologue:	
roles	in	DNA	double	strand	break	rejoining	and	in	telomeric	maintenance.	Nucleic	Acids	Res,	
1996.	24(23):	p.	4639-48.	
188.	 Liang,	F.,	et	al.,	Chromosomal	double-strand	break	repair	in	Ku80-deficient	cells.	Proc	Natl	
Acad	Sci	U	S	A,	1996.	93(17):	p.	8929-33.	
189.	 Lee,	K.	and	S.E.	Lee,	Saccharomyces	cerevisiae	Sae2-	and	Tel1-dependent	single-strand	DNA	
formation	at	DNA	break	promotes	microhomology-mediated	end	joining.	Genetics,	2007.	
176(4):	p.	2003-14.	
190.	 Ma,	J.L.,	et	al.,	Yeast	Mre11	and	Rad1	proteins	define	a	Ku-independent	mechanism	to	repair	
double-strand	breaks	lacking	overlapping	end	sequences.	Molecular	and	cellular	biology,	
2003.	23(23):	p.	8820-8.	
191.	 Decottignies,	A.,	Microhomology-mediated	end	joining	in	fission	yeast	is	repressed	by	pku70	
and	relies	on	genes	involved	in	homologous	recombination.	Genetics,	2007.	176(3):	p.	1403-
15.	
192.	 Liang,	L.,	et	al.,	Human	DNA	ligases	I	and	III,	but	not	ligase	IV,	are	required	for	
microhomology-mediated	end	joining	of	DNA	double-strand	breaks.	Nucleic	acids	research,	
2008.	36(10):	p.	3297-310.	
193.	 Pan-Hammarstrom,	Q.,	et	al.,	Impact	of	DNA	ligase	IV	on	nonhomologous	end	joining	
pathways	during	class	switch	recombination	in	human	cells.	The	Journal	of	experimental	
medicine,	2005.	201(2):	p.	189-94.	
194.	 Audebert,	M.,	B.	Salles,	and	P.	Calsou,	Involvement	of	poly(ADP-ribose)	polymerase-1	and	
XRCC1/DNA	ligase	III	in	an	alternative	route	for	DNA	double-strand	breaks	rejoining.	The	
Journal	of	biological	chemistry,	2004.	279(53):	p.	55117-26.	
195.	 Wang,	M.,	et	al.,	PARP-1	and	Ku	compete	for	repair	of	DNA	double	strand	breaks	by	distinct	
NHEJ	pathways.	Nucleic	acids	research,	2006.	34(21):	p.	6170-82.	
196.	 Weinfeld,	M.,	et	al.,	Interaction	of	DNA-dependent	protein	kinase	and	poly(ADP-ribose)	
polymerase	with	radiation-induced	DNA	strand	breaks.	Radiation	research,	1997.	148(1):	p.	
22-8.	
197.	 D'Silva,	I.,	et	al.,	Relative	affinities	of	poly(ADP-ribose)	polymerase	and	DNA-dependent	
protein	kinase	for	DNA	strand	interruptions.	Biochimica	et	biophysica	acta,	1999.	1430(1):	p.	
119-26.	
198.	 Gellert,	M.,	V(D)J	recombination:	RAG	proteins,	repair	factors,	and	regulation.	Annu	Rev	
Biochem,	2002.	71:	p.	101-32.	
199.	 Swanson,	P.C.,	The	bounty	of	RAGs:	recombination	signal	complexes	and	reaction	outcomes.	
Immunol	Rev,	2004.	200:	p.	90-114.	
200.	 Schatz,	D.G.	and	P.C.	Swanson,	V(D)J	recombination:	mechanisms	of	initiation.	Annual	review	
of	genetics,	2011.	45:	p.	167-202.	
201.	 Peled,	J.U.,	et	al.,	The	biochemistry	of	somatic	hypermutation.	Annual	review	of	immunology,	
2008.	26:	p.	481-511.	
202.	 Orthwein,	A.	and	J.M.	Di	Noia,	Activation	induced	deaminase:	how	much	and	where?	
Seminars	in	immunology,	2012.	24(4):	p.	246-54.	
203.	 Neuberger,	M.S.	and	C.	Milstein,	Somatic	hypermutation.	Current	opinion	in	immunology,	
1995.	7(2):	p.	248-54.	
204.	 Rogozin,	I.B.,	T.A.	Kunkel,	and	Y.I.	Pavlov,	Double-strand	breaks	in	DNA	during	somatic	
hypermutation	of	Ig	genes:	cause	or	consequence?	Trends	in	immunology,	2002.	23(1):	p.	12-
3.	
																																																																																																																																																																													REFERENCES		
	____________________________________________________________________________________________________________________	139	
205.	 Manis,	J.P.,	M.	Tian,	and	F.W.	Alt,	Mechanism	and	control	of	class-switch	recombination.	
Trends	in	immunology,	2002.	23(1):	p.	31-9.	
206.	 Teng,	G.	and	F.N.	Papavasiliou,	Immunoglobulin	somatic	hypermutation.	Annual	review	of	
genetics,	2007.	41:	p.	107-20.	
207.	 Muramatsu,	M.,	et	al.,	Specific	expression	of	activation-induced	cytidine	deaminase	(AID),	a	
novel	member	of	the	RNA-editing	deaminase	family	in	germinal	center	B	cells.	The	Journal	of	
biological	chemistry,	1999.	274(26):	p.	18470-6.	
208.	 Dickerson,	S.K.,	et	al.,	AID	mediates	hypermutation	by	deaminating	single	stranded	DNA.	J	
Exp	Med,	2003.	197(10):	p.	1291-6.	
209.	 Bransteitter,	R.,	et	al.,	Activation-induced	cytidine	deaminase	deaminates	deoxycytidine	on	
single-stranded	DNA	but	requires	the	action	of	RNase.	Proc	Natl	Acad	Sci	U	S	A,	2003.	100(7):	
p.	4102-7.	
210.	 Fukita,	Y.,	H.	Jacobs,	and	K.	Rajewsky,	Somatic	hypermutation	in	the	heavy	chain	locus	
correlates	with	transcription.	Immunity,	1998.	9(1):	p.	105-14.	
211.	 Bachl,	J.,	et	al.,	Increased	transcription	levels	induce	higher	mutation	rates	in	a	hypermutating	
cell	line.	J	Immunol,	2001.	166(8):	p.	5051-7.	
212.	 Chaudhuri,	J.,	C.	Khuong,	and	F.W.	Alt,	Replication	protein	A	interacts	with	AID	to	promote	
deamination	of	somatic	hypermutation	targets.	Nature,	2004.	430(7003):	p.	992-8.	
213.	 Shen,	H.M.	and	U.	Storb,	Activation-induced	cytidine	deaminase	(AID)	can	target	both	DNA	
strands	when	the	DNA	is	supercoiled.	Proc	Natl	Acad	Sci	U	S	A,	2004.	101(35):	p.	12997-3002.	
214.	 Larijani,	M.	and	A.	Martin,	Single-stranded	DNA	structure	and	positional	context	of	the	target	
cytidine	determine	the	enzymatic	efficiency	of	AID.	Mol	Cell	Biol,	2007.	27(23):	p.	8038-48.	
215.	 Rogozin,	I.B.	and	N.A.	Kolchanov,	Somatic	hypermutagenesis	in	immunoglobulin	genes.	II.	
Influence	of	neighbouring	base	sequences	on	mutagenesis.	Biochim	Biophys	Acta,	1992.	
1171(1):	p.	11-8.	
216.	 Conticello,	S.G.,	et	al.,	DNA	deamination	in	immunity:	AID	in	the	context	of	its	APOBEC	
relatives.	Adv	Immunol,	2007.	94:	p.	37-73.	
217.	 Larijani,	M.,	et	al.,	AID	associates	with	single-stranded	DNA	with	high	affinity	and	a	long	
complex	half-life	in	a	sequence-independent	manner.	Mol	Cell	Biol,	2007.	27(1):	p.	20-30.	
218.	 Barreto,	V.,	et	al.,	C-terminal	deletion	of	AID	uncouples	class	switch	recombination	from	
somatic	hypermutation	and	gene	conversion.	Mol	Cell,	2003.	12(2):	p.	501-8.	
219.	 Ranjit,	S.,	et	al.,	AID	binds	cooperatively	with	UNG	and	Msh2-Msh6	to	Ig	switch	regions	
dependent	upon	the	AID	C	terminus.	Journal	of	immunology,	2011.	187(5):	p.	2464-75.	
220.	 Shinkura,	R.,	et	al.,	Separate	domains	of	AID	are	required	for	somatic	hypermutation	and	
class-switch	recombination.	Nat	Immunol,	2004.	5(7):	p.	707-12.	
221.	 Zan,	H.	and	P.	Casali,	Regulation	of	Aicda	expression	and	AID	activity.	Autoimmunity,	2013.	
46(2):	p.	83-101.	
222.	 Hase,	K.,	et	al.,	Activation-induced	cytidine	deaminase	deficiency	causes	organ-specific	
autoimmune	disease.	PloS	one,	2008.	3(8):	p.	e3033.	
223.	 Dorsett,	Y.,	et	al.,	MicroRNA-155	suppresses	activation-induced	cytidine	deaminase-mediated	
Myc-Igh	translocation.	Immunity,	2008.	28(5):	p.	630-8.	
224.	 Robbiani,	D.F.,	et	al.,	AID	produces	DNA	double-strand	breaks	in	non-Ig	genes	and	mature	B	
cell	lymphomas	with	reciprocal	chromosome	translocations.	Molecular	cell,	2009.	36(4):	p.	
631-41.	
225.	 Jiang,	C.,	M.L.	Zhao,	and	M.	Diaz,	Activation-induced	deaminase	heterozygous	MRL/lpr	mice	
are	delayed	in	the	production	of	high-affinity	pathogenic	antibodies	and	in	the	development	
of	lupus	nephritis.	Immunology,	2009.	126(1):	p.	102-13.	
226.	 Okazaki,	I.M.,	et	al.,	Constitutive	expression	of	AID	leads	to	tumorigenesis.	The	Journal	of	
experimental	medicine,	2003.	197(9):	p.	1173-81.	
227.	 de	Yebenes,	V.G.,	et	al.,	miR-181b	negatively	regulates	activation-induced	cytidine	deaminase	
in	B	cells.	The	Journal	of	experimental	medicine,	2008.	205(10):	p.	2199-206.	
																																																																																																																																																																													REFERENCES		
	____________________________________________________________________________________________________________________	140	
228.	 Aoufouchi,	S.,	et	al.,	Proteasomal	degradation	restricts	the	nuclear	lifespan	of	AID.	The	
Journal	of	experimental	medicine,	2008.	205(6):	p.	1357-68.	
229.	 Brar,	S.S.,	M.	Watson,	and	M.	Diaz,	Activation-induced	cytosine	deaminase	(AID)	is	actively	
exported	out	of	the	nucleus	but	retained	by	the	induction	of	DNA	breaks.	The	Journal	of	
biological	chemistry,	2004.	279(25):	p.	26395-401.	
230.	 Ito,	S.,	et	al.,	Activation-induced	cytidine	deaminase	shuttles	between	nucleus	and	cytoplasm	
like	apolipoprotein	B	mRNA	editing	catalytic	polypeptide	1.	Proceedings	of	the	National	
Academy	of	Sciences	of	the	United	States	of	America,	2004.	101(7):	p.	1975-80.	
231.	 Basu,	U.,	et	al.,	The	AID	antibody	diversification	enzyme	is	regulated	by	protein	kinase	A	
phosphorylation.	Nature,	2005.	438(7067):	p.	508-11.	
232.	 McBride,	K.M.,	et	al.,	Regulation	of	hypermutation	by	activation-induced	cytidine	deaminase	
phosphorylation.	Proc	Natl	Acad	Sci	U	S	A,	2006.	103(23):	p.	8798-803.	
233.	 McBride,	K.M.,	et	al.,	Regulation	of	class	switch	recombination	and	somatic	mutation	by	AID	
phosphorylation.	J	Exp	Med,	2008.	205(11):	p.	2585-94.	
234.	 Pasqualucci,	L.,	et	al.,	PKA-mediated	phosphorylation	regulates	the	function	of	activation-
induced	deaminase	(AID)	in	B	cells.	Proc	Natl	Acad	Sci	U	S	A,	2006.	103(2):	p.	395-400.	
235.	 Larijani,	M.,	et	al.,	Methylation	protects	cytidines	from	AID-mediated	deamination.	Mol	
Immunol,	2005.	42(5):	p.	599-604.	
236.	 Nabel,	C.S.,	et	al.,	AID/APOBEC	deaminases	disfavor	modified	cytosines	implicated	in	DNA	
demethylation.	Nature	chemical	biology,	2012.	8(9):	p.	751-8.	
237.	 Morgan,	H.D.,	et	al.,	Activation-induced	cytidine	deaminase	deaminates	5-methylcytosine	in	
DNA	and	is	expressed	in	pluripotent	tissues:	implications	for	epigenetic	reprogramming.	The	
Journal	of	biological	chemistry,	2004.	279(50):	p.	52353-60.	
238.	 Bhutani,	N.,	et	al.,	Reprogramming	towards	pluripotency	requires	AID-dependent	DNA	
demethylation.	Nature,	2010.	463(7284):	p.	1042-7.	
239.	 Vuong,	B.Q.	and	J.	Chaudhuri,	Combinatorial	mechanisms	regulating	AID-dependent	DNA	
deamination:	interacting	proteins	and	post-translational	modifications.	Seminars	in	
immunology,	2012.	24(4):	p.	264-72.	
240.	 Casellas,	R.,	et	al.,	Ku80	is	required	for	immunoglobulin	isotype	switching.	The	EMBO	journal,	
1998.	17(8):	p.	2404-11.	
241.	 Manis,	J.P.,	et	al.,	Ku70	is	required	for	late	B	cell	development	and	immunoglobulin	heavy	
chain	class	switching.	The	Journal	of	experimental	medicine,	1998.	187(12):	p.	2081-9.	
242.	 Kotnis,	A.,	et	al.,	Non-homologous	end	joining	in	class	switch	recombination:	the	beginning	of	
the	end.	Philosophical	transactions	of	the	Royal	Society	of	London.	Series	B,	Biological	
sciences,	2009.	364(1517):	p.	653-65.	
243.	 Xu,	Z.,	et	al.,	Immunoglobulin	class-switch	DNA	recombination:	induction,	targeting	and	
beyond.	Nature	reviews.	Immunology,	2012.	12(7):	p.	517-31.	
244.	 Imai,	K.,	et	al.,	Human	uracil-DNA	glycosylase	deficiency	associated	with	profoundly	impaired	
immunoglobulin	class-switch	recombination.	Nat	Immunol,	2003.	4(10):	p.	1023-8.	
245.	 Schrader,	C.E.,	J.	Vardo,	and	J.	Stavnezer,	Role	for	mismatch	repair	proteins	Msh2,	Mlh1,	and	
Pms2	in	immunoglobulin	class	switching	shown	by	sequence	analysis	of	recombination	
junctions.	The	Journal	of	experimental	medicine,	2002.	195(3):	p.	367-73.	
246.	 Soulas-Sprauel,	P.,	et	al.,	Role	for	DNA	repair	factor	XRCC4	in	immunoglobulin	class	switch	
recombination.	The	Journal	of	experimental	medicine,	2007.	204(7):	p.	1717-27.	
247.	 Stavnezer,	J.	and	C.E.	Schrader,	Mismatch	repair	converts	AID-instigated	nicks	to	double-
strand	breaks	for	antibody	class-switch	recombination.	Trends	Genet,	2006.	22(1):	p.	23-8.	
248.	 Aranda,	S.,	G.	Mas,	and	L.	Di	Croce,	Regulation	of	gene	transcription	by	Polycomb	proteins.	
Sci	Adv,	2015.	1(11):	p.	e1500737.	
249.	 Trojer,	P.	and	D.	Reinberg,	Facultative	heterochromatin:	is	there	a	distinctive	molecular	
signature?	Mol	Cell,	2007.	28(1):	p.	1-13.	
250.	 Fabian,	M.R.,	N.	Sonenberg,	and	W.	Filipowicz,	Regulation	of	mRNA	translation	and	stability	
by	microRNAs.	Annu	Rev	Biochem,	2010.	79:	p.	351-79.	
																																																																																																																																																																													REFERENCES		
	____________________________________________________________________________________________________________________	141	
251.	 Khraiwesh,	B.,	et	al.,	Transcriptional	control	of	gene	expression	by	microRNAs.	Cell,	2010.	
140(1):	p.	111-22.	
252.	 Kung,	J.T.,	D.	Colognori,	and	J.T.	Lee,	Long	noncoding	RNAs:	past,	present,	and	future.	
Genetics,	2013.	193(3):	p.	651-69.	
253.	 Mercer,	T.R.	and	J.S.	Mattick,	Structure	and	function	of	long	noncoding	RNAs	in	epigenetic	
regulation.	Nat	Struct	Mol	Biol,	2013.	20(3):	p.	300-7.	
254.	 Kalashnikova,	A.A.,	R.A.	Rogge,	and	J.C.	Hansen,	Linker	histone	H1	and	protein-protein	
interactions.	Biochim	Biophys	Acta,	2016.	1859(3):	p.	455-61.	
255.	 Allfrey,	V.G.,	R.	Faulkner,	and	A.E.	Mirsky,	Acetylation	and	Methylation	of	Histones	and	Their	
Possible	Role	in	the	Regulation	of	Rna	Synthesis.	Proc	Natl	Acad	Sci	U	S	A,	1964.	51:	p.	786-94.	
256.	 Hassan,	A.H.,	et	al.,	Function	and	selectivity	of	bromodomains	in	anchoring	chromatin-
modifying	complexes	to	promoter	nucleosomes.	Cell,	2002.	111(3):	p.	369-79.	
257.	 Kim,	J.,	et	al.,	Tudor,	MBT	and	chromo	domains	gauge	the	degree	of	lysine	methylation.	
EMBO	Rep,	2006.	7(4):	p.	397-403.	
258.	 Hon,	G.C.,	R.D.	Hawkins,	and	B.	Ren,	Predictive	chromatin	signatures	in	the	mammalian	
genome.	Hum	Mol	Genet,	2009.	18(R2):	p.	R195-201.	
259.	 Barski,	A.,	et	al.,	High-resolution	profiling	of	histone	methylations	in	the	human	genome.	Cell,	
2007.	129(4):	p.	823-37.	
260.	 Schneider,	R.,	et	al.,	Histone	H3	lysine	4	methylation	patterns	in	higher	eukaryotic	genes.	Nat	
Cell	Biol,	2004.	6(1):	p.	73-7.	
261.	 Sims,	R.J.,	3rd,	et	al.,	Human	but	not	yeast	CHD1	binds	directly	and	selectively	to	histone	H3	
methylated	at	lysine	4	via	its	tandem	chromodomains.	J	Biol	Chem,	2005.	280(51):	p.	41789-
92.	
262.	 Zegerman,	P.,	et	al.,	Histone	H3	lysine	4	methylation	disrupts	binding	of	nucleosome	
remodeling	and	deacetylase	(NuRD)	repressor	complex.	J	Biol	Chem,	2002.	277(14):	p.	11621-
4.	
263.	 Bannister,	A.J.,	et	al.,	Spatial	distribution	of	di-	and	tri-methyl	lysine	36	of	histone	H3	at	active	
genes.	J	Biol	Chem,	2005.	280(18):	p.	17732-6.	
264.	 Juan,	A.H.,	et	al.,	Roles	of	H3K27me2	and	H3K27me3	Examined	during	Fate	Specification	of	
Embryonic	Stem	Cells.	Cell	Rep,	2016.	17(5):	p.	1369-1382.	
265.	 Bannister,	A.J.,	et	al.,	Selective	recognition	of	methylated	lysine	9	on	histone	H3	by	the	HP1	
chromo	domain.	Nature,	2001.	410(6824):	p.	120-4.	
266.	 Lachner,	M.,	et	al.,	Methylation	of	histone	H3	lysine	9	creates	a	binding	site	for	HP1	proteins.	
Nature,	2001.	410(6824):	p.	116-20.	
267.	 Lehnertz,	B.,	et	al.,	Suv39h-mediated	histone	H3	lysine	9	methylation	directs	DNA	methylation	
to	major	satellite	repeats	at	pericentric	heterochromatin.	Curr	Biol,	2003.	13(14):	p.	1192-
200.	
268.	 Bartke,	T.,	et	al.,	Nucleosome-interacting	proteins	regulated	by	DNA	and	histone	methylation.	
Cell,	2010.	143(3):	p.	470-84.	
269.	 Bannister,	A.J.	and	T.	Kouzarides,	Regulation	of	chromatin	by	histone	modifications.	Cell	Res,	
2011.	21(3):	p.	381-95.	
270.	 Lawrence,	M.,	S.	Daujat,	and	R.	Schneider,	Lateral	Thinking:	How	Histone	Modifications	
Regulate	Gene	Expression.	Trends	Genet,	2016.	32(1):	p.	42-56.	
271.	 Gold,	M.	and	J.	Hurwitz,	The	Enzymatic	Methylation	of	Ribonucleic	Acid	and	Deoxyribonucleic	
Acid.	V.	Purification	and	Properties	of	the	Deoxyribonucleic	Acid-Methylating	Activity	of	
Escherichia	Coli.	J	Biol	Chem,	1964.	239:	p.	3858-65.	
272.	 Hurwitz,	J.,	M.	Gold,	and	M.	Anders,	The	Enzymatic	Methylation	of	Ribonucleic	Acid	and	
Deoxyribonucleic	Acid.	Iv.	The	Properties	of	the	Soluble	Ribonucleic	Acid-Methylating	
Enzymes.	J	Biol	Chem,	1964.	239:	p.	3474-82.	
273.	 Arber,	W.	and	D.	Dussoix,	Host	specificity	of	DNA	produced	by	Escherichia	coli.	I.	Host	
controlled	modification	of	bacteriophage	lambda.	J	Mol	Biol,	1962.	5:	p.	18-36.	
																																																																																																																																																																													REFERENCES		
	____________________________________________________________________________________________________________________	142	
274.	 Dussoix,	D.	and	W.	Arber,	Host	specificity	of	DNA	produced	by	Escherichia	coli.	II.	Control	over	
acceptance	of	DNA	from	infecting	phage	lambda.	J	Mol	Biol,	1962.	5:	p.	37-49.	
275.	 Arber,	W.,	Host	Specificity	of	DNA	Produced	by	Escherichia	Coli	V	.	The	Role	of	Methionine	in	
the	Production	of	Host	Specificity.	J	Mol	Biol,	1965.	11:	p.	247-56.	
276.	 Arber,	W.	and	M.L.	Morse,	Host	Specificity	of	DNA	Produced	by	Escherichia	Coli.	Vi.	Effects	on	
Bacterial	Conjugation.	Genetics,	1965.	51:	p.	137-48.	
277.	 Dussoix,	D.	and	W.	Arber,	Host	Specificity	of	DNA	Produced	by	Escherichia	Coli.	Iv.	Host	
Specificity	of	Infectious	DNA	from	Bacteriophage	Lambda.	J	Mol	Biol,	1965.	11:	p.	238-46.	
278.	 Kelly,	T.J.,	Jr.	and	H.O.	Smith,	A	restriction	enzyme	from	Hemophilus	influenzae.	II.	J	Mol	Biol,	
1970.	51(2):	p.	393-409.	
279.	 Smith,	H.O.	and	K.W.	Wilcox,	A	restriction	enzyme	from	Hemophilus	influenzae.	I.	Purification	
and	general	properties.	J	Mol	Biol,	1970.	51(2):	p.	379-91.	
280.	 Adler,	S.P.	and	D.	Nathans,	Studies	of	SV	40	DNA.	V.	Conversion	of	circular	to	linear	SV	40	
DNA	by	restriction	endonuclease	from	Escherichia	coli	B.	Biochim	Biophys	Acta,	1973.	299(2):	
p.	177-88.	
281.	 Danna,	K.	and	D.	Nathans,	Specific	cleavage	of	simian	virus	40	DNA	by	restriction	
endonuclease	of	Hemophilus	influenzae.	Proc	Natl	Acad	Sci	U	S	A,	1971.	68(12):	p.	2913-7.	
282.	 Danna,	K.J.,	G.H.	Sack,	Jr.,	and	D.	Nathans,	Studies	of	simian	virus	40	DNA.	VII.	A	cleavage	
map	of	the	SV40	genome.	J	Mol	Biol,	1973.	78(2):	p.	363-76.	
283.	 Khoury,	G.,	et	al.,	Characterization	of	a	rearrangement	in	viral	DNA:	mapping	of	the	circular	
simian	virus	40-like	DNA	containing	a	triplication	of	a	specific	one-third	of	the	viral	genome.	J	
Mol	Biol,	1974.	87(2):	p.	289-301.	
284.	 Martin,	M.A.,	et	al.,	Characterization	of	"heavy"	and	"light"	SV40-like	particles	from	a	patient	
with	PML.	Virology,	1974.	59(1):	p.	179-89.	
285.	 Sack,	G.H.,	Jr.	and	D.	Nathans,	Studies	of	SV40	DNA.	VI.	Cleavage	of	SV40	DNA	by	restriction	
endonuclease	from	Hemophilus	parainfluenzae.	Virology,	1973.	51(2):	p.	517-20.	
286.	 Glickman,	B.W.	and	M.	Radman,	Escherichia	coli	mutator	mutants	deficient	in	methylation-
instructed	DNA	mismatch	correction.	Proc	Natl	Acad	Sci	U	S	A,	1980.	77(2):	p.	1063-7.	
287.	 Marinus,	M.G.,	Adenine	methylation	of	Okazaki	fragments	in	Escherichia	coli.	J	Bacteriol,	
1976.	128(3):	p.	853-4.	
288.	 Marinus,	M.G.	and	E.B.	Konrad,	Hyper-recombination	in	dam	mutants	of	Escherichia	coli	K-12.	
Mol	Gen	Genet,	1976.	149(3):	p.	273-7.	
289.	 Radman,	M.,	et	al.,	Replicational	fidelity:	mechanisms	of	mutation	avoidance	and	mutation	
fixation.	Cold	Spring	Harb	Symp	Quant	Biol,	1979.	43	Pt	2:	p.	937-46.	
290.	 Marinus,	M.G.	and	N.R.	Morris,	Biological	function	for	6-methyladenine	residues	in	the	DNA	
of	Escherichia	coli	K12.	J	Mol	Biol,	1974.	85(2):	p.	309-22.	
291.	 Marinus,	M.G.,	A.	Poteete,	and	J.A.	Arraj,	Correlation	of	DNA	adenine	methylase	activity	with	
spontaneous	mutability	in	Escherichia	coli	K-12.	Gene,	1984.	28(1):	p.	123-5.	
292.	 Schlagman,	S.L.,	S.	Hattman,	and	M.G.	Marinus,	Direct	role	of	the	Escherichia	coli	Dam	DNA	
methyltransferase	in	methylation-directed	mismatch	repair.	J	Bacteriol,	1986.	165(3):	p.	896-
900.	
293.	 Herman,	G.E.	and	P.	Modrich,	Escherichia	coli	K-12	clones	that	overproduce	dam	methylase	
are	hypermutable.	J	Bacteriol,	1981.	145(1):	p.	644-6.	
294.	 Rydberg,	B.,	Bromouracil	mutagenesis	and	mismatch	repair	in	mutator	strains	of	Escherichia	
coli.	Mutat	Res,	1978.	52(1):	p.	11-24.	
295.	 Bauer,	J.,	G.	Krammer,	and	R.	Knippers,	Asymmetric	repair	of	bacteriophage	T7	heteroduplex	
DNA.	Mol	Gen	Genet,	1981.	181(4):	p.	541-7.	
296.	 Sheid,	B.,	P.R.	Srinivasan,	and	E.	Borek,	Deoxyribonucleic	acid	methylase	of	mammalian	
tissues.	Biochemistry,	1968.	7(1):	p.	280-5.	
297.	 Kalousek,	F.	and	N.R.	Morris,	Deoxyribonucleic	acid	methylase	activity	in	rat	spleen.	J	Biol	
Chem,	1968.	243(9):	p.	2440-2.	
																																																																																																																																																																													REFERENCES		
	____________________________________________________________________________________________________________________	143	
298.	 Gruenbaum,	Y.,	et	al.,	Sequence	specificity	of	methylation	in	higher	plant	DNA.	Nature,	1981.	
292(5826):	p.	860-2.	
299.	 Hardcastle,	T.J.,	High-throughput	sequencing	of	cytosine	methylation	in	plant	DNA.	Plant	
Methods,	2013.	9(1):	p.	16.	
300.	 Gruenbaum,	Y.,	et	al.,	Methylation	of	CpG	sequences	in	eukaryotic	DNA.	FEBS	Lett,	1981.	
124(1):	p.	67-71.	
301.	 Naveh-Many,	T.	and	H.	Cedar,	Active	gene	sequences	are	undermethylated.	Proc	Natl	Acad	
Sci	U	S	A,	1981.	78(7):	p.	4246-50.	
302.	 Swartz,	M.N.,	T.A.	Trautner,	and	A.	Kornberg,	Enzymatic	synthesis	of	deoxyribonucleic	acid.	
XI.	Further	studies	on	nearest	neighbor	base	sequences	in	deoxyribonucleic	acids.	J	Biol	Chem,	
1962.	237:	p.	1961-7.	
303.	 Coulondre,	C.,	et	al.,	Molecular	basis	of	base	substitution	hotspots	in	Escherichia	coli.	Nature,	
1978.	274(5673):	p.	775-80.	
304.	 Bird,	A.P.,	DNA	methylation	and	the	frequency	of	CpG	in	animal	DNA.	Nucleic	Acids	Res,	1980.	
8(7):	p.	1499-504.	
305.	 Sved,	J.	and	A.	Bird,	The	expected	equilibrium	of	the	CpG	dinucleotide	in	vertebrate	genomes	
under	a	mutation	model.	Proc	Natl	Acad	Sci	U	S	A,	1990.	87(12):	p.	4692-6.	
306.	 Cooper,	D.N.	and	H.	Youssoufian,	The	CpG	dinucleotide	and	human	genetic	disease.	Hum	
Genet,	1988.	78(2):	p.	151-5.	
307.	 Bulmer,	M.,	Neighboring	base	effects	on	substitution	rates	in	pseudogenes.	Mol	Biol	Evol,	
1986.	3(4):	p.	322-9.	
308.	 Cooper,	D.N.,	M.H.	Taggart,	and	A.P.	Bird,	Unmethylated	domains	in	vertebrate	DNA.	Nucleic	
Acids	Res,	1983.	11(3):	p.	647-58.	
309.	 McClelland,	M.	and	R.	Ivarie,	Asymmetrical	distribution	of	CpG	in	an	'average'	mammalian	
gene.	Nucleic	Acids	Res,	1982.	10(23):	p.	7865-77.	
310.	 Stein,	R.,	et	al.,	Pattern	of	methylation	of	two	genes	coding	for	housekeeping	functions.	Proc	
Natl	Acad	Sci	U	S	A,	1983.	80(9):	p.	2422-6.	
311.	 Busslinger,	M.,	J.	Hurst,	and	R.A.	Flavell,	DNA	methylation	and	the	regulation	of	globin	gene	
expression.	Cell,	1983.	34(1):	p.	197-206.	
312.	 Liskay,	R.M.	and	R.J.	Evans,	Inactive	X	chromosome	DNA	does	not	function	in	DNA-mediated	
cell	transformation	for	the	hypoxanthine	phosphoribosyltransferase	gene.	Proc	Natl	Acad	Sci	
U	S	A,	1980.	77(8):	p.	4895-8.	
313.	 Venolia,	L.,	et	al.,	Transformation	with	DNA	from	5-azacytidine-reactivated	X	chromosomes.	
Proc	Natl	Acad	Sci	U	S	A,	1982.	79(7):	p.	2352-4.	
314.	 Yen,	P.H.,	et	al.,	Differential	methylation	of	hypoxanthine	phosphoribosyltransferase	genes	on	
active	and	inactive	human	X	chromosomes.	Proc	Natl	Acad	Sci	U	S	A,	1984.	81(6):	p.	1759-63.	
315.	 Tykocinski,	M.L.	and	E.E.	Max,	CG	dinucleotide	clusters	in	MHC	genes	and	in	5'	demethylated	
genes.	Nucleic	Acids	Res,	1984.	12(10):	p.	4385-96.	
316.	 Bird,	A.P.,	CpG-rich	islands	and	the	function	of	DNA	methylation.	Nature,	1986.	321(6067):	p.	
209-13.	
317.	 Riggs,	A.D.	and	G.P.	Pfeifer,	X-chromosome	inactivation	and	cell	memory.	Trends	Genet,	
1992.	8(5):	p.	169-74.	
318.	 Neumann,	B.	and	D.P.	Barlow,	Multiple	roles	for	DNA	methylation	in	gametic	imprinting.	Curr	
Opin	Genet	Dev,	1996.	6(2):	p.	159-63.	
319.	 Razin,	A.	and	H.	Cedar,	DNA	methylation	and	genomic	imprinting.	Cell,	1994.	77(4):	p.	473-6.	
320.	 Bird,	A.P.,	The	relationship	of	DNA	methylation	to	cancer.	Cancer	Surv,	1996.	28:	p.	87-101.	
321.	 Herman,	J.G.	and	S.B.	Baylin,	Gene	silencing	in	cancer	in	association	with	promoter	
hypermethylation.	N	Engl	J	Med,	2003.	349(21):	p.	2042-54.	
322.	 Esteller,	M.,	et	al.,	MLH1	promoter	hypermethylation	is	associated	with	the	microsatellite	
instability	phenotype	in	sporadic	endometrial	carcinomas.	Oncogene,	1998.	17(18):	p.	2413-
7.	
																																																																																																																																																																													REFERENCES		
	____________________________________________________________________________________________________________________	144	
323.	 Kanaya,	T.,	et	al.,	Frequent	hypermethylation	of	MLH1	promoter	in	normal	endometrium	of	
patients	with	endometrial	cancers.	Oncogene,	2003.	22(15):	p.	2352-60.	
324.	 Li,	X.,	et	al.,	MLH1	promoter	methylation	frequency	in	colorectal	cancer	patients	and	related	
clinicopathological	and	molecular	features.	PLoS	One,	2013.	8(3):	p.	e59064.	
325.	 Simpkins,	S.B.,	et	al.,	MLH1	promoter	methylation	and	gene	silencing	is	the	primary	cause	of	
microsatellite	instability	in	sporadic	endometrial	cancers.	Hum	Mol	Genet,	1999.	8(4):	p.	661-
6.	
326.	 Okano,	M.,	S.	Xie,	and	E.	Li,	Cloning	and	characterization	of	a	family	of	novel	mammalian	
DNA	(cytosine-5)	methyltransferases.	Nat	Genet,	1998.	19(3):	p.	219-20.	
327.	 Wu,	H.,	et	al.,	Genome-wide	analysis	of	5-hydroxymethylcytosine	distribution	reveals	its	dual	
function	in	transcriptional	regulation	in	mouse	embryonic	stem	cells.	Genes	Dev,	2011.	25(7):	
p.	679-84.	
328.	 Ficz,	G.,	et	al.,	Dynamic	regulation	of	5-hydroxymethylcytosine	in	mouse	ES	cells	and	during	
differentiation.	Nature,	2011.	473(7347):	p.	398-402.	
329.	 Wu,	H.,	et	al.,	Dual	functions	of	Tet1	in	transcriptional	regulation	in	mouse	embryonic	stem	
cells.	Nature,	2011.	473(7347):	p.	389-93.	
330.	 Ben-Hattar,	J.	and	J.	Jiricny,	Methylation	of	single	CpG	dinucleotides	within	a	promoter	
element	of	the	Herpes	simplex	virus	tk	gene	reduces	its	transcription	in	vivo.	Gene,	1988.	
65(2):	p.	219-27.	
331.	 Saluz,	H.P.,	et	al.,	Genomic	sequencing	and	in	vivo	footprinting	of	an	expression-specific	
DNase	I-hypersensitive	site	of	avian	vitellogenin	II	promoter	reveal	a	demethylation	of	a	
mCpG	and	a	change	in	specific	interactions	of	proteins	with	DNA.	Proc	Natl	Acad	Sci	U	S	A,	
1988.	85(18):	p.	6697-700.	
332.	 Saluz,	H.P.,	J.	Jiricny,	and	J.P.	Jost,	Genomic	sequencing	reveals	a	positive	correlation	between	
the	kinetics	of	strand-specific	DNA	demethylation	of	the	overlapping	estradiol/glucocorticoid-
receptor	binding	sites	and	the	rate	of	avian	vitellogenin	mRNA	synthesis.	Proceedings	of	the	
National	Academy	of	Sciences	of	the	United	States	of	America,	1986.	83(19):	p.	7167-71.	
333.	 Keshet,	I.,	J.	Lieman-Hurwitz,	and	H.	Cedar,	DNA	methylation	affects	the	formation	of	active	
chromatin.	Cell,	1986.	44(4):	p.	535-43.	
334.	 Becker,	P.B.,	S.	Ruppert,	and	G.	Schutz,	Genomic	footprinting	reveals	cell	type-specific	DNA	
binding	of	ubiquitous	factors.	Cell,	1987.	51(3):	p.	435-43.	
335.	 Iguchi-Ariga,	S.M.	and	W.	Schaffner,	CpG	methylation	of	the	cAMP-responsive	
enhancer/promoter	sequence	TGACGTCA	abolishes	specific	factor	binding	as	well	as	
transcriptional	activation.	Genes	Dev,	1989.	3(5):	p.	612-9.	
336.	 Medvedeva,	Y.A.,	et	al.,	Effects	of	cytosine	methylation	on	transcription	factor	binding	sites.	
BMC	Genomics,	2014.	15:	p.	119.	
337.	 Comb,	M.	and	H.M.	Goodman,	CpG	methylation	inhibits	proenkephalin	gene	expression	and	
binding	of	the	transcription	factor	AP-2.	Nucleic	Acids	Res,	1990.	18(13):	p.	3975-82.	
338.	 Falzon,	M.	and	E.L.	Kuff,	Binding	of	the	transcription	factor	EBP-80	mediates	the	methylation	
response	of	an	intracisternal	A-particle	long	terminal	repeat	promoter.	Mol	Cell	Biol,	1991.	
11(1):	p.	117-25.	
339.	 Gaston,	K.	and	M.	Fried,	CpG	methylation	and	the	binding	of	YY1	and	ETS	proteins	to	the	Surf-
1/Surf-2	bidirectional	promoter.	Gene,	1995.	157(1-2):	p.	257-9.	
340.	 Gaston,	K.	and	M.	Fried,	CpG	methylation	has	differential	effects	on	the	binding	of	YY1	and	
ETS	proteins	to	the	bi-directional	promoter	of	the	Surf-1	and	Surf-2	genes.	Nucleic	Acids	Res,	
1995.	23(6):	p.	901-9.	
341.	 Radtke,	F.,	et	al.,	Differential	sensitivity	of	zinc	finger	transcription	factors	MTF-1,	Sp1	and	
Krox-20	to	CpG	methylation	of	their	binding	sites.	Biol	Chem	Hoppe	Seyler,	1996.	377(1):	p.	
47-56.	
342.	 Meehan,	R.R.,	et	al.,	Identification	of	a	mammalian	protein	that	binds	specifically	to	DNA	
containing	methylated	CpGs.	Cell,	1989.	58(3):	p.	499-507.	
																																																																																																																																																																													REFERENCES		
	____________________________________________________________________________________________________________________	145	
343.	 Boyes,	J.	and	A.	Bird,	DNA	methylation	inhibits	transcription	indirectly	via	a	methyl-CpG	
binding	protein.	Cell,	1991.	64(6):	p.	1123-34.	
344.	 Lewis,	J.D.,	et	al.,	Purification,	sequence,	and	cellular	localization	of	a	novel	chromosomal	
protein	that	binds	to	methylated	DNA.	Cell,	1992.	69(6):	p.	905-14.	
345.	 Nan,	X.,	et	al.,	DNA	methylation	specifies	chromosomal	localization	of	MeCP2.	Mol	Cell	Biol,	
1996.	16(1):	p.	414-21.	
346.	 Tate,	P.,	W.	Skarnes,	and	A.	Bird,	The	methyl-CpG	binding	protein	MeCP2	is	essential	for	
embryonic	development	in	the	mouse.	Nat	Genet,	1996.	12(2):	p.	205-8.	
347.	 Nan,	X.,	F.J.	Campoy,	and	A.	Bird,	MeCP2	is	a	transcriptional	repressor	with	abundant	binding	
sites	in	genomic	chromatin.	Cell,	1997.	88(4):	p.	471-81.	
348.	 Nan,	X.,	et	al.,	Transcriptional	repression	by	the	methyl-CpG-binding	protein	MeCP2	involves	a	
histone	deacetylase	complex.	Nature,	1998.	393(6683):	p.	386-9.	
349.	 Ng,	H.H.,	et	al.,	MBD2	is	a	transcriptional	repressor	belonging	to	the	MeCP1	histone	
deacetylase	complex.	Nat	Genet,	1999.	23(1):	p.	58-61.	
350.	 Hendrich,	B.,	et	al.,	Closely	related	proteins	MBD2	and	MBD3	play	distinctive	but	interacting	
roles	in	mouse	development.	Genes	Dev,	2001.	15(6):	p.	710-23.	
351.	 Martin	Caballero,	I.,	et	al.,	The	methyl-CpG	binding	proteins	Mecp2,	Mbd2	and	Kaiso	are	
dispensable	for	mouse	embryogenesis,	but	play	a	redundant	function	in	neural	
differentiation.	PLoS	One,	2009.	4(1):	p.	e4315.	
352.	 Amir,	R.E.,	et	al.,	Rett	syndrome	is	caused	by	mutations	in	X-linked	MECP2,	encoding	methyl-
CpG-binding	protein	2.	Nat	Genet,	1999.	23(2):	p.	185-8.	
353.	 Moretti,	P.,	et	al.,	Learning	and	memory	and	synaptic	plasticity	are	impaired	in	a	mouse	
model	of	Rett	syndrome.	J	Neurosci,	2006.	26(1):	p.	319-27.	
354.	 Moretti,	P.	and	H.Y.	Zoghbi,	MeCP2	dysfunction	in	Rett	syndrome	and	related	disorders.	Curr	
Opin	Genet	Dev,	2006.	16(3):	p.	276-81.	
355.	 Guy,	J.,	et	al.,	Reversal	of	neurological	defects	in	a	mouse	model	of	Rett	syndrome.	Science,	
2007.	315(5815):	p.	1143-7.	
356.	 Struhl,	K.,	Helix-turn-helix,	zinc-finger,	and	leucine-zipper	motifs	for	eukaryotic	transcriptional	
regulatory	proteins.	Trends	Biochem	Sci,	1989.	14(4):	p.	137-40.	
357.	 Busch,	S.J.	and	P.	Sassone-Corsi,	Dimers,	leucine	zippers	and	DNA-binding	domains.	Trends	
Genet,	1990.	6(2):	p.	36-40.	
358.	 Abel,	T.	and	T.	Maniatis,	Gene	regulation.	Action	of	leucine	zippers.	Nature,	1989.	341(6237):	
p.	24-5.	
359.	 Luscher,	B.	and	L.G.	Larsson,	The	basic	region/helix-loop-helix/leucine	zipper	domain	of	Myc	
proto-oncoproteins:	function	and	regulation.	Oncogene,	1999.	18(19):	p.	2955-66.	
360.	 Boyes,	J.	and	A.	Bird,	Repression	of	genes	by	DNA	methylation	depends	on	CpG	density	and	
promoter	strength:	evidence	for	involvement	of	a	methyl-CpG	binding	protein.	EMBO	J,	1992.	
11(1):	p.	327-33.	
361.	 Hsieh,	C.L.,	Dependence	of	transcriptional	repression	on	CpG	methylation	density.	Mol	Cell	
Biol,	1994.	14(8):	p.	5487-94.	
362.	 Kass,	S.U.,	N.	Landsberger,	and	A.P.	Wolffe,	DNA	methylation	directs	a	time-dependent	
repression	of	transcription	initiation.	Curr	Biol,	1997.	7(3):	p.	157-65.	
363.	 Kass,	S.U.,	D.	Pruss,	and	A.P.	Wolffe,	How	does	DNA	methylation	repress	transcription?	
Trends	Genet,	1997.	13(11):	p.	444-9.	
364.	 Stringer,	K.F.,	C.J.	Ingles,	and	J.	Greenblatt,	Direct	and	selective	binding	of	an	acidic	
transcriptional	activation	domain	to	the	TATA-box	factor	TFIID.	Nature,	1990.	345(6278):	p.	
783-6.	
365.	 Courey,	A.J.	and	R.	Tjian,	Analysis	of	Sp1	in	vivo	reveals	multiple	transcriptional	domains,	
including	a	novel	glutamine-rich	activation	motif.	Cell,	1988.	55(5):	p.	887-98.	
366.	 Dynan,	W.S.	and	R.	Tjian,	The	promoter-specific	transcription	factor	Sp1	binds	to	upstream	
sequences	in	the	SV40	early	promoter.	Cell,	1983.	35(1):	p.	79-87.	
																																																																																																																																																																													REFERENCES		
	____________________________________________________________________________________________________________________	146	
367.	 Emili,	A.,	J.	Greenblatt,	and	C.J.	Ingles,	Species-specific	interaction	of	the	glutamine-rich	
activation	domains	of	Sp1	with	the	TATA	box-binding	protein.	Mol	Cell	Biol,	1994.	14(3):	p.	
1582-93.	
368.	 Sentenac,	A.,	Eukaryotic	RNA	polymerases.	CRC	Crit	Rev	Biochem,	1985.	18(1):	p.	31-90.	
369.	 Turowski,	T.W.	and	D.	Tollervey,	Transcription	by	RNA	polymerase	III:	insights	into	
mechanism	and	regulation.	Biochem	Soc	Trans,	2016.	44(5):	p.	1367-1375.	
370.	 Allison,	L.A.,	et	al.,	The	C-terminal	domain	of	the	largest	subunit	of	RNA	polymerase	II	of	
Saccharomyces	cerevisiae,	Drosophila	melanogaster,	and	mammals:	a	conserved	structure	
with	an	essential	function.	Mol	Cell	Biol,	1988.	8(1):	p.	321-9.	
371.	 Hsin,	J.P.	and	J.L.	Manley,	The	RNA	polymerase	II	CTD	coordinates	transcription	and	RNA	
processing.	Genes	Dev,	2012.	26(19):	p.	2119-37.	
372.	 Lee,	T.I.	and	R.A.	Young,	Transcription	of	eukaryotic	protein-coding	genes.	Annu	Rev	Genet,	
2000.	34:	p.	77-137.	
373.	 Hermann,	A.,	S.	Schmitt,	and	A.	Jeltsch,	The	human	Dnmt2	has	residual	DNA-(cytosine-C5)	
methyltransferase	activity.	J	Biol	Chem,	2003.	278(34):	p.	31717-21.	
374.	 Aapola,	U.,	et	al.,	Isolation	and	initial	characterization	of	a	novel	zinc	finger	gene,	DNMT3L,	
on	21q22.3,	related	to	the	cytosine-5-methyltransferase	3	gene	family.	Genomics,	2000.	
65(3):	p.	293-8.	
375.	 Chedin,	F.,	M.R.	Lieber,	and	C.L.	Hsieh,	The	DNA	methyltransferase-like	protein	DNMT3L	
stimulates	de	novo	methylation	by	Dnmt3a.	Proc	Natl	Acad	Sci	U	S	A,	2002.	99(26):	p.	16916-
21.	
376.	 Gowher,	H.,	et	al.,	Mechanism	of	stimulation	of	catalytic	activity	of	Dnmt3A	and	Dnmt3B	
DNA-(cytosine-C5)-methyltransferases	by	Dnmt3L.	J	Biol	Chem,	2005.	280(14):	p.	13341-8.	
377.	 Santi,	D.V.,	C.E.	Garrett,	and	P.J.	Barr,	On	the	mechanism	of	inhibition	of	DNA-cytosine	
methyltransferases	by	cytosine	analogs.	Cell,	1983.	33(1):	p.	9-10.	
378.	 Santi,	D.V.,	A.	Norment,	and	C.E.	Garrett,	Covalent	bond	formation	between	a	DNA-cytosine	
methyltransferase	and	DNA	containing	5-azacytosine.	Proc	Natl	Acad	Sci	U	S	A,	1984.	81(22):	
p.	6993-7.	
379.	 Wu,	J.C.	and	D.V.	Santi,	Kinetic	and	catalytic	mechanism	of	HhaI	methyltransferase.	J	Biol	
Chem,	1987.	262(10):	p.	4778-86.	
380.	 Chen,	L.,	et	al.,	Direct	identification	of	the	active-site	nucleophile	in	a	DNA	(cytosine-5)-
methyltransferase.	Biochemistry,	1991.	30(46):	p.	11018-25.	
381.	 Smith,	S.S.,	et	al.,	Mechanism	of	human	methyl-directed	DNA	methyltransferase	and	the	
fidelity	of	cytosine	methylation.	Proc	Natl	Acad	Sci	U	S	A,	1992.	89(10):	p.	4744-8.	
382.	 Klimasauskas,	S.,	et	al.,	HhaI	methyltransferase	flips	its	target	base	out	of	the	DNA	helix.	Cell,	
1994.	76(2):	p.	357-69.	
383.	 Bestor,	T.,	et	al.,	Cloning	and	sequencing	of	a	cDNA	encoding	DNA	methyltransferase	of	
mouse	cells.	The	carboxyl-terminal	domain	of	the	mammalian	enzymes	is	related	to	bacterial	
restriction	methyltransferases.	J	Mol	Biol,	1988.	203(4):	p.	971-83.	
384.	 Yoder,	J.A.,	et	al.,	DNA	(cytosine-5)-methyltransferases	in	mouse	cells	and	tissues.	Studies	
with	a	mechanism-based	probe.	J	Mol	Biol,	1997.	270(3):	p.	385-95.	
385.	 Arita,	K.,	et	al.,	Recognition	of	hemi-methylated	DNA	by	the	SRA	protein	UHRF1	by	a	base-
flipping	mechanism.	Nature,	2008.	455(7214):	p.	818-21.	
386.	 Sharif,	J.,	et	al.,	The	SRA	protein	Np95	mediates	epigenetic	inheritance	by	recruiting	Dnmt1	to	
methylated	DNA.	Nature,	2007.	450(7171):	p.	908-12.	
387.	 Dhe-Paganon,	S.,	F.	Syeda,	and	L.	Park,	DNA	methyl	transferase	1:	regulatory	mechanisms	
and	implications	in	health	and	disease.	Int	J	Biochem	Mol	Biol,	2011.	2(1):	p.	58-66.	
388.	 Schermelleh,	L.,	et	al.,	Dynamics	of	Dnmt1	interaction	with	the	replication	machinery	and	its	
role	in	postreplicative	maintenance	of	DNA	methylation.	Nucleic	Acids	Res,	2007.	35(13):	p.	
4301-12.	
389.	 Spada,	F.,	et	al.,	DNMT1	but	not	its	interaction	with	the	replication	machinery	is	required	for	
maintenance	of	DNA	methylation	in	human	cells.	J	Cell	Biol,	2007.	176(5):	p.	565-71.	
																																																																																																																																																																													REFERENCES		
	____________________________________________________________________________________________________________________	147	
390.	 Bestor,	T.H.,	Activation	of	mammalian	DNA	methyltransferase	by	cleavage	of	a	Zn	binding	
regulatory	domain.	EMBO	J,	1992.	11(7):	p.	2611-7.	
391.	 Bacolla,	A.,	et	al.,	Recombinant	human	DNA	(cytosine-5)	methyltransferase.	II.	Steady-state	
kinetics	reveal	allosteric	activation	by	methylated	dna.	J	Biol	Chem,	1999.	274(46):	p.	33011-
9.	
392.	 Pradhan,	S.,	et	al.,	Recombinant	human	DNA	(cytosine-5)	methyltransferase.	I.	Expression,	
purification,	and	comparison	of	de	novo	and	maintenance	methylation.	J	Biol	Chem,	1999.	
274(46):	p.	33002-10.	
393.	 Lei,	H.,	et	al.,	De	novo	DNA	cytosine	methyltransferase	activities	in	mouse	embryonic	stem	
cells.	Development,	1996.	122(10):	p.	3195-205.	
394.	 Li,	E.,	T.H.	Bestor,	and	R.	Jaenisch,	Targeted	mutation	of	the	DNA	methyltransferase	gene	
results	in	embryonic	lethality.	Cell,	1992.	69(6):	p.	915-26.	
395.	 Hsieh,	C.L.,	In	vivo	activity	of	murine	de	novo	methyltransferases,	Dnmt3a	and	Dnmt3b.	Mol	
Cell	Biol,	1999.	19(12):	p.	8211-8.	
396.	 Okano,	M.,	et	al.,	DNA	methyltransferases	Dnmt3a	and	Dnmt3b	are	essential	for	de	novo	
methylation	and	mammalian	development.	Cell,	1999.	99(3):	p.	247-57.	
397.	 Miniou,	P.,	et	al.,	Abnormal	methylation	pattern	in	constitutive	and	facultative	(X	inactive	
chromosome)	heterochromatin	of	ICF	patients.	Hum	Mol	Genet,	1994.	3(12):	p.	2093-102.	
398.	 Hansen,	R.S.,	et	al.,	Escape	from	gene	silencing	in	ICF	syndrome:	evidence	for	advanced	
replication	time	as	a	major	determinant.	Hum	Mol	Genet,	2000.	9(18):	p.	2575-87.	
399.	 Kondo,	T.,	et	al.,	Whole-genome	methylation	scan	in	ICF	syndrome:	hypomethylation	of	non-
satellite	DNA	repeats	D4Z4	and	NBL2.	Hum	Mol	Genet,	2000.	9(4):	p.	597-604.	
400.	 Xu,	G.L.,	et	al.,	Chromosome	instability	and	immunodeficiency	syndrome	caused	by	mutations	
in	a	DNA	methyltransferase	gene.	Nature,	1999.	402(6758):	p.	187-91.	
401.	 Wijmenga,	C.,	et	al.,	Genetic	variation	in	ICF	syndrome:	evidence	for	genetic	heterogeneity.	
Hum	Mutat,	2000.	16(6):	p.	509-17.	
402.	 Ehrlich,	M.,	The	ICF	syndrome,	a	DNA	methyltransferase	3B	deficiency	and	immunodeficiency	
disease.	Clin	Immunol,	2003.	109(1):	p.	17-28.	
403.	 Jin,	B.	and	K.D.	Robertson,	DNA	methyltransferases,	DNA	damage	repair,	and	cancer.	Adv	Exp	
Med	Biol,	2013.	754:	p.	3-29.	
404.	 Subramaniam,	D.,	et	al.,	DNA	methyltransferases:	a	novel	target	for	prevention	and	therapy.	
Front	Oncol,	2014.	4:	p.	80.	
405.	 Issa,	J.P.,	Decitabine.	Curr	Opin	Oncol,	2003.	15(6):	p.	446-51.	
406.	 Issa,	J.P.,	et	al.,	Phase	1	study	of	low-dose	prolonged	exposure	schedules	of	the	
hypomethylating	agent	5-aza-2'-deoxycytidine	(decitabine)	in	hematopoietic	malignancies.	
Blood,	2004.	103(5):	p.	1635-40.	
407.	 Kantarjian,	H.M.,	et	al.,	Results	of	decitabine	(5-aza-2'deoxycytidine)	therapy	in	130	patients	
with	chronic	myelogenous	leukemia.	Cancer,	2003.	98(3):	p.	522-8.	
408.	 Momparler,	R.L.	and	J.	Ayoub,	Potential	of	5-aza-2'-deoxycytidine	(Decitabine)	a	potent	
inhibitor	of	DNA	methylation	for	therapy	of	advanced	non-small	cell	lung	cancer.	Lung	
Cancer,	2001.	34	Suppl	4:	p.	S111-5.	
409.	 Mayer,	W.,	et	al.,	Demethylation	of	the	zygotic	paternal	genome.	Nature,	2000.	403(6769):	p.	
501-2.	
410.	 Oswald,	J.,	et	al.,	Active	demethylation	of	the	paternal	genome	in	the	mouse	zygote.	Current	
biology	:	CB,	2000.	10(8):	p.	475-8.	
411.	 Hajkova,	P.,	et	al.,	Epigenetic	reprogramming	in	mouse	primordial	germ	cells.	Mechanisms	of	
development,	2002.	117(1-2):	p.	15-23.	
412.	 Seisenberger,	S.,	et	al.,	The	dynamics	of	genome-wide	DNA	methylation	reprogramming	in	
mouse	primordial	germ	cells.	Mol	Cell,	2012.	48(6):	p.	849-62.	
413.	 Zhu,	J.K.,	Active	DNA	demethylation	mediated	by	DNA	glycosylases.	Annu	Rev	Genet,	2009.	
43:	p.	143-66.	
																																																																																																																																																																													REFERENCES		
	____________________________________________________________________________________________________________________	148	
414.	 Jost,	J.P.,	et	al.,	Mechanisms	of	DNA	demethylation	in	chicken	embryos.	Purification	and	
properties	of	a	5-methylcytosine-DNA	glycosylase.	J	Biol	Chem,	1995.	270(17):	p.	9734-9.	
415.	 Vairapandi,	M.	and	N.J.	Duker,	Enzymic	removal	of	5-methylcytosine	from	DNA	by	a	human	
DNA-glycosylase.	Nucleic	Acids	Res,	1993.	21(23):	p.	5323-7.	
416.	 Popp,	C.,	et	al.,	Genome-wide	erasure	of	DNA	methylation	in	mouse	primordial	germ	cells	is	
affected	by	AID	deficiency.	Nature,	2010.	463(7284):	p.	1101-5.	
417.	 Santos,	F.,	et	al.,	Active	demethylation	in	mouse	zygotes	involves	cytosine	deamination	and	
base	excision	repair.	Epigenetics	Chromatin,	2013.	6(1):	p.	39.	
418.	 Lorsbach,	R.B.,	et	al.,	TET1,	a	member	of	a	novel	protein	family,	is	fused	to	MLL	in	acute	
myeloid	leukemia	containing	the	t(10;11)(q22;q23).	Leukemia,	2003.	17(3):	p.	637-41.	
419.	 Ono,	R.,	et	al.,	LCX,	leukemia-associated	protein	with	a	CXXC	domain,	is	fused	to	MLL	in	acute	
myeloid	leukemia	with	trilineage	dysplasia	having	t(10;11)(q22;q23).	Cancer	Res,	2002.	
62(14):	p.	4075-80.	
420.	 Maiti,	A.	and	A.C.	Drohat,	Thymine	DNA	glycosylase	can	rapidly	excise	5-formylcytosine	and	
5-carboxylcytosine:	potential	implications	for	active	demethylation	of	CpG	sites.	J	Biol	Chem,	
2011.	286(41):	p.	35334-8.	
421.	 Szwagierczak,	A.,	et	al.,	Sensitive	enzymatic	quantification	of	5-hydroxymethylcytosine	in	
genomic	DNA.	Nucleic	Acids	Res,	2010.	38(19):	p.	e181.	
422.	 Globisch,	D.,	et	al.,	Tissue	distribution	of	5-hydroxymethylcytosine	and	search	for	active	
demethylation	intermediates.	PLoS	One,	2010.	5(12):	p.	e15367.	
423.	 Kriaucionis,	S.	and	N.	Heintz,	The	nuclear	DNA	base	5-hydroxymethylcytosine	is	present	in	
Purkinje	neurons	and	the	brain.	Science,	2009.	324(5929):	p.	929-30.	
424.	 Pastor,	W.A.,	L.	Aravind,	and	A.	Rao,	TETonic	shift:	biological	roles	of	TET	proteins	in	DNA	
demethylation	and	transcription.	Nat	Rev	Mol	Cell	Biol,	2013.	14(6):	p.	341-56.	
425.	 Loenarz,	C.	and	C.J.	Schofield,	Expanding	chemical	biology	of	2-oxoglutarate	oxygenases.	Nat	
Chem	Biol,	2008.	4(3):	p.	152-6.	
426.	 Loenarz,	C.	and	C.J.	Schofield,	Physiological	and	biochemical	aspects	of	hydroxylations	and	
demethylations	catalyzed	by	human	2-oxoglutarate	oxygenases.	Trends	Biochem	Sci,	2011.	
36(1):	p.	7-18.	
427.	 Ponnaluri,	V.K.,	J.P.	Maciejewski,	and	M.	Mukherji,	A	mechanistic	overview	of	TET-mediated	
5-methylcytosine	oxidation.	Biochem	Biophys	Res	Commun,	2013.	436(2):	p.	115-20.	
428.	 Kovaleva,	E.G.	and	J.D.	Lipscomb,	Versatility	of	biological	non-heme	Fe(II)	centers	in	oxygen	
activation	reactions.	Nat	Chem	Biol,	2008.	4(3):	p.	186-93.	
429.	 Minor,	E.A.,	et	al.,	Ascorbate	induces	ten-eleven	translocation	(Tet)	methylcytosine	
dioxygenase-mediated	generation	of	5-hydroxymethylcytosine.	J	Biol	Chem,	2013.	288(19):	p.	
13669-74.	
430.	 Costas,	M.,	et	al.,	Dioxygen	activation	at	mononuclear	nonheme	iron	active	sites:	enzymes,	
models,	and	intermediates.	Chem	Rev,	2004.	104(2):	p.	939-86.	
431.	 Ozer,	A.	and	R.K.	Bruick,	Non-heme	dioxygenases:	cellular	sensors	and	regulators	jelly	rolled	
into	one?	Nat	Chem	Biol,	2007.	3(3):	p.	144-53.	
432.	 Hashimoto,	H.,	et	al.,	Structure	of	Naegleria	Tet-like	dioxygenase	(NgTet1)	in	complexes	with	
a	reaction	intermediate	5-hydroxymethylcytosine	DNA.	Nucleic	Acids	Res,	2015.	43(22):	p.	
10713-21.	
433.	 Hashimoto,	H.,	et	al.,	Structure	of	a	Naegleria	Tet-like	dioxygenase	in	complex	with	5-
methylcytosine	DNA.	Nature,	2014.	506(7488):	p.	391-5.	
434.	 Hu,	L.,	et	al.,	Structural	insight	into	substrate	preference	for	TET-mediated	oxidation.	Nature,	
2015.	527(7576):	p.	118-22.	
435.	 Allen,	M.D.,	et	al.,	Solution	structure	of	the	nonmethyl-CpG-binding	CXXC	domain	of	the	
leukaemia-associated	MLL	histone	methyltransferase.	EMBO	J,	2006.	25(19):	p.	4503-12.	
436.	 Lee,	J.H.,	K.S.	Voo,	and	D.G.	Skalnik,	Identification	and	characterization	of	the	DNA	binding	
domain	of	CpG-binding	protein.	J	Biol	Chem,	2001.	276(48):	p.	44669-76.	
																																																																																																																																																																													REFERENCES		
	____________________________________________________________________________________________________________________	149	
437.	 Hu,	L.,	et	al.,	Crystal	structure	of	TET2-DNA	complex:	insight	into	TET-mediated	5mC	
oxidation.	Cell,	2013.	155(7):	p.	1545-55.	
438.	 Iqbal,	K.,	et	al.,	Reprogramming	of	the	paternal	genome	upon	fertilization	involves	genome-
wide	oxidation	of	5-methylcytosine.	Proc	Natl	Acad	Sci	U	S	A,	2011.	108(9):	p.	3642-7.	
439.	 Wossidlo,	M.,	et	al.,	5-Hydroxymethylcytosine	in	the	mammalian	zygote	is	linked	with	
epigenetic	reprogramming.	Nat	Commun,	2011.	2:	p.	241.	
440.	 Williams,	K.,	et	al.,	TET1	and	hydroxymethylcytosine	in	transcription	and	DNA	methylation	
fidelity.	Nature,	2011.	473(7347):	p.	343-8.	
441.	 Pastor,	W.A.,	et	al.,	Genome-wide	mapping	of	5-hydroxymethylcytosine	in	embryonic	stem	
cells.	Nature,	2011.	473(7347):	p.	394-7.	
442.	 Dawlaty,	M.M.,	et	al.,	Tet1	is	dispensable	for	maintaining	pluripotency	and	its	loss	is	
compatible	with	embryonic	and	postnatal	development.	Cell	Stem	Cell,	2011.	9(2):	p.	166-75.	
443.	 Zhao,	Z.,	et	al.,	Combined	Loss	of	Tet1	and	Tet2	Promotes	B	Cell,	but	Not	Myeloid	
Malignancies,	in	Mice.	Cell	Rep,	2015.	13(8):	p.	1692-704.	
444.	 Hackett,	J.A.,	et	al.,	Germline	DNA	demethylation	dynamics	and	imprint	erasure	through	5-
hydroxymethylcytosine.	Science,	2013.	339(6118):	p.	448-52.	
445.	 Vincent,	J.J.,	et	al.,	Stage-specific	roles	for	tet1	and	tet2	in	DNA	demethylation	in	primordial	
germ	cells.	Cell	Stem	Cell,	2013.	12(4):	p.	470-8.	
446.	 Ko,	M.,	et	al.,	Impaired	hydroxylation	of	5-methylcytosine	in	myeloid	cancers	with	mutant	
TET2.	Nature,	2010.	468(7325):	p.	839-43.	
447.	 Langemeijer,	S.M.,	et	al.,	Acquired	mutations	in	TET2	are	common	in	myelodysplastic	
syndromes.	Nat	Genet,	2009.	41(7):	p.	838-42.	
448.	 Smith,	A.E.,	et	al.,	Next-generation	sequencing	of	the	TET2	gene	in	355	MDS	and	CMML	
patients	reveals	low-abundance	mutant	clones	with	early	origins,	but	indicates	no	definite	
prognostic	value.	Blood,	2010.	116(19):	p.	3923-32.	
449.	 Li,	Z.,	et	al.,	Deletion	of	Tet2	in	mice	leads	to	dysregulated	hematopoietic	stem	cells	and	
subsequent	development	of	myeloid	malignancies.	Blood,	2011.	118(17):	p.	4509-18.	
450.	 Moran-Crusio,	K.,	et	al.,	Tet2	loss	leads	to	increased	hematopoietic	stem	cell	self-renewal	and	
myeloid	transformation.	Cancer	Cell,	2011.	20(1):	p.	11-24.	
451.	 Ito,	S.,	et	al.,	Role	of	Tet	proteins	in	5mC	to	5hmC	conversion,	ES-cell	self-renewal	and	inner	
cell	mass	specification.	Nature,	2010.	466(7310):	p.	1129-33.	
452.	 Gu,	T.P.,	et	al.,	The	role	of	Tet3	DNA	dioxygenase	in	epigenetic	reprogramming	by	oocytes.	
Nature,	2011.	477(7366):	p.	606-10.	
453.	 Amouroux,	R.,	et	al.,	De	novo	DNA	methylation	drives	5hmC	accumulation	in	mouse	zygotes.	
Nat	Cell	Biol,	2016.	18(2):	p.	225-33.	
454.	 Inoue,	A.,	et	al.,	Generation	and	replication-dependent	dilution	of	5fC	and	5caC	during	mouse	
preimplantation	development.	Cell	Res,	2011.	21(12):	p.	1670-6.	
455.	 Inoue,	A.	and	Y.	Zhang,	Replication-dependent	loss	of	5-hydroxymethylcytosine	in	mouse	
preimplantation	embryos.	Science,	2011.	334(6053):	p.	194.	
456.	 Valinluck,	V.	and	L.C.	Sowers,	Endogenous	cytosine	damage	products	alter	the	site	selectivity	
of	human	DNA	maintenance	methyltransferase	DNMT1.	Cancer	Res,	2007.	67(3):	p.	946-50.	
457.	 Hashimoto,	H.,	et	al.,	Recognition	and	potential	mechanisms	for	replication	and	erasure	of	
cytosine	hydroxymethylation.	Nucleic	Acids	Res,	2012.	40(11):	p.	4841-9.	
458.	 Chen,	D.,	et	al.,	T:G	mismatch-specific	thymine-DNA	glycosylase	potentiates	transcription	of	
estrogen-regulated	genes	through	direct	interaction	with	estrogen	receptor	alpha.	J	Biol	
Chem,	2003.	278(40):	p.	38586-92.	
459.	 Jost,	J.P.,	S.	Thiry,	and	M.	Siegmann,	Estradiol	receptor	potentiates,	in	vitro,	the	activity	of	5-
methylcytosine	DNA	glycosylase.	FEBS	Lett,	2002.	527(1-3):	p.	63-6.	
460.	 Zhu,	B.,	et	al.,	Overexpression	of	5-methylcytosine	DNA	glycosylase	in	human	embryonic	
kidney	cells	EcR293	demethylates	the	promoter	of	a	hormone-regulated	reporter	gene.	Proc	
Natl	Acad	Sci	U	S	A,	2001.	98(9):	p.	5031-6.	
																																																																																																																																																																													REFERENCES		
	____________________________________________________________________________________________________________________	150	
461.	 Tini,	M.,	et	al.,	Association	of	CBP/p300	acetylase	and	thymine	DNA	glycosylase	links	DNA	
repair	and	transcription.	Mol	Cell,	2002.	9(2):	p.	265-77.	
462.	 Tanaka,	Y.,	et	al.,	Extensive	brain	hemorrhage	and	embryonic	lethality	in	a	mouse	null	mutant	
of	CREB-binding	protein.	Mech	Dev,	2000.	95(1-2):	p.	133-45.	
463.	 Yao,	T.P.,	et	al.,	Gene	dosage-dependent	embryonic	development	and	proliferation	defects	in	
mice	lacking	the	transcriptional	integrator	p300.	Cell,	1998.	93(3):	p.	361-72.	
464.	 Jost,	J.P.,	et	al.,	5-Methylcytosine	DNA	glycosylase	participates	in	the	genome-wide	loss	of	
DNA	methylation	occurring	during	mouse	myoblast	differentiation.	Nucleic	Acids	Res,	2001.	
29(21):	p.	4452-61.	
465.	 Hu,	X.V.,	et	al.,	Identification	of	RING	finger	protein	4	(RNF4)	as	a	modulator	of	DNA	
demethylation	through	a	functional	genomics	screen.	Proc	Natl	Acad	Sci	U	S	A,	2010.	107(34):	
p.	15087-92.	
466.	 Wang,	Y.,	RING	finger	protein	4	(RNF4)	derepresses	gene	expression	from	DNA	methylation.	J	
Biol	Chem,	2014.	289(49):	p.	33808-13.	
467.	 Xu,	J.,	et	al.,	Pioneer	factor	interactions	and	unmethylated	CpG	dinucleotides	mark	silent	
tissue-specific	enhancers	in	embryonic	stem	cells.	Proc	Natl	Acad	Sci	U	S	A,	2007.	104(30):	p.	
12377-82.	
468.	 Thomassin,	H.,	et	al.,	Glucocorticoid-induced	DNA	demethylation	and	gene	memory	during	
development.	EMBO	J,	2001.	20(8):	p.	1974-83.	
469.	 Barreto,	G.,	et	al.,	Gadd45a	promotes	epigenetic	gene	activation	by	repair-mediated	DNA	
demethylation.	Nature,	2007.	445(7128):	p.	671-5.	
470.	 Jin,	S.G.,	C.	Guo,	and	G.P.	Pfeifer,	GADD45A	does	not	promote	DNA	demethylation.	PLoS	
Genet,	2008.	4(3):	p.	e1000013.	
471.	 Shen,	L.,	et	al.,	Genome-wide	Analysis	Reveals	TET-	and	TDG-Dependent	5-Methylcytosine	
Oxidation	Dynamics.	Cell,	2013.	153(3):	p.	692-706.	
472.	 Song,	C.X.,	et	al.,	Genome-wide	Profiling	of	5-Formylcytosine	Reveals	Its	Roles	in	Epigenetic	
Priming.	Cell,	2013.	153(3):	p.	678-91.	
473.	 Kangaspeska,	S.,	et	al.,	Transient	cyclical	methylation	of	promoter	DNA.	Nature,	2008.	
452(7183):	p.	112-5.	
474.	 Metivier,	R.,	et	al.,	Cyclical	DNA	methylation	of	a	transcriptionally	active	promoter.	Nature,	
2008.	452(7183):	p.	45-50.	
475.	 Di	Croce,	L.,	et	al.,	Methyltransferase	recruitment	and	DNA	hypermethylation	of	target	
promoters	by	an	oncogenic	transcription	factor.	Science,	2002.	295(5557):	p.	1079-82.	
476.	 Yi,	Y.W.,	et	al.,	Gadd45	family	proteins	are	coactivators	of	nuclear	hormone	receptors.	
Biochem	Biophys	Res	Commun,	2000.	272(1):	p.	193-8.	
477.	 Berg,	J.M.,	DNA	binding	specificity	of	steroid	receptors.	Cell,	1989.	57(7):	p.	1065-8.	
478.	 Klug,	A.	and	J.W.	Schwabe,	Protein	motifs	5.	Zinc	fingers.	FASEB	J,	1995.	9(8):	p.	597-604.	
479.	 Beato,	M.,	Transcriptional	control	by	nuclear	receptors.	FASEB	J,	1991.	5(7):	p.	2044-51.	
480.	 Perlmann,	T.,	et	al.,	Determinants	for	selective	RAR	and	TR	recognition	of	direct	repeat	HREs.	
Genes	Dev,	1993.	7(7B):	p.	1411-22.	
481.	 Mangelsdorf,	D.J.,	et	al.,	The	nuclear	receptor	superfamily:	the	second	decade.	Cell,	1995.	
83(6):	p.	835-9.	
482.	 Wurtz,	J.M.,	et	al.,	A	canonical	structure	for	the	ligand-binding	domain	of	nuclear	receptors.	
Nat	Struct	Biol,	1996.	3(1):	p.	87-94.	
483.	 Warnmark,	A.,	et	al.,	Activation	functions	1	and	2	of	nuclear	receptors:	molecular	strategies	
for	transcriptional	activation.	Mol	Endocrinol,	2003.	17(10):	p.	1901-9.	
484.	 Pratt,	W.B.	and	D.O.	Toft,	Steroid	receptor	interactions	with	heat	shock	protein	and	
immunophilin	chaperones.	Endocr	Rev,	1997.	18(3):	p.	306-60.	
485.	 Xu,	J.	and	Q.	Li,	Review	of	the	in	vivo	functions	of	the	p160	steroid	receptor	coactivator	family.	
Mol	Endocrinol,	2003.	17(9):	p.	1681-92.	
																																																																																																																																																																													REFERENCES		
	____________________________________________________________________________________________________________________	151	
486.	 Grimaldi,	M.,	et	al.,	Reporter	Cell	Lines	for	the	Characterization	of	the	Interactions	between	
Human	Nuclear	Receptors	and	Endocrine	Disruptors.	Front	Endocrinol	(Lausanne),	2015.	6:	p.	
62.	
487.	 Green,	S.,	et	al.,	Human	oestrogen	receptor	cDNA:	sequence,	expression	and	homology	to	v-
erb-A.	Nature,	1986.	320(6058):	p.	134-9.	
488.	 Mosselman,	S.,	J.	Polman,	and	R.	Dijkema,	ER	beta:	identification	and	characterization	of	a	
novel	human	estrogen	receptor.	FEBS	Lett,	1996.	392(1):	p.	49-53.	
489.	 Klein-Hitpass,	L.,	et	al.,	A	13	bp	palindrome	is	a	functional	estrogen	responsive	element	and	
interacts	specifically	with	estrogen	receptor.	Nucleic	Acids	Res,	1988.	16(2):	p.	647-63.	
490.	 Enmark,	E.,	et	al.,	Human	estrogen	receptor	beta-gene	structure,	chromosomal	localization,	
and	expression	pattern.	J	Clin	Endocrinol	Metab,	1997.	82(12):	p.	4258-65.	
491.	 Kuiper,	G.G.,	et	al.,	Comparison	of	the	ligand	binding	specificity	and	transcript	tissue	
distribution	of	estrogen	receptors	alpha	and	beta.	Endocrinology,	1997.	138(3):	p.	863-70.	
492.	 Katzenellenbogen,	B.S.	and	J.A.	Katzenellenbogen,	Estrogen	receptor	transcription	and	
transactivation:	Estrogen	receptor	alpha	and	estrogen	receptor	beta:	regulation	by	selective	
estrogen	receptor	modulators	and	importance	in	breast	cancer.	Breast	Cancer	Res,	2000.	
2(5):	p.	335-44.	
493.	 Barkhem,	T.,	et	al.,	Differential	response	of	estrogen	receptor	alpha	and	estrogen	receptor	
beta	to	partial	estrogen	agonists/antagonists.	Mol	Pharmacol,	1998.	54(1):	p.	105-12.	
494.	 Kuiper,	G.G.,	et	al.,	Cloning	of	a	novel	receptor	expressed	in	rat	prostate	and	ovary.	Proc	Natl	
Acad	Sci	U	S	A,	1996.	93(12):	p.	5925-30.	
495.	 Tremblay,	G.B.,	et	al.,	Cloning,	chromosomal	localization,	and	functional	analysis	of	the	
murine	estrogen	receptor	beta.	Mol	Endocrinol,	1997.	11(3):	p.	353-65.	
496.	 Pfaffl,	M.W.,	et	al.,	Tissue-specific	expression	pattern	of	estrogen	receptors	(ER):	
quantification	of	ER	alpha	and	ER	beta	mRNA	with	real-time	RT-PCR.	APMIS,	2001.	109(5):	p.	
345-55.	
497.	 Klein-Hitpass,	L.,	et	al.,	Specific	binding	of	estrogen	receptor	to	the	estrogen	response	
element.	Mol	Cell	Biol,	1989.	9(1):	p.	43-9.	
498.	 Joshi,	S.R.,	R.B.	Ghattamaneni,	and	W.M.	Scovell,	Expanding	the	paradigm	for	estrogen	
receptor	binding	and	transcriptional	activation.	Mol	Endocrinol,	2011.	25(6):	p.	980-94.	
499.	 Fullwood,	M.J.,	et	al.,	An	oestrogen-receptor-alpha-bound	human	chromatin	interactome.	
Nature,	2009.	462(7269):	p.	58-64.	
500.	 Kraus,	W.L.	and	J.T.	Kadonaga,	p300	and	estrogen	receptor	cooperatively	activate	
transcription	via	differential	enhancement	of	initiation	and	reinitiation.	Genes	Dev,	1998.	
12(3):	p.	331-42.	
501.	 Duffy,	M.J.,	Estrogen	receptors:	role	in	breast	cancer.	Crit	Rev	Clin	Lab	Sci,	2006.	43(4):	p.	
325-47.	
502.	 Ali,	S.	and	R.C.	Coombes,	Estrogen	receptor	alpha	in	human	breast	cancer:	occurrence	and	
significance.	J	Mammary	Gland	Biol	Neoplasia,	2000.	5(3):	p.	271-81.	
503.	 Wilks,	A.F.,	et	al.,	Estrogen	induces	a	demethylation	at	the	5'	end	region	of	the	chicken	
vitellogenin	gene.	Proc	Natl	Acad	Sci	U	S	A,	1982.	79(14):	p.	4252-5.	
504.	 Meijlink,	F.C.,	et	al.,	Methylation	of	the	chicken	vitellogenin	gene:	influence	of	estradiol	
administration.	Nucleic	Acids	Res,	1983.	11(5):	p.	1361-73.	
505.	 Burch,	J.B.	and	H.	Weintraub,	Temporal	order	of	chromatin	structural	changes	associated	
with	activation	of	the	major	chicken	vitellogenin	gene.	Cell,	1983.	33(1):	p.	65-76.	
506.	 Wilks,	A.,	M.	Seldran,	and	J.P.	Jost,	An	estrogen-dependent	demethylation	at	the	5'	end	of	the	
chicken	vitellogenin	gene	is	independent	of	DNA	synthesis.	Nucleic	Acids	Res,	1984.	12(2):	p.	
1163-77.	
507.	 Maxam,	A.M.	and	W.	Gilbert,	A	new	method	for	sequencing	DNA.	Proc	Natl	Acad	Sci	U	S	A,	
1977.	74(2):	p.	560-4.	
508.	 Church,	G.M.	and	W.	Gilbert,	Genomic	sequencing.	Proc	Natl	Acad	Sci	U	S	A,	1984.	81(7):	p.	
1991-5.	
																																																																																																																																																																													REFERENCES		
	____________________________________________________________________________________________________________________	152	
509.	 Feavers,	I.M.,	et	al.,	Interaction	of	two	nonhistone	proteins	with	the	estradiol	response	
element	of	the	avian	vitellogenin	gene	modulates	the	binding	of	estradiol-receptor	complex.	
Proc	Natl	Acad	Sci	U	S	A,	1987.	84(21):	p.	7453-7.	
510.	 Burch,	J.B.,	et	al.,	Two	functional	estrogen	response	elements	are	located	upstream	of	the	
major	chicken	vitellogenin	gene.	Mol	Cell	Biol,	1988.	8(3):	p.	1123-31.	
511.	 Hoeijmakers,	J.H.,	DNA	damage,	aging,	and	cancer.	N	Engl	J	Med,	2009.	361(15):	p.	1475-85.	
512.	 O'Driscoll,	M.,	Diseases	associated	with	defective	responses	to	DNA	damage.	Cold	Spring	
Harb	Perspect	Biol,	2012.	4(12).	
513.	 Pekarik,	V.,	et	al.,	Screening	for	gene	function	in	chicken	embryo	using	RNAi	and	
electroporation.	Nature	biotechnology,	2003.	21(1):	p.	93-6.	
514.	 Baerenfaller,	K.,	F.	Fischer,	and	J.	Jiricny,	Characterization	of	the	"mismatch	repairosome"	and	
its	role	in	the	processing	of	modified	nucleosides	in	vitro.	Methods	in	enzymology,	2006.	408:	
p.	285-303.	
515.	 Baeriswyl,	T.,	O.	Mauti,	and	E.T.	Stoeckli,	Temporal	control	of	gene	silencing	by	in	ovo	
electroporation.	Methods	Mol	Biol,	2008.	442:	p.	231-44.	
516.	 Baeriswyl,	T.	and	E.T.	Stoeckli,	In	ovo	RNAi	opens	new	possibilities	for	temporal	and	spatial	
control	of	gene	silencing	during	development	of	the	vertebrate	nervous	system.	J	RNAi	Gene	
Silencing,	2006.	2(1):	p.	126-35.	
517.	 Bregenhorn,	S.,	et	al.,	Non-canonical	uracil	processing	in	DNA	gives	rise	to	double-strand	
breaks	and	deletions:	relevance	to	class	switch	recombination.	Nucleic	Acids	Res,	2016.	44(6):	
p.	2691-705.	
518.	 Luby,	T.M.,	et	al.,	The	mu	switch	region	tandem	repeats	are	important,	but	not	required,	for	
antibody	class	switch	recombination.	The	Journal	of	experimental	medicine,	2001.	193(2):	p.	
159-68.	
519.	 Min,	I.M.,	et	al.,	The	Smu	tandem	repeat	region	is	critical	for	Ig	isotype	switching	in	the	
absence	of	Msh2.	Immunity,	2003.	19(4):	p.	515-24.	
520.	 Wu,	X.	and	J.	Stavnezer,	DNA	polymerase	beta	is	able	to	repair	breaks	in	switch	regions	and	
plays	an	inhibitory	role	during	immunoglobulin	class	switch	recombination.	The	Journal	of	
experimental	medicine,	2007.	204(7):	p.	1677-89.	
521.	 Phan,	R.T.	and	R.	Dalla-Favera,	The	BCL6	proto-oncogene	suppresses	p53	expression	in	
germinal-centre	B	cells.	Nature,	2004.	432(7017):	p.	635-9.	
522.	 Kuppers,	R.,	Mechanisms	of	B-cell	lymphoma	pathogenesis.	Nature	reviews.	Cancer,	2005.	
5(4):	p.	251-62.	
523.	 Jankovic,	M.,	A.	Nussenzweig,	and	M.C.	Nussenzweig,	Antigen	receptor	diversification	and	
chromosome	translocations.	Nature	immunology,	2007.	8(8):	p.	801-8.	
524.	 Baron,	B.W.,	et	al.,	Identification	of	the	gene	associated	with	the	recurring	chromosomal	
translocations	t(3;14)(q27;q32)	and	t(3;22)(q27;q11)	in	B-cell	lymphomas.	Proceedings	of	the	
National	Academy	of	Sciences	of	the	United	States	of	America,	1993.	90(11):	p.	5262-6.	
525.	 Iida,	S.,	et	al.,	The	t(9;14)(p13;q32)	chromosomal	translocation	associated	with	
lymphoplasmacytoid	lymphoma	involves	the	PAX-5	gene.	Blood,	1996.	88(11):	p.	4110-7.	
526.	 Neri,	A.,	et	al.,	B	cell	lymphoma-associated	chromosomal	translocation	involves	candidate	
oncogene	lyt-10,	homologous	to	NF-kappa	B	p50.	Cell,	1991.	67(6):	p.	1075-87.	
527.	 Ye,	B.H.,	et	al.,	Cloning	of	bcl-6,	the	locus	involved	in	chromosome	translocations	affecting	
band	3q27	in	B-cell	lymphoma.	Cancer	research,	1993.	53(12):	p.	2732-5.	
528.	 Nussenzweig,	A.	and	M.C.	Nussenzweig,	Origin	of	chromosomal	translocations	in	lymphoid	
cancer.	Cell,	2010.	141(1):	p.	27-38.	
529.	 Kuppers,	R.	and	R.	Dalla-Favera,	Mechanisms	of	chromosomal	translocations	in	B	cell	
lymphomas.	Oncogene,	2001.	20(40):	p.	5580-94.	
530.	 Ruiz,	J.F.,	B.	Gomez-Gonzalez,	and	A.	Aguilera,	AID	induces	double-strand	breaks	at	
immunoglobulin	switch	regions	and	c-MYC	causing	chromosomal	translocations	in	yeast	THO	
mutants.	PLoS	genetics,	2011.	7(2):	p.	e1002009.	
																																																																																																																																																																													REFERENCES		
	____________________________________________________________________________________________________________________	153	
531.	 Difilippantonio,	M.J.,	et	al.,	DNA	repair	protein	Ku80	suppresses	chromosomal	aberrations	
and	malignant	transformation.	Nature,	2000.	404(6777):	p.	510-4.	
532.	 Gao,	Y.,	et	al.,	Interplay	of	p53	and	DNA-repair	protein	XRCC4	in	tumorigenesis,	genomic	
stability	and	development.	Nature,	2000.	404(6780):	p.	897-900.	
533.	 Jones,	S.,	An	overview	of	the	basic	helix-loop-helix	proteins.	Genome	Biol,	2004.	5(6):	p.	226.	
534.	 Fairman,	R.,	et	al.,	Multiple	oligomeric	states	regulate	the	DNA	binding	of	helix-loop-helix	
peptides.	Proc	Natl	Acad	Sci	U	S	A,	1993.	90(22):	p.	10429-33.	
535.	 Prendergast,	G.C.,	D.	Lawe,	and	E.B.	Ziff,	Association	of	Myn,	the	murine	homolog	of	max,	
with	c-Myc	stimulates	methylation-sensitive	DNA	binding	and	ras	cotransformation.	Cell,	
1991.	65(3):	p.	395-407.	
536.	 Prendergast,	G.C.	and	E.B.	Ziff,	Methylation-sensitive	sequence-specific	DNA	binding	by	the	c-
Myc	basic	region.	Science,	1991.	251(4990):	p.	186-9.	
537.	 Xu,	L.,	et	al.,	Pyrene-based	quantitative	detection	of	the	5-formylcytosine	loci	symmetry	in	the	
CpG	duplex	content	during	TET-dependent	demethylation.	Angew	Chem	Int	Ed	Engl,	2014.	
53(42):	p.	11223-7.	
538.	 Crawford,	D.J.,	et	al.,	Tet2	Catalyzes	Stepwise	5-Methylcytosine	Oxidation	by	an	Iterative	and	
de	novo	Mechanism.	J	Am	Chem	Soc,	2016.	138(3):	p.	730-3.	
539.	 Tamanaha,	E.,	et	al.,	Distributive	Processing	by	the	Iron(II)/alpha-Ketoglutarate-Dependent	
Catalytic	Domains	of	the	TET	Enzymes	Is	Consistent	with	Epigenetic	Roles	for	Oxidized	5-
Methylcytosine	Bases.	J	Am	Chem	Soc,	2016.	138(30):	p.	9345-8.	
540.	 Munzel,	M.,	et	al.,	Quantification	of	the	sixth	DNA	base	hydroxymethylcytosine	in	the	brain.	
Angew	Chem	Int	Ed	Engl,	2010.	49(31):	p.	5375-7.	
541.	 Pfaffeneder,	T.,	et	al.,	The	discovery	of	5-formylcytosine	in	embryonic	stem	cell	DNA.	Angew	
Chem	Int	Ed	Engl,	2011.	50(31):	p.	7008-12.	
542.	 Raiber,	E.A.,	et	al.,	Genome-wide	distribution	of	5-formylcytosine	in	embryonic	stem	cells	is	
associated	with	transcription	and	depends	on	thymine	DNA	glycosylase.	Genome	Biol,	2012.	
13(8):	p.	R69.	
543.	 Quivoron,	C.,	et	al.,	TET2	inactivation	results	in	pleiotropic	hematopoietic	abnormalities	in	
mouse	and	is	a	recurrent	event	during	human	lymphomagenesis.	Cancer	Cell,	2011.	20(1):	p.	
25-38.	
544.	 Figueroa,	M.E.,	et	al.,	Leukemic	IDH1	and	IDH2	mutations	result	in	a	hypermethylation	
phenotype,	disrupt	TET2	function,	and	impair	hematopoietic	differentiation.	Cancer	Cell,	
2010.	18(6):	p.	553-67.	
																																																																																																																																																																													ACKNOWLEDGEMENTS		
	____________________________________________________________________________________________________________________	154	
	
ACKNOWLEDGEMENTS	
First,	 I	want	to	thank	Joe	Jiricny	 for	giving	me	the	chance	to	do	my	PhD	in	his	 lab	and	for	being	an	
extremely	 supporting	 and	motivating	 boss.	His	 passion	 for	 science	 and	 never	 ending	 curiosity	was	
highly	contagious	during	my	whole	PhD.	WIth	great	devotion,	he	made	his	 lab	and	the	whole	IMCR	
an	inspiring	place	to	work	with	an	exceptional	atmosphere	of	helpfulness	and	care.	
Thank	you	also	 to	my	committee	members	Ueli,	Primo	and	 Jörn	 for	helpful	discussions	and	advice	
during	the	meetings	and	for	always	being	very	encouraging.	
Many	thanks	to	Andrea,	Weihong	and	Giancarlo	from	the	FGCZ	for	their	continuous	support	with	the	
sequencing	and	data	analysis.	
A	warm	thank	you	goes	to	my	fellow	sufferers	Julia,	Tine,	Martin,	Cosimo	and	Maryna,	who	made	
this	time	so	memorable,	in	the	lab,	as	well	as	outside	of	the	lab.	They	were	always	there	for	mental	
support	or	some	distraction.		
Then,	 I	 want	 to	 thank	 the	 present	members	 of	 the	 lab	 at	 ETH;	 Sara,	 Saho,	 Shun	 and	most	 of	 all	
Rachel,	 who	 is	 a	 invaluable	 help	 in	 the	 methylation	 project	 and	 manages	 the	 lab	 with	 great	
commitment.		
Many	 thanks	 also	 to	 the	 past	members	 of	 the	 Jiricny	 group;	Maite,	 Steffi,	Anja,	 Svenja,	 Simone,	
Mariela	and	Antonio,	for	being	good	friends	and	a	great	support	in	the	lab.	
I	am	very	grateful	to	the	people	at	the	IMCR	for	being	very	helpful	and	friendly	and	always	open	for	
little	chats	in	the	hallway.	Special	thanks	go	to	Farah	and	Odete	for	caring	so	much	for	the	institute	
and	making	our	lives	so	easy.	
My	biggest	thank	goes	to	my	family	and	friends.	They	support	me	in	whatever	I	do,	without	knowing	
what	I	actually	do.	They	were	always	there	to	distract	me	when	things	were	not	going	well	in	the	lab	
and	reminded	me	of	the	important	things	in	life.	
																																																																																																																																																																																																													.		
	____________________________________________________________________________________________________________________	155	
																																																																																																																																																																															CURRICULUM	VITAE.		
	____________________________________________________________________________________________________________________	156	
	
CURRICULUM	VITAE
	
	
	
	
L IA 	KALLENBERGER	
	Steinstrasse	23	CH-8003,	Zurich	+41	79	258	82	89	lia@kallenberger.ch	
	Date	of	birth	 23.08.1989	Nationality	 Swiss,	Amriswil	TG	Marital	status	 unmarried	
 
 
 
EDUCATION 	
		
University	of	Zurich	 	 	 01/2014	-	05/2017	
PhD	in	cancer	biology	
Fasttrack	program	of	the	University	of	Zurich	
Cancer	Biology	PhD	Program	of	the	Life	Science	Zurich	Graduate	School	
(UZH	&	ETHZ)	
	
Thesis:	“Interplay	of	DNA	metabolic	pathways	involved	in	the	
regulation	of	gene	expression	and	genomic	rearrangements”	
	
University	of	Zurich	 	 08/2012	-	12/2013	
Master	in	Cell	-and	Molecular	Biology	
Fasttrack	Program	of	the	University	of	Zurich	
	
Thesis:	"Elucidating	the	role	of	mismatch	repair	in	the	induction	of	DNA	
double	strand	breaks	during	class	switch	recombination"	
	
University	of	Zurich	 	 09/2009	-	07/2012	
Bachelor	in	Biology	
	
Kantonsschule	Wiedikon	 08/2002	-	08/2008	
Matura,	Modern	languages	
	
RELEVANT 	WORK	EXPERIENCE 	
	
Zweifel	Pomy-Chips	AG	 	 	 04/2009	–	12/2013	
Internship	in	quality	control	
− Hourly	quality	control	of	the	chips	in	production	
− Precise	measurements	and	analysis	of	the	parameters	
	
University	Hospital	Zurich	 	 	 10/2008	–03/2009	
Internship	in	the	molecular	oncology	department	
− Investigation	of	biomarkers	for	the	differentiation	of	
mesothelioma	and	Non-small-cell	lung	cancer	
	
University	Hospital	Bern	 	 	 09/2008	
Internship	in	the	research	lab	of	the	intensive	care	unit	
− Introduction	into	cell	culture	work	and	molecular	biology	techniques	
	
																																																																																																																																																																															CURRICULUM	VITAE.		
	____________________________________________________________________________________________________________________	157	
	
CERTIF ICATES 	
	
Good	Clinical	Practice	course	 2015	
Clinical	Trials	Center	CTC	
Center	for	Clinical	Research	ZKF	 	
	
Animal	course	 2014	
Introductory	Course	in	Laboratory	Animal	Science	
Aquatic	animals	
Vetsuisse-faculty	
	
University	of	Cambridge	 2008	
Certificate	in	Advanced	English	
	
	
SELECTED 	CONFERENCES 	
	
Swiss	Meeting	on	Genome	Stability	&	Chromatin	Dynamics,	
Switzerland	 	 05/2014	
Poster	presentation:	"Investigation	of	the	molecular	mechanisms	of	5-
methylcytosine	metabolism"	
	
Student	Retreat,	Cancer	PhD	Program,	Switzerland	 02/2014	
Poster	presentation:	"Investigation	of	the	molecular	mechanisms	of	5-
methylcytosine	metabolism"	
	
Gordon	Conference	on	Mutagensis,	Girona	 06/2016	
Poster	presentation:	"Unravelling	the	mechanism	of	AID-induced	
translocations	by	analysis	of	the	interplay	between	
mismatch	repair	and	base	excision	repair"	
	 	 	
Epigenetics	and	Chromatin,	Cold	Spring	Harbor	 09/2016	
Poster	presentation:	"Investigation	of	the	role	of	TET-induced	cytosine	
modification	on	transcription	of	an	estrogen-responsive	
gene"	
	
PUBLICATIONS 	
	
	
"Mismatch	repair-dependent	metabolism	of	06-methylguanine-containing	DNA	in	Xenopus	laevis	egg	
extracts."	Olivera	Harris	M,	Kallenberger	L,	Artola	Boran	M.	Enoiu	M,	Constanzo	V,	Jiricny	J.	DNA	Repair	2015	
"Non-canonical	uracil	processing	in	DNA	gives	rise	to	double-strand	breaks	and	deletions:	relevance	to	class	
switch	recombination."	Bregenhorn	S,	Kallenberger	L,	Artola	Boran	M,	Peña-Diaz	J,	Jiricny	J.	NAR	2016	
"A	methylation-responsive	E-box	binding	protein	controls	estrogen-dependent	transcription	of	the	chicken	
vitellogenin	gene."	Kallenberger	L,	Erb	R,	Jiricny	J.	Manuscript	in	preparation.	
	
 
LANGUAGES 	
	
German:	mother	tongue	
English:	very	good	knowledge,	oral	and	written	
French:	good	knowledge,	oral	and	written	
Spanish:	good	knowledge,	oral	and	written	
	 	
PERSONAL 	 INTERESTS 		
Climbing,	snowboard,	hiking,	traveling,	reading,	cooking	
GCP	
CAE	
	
LTK	Module	20	
																																																																																																																																																																																																												..		
	____________________________________________________________________________________________________________________	158	
APPENDIX	
	
	
	
I	contributed	to	this	work	by	performing	MMR	assays	and	Western	Blots.	
DNA Repair 28  (2015) 1–7
Contents lists available at ScienceDirect
DNA  Repair
j ourna l ho  me  pa ge: www.elsev ier .com/ locate /dnarepai r
Brief  Communication
Mismatch  repair-dependent  metabolism  of
O6-methylguanine-containing  DNA  in  Xenopus  laevis  egg  extracts
Maite  Olivera  Harrisa,b, Lia  Kallenbergera, Mariela  Artola  Borána, Milica  Enoiua,
Vincenzo  Costanzoc, Josef  Jiricnya,b,∗
a Institute of  Molecular Cancer Research, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland
b Department of Biology, Swiss Federal Institute of Technology (ETH), Winterthurerstrasse 190, CH-8057 Zurich, Switzerland
c IFOM-European Institute of Oncology Campus, Via Adamello 16, 20139 Milano, Italy
a  r  t  i c  l  e  i  n f o
Article history:
Received 29  April 2014
Received in revised form 15 January 2015
Accepted 20 January 2015
Available online 4 February 2015
Keywords:
DNA damage signaling
DNA replication
O6-methylguanine
Mismatch repair
SN1-type alkylating agents
Xenopus laevis egg extracts
a  b  s  t  r a  c t
The cytotoxicity  of SN1-type alkylating  agents such  as  N-methyl-N′-nitrosourea  (MNU),  N-methyl-N′-
nitro-N-nitrosoguanidine  (MNNG),  or  the  cancer chemotherapeutics  temozolomide,  dacarbazine  and
streptozotocin  has  been  ascribed  to the  persistence  of O6-methylguanine  (meG) in genomic  DNA. One
hypothesis  posits  that meG  toxicity is  caused  by  futile  attempts of the  mismatch  repair (MMR)  system to
process meG/C or meG/T  mispairs arising during  replication,  while  an  alternative proposal  suggests that
the  latter  lesions  activate  DNA  damage  signaling,  cell  cycle  arrest and  apoptosis  directly. Attempts  to
elucidate  the  molecular  mechanism  of meG-induced cell killing  in  vivo  have  been hampered  by  the  fact
that  the  above  reagents  induce several types of modiﬁcations  in genomic  DNA,  which  are  processed  by
different repair pathways.  In  contrast,  deﬁned substrates studied  in vitro  did not undergo  replication.
We set out  to  re-examine  this  phenomenon  in replication-competent  Xenopus  laevis  egg extracts,  using
either phagemid  substrates  containing  a single meG  residue,  or  methylated sperm chromatin.  Our  ﬁndings
provide  further  support  for  the  futile  cycling hypothesis.
©  2015  Elsevier B.V.  All  rights  reserved.
1. Introduction
The postreplicative mismatch repair (MMR)  system improves
replication ﬁdelity by up to three orders of magnitude through
excising nucleotides misincorporated into the nascent strand by
DNA polymerases [1,2]. This task is  carried out predominantly by
the mismatch recognition protein MutS (a heterodimer of MSH2
and MSH6), the endonuclease MutL (MLH1/PMS2 heterodimer)
and EXO1 exonuclease, together with accessory replication factors
PCNA, RPA, RFC, polymerase- and DNA ligase I  [3,4].
In contrast to its key role as an antimutator [5],  MMR can perturb
genomic stability by attempting to  process DNA damage induced
by, for example, SN1-type methylating agents such as N-methyl-
N′-nitrosourea (MNU), N-methyl-N′-nitro-N-nitrosoguanidine
(MNNG) or temozolomide [6,7].  The toxicity of this class of
chemicals, some of which (e.g. temozolomide, dacarbazine,
∗ Corresponding author at: Institute of Molecular Cancer Research, University of
Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland.
Tel.: +41 044 6353450.
E-mail address: jiricny@imcr.uzh.ch (J. Jiricny).
streptozotocin) are used in  the therapy of various types of  cancer,
is linked to  their ability to generate O6-methylguanine (meG) in
DNA. This simple modiﬁcation can be  efﬁciently detoxiﬁed by O6-
methylguanine DNA-methyltransferase (MGMT), which transfers
the methyl group from the guanine onto a cysteine residue in its
active site [8]. Because MGMT  is  inactivated by this transaction,
and because some cells express only low amounts of this protein,
meG can persist in  genomic DNA after treatment with these chem-
icals and cause cytotoxicity. More than three decades ago, Karran
and Marinus showed that meG toxicity in  E. coli was dependent
on functional MMR  [9]. Like MMR-deﬁcient bacteria, mammalian
cells lacking MMR are also highly resistant to  killing by  SN1-type
methylating agents [7,10–12], but the molecular events leading
to cell death have been the subject of extensive discussion. One
hypothesis, referred to  as “futile cycling” [7],  posits that replicating
polymerases will incorporate a  C or a  T  opposite the meG.  As meG/C
and meG/T are not  Watson-Crick base pairs, they will activate MMR.
However, because MMR is directed to the nascent strand, EXO1
will catalyze degradation of the strand containing the mispaired
C or T. As the meG residue will remain in  the template strand,
repair synthesis will regenerate the meG/C or meG/T mispairs that
will trigger further, “futile” rounds of MMR-directed excision and
http://dx.doi.org/10.1016/j.dnarep.2015.01.014
1568-7864/© 2015 Elsevier B.V. All  rights reserved.
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resynthesis, which were suggested to  activate cell cycle arrest
and apoptosis. Support for this hypothesis comes from several
directions; iterative cycles of MMR-dependent excision and repair
synthesis were seen in in vitro assays [13],  and cell cycle arrest
induced by  treatment with SN1-type methylating agents was
shown to require two rounds of replication [14–16].  In an attempt
to  explain the latter ﬁnding, we  suggested that the MMR  machinery
might abandon its futile attempts at repair of the meG/C or meG/T
mispairs and that DNA synthesis might re-initiate downstream.
This would leave single-stranded gaps opposite meG, the collision
of which with replication forks in the subsequent S phase would
give rise to  double-strand breaks that would activate the ATR and
ATM checkpoint machineries and cause a  cell cycle arrest in  the
second G2/M [16].  In our later work, we succeeded in identifying
persistent gaps in  nascent DNA of cells treated with low MNNG
doses [14],  which provided further support for the above pathway.
Although the “futile cycling” hypothesis [7] has met  with broad
acceptance, work from the Hsieh laboratory suggested that MutS
may act as a  damage sensor that recruits and activates ATR directly
[17], and support for this hypothesis was provided by evidence
of interactions between MMR  proteins and the ATR checkpoint
machinery [18,19].  Although this “direct signaling” model fails to
explain why recognition of the meG-containing mismatches should
activate cell cycle arrest only in  the second S phase, there is  no rea-
son why the two scenarios should not co-exist, each addressing a
subset of lesions.
The experimental evidence described above has been obtained
either from in vitro MMR  assays [13,17],  or from cell culture experi-
ments [14–16]. The former system deploys heteroduplex substrates
that do not undergo replication in the human cell extracts, while
the latter is not amenable to manipulation. We therefore decided
to analyze the processing of meG-containing substrates in Xenopus
laevis egg extracts (XEE), an experimental system that permits the
study of DNA damage signaling, DNA replication and DNA repair
either in plasmid substrates or in  chromatin, under conditions that
can be altered at will [20,21]. We  show here that replication of
meG-containing DNA in XEE did indeed give rise to persistent single-
stranded gaps opposite meG. Furthermore, recruitment of MMR
proteins to the meG-containing DNA occurred throughout repli-
cation and persisted thereafter, which is  likely to be indicative
of repeated attempts to  repair the gaps. Importantly, recruitment
of MMR  proteins to alkylation-damaged chromatin did not  coin-
cide with that of the ATR  checkpoint machinery, and we detected
no evidence of checkpoint activation after the single replication
round. Our data thus provide further support for the “futile cycling”
hypothesis.
2. Materials and methods
Detailed information regarding antibodies, primers, DNA sub-
strates, X. laevis egg extract preparation, chromatin isolation and
MSH6 immunodepletion, as well as band-shift-, dot blot- and MMR
assays in  X. laevis extracts (xMMR) can be found in  Supplementary
Information.
2.1. X. laevis egg extracts and chromatin isolation
Lysolecithin-permeabilised X. laevis sperm nuclei (“sperm chro-
matin”) were prepared as described [22]. S  phase extract capable of
performing a  single round of replication was prepared as previously
described [23]. Brieﬂy, eggs were dejellied, activated with calcium
ionophore (Sigma), rinsed with S  buffer (50 mM  Hepes-KOH pH
7.5, 50 mM KCl, 2.5 mM MgCl2 and 250 mM sucrose), transferred to
2 ml  Eppendorf tubes and crushed by  centrifugation for 12 min  at
13′200 rpm. The cytoplasmic layer was removed and, after addition
of CytB (Sigma), cleared by centrifugation for 25 min  at 70′000 rpm
(Beckman TL199 ultracentrifuge, TL55 swing-bucket rotor). The
extract was supplemented with 250 g/l cycloheximide, 25 mM
phosphocreatine and 10 g/ml creatine phosphokinase before use.
Where indicated, sperm chromatin was exposed to  varying
doses of MNU, MNNG or  1%  MMS  (all from Sigma) for 30 min  at
RT.
HSS and NPE were prepared as described previously [24].  To
make NPE, unfractionated egg  extract (crude S  phase extract)
was supplemented with nocodazole (3.3 g/ml), cycloheximide
(50 g/ml), DTT (1 mM),  aprotinin/leupeptin (10 g/ml each) and
cytochalasin B (5 g/ml), and centrifuged at 10′000 rpm for 15 min
in  a Sorvall HB-6 rotor at 4 ◦C. The dark brown layer at the top of
the tube was  removed by aspiration and the extract was decanted
into a  fresh Falcon tube, supplemented with an ATP regeneration
system and demembranated sperm chromatin to a  concentration
of 4000 n/l.  The mixture was  incubated at room temperature for
75–90 min. To collect the nuclei, the reaction was centrifuged for
2 min  at 10,000 rpm at 4 ◦C in a Sorvall HB-6 rotor. The clear ∼4 mm
layer of nuclei was  removed from the top of the tube and trans-
ferred to 5 × 20 mm  ultracentrifuge tubes. It was then centrifuged
for 30 min  at 55,000 rpm in a  Beckmann TL55 rotor. After centrifu-
gation, lipids at the top of the sample were aspirated and the clear
nucleoplasm was  harvested.
2.2. Isolation of nuclear and chromatin fractions
To isolate sperm chromatin, sperm nuclei (4000 n/l)  were
added to S  phase extract for the indicated times. For Western blot-
ting, samples were diluted in ten volumes of EB  buffer (100 mM
KCl, 2.5 mM MgCl2 and 50 mM Hepes-KOH pH 7.5) containing
0.25% Nonidet P-40 and centrifuged through a 30% sucrose layer
at 10,000 rpm for 5 min  at 4 ◦C using a Sorvall HB-6 rotor, washed
twice with 500 l EB buffer and centrifuged at 10′000 rpm for 1 min.
The pellet was  resuspended in Laemmli loading buffer, the proteins
were resolved by either 4–15%, 7.5% or 10% SDS-PAGE and analyzed
by Western blotting with speciﬁc antibodies as indicated. Unless
otherwise indicated, Precision plus protein dual color standard
(Biorad) was used as a  size reference. Nuclei were isolated by the
same procedure, except that the EB buffer contained no detergent.
2.3. DNA replication
Replication of sperm chromatin in  S phase extract (4000 n/l)
was measured by monitoring the incorporation of [32P]dCMP for
120 min  at 23 ◦C as previously described [25].  Treatments are
indicated in the ﬁgure legends. 5 l  aliquots were removed and
combined with 15 l  of STOP mix (6 mM  EDTA, 0.13% phosphoric
acid, 10% Ficoll, 5% SDS, 0.2% bromophenol blue and 80 mM  Tris–HCl
pH 8). Proteinase K  (Roche) was then added to  a  ﬁnal concentra-
tion of 2 g/l  for 1 h at 37 ◦C. The samples were separated on
0.8% agarose/TAE gels, and the dried gels were exposed to  Phos-
phoImager screens. The images were quantitated with ImageQuant
software (GE Healthcare).
For plasmid replication, plasmid DNA pRichi2850t was initially
incubated in  6 l HSS for 30 min  at 23 ◦C, followed by  addition of a
2-fold volume of NPE. DNA replication was assayed by [-32P]dCMP
(32P) incorporation as described [24].  For substrate recovery, 40 l
STOP solution (5% SDS, 80 mM Tris–HCl pH 8 and 5 mg/ml RNase)
were added for 30 min at 37 ◦C. The reaction was then incubated
with Proteinase K (1 mg/ml) overnight at 37 ◦C.  Samples were puri-
ﬁed on MiniElute columns (Qiagen) and subjected to  restriction
digests in  the presence of RNase (0.5 mg/ml, 5prime). The digested
DNA was  cleaned up again and resolved on 1% TAE agarose gels
stained with GelRed.
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Fig. 1.  Replication-dependent and -independent MMR  activity in X. laevis egg extracts. (A) Schematic representation of the phagemid substrate and the fragments generated
by  HindIII/DraI  digestion. The HindIII site lies 12 bp from the SalI site that contains the mismatch (triangle). Nt.BstNBI generates a single nick in the 3197 bp substrate (not
depicted), either 363 nucleotides 5′ from the C, T or meG residue in the top (complementary) strand, or 376 nucleotides 3′ from the mispaired G, C or T in the bottom (viral)
strand. The  MMR  excision/resynthesis machinery is directed to the nicked strand. (B and C) MMR  assays in Patrin-2-pretreated HSS extracts with top- (B) or bottom- (C)
nicked  C/G, T/G, meG/C and meG/T substrates. The phagemids recovered from the reaction were digested with HindIII/DraI, and the restriction fragments were separated on
1%  agarose/TAE gels stained with GelRed. The  dried gels were then autoradiographed (32P).  Bar graphs represent data from three independent experiments, with error bars
showing standard deviation from the mean. (D) As in (B), but the meG/C or meG/T substrate was  incubated with Patrin-2-pretreated HSS extract, either mock- or Msh6-depleted.
The  MMR defect in the Msh6-depleted extracts could be rescued by the addition of recombinant human MutS. Bottom: Western blot showing Msh6 depletion efﬁciency in
the  extract. (E) Kinetic analysis of phagemid replication (supercoiled product, sc) in Patrin-2-pretreated X. laevis extract. The indicated substrates were incubated in HSS for
30  min  to allow the formation of a pre-replication complex, followed by  addition of NPE that initiates replication (see Supplemental Information for details). Aliquots were
withdrawn at  the indicated time points, cleaned up and loaded on  0.8% agarose/TAE gels. The  dried gels were then autoradiographed (32P). Middle panel: dot blot analysis
of  the replicated substrates with an anti-meG antibody. Bottom panel: bar graph depicting data quantiﬁcation from the top panel.
All replication reactions were carried out in the presence of
Patrin-2 [O6-(4-bromoethynyl)guanine; 100–150 M],  unless oth-
erwise indicated.
3. Results and discussion
We ﬁrst set out to examine MMR  activity in X. laevis egg  extracts,
using circular heteroduplex substrates (Fig. 1A) containing either a
single T/G, meG/C or meG/T mismatch. The substrates, as well as the
control C/G homoduplex, were generated by primer extension on
single-stranded phagemid DNA, using synthetic oligonucleotides as
primers. The mispairs were situated within the unique SalI restric-
tion site (Fig. S1A), which makes the DNA refractory to cleavage by
this enzyme.
Chemical synthesis of oligonucleotides requires the presence of
an isopropyl protecting group on the N2 position of guanines, which
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Fig. 2. Replication of meG-containing DNA in X. laevis egg extracts gives rise to gaps that escape checkpoint monitoring but hinder further replication. (A) Analysis of checkpoint
activation after replication of the indicated substrates in Patrin-2-pretreated HSS + NPE. Aliquots removed at  the 120 min  time point were resolved by 7.5% SDS-PAGE and
probed  for phospho-Chk1 (S345, p-Chk1) and total Chk1. (B) Scheme of post-replicative gap-ﬁlling assays. (C) Schematic representation of the substrate digested with DrdI (left
panel)  and gap-ﬁlling reactions of the C/G and meG/C substrates (top right panel). Substrates were replicated in Patrin-2-pretreated extract without addition of radioactive
nucleotide (control sample was  spiked with [-32P]dCTP). Aphidicolin (7.5 M)  was added for 5 min  after the replication was complete, the substrate was  isolated and the
gap-ﬁlling  reaction with Klenow polymerase was  performed in the presence of [-32P]dCTP. The substrates were then digested with DrdI  (Dr) and the samples were separated
on  1% agarose/TAE gels stained with GelRed. The dried gels were subsequently autoradiographed (32P). Bottom panel: dot blot of the  replicated substrates with an anti-meG
antibody.  (D) Replication of the gapped meG/C and the control closed-circular C/G substrates in HSS +  NPE supplemented with [-32P]dCTP. Aliquots removed at the indicated
times  were divided in two, one portion was used to  extract the DNA, the other was  used for protein analysis. Top panel: autoradiograph of DNA molecules recovered from the
replication reactions and separated on 0.8% agarose/TAE gels. oc – open circular, sc  – supercoiled. Asterisk denotes supercoiled dimer C/G molecules. These are not visible in
the  gapped substrate reactions due to the substantially lower yield of supercoiled plasmids. Bar graph represents data from three independent experiments, with error bars
showing  standard deviation from  the mean. Bottom panel: Western blot of extract proteins resolved by 7.5% SDS-PAGE and probed for phoshpo-Chk1 (p-Chk1) and total
Chk1.
is removed in  the ﬁnal deprotection step by ammonia treatment.
The latter step cannot be used on oligonucleotides containing O6-
methylguanine, because ammonia would remove the 6-methoxy
group. An alternative deprotection is therefore used, but this is
often incomplete. In order to ensure that our oligonucleotides
indeed contained fully deprotected meG,  we annealed them to their
complementary sequences to  generate 31-mer duplexes contain-
ing meG/C or meG/T mispairs, and carried out gel-shift experiments
with puriﬁed human MutS. Neither oligonucleotide was bound
efﬁciently, but, upon treatment with recombinant X. laevis Mgmt
(Fig. S1B), a  strong gel-shift was observed with the meG/T oligonu-
cleotide, which is indicative of its efﬁcient conversion to G/T (Fig.
S1C).
We next  had to inhibit the Mgmt  activity in the extracts. Human
MGMT  is routinely inhibited by  O6-benzylguanine (BG), and this
was the case also for the X. laevis enzyme. As shown in  Fig S1D (left
panel), the meG/C substrate incubated with the high speed super-
natant (HSS) in the presence of 10 M BG was readily converted
to G/C, as shown by SalI  cleavage of the plasmid into fragments a
and b. Higher concentrations inhibited the cleavage, which showed
that the meG/C mismatch was intact. However, the high BG concen-
trations necessary to inhibit Mgmt  in the extracts inhibited also
the MMR  efﬁciency (data not shown). For this reason, we made
use of Patrin-2 [O6-(4-bromoethynyl)guanine; a  kind gift of Geoff
Margison], which inhibits Mgmt  with similar efﬁciency to BG (Fig.
S1D, right panel), but without the deleterious effect on MMR.
In  earlier studies, meG in DNA was  shown to be addressed by
MMR in  E. coli [26], S. cerevisiae [27] and human cells [13,28],
and we  set out to extend these ﬁndings to the X. laevis sys-
tem. Although the meG/C or meG/T oligonucleotide duplexes were
not efﬁciently bound by puriﬁed MutS in the extracts (Fig.
S1C), the circular phagemids containing a meG/C or meG/T mis-
pair and a  single nick in  either the complementary (Fig. 1B) or
the viral strand (Fig. 1C) activated excision and repair synthe-
sis, as shown by incorporation of [32P]dCMP predominantly into
fragments a and b of the phagemid DNA. This process was depend-
ent on MutS, as shown by immunodepletion of this factor from
the extracts with a X. laevis anti-Msh6 antibody (Fig. S1E–G)
and subsequent rescue with puriﬁed recombinant human MutS
(Fig. 1D).
We next set out to ask whether the presence of meG in DNA
affects replication. As shown in  Fig. 1E, the covalently closed
T/G, meG/C, meG/T and the C/G control phagemids were replicated
efﬁciently in a mixture of high speed supernatant (HSS) and nucleo-
plasmic extracts (NPE) of X. laevis eggs, with the meG-containing
substrates showing only a  slight decrease in [32P]dCMP incorpo-
ration (5–13%). Importantly, meG could be shown to  persist in
the meG/C and meG/T substrates after replication was  completed
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Fig. 3. Recruitment of X. laevis MMR  proteins to MNU-treated sperm chromatin. (A) Schematic representation of the chromatin association assay. (B) Western blot of
recruitment  of replication- and MMR  proteins to sperm chromatin treated with 1.5 mM MNU. (C) Western blot of recruitment of MMR  proteins to  undamaged or MNU-
treated (1.5 mM)  sperm chromatin, incubated for 90 min  with extracts pretreated with DMSO (control) or Patrin-2 (150 M).  (D)  Efﬁciency of replication of MNU-treated sperm
chromatin in S phase extracts, monitored by supplementing the extracts with [-32P]dCTP (32P) and incubation for 120 min  (sc-supercoiled DNA). Top  panel: autoradiograph
of  a 0.8% agarose/TAE gel (32P).  Bottom panel: column graph of data from three independent experiments, with error bars representing standard deviation from the mean.
(E)  Western blot showing recruitment of MMR-  and checkpoint proteins to  sperm chromatin treated with increasing concentrations of MNU. Extracts were pretreated with
Patrin-2. MMS  (1%) treatment was used as a positive control of checkpoint activation and Orc2 was used as a loading control. (F) Phosphorylation of Chk1 (S345)  in Patrin-2-
pretreated S  phase extracts in response to MNU. Nuclei were isolated after 120 min  and probed for p-Chk1 and total Chk1. (G) MMR-independent phosphorylation of Chk1
in  S phase extracts in response to high MNU concentrations. Nuclei were isolated after 120 min  and probed for p-Chk1 and total Chk1. (H) Re-replication of MNU-treated
sperm chromatin. As shown in the scheme, the chromatin was  ﬁrst replicated in Patrin-2 pretreated extracts, isolated, and incubated with fresh extracts that were either
pretreated with Patrin-2 or only with DMSO. The extracted DNA was  separated on  0.8% agarose/TAE gels and autoradiographed (32P). ExoIII-pre-treated chromatin was used
as  positive control; this  treatment generates single-stranded gaps from random strand breaks in the DNA.
(120 min), as conﬁrmed in the dot blot assay using a  speciﬁc anti-
body against meG (a kind gift of Jürgen Thomale).
To test whether replication of meG-containing substrates
induced DNA damage signaling in the extracts, we incubated the
heteroduplexes with HSS and NPE as above. The control, C/G
phagemid, either untreated or treated with MMS  (commonly used
to trigger DNA damage signaling in X. laevis extracts), was used as
a  control. As shown in Fig. 2A, only the MMS-treated C/G substrate
gave rise to signiﬁcant ATR activation upon replication completion
(120 min), as seen by phosphorylation of the ATR downstream tar-
get Chk1. Closer analysis of this signaling indicated that replication
of the meG/C substrate also activated ATR at the 30 min. time point,
but the phospho-Chk1 signal did not persist until replication was
completed (Fig. S2A). It is possible that this transient activation
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reﬂected an interaction of MMR  with the checkpoint machinery as
observed previously both in vitro [17,18] and in vivo [19,29].
As mentioned above, DNA damage signaling induced by SN1
type methylating agents in human cells is activated after the ﬁrst
S phase, but cell cycle arrest occurs in  the second G2/M phase
[10,16], believed to be triggered by single-stranded gaps resulting
from replication re-initiation behind the unrepaired meG residues
[14]. We  therefore searched for the presence of such gaps in our
in vitro-replicated substrates. We  designed an experimental pro-
tocol shown schematically in Fig. 2B,  in which we incubated the
C/G and meG/C phagemids with HSS and NPE, isolated the repli-
cated DNA, incubated it with Klenow polymerase in  the presence of
aphidicolin, dATP, dGTP, dTTP and [-32P]dCTP, and then digested
it with DrdI. As shown in Fig. 2C, only the meG/C substrate incorpo-
rated substantial amounts of [32P]dCMP into fragment a. Because
this fragment contains the meG residue, it is most likely that the
radionucleotide was incorporated into gaps remaining opposite
this modiﬁed base after replication. This ﬁnding was  comple-
mented by  the fact that the non-denatured phagemid isolated from
the replication mixture reacted with an anti-meG antibody in  a dot
blot assay (Fig. 2C, lowest panel).
The futile cycling hypothesis [7] posits that the single-stranded
gaps opposite meG would be effectively irreparable, because
polymerases attempting gap-ﬁlling would be aborted by  MMR acti-
vation [13]. We therefore set out to test this prediction in  X. laevis
egg extracts. We  anticipated that replication of the control C/G
plasmid would give rise predominantly to supercoiled molecules,
whereas replication of the meG/C plasmid in which a  gap had been
generated opposite the methylated guanine (Fig. S2B–D) would
give rise to open-circular molecules that  should be  converted to
supercoiled DNA with only low efﬁciency. However, pretreatment
of the latter gapped plasmid with Mgmt,  which will have con-
vertedmeG to  G, should give rise to proportionally more supercoiled
plasmid DNA. This was indeed the case, as shown in  Fig. 2D. Inter-
estingly, the gapped meG/C phagemid did give rise to  supercoiled
molecules at the later time points, which indicates that the gaps
were eventually repaired. This would happen if a  DNA polymerase
succeeded in  ﬁlling the gap completely such that the 3′ terminus of
the resynthesized strand could be ligated to  the 5′ terminus of the
downstream nascent DNA strand generated by replication reini-
tiation. In this scenario, the meG would still be in the DNA, but
the duplex would be largely refractory to MMR,  as there would
be no strand discontinuity in  the vicinity. We also detected ATR
activation, as shown by phosphorylation of Chk1 that appeared
already prior to replication, as seen previously with gapped sub-
strates [30,31]. Importantly, in  the case of the gapped meG plasmid,
the signal persisted throughout the 120 min  time course of the
assay, but not when the same plasmid was pre-treated with Mgmt
(Fig. 2D, bottom panel).
In order to gain more information about the interplay between
replication and MMR-dependent DNA damage signaling in a  more
physiologically relevant setting, we studied the recruitment of
the respective proteins to  X. laevis sperm chromatin, as shown
schematically in  Fig. 3A. Using in-house-generated rabbit poly-
clonal antibodies against frog polypeptides (Fig. S1E–G), as well
as other antibodies generously provided by others (see  M&M),
we ﬁrst monitored protein recruitment to  undamaged chromatin
in S phase extracts. As shown in Fig. 3B,  Msh2, Msh6, Mlh1 and
Exo1 were recruited with kinetics similar to those of the three
replicative polymerases and several other replication factors,
which conﬁrms that MMR  and replication are closely associated
[32,33]. When we repeated the experiment with chromatin treated
with 1.5 mM MNU (Fig. 3A and C), MMR  protein recruitment was
signiﬁcantly increased when the chromatin was incubated with
extracts pre-treated with the Mgmt  inhibitor Patrin-2, which
ensured that meG persisted in  the DNA. Treatment with different
doses of the methylating agent showed that replication was dele-
teriously affected only at MNU  concentrations exceeding 80 mM
(Fig. 3D); the observed protein recruitment was thus not the
result of blocked replication. Similar experiments carried out with
MNNG-treated chromatin (Fig. S3A and B)  conﬁrmed that, at doses
that do not affect DNA replication, MMR proteins are recruited
to methylated chromatin together with replication factors, and
persist because of the presence of meG in  the DNA.
In in vitro assays, MMR  proteins were shown to  directly interact
with the checkpoint machinery upon meG recognition [17,18].  In
contrast, our in vivo data indicated that activation of DNA damage
signaling required replication. In order to  gain more insight into this
phenomenon, we  examined the recruitment and activation of  DNA
damage signaling factors to MNU-treated sperm chromatin during
a single round of replication in  the naturally synchronous Patrin-2
pre-treated XEE. As control we used either untreated chromatin,
or chromatin treated with MMS,  which is  known to  elicit a  potent
checkpoint response in the extract [34]. As shown in Fig. 3E, treat-
ment with 1% (110 mM)  MMS  resulted in  the ready recruitment
of DNA damage signaling machinery. In  contrast, no comparable
recruitment could be seen to chromatin treated with MNU, even at a
dose of 80 mM,  which led to MMR protein recruitment comparable
to that seen with 1% MMS and which would have generated similar
amount of methylation damage other thanmeG (predominantly N7-
methylguanine and N3-methyladenine). At this dose, replication
efﬁciency was  beginning to  decrease (Fig. 3D), while phosphoryla-
tion of Chk1, a downstream target of ATR became detectable and
continued to increase up to  500 mM  MNU  (Fig. 3F and G), a  concen-
tration that severely inhibited replication (Fig. 3D).  Moreover, Chk1
phosphorylation became Mgmt/Patrin-2 independent (Fig. 3G) and
therefore independent of MMR-mediated processing of meG. Simi-
lar results were obtained with MNNG (Fig. S3C).
To test whether the presence of meG-containing gaps impairs
replication in  genomic DNA, we carried out a re-replication reaction
with untreated- or MNU-treated sperm chromatin. The chromatin
was ﬁrst allowed to replicate in  Patrin-2 pretreated extracts, iso-
lated, and incubated with fresh extracts that were either pretreated
with Patrin-2 or  only with DMSO. As shown in  Fig. 3H, re-replication
of themeG-containing chromatin in  the Patrin-2 pretreated extracts
was severely impaired, but was unaffected in  mock (DMSO) treated
ones.
4. Conclusions
X. laevis egg  extracts represent an in vitro experimental system
that permits the dissection of biological processes that can other-
wise be studied only in vivo. In this study, we set out to deploy
this system to help us identify key processes and intermediates
that bring about the cytotoxicity of meG residues generated by  SN1-
type methylating agents. We  demonstrate here that the presence
of meG in DNA does not hinder replication, but that both meG/C
and meG/T mispairs activate MMR.  In contrast to a  previous report
[35],  we show that, analogously to human cell extracts, the MMR
process is nick-directed. We  also show that meG in the template
strand is not removed by MMR-mediated excision, but that its
processing results in the generation of single-stranded gaps oppo-
site the meG residues. The sluggish repair of these gaps is suggestive
of iterative MMR-dependent resection/resynthesis. Unexpectedly,
the checkpoint machinery activation was  only weak, which sug-
gested that the gaps were possibly shielded from signaling and
thus unlikely to trigger a  cell cycle arrest during the ﬁrst repli-
cation round. However, the structures remaining in  the DNA
following one round of replication inhibited the subsequent repli-
cation round. This is  consistent with the ﬁnding that the cell
cycle arrest induced by SN1-type methylating agents in vivo is
M. Olivera Harris et al. /  DNA Repair 28 (2015) 1–7 7
activated only after the second S phase, possibly through collision
of the gaps with replication forks, which would give rise to  double
strand breaks that would activate the ATR-dependent G2/M check-
point and subsequently also apoptosis. Taken together, the above
evidence provides further experimental support for the hypothe-
sis that MMR-mediated processing of meG-containing mismatches
arising during DNA replication rather than direct signaling of these
mispairs to the apoptotic machinery is  the underlying cause of the
toxicity of SN1-type methylating agents.
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Supplementary Information 
 
 
DNA substrates and X. laevis MMR assay  
The substrates were generated as described previously (Baerenfaller et al, 
2006). Briefly, the hetero- and homoduplexes were constructed by primer 
extension using the oligonucleotides listed below as primers and the single-
stranded phagemid DNA as template. pRichi2850topSalI (pRichi2850t SalI) 
pRichi2850bottom AclI (pRichi2850b) and pRichi2850top AclI (pRichi2850t) 
that create 5' top-nicked or 3’ bottom-nicked substrates were used as the 
ssDNA templates. A single mutation abrogating an AclI site and creating a 
SalI site was used to generate the pRichi2850top SalI phagemid. After primer 
extension and ligation, the desired supercoiled heteroduplex substrates were 
purified on CsCl gradients. 
Mismatch-provoked excision/resynthesis assays were performed as 
previously described (Varlet et al, 1990) in the presence of 100 ng DNA 
substrate and 26 µl S phase extract in a total volume of 30 µl in a buffer 
containing 15 mM Hepes-KOH pH 7.4, 15 mM potassium glutamate, 8.75 mM 
magnesium acetate, and 2 µCi of [α-32P]dCTP. The extracts were incubated 
at 23°C for 45 min. The reaction was stopped by adding 70 µl STOP solution 
containing 1 mM EDTA, 3% SDS and 5 mg/ml proteinase K (Roche). The 
samples were incubated at 55°C for 30 min, purified on MinElute columns 
(Qiagen) and subjected to restriction digests in the presence of RNase 
(5prime) at 37°C overnight. The digested DNA was cleaned up again and 
resolved on 1% agarose/TAE gels stained with GelRed. 
 
Primers 
All primers were obtained from Microsynth (Balgach, Switzerland). The 
sequences are indicated below. The SalI restriction site (GTCGAC) is 
underlined. The mispaired residue is highlighted in bold.  
C/G-SalI primer:  
5' CCAGACGTCTGTCGACGTTGGGAAGCTTGAG 3’ 
T/G-SalI primer:  
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5' CCAGACGTCTGTTGACGTTGGGAAGCTTGAG 3’ 
meG/C and meG/T *-SalI primer: 
 5' CCAGACGTCTGTCmeGACGTTGGGAAGCTTGAG 3’ 
* pRichi2850top AclI was used for this substrate to pair a T with meG  
 
Production of recombinant proteins  
Fragments of X. leavis MMR proteins and full-length X. laevis Mgmt were 
PCR-amplified from EST clones obtained from Imagenes using primers 
containing restriction sites for NcoI and XhoI. The PCR products were then 
cloned in a pET28B(+) vector (Novagen). 6xHis-tagged protein fragments 
(Msh2F1: 258-404 aa, Mlh1F1: 615-744aa, Msh6F1: 128-249aa, Exo1F1: 
344-450aa) were expressed in BL21 cells (Invitrogen) and purified on Ni-NTA 
agarose columns (Qiagen) according to the manufacturer’s protocol.  
 
Antibodies 
Rabbit anti-X. laevis Msh2, Msh6, Mlh1 and Exo1 antisera were generated by 
the Institute of Laboratory Animal Science (University of Zurich) against 
recombinant 6xHis-tagged protein fragments described above. Two rabbits 
per fragment were injected. Immunoglobulins specific for the X. laevis MMR 
proteins were affinity-purified using Hitrap NHS-activated HP (GE healthcare) 
according to standard protocols. Only the Msh6 and Exo1 sera were suitable 
for immunodepletions.  
Rabbit polyclonal antibodies against X. laevis TopBP1, Atr, Rad9, Rad1, 
Hus1, Rad17, Orc2, Pol δ and Pol ε were gifts from Masahiro Akiyama (Nara 
Institute of Science and Technology), Julian Blow (Dundee University), 
Karlene Cimprich (Stanford University), William Dunphy (California Institute of 
Technology), Howard Lindsay (Lancaster University) and Shou Waga (Japan 
Women's University).  Antibodies against human PCNA (Santa Cruz), MCM7 
(Sigma), CHK1 (Santa Cruz), polymerase α (Abcam) and RPA32 subunit 
(Abcam), which cross-react with the X. laevis proteins, were obtained 
commercially. The antibody that recognizes phospho-S345 of X. laevis p-Chk1 
Olivera et al., SI 
was purchased from Cell Signaling Technology. Anti-meG (EM2-3) antibody 
was a kind gift of Jürgen Thomale (Duisburg-Essen University). 
Western blot procedures were performed using ECL or ECL advanced (GE 
Healthcare). Antibodies for Western blots were used at 1:1000 dilutions, 
unless otherwise specified. 
 
Dot blots 
The dot blot procedure was described previously in “Technologies for 
detection of DNA damage and mutations” (G.P. Pfeifer, 1996 edition). Briefly, 
200 ng of pRichi2850t SalI substrates were heat-denatured at 100°C for 10 
min, 2 M ammonium acetate was added to a final concentration of 1 M and 
the samples were blotted onto pre-wetted nitrocellulose. The membrane was 
rinsed in 5 x SSC (0.75 M sodium chloride and 75 mM trisodium citrate) and 
blocked for 1 h in PBS/0.5% Casein/0.1% deoxycholate for 1 h at RT. Anti-
meG antibody (EM2-3) was used at 1:10 000 dilution for 1 h at RT in the same 
solution. Membranes were washed with PBS/160 mM NaCl/0.1% Triton X-100 
for 3 x 5 min, incubated with a secondary anti-mouse antibody, washed 
further 3 times and developed. 
 
Band-shift assays 
The oligonucleotide heteroduplexes were created by annealing the 5' labeled 
oligonucleotide meG, primer for synthesis of the top (complementary) strand of 
the heteroduplex, with its complementary oligonucleotides containing a C or a 
T opposite the meG. Where indicated, the annealed substrates were pre-
treated with Mgmt. The binding reaction mixtures (50 mM Hepes pH 7.5, 0.5 
mM EDTA, 10% glycerol, 0.5 mM DTT, 0.5 mg/ml BSA and 20 ng poly(dI-C) 
contained 40 fmol duplex meG/C or meG/T and human MSH2/MSH6 (250 ng). 
Protein-bound substrates were separated from the free probes by 
electrophoresis on 6% native polyacrylamide gels eluted with TAE. 
 
Xenopus laevis MSH6 immunodepletion 
To prepare Msh6-depleted extracts, 100 µl of the extract were incubated 3 
times for 30 min with 33 µl protein A-Sepharose beads 4B fast flow (Sigma) 
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coupled to 100 µl of Msh6 antiserum. Mock depletion was performed using 
beads coupled to the pre-immune serum. Coupling to the beads was 
performed overnight at 4°C without dilution. After the coupling reaction, the 
beads were washed extensively with EB buffer. The extract was reconstituted 
with 1 µg hMutSα where indicated.  
 
 
Supplementary Figure Legends 
 
Figure S1. Purification of recombinant X. laevis Mgmt, quality control of 
meG-containing substrates in XEE, Mgmt inhibitor testing and antibody 
generation. A, Sequences of pRichi2850 substrates depicting the position of 
the T/G, meG/C and meG/T mismatches with respect to the restriction sites 
used in this study (GTCGAC, SalI, TTCGAA, HindIII). B, SDS-PAGE of full-
length 6xHis-tagged Mgmt (25kDa, 1 µg/µl). C, Band shift assay with 
hMutSα and meG/C or meG/T substrates. Treatment of the substrates with 
Mgmt prior to incubation with hMutSα converted the oligos to C/G and T/G, 
respectively. D, Efficiency of the Mgmt inhibitors O6-benzylguanine (BG) and 
O6-(4-bromothenyl)guanine (Patrin-2) in XEE. HSS was incubated for 10 min 
with increasing concentrations of either BG or Patrin-2 and then the meG/C 
substrate was added to the mix for a further 30 min. This was followed by SalI 
cleavage of the substrate and analysis on 0.8% agarose/TAE gels to 
determine the most effective dose of the inhibitor. Lack of cleavage indicates 
presence of meG/C in the SalI site. Left panel: GelRed-stained gel of a 
representative assay for BG efficiency. Right: Quantification of experiments 
done with BG and Patrin-2. E, BLAST search showing degree of conservation 
between H. sapiens and X. laevis MMR proteins of interest. F, Coomasie-
stained 6xHis-tagged MMR protein fragments resolved on a 15% SDS-PAGE. 
3 µg of purified fragment F1 was loaded per lane (Msh2F1: 1.5 µg/µl, 
Msh6F1: 1.5 µg/µl, Mlh1F1: 3 µg/µl, Exo1F1: 1.2 µg/µl). M, size marker in 
kDa. G, Western blot analysis of the X. laevis egg extract (NPE, 1µl) with the 
affinity-purified MMR antibodies using the following dilutions (Msh2: 1:5000, 
Msh6: 1:5000, Mlh1: 1:500, Exo1: 1:1000). 
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Figure S2. DNA damage signaling, gapped substrate preparation and 
restriction digest analysis. 
A, Kinetic analysis of checkpoint activation (p-Chk1) during replication of the 
indicated substrates in HSS+NPE. Aliquots removed at the indicated times 
were resolved on a 7.5% SDS-PAGE and probed for p-Chk1 (S345) and total 
Chk1. Time point 0 indicates addition of NPE to the HSS/DNA mix. B, 
GelRed-stained 0.8% agarose/TAE gel showing the following samples (from 
left to right): 1kb DNA ladder, single-stranded phagemid pRichi350 (200 ng), 
supercoiled pRichi350 (300 ng), bottom-nicked pRichi350 (150 ng) and 
gapped pRichi350 substrate (150 ng). The latter was made by incubating 10 
µg of the bottom-nicked meG/C substrate with recombinant human Exo1 (28.5 
nM) for 5 min at 37˚C. When nicked by Nt.BstNB1, the nick occurs at position 
350 in the 3197 bp pRichi350 substrate (308 bp from meG, not depicted). C, 
Top panel: Schematic representation of the restriction sites for NotI (30 bp 
from meG), NdeI (730 bp from meG) and XmnI (1,3 kb from meG) in the 
pRichi350 substrate with regard to the meG (triangle). Bottom panel: GelRed-
stained 0.8% agarose/TAE gel showing restriction digest analysis of the 
gapped pRichi350 substrate (150 ng). The restriction enzymes used are 
indicated above the gel. The result shows that the gaps extended past the 
NotI site but did not reach the NdeI site.  
 
Figure S3. Recruitment of MMR and replication factors to chromatin and 
DNA damage signaling induced by MNNG. A, Kinetic analysis of replication 
of undamaged- and 1.5 mM MNNG-damaged sperm chromatin in the 
absence or presence of the Mgmt inhibitor Patrin-2. Recruitment of Msh2, 
MCM7 and pol-ε to chromatin was monitored by Western blotting. B, meG-
dependent recruitment of MMR proteins to chromatin. Binding of mismatch 
repair proteins Msh2, Msh6 and Mlh1 to undamaged- or MNNG-damaged 
chromatin in the absence or presence of the Mgmt inhibitor Patrin-2. The 
samples were assayed after 120 min. E, extract. C, Checkpoint activation in 
XEE in response to the indicated MNNG concentrations. Undamaged- or 
MNNG-damaged sperm chromatin was replicated in S phase extracts in the 
Olivera et al., SI 
absence or presence of Patrin-2. Nuclear proteins were isolated after 120 min 
and probed for p-Chk1 (S345) and Chk1.  
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